细胞株Cell Lines 52-BioVector NTCC质粒载体菌种细胞蛋白抗体基因保藏中心http://www.biovector.net
- 价 格：¥19200
- 货 号：NTCC-CV52
- 产 地：北京
- BioVector NTCC典型培养物保藏中心
- 联系人：Dr.Xu, Biovector NTCC Inc.
电话：400-800-2947 工作QQ:1843439339 (微信同号)
邮件：Biovector@163.com
手机：18901268599
地址：北京
- 已注册
细胞株Cell Lines-BioVector NTCC质粒载体菌种细胞蛋白抗体基因保藏中心
ID M080904B
AC CVCL_AT54
RX PubMed=24581590;
CC From: URPP biobank; University of Zurich; Switzerland.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_AT53 ! M080904
CA Cancer cell line
//
ID M081008
AC CVCL_AT64
RX PubMed=22336146;
CC From: URPP biobank; University of Zurich; Switzerland.
CC Omics: Transcriptome analysis.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID M081021
AC CVCL_AT55
RX PubMed=24581590;
CC From: URPP biobank; University of Zurich; Switzerland.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID M081028
AC CVCL_AT56
RX PubMed=24581590;
CC From: URPP biobank; University of Zurich; Switzerland.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID M1
AC CVCL_2107
SY M 1; M-1 myeloid leukemia
DR BTO; BTO:0002037
DR CLO; CLO_0007437
DR CLO; CLO_0007448
DR CLO; CLO_0050175
DR CLDB; cl3308
DR CLDB; cl3309
DR CLDB; cl5166
DR ATCC; TIB-192
DR DSMZ; ACC-331
DR ECACC; 91110711
DR ECACC; 93120826
DR IFO; IFO50006
DR IZSLER; BS TCL 71
DR KCLB; 40192
DR RCB; RCB0169
DR TOKU-E; 2269
RX PubMed=4187945;
WW http://www.cells-talk.com/index.php/page/copelibrary?key=M1
WW http://www.infarktforschung.de/macrophages_cell_lines.html
CC Doubling time: ~25-50 hours (DSMZ).
CC Breed/subspecies: SL.
DI NCIt; C21889; Mouse myeloid leukemia
OX NCBI_TaxID=10090; ! Mus musculus
CA Cancer cell line
//
ID M1-4HSC
AC CVCL_M114
DR BTO; BTO:0003531
RX PubMed=15878400;
RX PubMed=17760834;
CC Knockout cell: Method=KO mouse; MGI; MGI:104738; Cdkn2a.
OX NCBI_TaxID=10090; ! Mus musculus
SX Male
CA Spontaneously immortalized cell line
//
ID M1-T22
AC CVCL_8368
SY M1 clone T22
DR JCRB; JCRB0110
CC Breed/subspecies: SL.
DI NCIt; C21889; Mouse myeloid leukemia
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_2107 ! M1
CA Cancer cell line
//
ID M1.4
AC CVCL_9203
DR CLO; CLO_0007450
DR ATCC; CRL-2464
RX PubMed=9609824;
CC Monoclonal antibody target: UniProtKB; Q62005; Mouse Zp1.
OX NCBI_TaxID=10090; ! Mus musculus
OX NCBI_TaxID=10116; ! Rattus norvegicus
HI CVCL_2199 ! Sp2/0-Ag14
CA Hybridoma
//
ID M1/22.25.8.HL
AC CVCL_9204
SY M1 clone 22.25
DR CLO; CLO_0007451
DR ATCC; TIB-121
RX PubMed=81133;
OX NCBI_TaxID=10090; ! Mus musculus
OX NCBI_TaxID=10116; ! Rattus norvegicus
HI CVCL_2155 ! P3/NS1/1-Ag4.1
CA Hybridoma
//
ID M1/42.3.9.8.HLK
AC CVCL_9205
DR CLO; CLO_0007452
DR ATCC; TIB-126
OX NCBI_TaxID=10090; ! Mus musculus
OX NCBI_TaxID=10116; ! Rattus norvegicus
HI CVCL_2155 ! P3/NS1/1-Ag4.1
CA Hybridoma
//
ID M1/69.16.11.HL
AC CVCL_9206
SY M1 clone 69.16
DR CLO; CLO_0007453
DR ATCC; TIB-125
RX PubMed=81133;
OX NCBI_TaxID=10090; ! Mus musculus
OX NCBI_TaxID=10116; ! Rattus norvegicus
HI CVCL_2155 ! P3/NS1/1-Ag4.1
CA Hybridoma
//
ID M1/70.15.11.5.HL
AC CVCL_9207
SY M1 clone 70.15
DR CLO; CLO_0007454
DR ATCC; TIB-128
DR BCRJ; 0152
RX PubMed=81133;
OX NCBI_TaxID=10090; ! Mus musculus
OX NCBI_TaxID=10116; ! Rattus norvegicus
HI CVCL_2155 ! P3/NS1/1-Ag4.1
CA Hybridoma
//
ID M1/75.16.4.HLK
AC CVCL_9208
DR CLO; CLO_0007455
DR ATCC; TIB-127
CC Monoclonal antibody target: UniProtKB; P24807; Mouse Cd24.
OX NCBI_TaxID=10090; ! Mus musculus
OX NCBI_TaxID=10116; ! Rattus norvegicus
HI CVCL_2155 ! P3/NS1/1-Ag4.1
CA Hybridoma
//
ID M1/87.27.7.HLK
AC CVCL_9209
SY M1 clone 82.27
DR CLO; CLO_0007456
DR ATCC; TIB-123
RX PubMed=81133;
OX NCBI_TaxID=10090; ! Mus musculus
OX NCBI_TaxID=10116; ! Rattus norvegicus
HI CVCL_2155 ! P3/NS1/1-Ag4.1
CA Hybridoma
//
ID M1/89.18.7.HK
AC CVCL_9210
SY M1 clone 89.18
DR CLO; CLO_0007457
DR ATCC; TIB-124
RX PubMed=81133;
OX NCBI_TaxID=10090; ! Mus musculus
OX NCBI_TaxID=10116; ! Rattus norvegicus
HI CVCL_2155 ! P3/NS1/1-Ag4.1
CA Hybridoma
//
ID M1/9.3.4.HL.2
AC CVCL_9211
SY M1 clone 9.3
DR CLO; CLO_0007458
DR ATCC; TIB-122
RX PubMed=81133;
OX NCBI_TaxID=10090; ! Mus musculus
OX NCBI_TaxID=10116; ! Rattus norvegicus
HI CVCL_2155 ! P3/NS1/1-Ag4.1
CA Hybridoma
//
ID M1(D+)
AC CVCL_C021
DR CLO; CLO_0050222
DR RCB; RCB2621
DR TKG; TKG 0319
CC Breed/subspecies: SL.
DI NCIt; C21889; Mouse myeloid leukemia
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_2107 ! M1
CA Cancer cell line
//
ID M10 [Human melanoma]
AC CVCL_4715
SY UCLA-SO-M10; UCLA SO M10; UCLA-SO-10; Melanoma 10
DR BTO; BTO:0002965
DR ATCC; CRL-12269
RX Patent=US5840317;
RX Patent=US5993828;
RX PubMed=204583;
RX PubMed=945229;
RX PubMed=954005;
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID M10 [Mouse leukemia]
AC CVCL_L284
DR CLO; CLO_0050171
DR RCB; RCB0136
RX PubMed=221956;
CC Breed/subspecies: DBA/2.
DI NCIt; C21604; Mouse leukemia
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_2097 ! L-5178-Y
SX Female
CA Cancer cell line
//
ID M10^(-)
AC CVCL_L285
DR CLO; CLO_0050170
DR RCB; RCB0137
CC Breed/subspecies: DBA/2.
DI NCIt; C21604; Mouse leukemia
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_L284 ! M10 [Mouse leukemia]
SX Female
CA Cancer cell line
//
ID M101
AC CVCL_L438
SY UCLA-SO-M101
DR ATCC; CRL-12271
RX Patent=US5840317;
RX Patent=US5993828;
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID M109
AC CVCL_H602
SY Madison 109; Madison lung; Madison; MADISON LUNG TA-109
DR CLO; CLO_0007527
DR CLDB; cl3333
DR ChEMBL-Cells; CHEMBL3307527
DR ChEMBL-Targets; CHEMBL614073
RX PubMed=194826;
CC Breed/subspecies: BALB/c.
DI NCIt; C21769; Malignant tumors of the mouse pulmonary system
OX NCBI_TaxID=10090; ! Mus musculus
CA Cancer cell line
//
ID M10K
AC CVCL_8100
DR Cosmic; 733821
DR Cosmic; 933013
RX CelloPub=CLPUB00243;
RX PubMed=1568228;
RX PubMed=2323006;
RX PubMed=11283936;
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C3234; Mesothelioma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID M10T
AC CVCL_M094
DR BioSample; SAMN03151740
RX PubMed=1246601;
RX PubMed=20143388;
WW http://iclac.org/wp-content/uploads/Cross-Contaminations-v8_0.pdf
CC Problematic cell line: Contaminated. Shown to be a HeLa derivative (PubMed=1246601, PubMed=20143388).
CC Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18).
DI NCIt; C4029; Cervical adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0030 ! HeLa
SX Female
CA Cancer cell line
//
ID M12 [Human melanoma]
AC CVCL_5T78
SY UCLA-SO-M12; Melanoma 12
RX PubMed=945229;
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID M12 [Human prostate]
AC CVCL_4860
DR BTO; BTO:0005128
RX PubMed=9496902;
WW http://capcelllines.ca/details.asp?id=149
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40).
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_4865 ! M2182
SX Male
CA Transformed cell line
//
ID M12 [Mouse lymphoma]
AC CVCL_IU99
RX PubMed=310843;
CC Breed/subspecies: BALB/c.
DI NCIt; C21602; Mouse lymphoma
OX NCBI_TaxID=10090; ! Mus musculus
CA Cancer cell line
//
ID M12.4
AC CVCL_IV00
SY m12.4
WW http://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/m/cell-lines-detail-387.html
CC Breed/subspecies: BALB/c.
DI NCIt; C21602; Mouse lymphoma
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_IU99 ! M12 [Mouse lymphoma]
CA Cancer cell line
//
ID M12.4.1
AC CVCL_0402
SY M1241
DR MCCL; MCC:0000296
RX PubMed=6809823;
CC Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; 6-TG).
CC Transformant: ChEBI; CHEBI:23994; Ethyl methanesulfonate (Methylsulfonic acid ethyl ester; MSEE).
CC Breed/subspecies: BALB/c.
DI NCIt; C21602; Mouse lymphoma
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_IV00 ! M12.4
CA Cancer cell line
//
ID M12.4.5
AC CVCL_0403
SY M1245
DR MCCL; MCC:0000297
CC Transformant: ChEBI; CHEBI:23994; Ethyl methanesulfonate (Methylsulfonic acid ethyl ester; MSEE).
CC Breed/subspecies: BALB/c.
DI NCIt; C21602; Mouse lymphoma
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_IV00 ! M12.4
CA Cancer cell line
//
ID M14
AC CVCL_1395
SY M14-MEL; UCLA-SO-M14; UCLA SO M14; UCLA-SO-14; Melanoma 14
DR BTO; BTO:0002805
DR EFO; EFO_0003056
DR ChEMBL-Cells; CHEMBL3307591
DR ChEMBL-Targets; CHEMBL614317
DR Cosmic; 686479
DR Cosmic; 687445
DR Cosmic; 875889
DR Cosmic; 897467
DR Cosmic; 905975
DR Cosmic; 974068
DR Cosmic; 974261
DR Cosmic; 1022278
DR Cosmic; 1044265
DR Cosmic; 1092611
DR Cosmic; 1109808
DR Cosmic; 1132591
DR Cosmic; 1158815
DR Cosmic; 1295340
DR Cosmic; 1303040
DR Cosmic; 1305365
DR Cosmic; 1312348
DR Cosmic; 1459642
DR Cosmic; 1537485
DR Cosmic; 1888913
DR Cosmic; 1998453
DR Cosmic-CLP; 905975
DR GDSC; 905975
DR GEO; GSM50201
DR GEO; GSM50263
DR GEO; GSM188222
DR GEO; GSM188252
DR GEO; GSM188311
DR GEO; GSM750799
DR GEO; GSM799352
DR GEO; GSM799415
DR GEO; GSM847034
DR GEO; GSM844583
DR GEO; GSM1153422
DR GEO; GSM1181292
DR GEO; GSM1181336
DR GEO; GSM1670072
DR SKY/M-FISH/CGH; 2813
RX DOI=10.4172/2157-7145.S2-005;
RX PubMed=204583;
RX PubMed=954005;
RX PubMed=945229;
RX PubMed=1260767;
RX PubMed=1918136;
RX PubMed=2041050;
RX PubMed=2060184;
RX PubMed=3046746;
RX PubMed=6470027;
RX PubMed=6876798;
RX PubMed=17088437;
RX PubMed=19372543;
RX PubMed=19549886;
RX PubMed=19727395;
RX PubMed=23856246;
RX PubMed=23933261;
RX PubMed=27397505;
RX PubMed=27807467;
RX PubMed=28196595;
WW https://dtp.cancer.gov/discovery_development/nci-60/cell_list.htm
WW https://strap.nci.nih.gov/celline_detail.php?sample_id=48
WW http://tcpaportal.org/mclp/
CC Part of: MD Anderson Cell Lines Project.
CC Part of: NCI60 cancer cell line panel.
CC Doubling time: 26.3 hours (DTP).
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Omics: Deep exome analysis.
CC Omics: Deep proteome analysis.
CC Omics: DNA methylation analysis.
CC Omics: Protein expression by reverse-phase protein arrays.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
CC Derived from metastatic site: Subcutaneous; right buttock.
ST Source(s): Cosmic-CLP; DOI=10.4172/2157-7145.S2-005; PubMed=19372543
ST Amelogenin: X
ST CSF1PO: 11
ST D13S317: 12
ST D16S539: 9,13
ST D18S51: 13,17
ST D19S433: 14,15
ST D21S11: 30
ST D2S1338: 19,24
ST D3S1358: 14,16
ST D5S818: 11,12
ST D7S820: 8,10
ST D8S1179: 13
ST FGA: 21
ST TH01: 6,7
ST TPOX: 8,11
ST vWA: 16,18
DI NCIt; C3802; Amelanotic melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_DI53 ! MF14
OI CVCL_DI50 ! ML14
SX Male
CA Cancer cell line
//
ID M14-A
AC CVCL_A779
SY M14-ascitic form
RX PubMed=6470027;
CC Derived from metastatic site: Subcutaneous; right buttock.
DI NCIt; C3802; Amelanotic melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_1395 ! M14
SX Male
CA Cancer cell line
//
ID M146I-hiPSC
AC CVCL_DQ95
RX PubMed=27345998;
DI NCIt; C123412; Familial Alzheimer's disease, type 3
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Induced pluripotent stem cell
//
ID M14K
AC CVCL_8102
AS CVCL_M199
SY M-14-K; M14
DR BTO; BTO:0003999
DR Cosmic; 733822
RX CelloPub=CLPUB00243;
RX PubMed=1568228;
RX PubMed=2323006;
RX PubMed=11283936;
RX PubMed=9533946;
DI NCIt; C3234; Mesothelioma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_U345 ! M14P
OI CVCL_8103 ! M20 [Human mesothelioma]
SX Male
CA Cancer cell line
//
ID M14M
AC CVCL_U460
DR Cosmic; 733824
DR Cosmic; 934557
RX PubMed=1568228;
DI NCIt; C3234; Mesothelioma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_U345 ! M14P
SX Male
CA Cancer cell line
//
ID M14P
AC CVCL_U345
DR Cosmic; 733823
RX PubMed=1568228;
RX PubMed=2323006;
DI NCIt; C3234; Mesothelioma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_8102 ! M14K
OI CVCL_8103 ! M20 [Human mesothelioma]
SX Male
CA Cancer cell line
//
ID M15 [Human mesothelioma]
AC CVCL_U344
DR Cosmic; 733825
RX PubMed=1568228;
DI NCIt; C3234; Mesothelioma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID M15 [Human prostate]
AC CVCL_4861
RX PubMed=9496902;
WW http://capcelllines.ca/details.asp?id=150
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40).
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_4865 ! M2182
SX Male
CA Transformed cell line
//
ID M15 [Mouse]
AC CVCL_3841
SY Meso15
DR CLO; CLO_0007461
DR CLDB; cl3312
DR ECACC; 95102517
OX NCBI_TaxID=10090; ! Mus musculus
CA Transformed cell line
//
ID m17.ASC
AC CVCL_G357
DR ECACC; 11112201
RX Patent=US8835165;
RX PubMed=23777308;
CC Registration: International Depositary Authority, Advanced Biotechnology Center (ABC), Interlab Cell Line Collection (ICLC), Italy; PD 10001.
OX NCBI_TaxID=10090; ! Mus musculus
CA Adult stem cell
//
ID M17/4.4.11.9
AC CVCL_9212
DR CLO; CLO_0007463
DR ATCC; TIB-217
OX NCBI_TaxID=10090; ! Mus musculus
OX NCBI_TaxID=10116; ! Rattus norvegicus
HI CVCL_2155 ! P3/NS1/1-Ag4.1
CA Hybridoma
//
ID M17/5.2
AC CVCL_9213
DR CLO; CLO_0007464
DR ATCC; TIB-237
OX NCBI_TaxID=10090; ! Mus musculus
OX NCBI_TaxID=10116; ! Rattus norvegicus
HI CVCL_2155 ! P3/NS1/1-Ag4.1
CA Hybridoma
//
ID M18
AC CVCL_D029
SY EST133
DR Cosmic; 1047644
DR Cosmic; 2163832
DR ESTDAB; ESTDAB-133
DR GEO; GSM156004
RX PubMed=17260012;
CC Omics: Array-based CGH.
ST Source(s): ESTDAB
ST Amelogenin: X
ST CSF1PO: 12
ST D13S317: 11
ST D3S1358: 14,16
ST D5S818: 11
ST D7S820: 8
ST FGA: 21,23
ST TH01: 8
ST TPOX: 11
ST vWA: 17
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID M18/2.a.12.7
AC CVCL_7681
DR CLO; CLO_0007465
DR ATCC; TIB-218
DR CCRID; 3131C0001000600033
CC Monoclonal antibody target: UniProtKB; P11835; Mouse Itgb2/Cd18.
OX NCBI_TaxID=10090; ! Mus musculus
OX NCBI_TaxID=10116; ! Rattus norvegicus
HI CVCL_G215 ! M18/2.a.8
CA Hybridoma
//
ID M18/2.a.8
AC CVCL_G215
RX PubMed=6193226;
CC Monoclonal antibody target: UniProtKB; P11835; Mouse Itgb2/Cd18.
OX NCBI_TaxID=10090; ! Mus musculus
OX NCBI_TaxID=10116; ! Rattus norvegicus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID M18/B7
AC CVCL_D030
DR ESTDAB; ESTDAB-041
CC Transfected with: HGNC; 1700; CD80.
ST Source(s): ESTDAB
ST Amelogenin: X
ST CSF1PO: 12
ST D13S317: 11
ST D3S1358: 14,16
ST D5S818: 11
ST D7S820: 8
ST FGA: 21,23
ST TH01: 8
ST TPOX: 11
ST vWA: 17
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_D029 ! M18
CA Cancer cell line
//
ID M19
AC CVCL_M198
DR Cosmic; 733827
DR Cosmic; 934558
RX PubMed=1568228;
RX PubMed=2323006;
DI NCIt; C3234; Mesothelioma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_M197 ! M22K
SX Male
CA Cancer cell line
//
ID M19-MEL
AC CVCL_B415
SY M19
DR ChEMBL-Cells; CHEMBL3307506
DR ChEMBL-Targets; CHEMBL614019
DR Cosmic; 1181741
DR Cosmic; 1303041
RX PubMed=7999427;
WW https://dtp.cancer.gov/discovery_development/nci-60/cell_list.htm
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID M1929
AC CVCL_4864
RX PubMed=8077059;
WW http://capcelllines.ca/details.asp?id=146
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40).
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_4875 ! P69SV40T
SX Male
CA Transformed cell line
//
ID M195
AC CVCL_L542
DR CLO; CLO_0007466
DR ATCC; HB-10306
RX Patent=US5730982;
RX Patent=US6007814;
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_2199 ! Sp2/0-Ag14
CA Hybridoma
//
ID M1Do
AC CVCL_W290
SY M1 (Do); M1
RX DOI=10.1007/BF01753729;
RX PubMed=3882112;
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID M1RW
AC CVCL_4Z11
SY MIRW
RX PubMed=6770995;
RX PubMed=6773878;
CC Doubling time: 24 hours (PubMed=6770995); 23.6 hours (PubMed=6773878).
CC Derived from metastatic site: Subcutaneous.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID M1RW5
AC CVCL_4Z12
SY MIRW5
RX PubMed=3079741;
RX PubMed=3667379;
RX PubMed=3864528;
RX PubMed=6581509;
CC Derived from metastatic site: Lymph node.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_4Z11 ! M1RW
SX Male
CA Cancer cell line
//
ID M1WT2
AC CVCL_3842
DR CLO; CLO_0007467
DR ATCC; CRL-1984
OX NCBI_TaxID=10029; ! Cricetulus griseus
HI CVCL_0214 ! CHO-K1
SX Female
CA Spontaneously immortalized cell line
//
ID M1WT3
AC CVCL_3843
DR CLO; CLO_0007468
DR CLDB; cl3314
DR ATCC; CRL-1985
DR ECACC; 940822109
OX NCBI_TaxID=10029; ! Cricetulus griseus
HI CVCL_0214 ! CHO-K1
SX Female
CA Spontaneously immortalized cell line
//
ID M1WT5
AC CVCL_3844
DR CLO; CLO_0007469
DR ATCC; CRL-1986
OX NCBI_TaxID=10029; ! Cricetulus griseus
HI CVCL_0214 ! CHO-K1
SX Female
CA Spontaneously immortalized cell line
//
ID M2-1
AC CVCL_2Z36
SY WC00001
DR CLO; CLO_0013435
DR BioSamples; SAME17773
DR Coriell; WC00001
CC Discontinued: Coriell; WC00001; probable.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID M2-10B4
AC CVCL_5794
DR CLO; CLO_0007470
DR BCRC; 60228
DR ATCC; CRL-1972
DR CLS; 400428/p589_M2-10B4
DR IZSLER; BS CL 199
DR KCLB; 21972
RX PubMed=3261251;
CC Breed/subspecies: C57BL/6J x C3H/HeJ.
OX NCBI_TaxID=10090; ! Mus musculus
CA Spontaneously immortalized cell line
//
ID M2-1C6-4R3
AC CVCL_4538
SY M2-1C6; M2-1C6-5; WC00017
DR CLO; CLO_0007471
DR CLO; CLO_0012695
DR CLDB; cl5224
DR ATCC; HB-64
DR BioSamples; SAME17713
DR Coriell; WC00017
DR IZSLER; BS Hy 29
RX PubMed=7217668;
CC Monoclonal antibody target: Influenza A virus matrix protein (M).
CC Discontinued: Coriell; WC00017; probable.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID M2-21-4.6
AC CVCL_5K10
SY WC00028
DR CLO; CLO_0012716
DR BioSamples; SAME17797
DR Coriell; WC00028
CC Monoclonal antibody target: Influenza A virus matrix protein (M).
CC Discontinued: Coriell; WC00028; probable.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID M2-40
AC CVCL_5K04
SY WC00016
DR CLO; CLO_0012694
DR BioSamples; SAME17709
DR Coriell; WC00016
CC Discontinued: Coriell; WC00016; probable.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID M2-58
AC CVCL_5K05
SY WC00043
DR CLO; CLO_0012734
DR BioSamples; SAME17829
DR Coriell; WC00043
CC Discontinued: Coriell; WC00043; probable.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID M20 [Human melanoma]
AC CVCL_DI51
SY M-20; UCLA-SO-M20
RX PubMed=954005;
RX PubMed=6876798;
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_DI54 ! MF20
CA Cancer cell line
//
ID M20 [Human mesothelioma]
AC CVCL_8103
DR Cosmic; 733828
RX PubMed=1568228;
RX PubMed=2323006;
DI NCIt; C3234; Mesothelioma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_8102 ! M14K
OI CVCL_U345 ! M14P
SX Male
CA Cancer cell line
//
ID M202
AC CVCL_D746
DR Cosmic; 1425343
DR Cosmic; 1459667
DR Cosmic; 1665002
RX PubMed=20406486;
RX PubMed=20689758;
RX PubMed=22515704;
RX PubMed=28196595;
WW http://tcpaportal.org/mclp/
CC Part of: MD Anderson Cell Lines Project.
CC Omics: Protein expression by reverse-phase protein arrays.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID M207
AC CVCL_D747
DR Cosmic; 1425344
DR Cosmic; 1459669
DR Cosmic; 1665003
RX PubMed=20406486;
RX PubMed=20689758;
RX PubMed=22515704;
RX PubMed=28196595;
WW http://tcpaportal.org/mclp/
CC Part of: MD Anderson Cell Lines Project.
CC Omics: Protein expression by reverse-phase protein arrays.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID M21
AC CVCL_D031
SY UCLA-SO-M21; UCLA SO M21
DR ChEMBL-Cells; CHEMBL3307769
DR ChEMBL-Targets; CHEMBL614117
DR Cosmic; 928695
DR ESTDAB; ESTDAB-042
WW http://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/m/cell-lines-detail-388.html
ST Source(s): ESTDAB
ST Amelogenin: X
ST CSF1PO: 10
ST D13S317: 8,9
ST D3S1358: 14,18
ST D5S818: 10,13
ST D7S820: 10,12
ST FGA: 20
ST TH01: 6
ST TPOX: 8,11
ST vWA: 14
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID M2182
AC CVCL_4865
RX PubMed=8077059;
RX PubMed=9496902;
WW http://capcelllines.ca/details.asp?id=147
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40).
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_4864 ! M1929
SX Male
CA Transformed cell line
//
ID M22
AC CVCL_U978
DR BTO; BTO:0002197
RX PubMed=11751433;
RX PubMed=12075625;
CC Breed/subspecies: Sprague-Dawley.
OX NCBI_TaxID=10116; ! Rattus norvegicus
HI CVCL_U976 ! OC/CDE 22
SX Male
CA Cancer cell line
//
ID M2205
AC CVCL_4866
RX PubMed=8077059;
RX PubMed=9496902;
RX PubMed=12581899;
WW http://capcelllines.ca/details.asp?id=148
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40).
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_4875 ! P69SV40T
SX Male
CA Transformed cell line
//
ID M229
AC CVCL_D748
DR Cosmic; 1425351
DR Cosmic; 1459649
DR Cosmic; 1665011
DR GEO; GSM612085
DR GEO; GSM612086
DR GEO; GSM1588914
RX PubMed=20406486;
RX PubMed=20689758;
RX PubMed=22515704;
RX PubMed=28196595;
WW http://tcpaportal.org/mclp/
CC Part of: MD Anderson Cell Lines Project.
CC Omics: Protein expression by reverse-phase protein arrays.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID M229 R1
AC CVCL_EI76
DR Cosmic; 1545601
RX PubMed=21107323;
CC Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf; PLX4032).
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_D748 ! M229
CA Cancer cell line
//
ID M229 R10
AC CVCL_EI77
DR Cosmic; 1545610
RX PubMed=21107323;
CC Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf; PLX4032).
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_D748 ! M229
CA Cancer cell line
//
ID M229 R11
AC CVCL_EI78
DR Cosmic; 1545611
RX PubMed=21107323;
CC Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf; PLX4032).
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_D748 ! M229
CA Cancer cell line
//
ID M229 R12
AC CVCL_EI79
DR Cosmic; 1545612
RX PubMed=21107323;
CC Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf; PLX4032).
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_D748 ! M229
CA Cancer cell line
//
ID M229 R13
AC CVCL_EI80
DR Cosmic; 1545613
RX PubMed=21107323;
CC Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf; PLX4032).
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_D748 ! M229
CA Cancer cell line
//
ID M229 R14
AC CVCL_EI81
DR Cosmic; 1545614
RX PubMed=21107323;
CC Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf; PLX4032).
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_D748 ! M229
CA Cancer cell line
//
ID M229 R15
AC CVCL_EI82
DR Cosmic; 1545615
RX PubMed=21107323;
CC Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf; PLX4032).
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_D748 ! M229
CA Cancer cell line
//
ID M229 R2
AC CVCL_EI83
DR Cosmic; 1545602
RX PubMed=21107323;
CC Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf; PLX4032).
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_D748 ! M229
CA Cancer cell line
//
ID M229 R3
AC CVCL_EI84
DR Cosmic; 1545603
RX PubMed=21107323;
CC Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf; PLX4032).
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_D748 ! M229
CA Cancer cell line
//
ID M229 R4
AC CVCL_EI85
DR Cosmic; 1545604
RX PubMed=21107323;
CC Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf; PLX4032).
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_D748 ! M229
CA Cancer cell line
//
ID M229 R5
AC CVCL_EI86
DR Cosmic; 1545605
RX PubMed=21107323;
CC Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf; PLX4032).
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_D748 ! M229
CA Cancer cell line
//
ID M229 R6
AC CVCL_EI87
DR Cosmic; 1545606
RX PubMed=21107323;
CC Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf; PLX4032).
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_D748 ! M229
CA Cancer cell line
//
ID M229 R7
AC CVCL_EI88
DR Cosmic; 1545607
RX PubMed=21107323;
CC Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf; PLX4032).
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_D748 ! M229
CA Cancer cell line
//
ID M229 R8
AC CVCL_EI89
DR Cosmic; 1545608
RX PubMed=21107323;
CC Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf; PLX4032).
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_D748 ! M229
CA Cancer cell line
//
ID M229 R9
AC CVCL_EI90
DR Cosmic; 1545609
RX PubMed=21107323;
CC Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf; PLX4032).
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_D748 ! M229
CA Cancer cell line
//
ID M229DDRpoly-PLXAZD
AC CVCL_IM72
DR GEO; GSM1588916
RX PubMed=26359985;
CC Selected for resistance to: ChEBI; CHEBI:90227; Selumetinib (AZD6244).
CC Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf; PLX4032).
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_D748 ! M229
CA Cancer cell line
//
ID M229R5-PLX
AC CVCL_IM73
DR GEO; GSM1588915
RX PubMed=26359985;
CC Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf; PLX4032).
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_D748 ! M229
CA Cancer cell line
//
ID M22K
AC CVCL_M197
RX PubMed=2323006;
DI NCIt; C3234; Mesothelioma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_M198 ! M19
SX Male
CA Cancer cell line
//
ID M230
AC CVCL_D749
DR Cosmic; 1665177
RX PubMed=22515704;
RX PubMed=28196595;
WW http://tcpaportal.org/mclp/
CC Part of: MD Anderson Cell Lines Project.
CC Omics: Protein expression by reverse-phase protein arrays.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID M233
AC CVCL_D750
DR Cosmic; 1425345
DR Cosmic; 1459657
DR Cosmic; 1665012
RX PubMed=20406486;
RX PubMed=20689758;
RX PubMed=22515704;
RX PubMed=28196595;
WW http://tcpaportal.org/mclp/
CC Part of: MD Anderson Cell Lines Project.
CC Omics: Protein expression by reverse-phase protein arrays.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID M238
AC CVCL_D751
DR Cosmic; 1425352
DR Cosmic; 1459647
DR Cosmic; 1665013
DR GEO; GSM612087
DR GEO; GSM612088
DR GEO; GSM1588917
RX PubMed=20406486;
RX PubMed=20689758;
RX PubMed=22515704;
RX PubMed=28196595;
WW http://tcpaportal.org/mclp/
CC Part of: MD Anderson Cell Lines Project.
CC Omics: Protein expression by reverse-phase protein arrays.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID M238 R1
AC CVCL_EI91
DR Cosmic; 1545616
RX PubMed=21107323;
CC Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf; PLX4032).
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_D751 ! M238
CA Cancer cell line
//
ID M238 R2
AC CVCL_EI92
DR Cosmic; 1545617
RX PubMed=21107323;
CC Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf; PLX4032).
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_D751 ! M238
CA Cancer cell line
//
ID M238R1-PLX
AC CVCL_IM74
DR GEO; GSM1588918
RX PubMed=26359985;
CC Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf; PLX4032).
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_D751 ! M238
CA Cancer cell line
//
ID M24
AC CVCL_D032
SY UCLA-SO-M24; UCLA-SO-24
DR ATCC; CRL-12270
DR Cosmic; 2163789
DR ESTDAB; ESTDAB-043
DR ESTDAB; ESTDAB-134
RX Patent=US5840317;
RX Patent=US5993828;
RX PubMed=2009538;
ST Source(s): ESTDAB
ST Amelogenin: X,Y
ST CSF1PO: 12
ST D13S317: 8,11
ST D3S1358: 14,16
ST D5S818: 13
ST D7S820: 9
ST FGA: 18,19
ST TH01: 6
ST TPOX: 8,11
ST vWA: 16
DI NCIt; C3802; Amelanotic melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID M243
AC CVCL_D752
DR Cosmic; 1459663
DR Cosmic; 1665004
RX PubMed=20689758;
RX PubMed=22515704;
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID M244
AC CVCL_D753
DR Cosmic; 1459664
DR Cosmic; 1665006
RX PubMed=20689758;
RX PubMed=22515704;
RX PubMed=28196595;
WW http://tcpaportal.org/mclp/
CC Part of: MD Anderson Cell Lines Project.
CC Omics: Protein expression by reverse-phase protein arrays.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID M245
AC CVCL_D754
DR Cosmic; 1459661
DR Cosmic; 1665005
RX PubMed=20689758;
RX PubMed=22515704;
RX PubMed=28196595;
WW http://tcpaportal.org/mclp/
CC Part of: MD Anderson Cell Lines Project.
CC Omics: Protein expression by reverse-phase protein arrays.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID M249
AC CVCL_D755
DR Cosmic; 1425353
DR Cosmic; 1459652
DR Cosmic; 1545618
DR Cosmic; 1665014
RX PubMed=20406486;
RX PubMed=20689758;
RX PubMed=22515704;
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID M249 R4
AC CVCL_EI93
DR Cosmic; 1545619
RX PubMed=21107323;
CC Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf; PLX4032).
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_D755 ! M249
CA Cancer cell line
//
ID M24K
AC CVCL_8104
DR Cosmic; 733829
DR Cosmic; 933012
DR Cosmic; 934556
RX CelloPub=CLPUB00243;
RX PubMed=1568228;
RX PubMed=11283936;
DI NCIt; C3234; Mesothelioma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID M24met
AC CVCL_3915
SY M24 met
RX PubMed=2009538;
DI NCIt; C3802; Amelanotic melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_D032 ! M24
SX Male
CA Cancer cell line
//
ID M24met H1.11
AC CVCL_3916
DI NCIt; C3802; Amelanotic melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_3915 ! M24met
SX Male
CA Cancer cell line
//
ID M25.18A1
AC CVCL_S554
DR ATCC; HB-12152
RX Patent=US5955311;
RX Patent=US6365157;
RX Patent=US6448077;
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_2155 ! P3/NS1/1-Ag4.1
CA Hybridoma
//
ID M255
AC CVCL_D756
DR Cosmic; 1425346
DR Cosmic; 1665015
RX PubMed=20406486;
RX PubMed=22515704;
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID M257
AC CVCL_D757
DR Cosmic; 1425342
DR Cosmic; 1459668
DR Cosmic; 1665178
DR Cosmic; 1949555
RX PubMed=20406486;
RX PubMed=20689758;
RX PubMed=22515704;
RX PubMed=28196595;
WW http://tcpaportal.org/mclp/
CC Part of: MD Anderson Cell Lines Project.
CC Omics: Protein expression by reverse-phase protein arrays.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID M25K
AC CVCL_8105
DR Cosmic; 733830
RX CelloPub=CLPUB00243;
RX PubMed=1568228;
RX PubMed=11283936;
DI NCIt; C3234; Mesothelioma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID M26
AC CVCL_B416
DR Cosmic; 1181765
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID M262
AC CVCL_D758
DR Cosmic; 1425354
DR Cosmic; 1459641
DR Cosmic; 1665016
RX PubMed=20406486;
RX PubMed=20689758;
RX PubMed=22515704;
RX PubMed=28196595;
WW http://tcpaportal.org/mclp/
CC Part of: MD Anderson Cell Lines Project.
CC Omics: Protein expression by reverse-phase protein arrays.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID M263
AC CVCL_D759
DR Cosmic; 1425348
DR Cosmic; 1459658
DR Cosmic; 1665017
RX PubMed=20406486;
RX PubMed=20689758;
RX PubMed=22515704;
RX PubMed=28196595;
WW http://tcpaportal.org/mclp/
CC Part of: MD Anderson Cell Lines Project.
CC Omics: Protein expression by reverse-phase protein arrays.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID M275
AC CVCL_D760
DR Cosmic; 1459646
DR Cosmic; 1665018
RX PubMed=20689758;
RX PubMed=22515704;
RX PubMed=28196595;
WW http://tcpaportal.org/mclp/
CC Part of: MD Anderson Cell Lines Project.
CC Omics: Protein expression by reverse-phase protein arrays.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID M285
AC CVCL_D761
DR Cosmic; 1665179
RX PubMed=22515704;
RX PubMed=28196595;
WW http://tcpaportal.org/mclp/
CC Part of: MD Anderson Cell Lines Project.
CC Omics: Protein expression by reverse-phase protein arrays.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID M288
AC CVCL_D762
DR Cosmic; 1459640
RX PubMed=20689758;
RX PubMed=28196595;
WW http://tcpaportal.org/mclp/
CC Part of: MD Anderson Cell Lines Project.
CC Omics: Protein expression by reverse-phase protein arrays.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID M28K
AC CVCL_8106
SY M-28-K
DR BTO; BTO:0004000
DR Cosmic; 733831
RX CelloPub=CLPUB00243;
RX PubMed=1568228;
RX PubMed=11283936;
DI NCIt; C3234; Mesothelioma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID M290
AC CVCL_L705
DR ECACC; 93012001
CC Monoclonal antibody target: UniProtKB; Q60677; Mouse Itgae/Cd103.
OX NCBI_TaxID=10090; ! Mus musculus
OX NCBI_TaxID=10116; ! Rattus norvegicus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID M296
AC CVCL_D763
DR Cosmic; 1459670
DR Cosmic; 1665007
RX PubMed=20689758;
RX PubMed=22515704;
RX PubMed=28196595;
WW http://tcpaportal.org/mclp/
CC Part of: MD Anderson Cell Lines Project.
CC Omics: Protein expression by reverse-phase protein arrays.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID M297
AC CVCL_D764
DR Cosmic; 1665019
RX PubMed=22515704;
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID M299
AC CVCL_D765
DR Cosmic; 1459654
DR Cosmic; 1665020
RX PubMed=20689758;
RX PubMed=22515704;
RX PubMed=28196595;
WW http://tcpaportal.org/mclp/
CC Part of: MD Anderson Cell Lines Project.
CC Omics: Protein expression by reverse-phase protein arrays.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID M2A7
AC CVCL_3486
SY A7
DR CLO; CLO_0001608
DR EFO; EFO_0002107
DR CLDB; cl212
DR ATCC; CRL-2500
DR BioSample; SAMN03471597
DR IGRhCellID; A7
RX PubMed=1549777;
CC Transfected with: HGNC; 3754; FLNA.
ST Source(s): ATCC
ST Amelogenin: X
ST CSF1PO: 9
ST D13S317: 8
ST D16S539: 11
ST D5S818: 12
ST D7S820: 9,12
ST TH01: 7
ST TPOX: 7
ST vWA: 17
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_M543 ! RPM-MC
CA Cancer cell line
//
ID M2B
AC CVCL_DD25
RX PubMed=25647616;
CC Characteristics: Cell line persistantly infected with proteinase K resistant BSE (PrP(BSE)).
CC Transfected with: UniProtKB; P10279; Bovine PRNP.
OX NCBI_TaxID=9913; ! Bos taurus
HI CVCL_0421 ! MDBK
SX Male
CA Spontaneously immortalized cell line
//
ID M2Ge
AC CVCL_W291
SY M2 (Ge); M2
RX DOI=10.1007/BF01753729;
RX PubMed=3882112;
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID M3
AC CVCL_4Y25
DR BCRJ; 0154
CC Breed/subspecies: BALB/c.
DI NCIt; C21678; Malignant neoplasms of the mouse mammary gland
OX NCBI_TaxID=10090; ! Mus musculus
SX Female
CA Cancer cell line
//
ID M3/38.1.2.8 HL.2
AC CVCL_7683
SY M3/38.1.2.8.HL.2
DR CLO; CLO_0007475
DR ATCC; TIB-166
DR BCRJ; 0155
DR CCRID; 3131C0001000600031
OX NCBI_TaxID=10090; ! Mus musculus
OX NCBI_TaxID=10116; ! Rattus norvegicus
HI CVCL_2155 ! P3/NS1/1-Ag4.1
CA Hybridoma
//
ID M3/84.6.34
AC CVCL_9214
DR CLO; CLO_0007476
DR ATCC; TIB-168
DR BCRJ; 0156
OX NCBI_TaxID=10090; ! Mus musculus
OX NCBI_TaxID=10116; ! Rattus norvegicus
HI CVCL_2155 ! P3/NS1/1-Ag4.1
CA Hybridoma
//
ID M308
AC CVCL_D766
DR Cosmic; 1425347
DR Cosmic; 1459666
DR Cosmic; 1665021
RX PubMed=20406486;
RX PubMed=20689758;
RX PubMed=22515704;
RX PubMed=28196595;
WW http://tcpaportal.org/mclp/
CC Part of: MD Anderson Cell Lines Project.
CC Omics: Protein expression by reverse-phase protein arrays.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID M311
AC CVCL_M771
DR NIH-ARP; 1295-123
RX PubMed=3422113;
DI NCIt; C9142; Adult T acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0013 ! MOLT-4
SX Male
CA Cancer cell line
//
ID M318
AC CVCL_D767
DR Cosmic; 1459660
DR Cosmic; 1665008
RX PubMed=20689758;
RX PubMed=22515704;
RX PubMed=28196595;
WW http://tcpaportal.org/mclp/
CC Part of: MD Anderson Cell Lines Project.
CC Omics: Protein expression by reverse-phase protein arrays.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID M321
AC CVCL_D768
DR Cosmic; 1425349
DR Cosmic; 1459653
RX PubMed=20406486;
RX PubMed=20689758;
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID M328
AC CVCL_IW41
RX PubMed=28196595;
WW http://tcpaportal.org/mclp/
CC Part of: MD Anderson Cell Lines Project.
CC Omics: Protein expression by reverse-phase protein arrays.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID M32K
AC CVCL_U343
DR Cosmic; 733832
RX PubMed=1568228;
DI NCIt; C3234; Mesothelioma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID M33K
AC CVCL_8107
DR Cosmic; 733833
DR Cosmic; 933011
DR Cosmic; 934559
RX CelloPub=CLPUB00243;
RX PubMed=1568228;
RX PubMed=2323006;
RX PubMed=11283936;
DI NCIt; C3234; Mesothelioma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID M34
AC CVCL_S680
DR Cosmic; 1244761
DR GEO; GSM202112
DR IGRhCellID; M34%20GEO
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID M35/01
AC CVCL_M577
RX PubMed=16368560;
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID M368
AC CVCL_D769
DR Cosmic; 1665180
RX PubMed=22515704;
RX PubMed=28196595;
WW http://tcpaportal.org/mclp/
CC Part of: MD Anderson Cell Lines Project.
CC Omics: Protein expression by reverse-phase protein arrays.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID M375
AC CVCL_D770
DR Cosmic; 1665181
RX PubMed=22515704;
RX PubMed=28196595;
WW http://tcpaportal.org/mclp/
CC Part of: MD Anderson Cell Lines Project.
CC Omics: Protein expression by reverse-phase protein arrays.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID M38K
AC CVCL_8108
RX CelloPub=CLPUB00243;
RX PubMed=2323006;
RX PubMed=9533946;
RX PubMed=11283936;
DI NCIt; C3234; Mesothelioma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID M3Da
AC CVCL_8336
SY M3 (Da); M3
RX DOI=10.1007/BF01753729;
RX PubMed=3882112;
RX PubMed=8125107;
DI NCIt; C3802; Amelanotic melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID M3E3/C3
AC CVCL_2108
DR CLO; CLO_0007477
DR DSMZ; ACC-340
RX PubMed=6890064;
CC Doubling time: ~40 hours (DSMZ).
OX NCBI_TaxID=10036; ! Mesocricetus auratus
CA Spontaneously immortalized cell line
//
ID M3F-1
AC CVCL_0H19
DR SKIP; SKIP000611
RX PubMed=19269371;
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0G94 ! GM01786
SX Female
CA Induced pluripotent stem cell
//
ID M3F-2
AC CVCL_0H20
DR SKIP; SKIP000612
RX PubMed=19269371;
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0G94 ! GM01786
SX Female
CA Induced pluripotent stem cell
//
ID M3WT4
AC CVCL_4579
DR CLO; CLO_0007478
DR ATCC; CRL-1981
OX NCBI_TaxID=10029; ! Cricetulus griseus
HI CVCL_0214 ! CHO-K1
SX Female
CA Spontaneously immortalized cell line
//
ID M3WT5
AC CVCL_4580
DR CLO; CLO_0007479
DR ATCC; CRL-1982
OX NCBI_TaxID=10029; ! Cricetulus griseus
HI CVCL_0214 ! CHO-K1
SX Female
CA Spontaneously immortalized cell line
//
ID M3WT8
AC CVCL_4581
DR CLO; CLO_0007480
DR ATCC; CRL-1983
OX NCBI_TaxID=10029; ! Cricetulus griseus
HI CVCL_0214 ! CHO-K1
SX Female
CA Spontaneously immortalized cell line
//
ID M4
AC CVCL_U812
SY M-4
DR CLO; CLO_0050289
DR RCB; RCB1611
RX PubMed=6183338;
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID M40
AC CVCL_V744
SY MEL40
DR Cosmic; 1244758
DR GEO; GSM202135
DR IGRhCellID; MEL40%20GEO
RX PubMed=19047099;
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID M4A4
AC CVCL_B057
SY M-4A4
DR ATCC; CRL-2914
DR BioSample; SAMN03151831
DR BioSample; SAMN03471696
RX PubMed=14506175;
WW http://www.atcc.org/Products/Cells_and_Microorganisms/Cell_Lines/Misidentified_Cell_Lines.aspx
WW http://iclac.org/wp-content/uploads/Cross-Contaminations-v8_0.pdf
CC Problematic cell line: Contaminated. Parent cell line (MDA-MB-435) has been shown to be a M14 derivative.
CC Derived from metastatic site: Subcutaneous; right buttock.
ST Source(s): ATCC
ST Amelogenin: X
ST CSF1PO: 11
ST D13S317: 12
ST D16S539: 13
ST D5S818: 11,12
ST D7S820: 8,10
ST TH01: 6,7
ST TPOX: 8,11
ST vWA: 16,18
DI NCIt; C3802; Amelanotic melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0417 ! MDA-MB-435
SX Male
CA Cancer cell line
//
ID M4A4 GFP
AC CVCL_B058
SY M4A4-GFP; M-4A4-GFP
DR ATCC; CRL-2915
RX PubMed=14506175;
WW http://www.atcc.org/Products/Cells_and_Microorganisms/Cell_Lines/Misidentified_Cell_Lines.aspx
CC Problematic cell line: Contaminated. Grand-parent cell line (MDA-MB-435) has been shown to be a M14 derivative.
CC Transfected with: UniProtKB; P42212; GFP.
CC Derived from metastatic site: Subcutaneous; right buttock.
ST Source(s): ATCC
ST Amelogenin: X
ST CSF1PO: 11
ST D13S317: 12
ST D16S539: 13
ST D5S818: 11,12
ST D7S820: 8,10
ST TH01: 6,7
ST TPOX: 8,11
ST vWA: 16,18
DI NCIt; C3802; Amelanotic melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_B057 ! M4A4
SX Male
CA Cancer cell line
//
ID M4A4 LM3-2 GFP
AC CVCL_B059
DR ATCC; CRL-2916
WW http://www.atcc.org/Products/Cells_and_Microorganisms/Cell_Lines/Misidentified_Cell_Lines.aspx
CC Problematic cell line: Contaminated. Ancestral cell line (MDA-MB-435) has been shown to be a M14 derivative.
CC Transfected with: UniProtKB; P42212; GFP.
CC Derived from metastatic site: Subcutaneous; right buttock.
ST Source(s): ATCC
ST Amelogenin: X
ST CSF1PO: 11
ST D13S317: 12
ST D16S539: 13
ST D5S818: 11,12
ST D7S820: 8,10
ST TH01: 6,7
ST TPOX: 8,11
ST vWA: 16,18
DI NCIt; C3802; Amelanotic melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_B058 ! M4A4 GFP
SX Male
CA Cancer cell line
//
ID M4A4 LM3-4 CL16 GFP
AC CVCL_B060
DR ATCC; CRL-2917
WW http://www.atcc.org/Products/Cells_and_Microorganisms/Cell_Lines/Misidentified_Cell_Lines.aspx
CC Problematic cell line: Contaminated. Ancestral cell line (MDA-MB-435) has been shown to be a M14 derivative.
CC Transfected with: UniProtKB; P42212; GFP.
CC Derived from metastatic site: Subcutaneous; right buttock.
ST Source(s): ATCC
ST Amelogenin: X
ST CSF1PO: 11
ST D13S317: 12
ST D16S539: 13
ST D5S818: 11,12
ST D7S820: 8,10
ST TH01: 6,7
ST TPOX: 8,11
ST vWA: 16,18
DI NCIt; C3802; Amelanotic melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_B058 ! M4A4 GFP
SX Male
CA Cancer cell line
//
ID M4b
AC CVCL_9W66
RX PubMed=11933048;
CC Transformant: Unknown product of UCHT1 (CVCL_9W35) conditioned media.
CC Breed/subspecies: C57BL/6 x Rb(16.17)32Lub/Rb(11.16)2H.
OX NCBI_TaxID=10090; ! Mus musculus
CA Transformed cell line
//
ID M4Beu
AC CVCL_8337
SY M4 (Beu); M4Be; M4
DR ChEMBL-Cells; CHEMBL3307798
DR ChEMBL-Targets; CHEMBL612270
RX DOI=10.1007/BF01753729;
RX PubMed=1937961;
RX PubMed=3882112;
RX PubMed=8125107;
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID M4T.4
AC CVCL_DR62
SY M4T4
RX PubMed=12948546;
RX PubMed=21961028;
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40).
CC Breed/subspecies: SJL/J.
OX NCBI_TaxID=10090; ! Mus musculus
OI CVCL_DR63 ! M4T.6
SX Male
CA Transformed cell line
//
ID M4T.6
AC CVCL_DR63
RX PubMed=12948546;
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40).
CC Breed/subspecies: SJL/J.
OX NCBI_TaxID=10090; ! Mus musculus
OI CVCL_DR62 ! M4T.4
SX Male
CA Transformed cell line
//
ID M5/114.15.2
AC CVCL_9215
DR CLO; CLO_0007482
DR ATCC; TIB-120
OX NCBI_TaxID=10090; ! Mus musculus
OX NCBI_TaxID=10116; ! Rattus norvegicus
HI CVCL_2155 ! P3/NS1/1-Ag4.1
CA Hybridoma
//
ID M5/49.4.1
AC CVCL_9216
DR CLO; CLO_0007483
DR ATCC; TIB-238
DR BCRC; 60190
CC Monoclonal antibody target: UniProtKB; P01831; Mouse Thy1/Cd90.
OX NCBI_TaxID=10090; ! Mus musculus
OX NCBI_TaxID=10116; ! Rattus norvegicus
HI CVCL_2155 ! P3/NS1/1-Ag4.1
CA Hybridoma
//
ID M5/CDDP
AC CVCL_5T74
RX PubMed=8943689;
CC Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
CC Breed/subspecies: C57BL/6.
DI NCIt; C30056; Mouse ovarian histiocytic sarcoma
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_3997 ! M5076
CA Cancer cell line
//
ID M5/CDDPc
AC CVCL_5T75
RX PubMed=8943689;
CC Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
CC Breed/subspecies: C57BL/6.
DI NCIt; C30056; Mouse ovarian histiocytic sarcoma
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_3997 ! M5076
CA Cancer cell line
//
ID M5076
AC CVCL_3997
SY M5
DR BTO; BTO:0001915
DR CLO; CLO_0007484
DR CLDB; cl3317
DR CCRID; 3111C0001CCC000287
DR ChEMBL-Cells; CHEMBL3307538
DR ChEMBL-Targets; CHEMBL614120
DR KCLB; 80019
RX PubMed=7011532;
RX PubMed=8943689;
CC Discontinued: KCLB; 80019; probable.
CC Breed/subspecies: C57BL/6.
DI NCIt; C30056; Mouse ovarian histiocytic sarcoma
OX NCBI_TaxID=10090; ! Mus musculus
SX Female
CA Cancer cell line
//
ID m5S
AC CVCL_6417
DR JCRB; JCRB1322
RX PubMed=3571334;
CC Breed/subspecies: ICR/Jcl.
OX NCBI_TaxID=10090; ! Mus musculus
SX Male
CA Spontaneously immortalized cell line
//
ID M6/B7
AC CVCL_D034
SY EST45
DR Cosmic; 1047646
DR Cosmic; 2163790
DR ESTDAB; ESTDAB-045
DR GEO; GSM156007
RX PubMed=17260012;
CC Transfected with: HGNC; 1700; CD80.
CC Omics: Array-based CGH.
CC Derived from metastatic site: Lung.
ST Source(s): ESTDAB
ST Amelogenin: X
ST CSF1PO: 12
ST D13S317: 11,12
ST D3S1358: 17,18
ST D5S818: 11,13
ST D7S820: 9,10
ST FGA: 23,23.2
ST TH01: 6,9
ST TPOX: 8
ST vWA: 15,17
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_T324 ! CaCL 73-36
SX Female
CA Cancer cell line
//
ID M619
AC CVCL_8472
DR CCRID; 3111C0001CCC000224
RX PubMed=18689700;
ST Source(s): PubMed=18689700;
ST Amelogenin: X
ST CSF1PO: 10,11
ST D13S317: 11
ST D16S539: 8,12
ST D18S51: 15
ST D21S11: 30
ST D3S1358: 16
ST D5S818: 11,12
ST D7S820: 12
ST D8S1179: 13
ST FGA: 20,21
ST TH01: 8,9.3
ST TPOX: 11
ST vWA: 16,17
DI NCIt; C7712; Uveal melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_8471 ! C918
OI CVCL_3447 ! MuM-2B
SX Female
CA Cancer cell line
//
ID M7 [Human B-cell 12IHW]
AC CVCL_E767
DR dbMHC; 48963
DR ECACC; 94022543
DR IHW; IHW9215
DR IMGT/HLA; 11030
WW http://bioinformatics.hsanmartino.it/ecbr/cl215.html
CC Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Transformed cell line
//
ID M7 [Human melanoma]
AC CVCL_DI52
SY M-7; UCLA-SO-M7
RX PubMed=6876798;
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID M73.24
AC CVCL_S555
DR ATCC; HB-12153
RX Patent=US5955311;
RX Patent=US6365157;
RX Patent=US6448077;
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_2155 ! P3/NS1/1-Ag4.1
CA Hybridoma
//
ID M7609
AC CVCL_IW14
SY M-7609
RX PubMed=6998824;
RX PubMed=8758929;
DI NCIt; C4910; Colon carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID M7609/ADR
AC CVCL_IW15
RX PubMed=8758929;
CC Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Adriamycin).
DI NCIt; C4910; Colon carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_IW14 ! M7609
CA Cancer cell line
//
ID M7TS90
AC CVCL_0404
DR MCCL; MCC:0000298
RX PubMed=11980662;
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID M8166
AC CVCL_1H07
DR NIH-ARP; 11395-280
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_1099 ! C8166
CA Transformed cell line
//
ID M88
AC CVCL_D035
SY EST135
DR Cosmic; 1047645
DR Cosmic; 2163833
DR ESTDAB; ESTDAB-135
DR GEO; GSM156018
RX PubMed=17260012;
CC Omics: Array-based CGH.
ST Source(s): ESTDAB
ST Amelogenin: X,Y
ST CSF1PO: 9,11
ST D13S317: 11
ST D3S1358: 18
ST D5S818: 11
ST D7S820: 12
ST FGA: 25
ST TH01: 6
ST TPOX: 10
ST vWA: 16
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID M91-054
AC CVCL_1G26
SY M91 054
DR Cosmic; 1211154
RX PubMed=10952317;
RX PubMed=23039341;
CC Derived from metastatic site: Axillary lymph node.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID M92-001
AC CVCL_1G27
SY M92 001
DR Cosmic; 1211152
RX PubMed=10952317;
RX PubMed=23039341;
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID M93-047
AC CVCL_G298
DR BTO; BTO:0005062
RX PubMed=10952317;
CC Derived from metastatic site: Axillary lymph node.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID M950322
AC CVCL_DI46
DR GEO; GSM482469
CC From: URPP biobank; University of Zurich; Switzerland.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID M950504
AC CVCL_DI47
DR GEO; GSM482470
CC From: URPP biobank; University of Zurich; Switzerland.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID M961121
AC CVCL_DI48
DR GEO; GSM482477
CC From: URPP biobank; University of Zurich; Switzerland.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID M970109
AC CVCL_DI43
DR GEO; GSM482478
CC From: URPP biobank; University of Zurich; Switzerland.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID M970131
AC CVCL_DI44
DR GEO; GSM482480
CC From: URPP biobank; University of Zurich; Switzerland.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID M970805
AC CVCL_DI45
DR GEO; GSM482481
CC From: URPP biobank; University of Zurich; Switzerland.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID M971219
AC CVCL_AT57
RX PubMed=24581590;
CC From: URPP biobank; University of Zurich; Switzerland.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID M980513
AC CVCL_S675
RX PubMed=16827748;
RX PubMed=18245463;
RX PubMed=22336146;
CC From: URPP biobank; University of Zurich; Switzerland.
CC Omics: Transcriptome analysis.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID M990115
AC CVCL_S676
RX PubMed=16827748;
RX PubMed=24581590;
CC From: URPP biobank; University of Zurich; Switzerland.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID M990203
AC CVCL_AT58
RX PubMed=24581590;
CC From: URPP biobank; University of Zurich; Switzerland.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID M990514
AC CVCL_S677
RX PubMed=16827748;
CC From: URPP biobank; University of Zurich; Switzerland.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID M990802
AC CVCL_S678
DR GEO; GSM433917
DR IGRhCellID; M990802
CC From: URPP biobank; University of Zurich; Switzerland.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID M991121
AC CVCL_S679
RX PubMed=16827748;
RX PubMed=18245463;
CC From: URPP biobank; University of Zurich; Switzerland.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID M9A
AC CVCL_B417
DR BTO; BTO:0005074
RX PubMed=19116209;
CC Breed/subspecies: BALB/c.
DI NCIt; C21604; Mouse leukemia
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_0493 ! RAW 264.7
SX Male
CA Cancer cell line
//
ID M9K
AC CVCL_8109
SY M-9-K
DR BTO; BTO:0004001
DR Cosmic; 733820
DR Cosmic; 933010
DR Cosmic; 934555
RX PubMed=1568228;
RX PubMed=2323006;
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C3234; Mesothelioma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID MA 2
AC CVCL_7057
RX PubMed=9131270;
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4872; Breast carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID MA 3
AC CVCL_7058
RX PubMed=9131270;
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4872; Breast carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID Ma Not
AC CVCL_U784
DR ATCC; CRL-1263
CC Discontinued: ATCC; CRL-1263; true.
DI NCIt; C34807; Marfan syndrome
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Finite cell line
//
ID Ma San
AC CVCL_3739
DR CLO; CLO_0007493
DR ATCC; CRL-1148
DI NCIt; C125701; Ehlers-Danlos syndrome, type VII
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Finite cell line
//
ID Ma Tru
AC CVCL_U785
DR ATCC; CRL-1309
CC Discontinued: ATCC; CRL-1309; true.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Finite cell line
//
ID MA-1
AC CVCL_M665
SY Ma-1
DR BioSample; SAMN03151897
RX PubMed=21837708;
RX PubMed=23508748;
RX PubMed=23508779;
RX PubMed=23907998;
RX PubMed=24285409;
WW http://iclac.org/wp-content/uploads/Cross-Contaminations-v8_0.pdf
CC Problematic cell line: Contaminated. Shown to be a Pfeiffer derivative (PubMed=23907998) and not a mucosa-associated lymphoid tissue (MALT) lymphoma cell line. This finding is disputed by the original authors (see PubMed=24285409).
DI NCIt; C8851; Diffuse large B-cell lymphoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_3326 ! Pfeiffer
SX Male
CA Cancer cell line
//
ID Ma-1
AC CVCL_7059
SY Ma1
DR BTO; BTO:0004160
DR Cosmic; 801593
DR Cosmic; 844836
DR Cosmic; 876145
DR Cosmic; 917983
DR Cosmic; 1047095
DR Cosmic; 1128252
DR Cosmic; 1239874
DR Cosmic; 1656895
DR Cosmic; 2125271
RX PubMed=1650680;
RX PubMed=9393586;
RX PubMed=11005564;
RX PubMed=19472407;
RX PubMed=22313637;
CC Doubling time: 25.9 hours (PubMed=1650680).
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C3512; Lung adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Ma-10
AC CVCL_7061
SY Ma10
DR Cosmic; 801596
DR Cosmic; 844838
DR Cosmic; 876146
DR Cosmic; 917994
DR Cosmic; 1239875
DR Cosmic; 1656897
DR Cosmic; 2125272
RX PubMed=1650680;
RX PubMed=9393586;
RX PubMed=11005564;
RX PubMed=15802814;
RX PubMed=19472407;
RX PubMed=22313637;
CC Doubling time: 75.0 hours (PubMed=1650680).
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C3512; Lung adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID MA-10
AC CVCL_D789
SY MA10
DR BTO; BTO:0003050
DR ATCC; CRL-3050
RX PubMed=6257492;
RX PubMed=15541572;
OX NCBI_TaxID=10090; ! Mus musculus
OI CVCL_U444 ! MA-12
OI CVCL_3544 ! MLTC-1
SX Male
CA Cancer cell line
//
ID MA-101
AC CVCL_0A70
SY MA 101; MA101; Microbiological Associates-101
RX PubMed=4626908;
RX PubMed=6500159;
CC Group: Non-human primate cell line.
OX NCBI_TaxID=9544; ! Macaca mulatta
CA Finite cell line
//
ID MA-104
AC CVCL_3845
SY Ma-104; MA 104; MA104; Microbiological Associates-104
DR BTO; BTO:0004983
DR CLO; CLO_0007492
DR CLO; CLO_0007494
DR CLO; CLO_0051423
DR CLDB; cl3324
DR CLDB; cl3325
DR CLDB; cl3326
DR CLDB; cl3327
DR ATCC; CRL-2378
DR BCRJ; 0157
DR BioSample; SAMN03152038
DR CCLV; CCLV-RIE 0142
DR CCRID; 3142C0001000000041
DR ECACC; 85102918
DR GEO; GSM758845
DR GEO; GSM758846
DR GEO; GSM758847
DR GEO; GSM758848
DR GEO; GSM758849
DR GEO; GSM758850
DR GEO; GSM758851
DR GEO; GSM758852
DR GEO; GSM758853
DR GEO; GSM758854
DR GEO; GSM758855
DR GEO; GSM758856
DR GEO; GSM758857
DR GEO; GSM758858
DR GEO; GSM758859
DR IZSLER; BS CL 61
DR KCB; KCB 201001YJ
DR Lonza; 631
DR NCBI_Iran; C486
DR RCB; RCB0994
RX PubMed=4043530;
RX PubMed=4626908;
RX PubMed=19941903;
RX PubMed=20143388;
RX PubMed=26235236;
WW http://www.atcc.org/support/faqs/d0d17/MA104%20ATCC%20CRL2378-1067.aspx
WW http://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/m/cell-lines-detail-391.html
WW http://iclac.org/wp-content/uploads/Cross-Contaminations-v8_0.pdf
WW http://en.vircell.com/products/ma104-cell-line/
CC Group: Non-human primate cell line.
CC Problematic cell line: Misidentified. Originally thought to be of Rhesus macaque origin but found to be from African Green monkey (PubMed=4043530, PubMed=20143388).
CC Discontinued: ATCC; CRL-2378; true.
OX NCBI_TaxID=9534; ! Chlorocebus aethiops
SX Sex undetermined
CA Spontaneously immortalized cell line
//
ID MA-104 Clone 1
AC CVCL_3846
DR CLO; CLO_0007495
DR ATCC; CRL-2378.1
WW http://www.atcc.org/support/faqs/d0d17/MA104%20ATCC%20CRL2378-1067.aspx
CC Group: Non-human primate cell line.
CC Problematic cell line: Misidentified. Parent cell line (MA-104) has been shown to be from African Green monkey instead of Rhesus macaque.
OX NCBI_TaxID=9534; ! Chlorocebus aethiops
HI CVCL_3845 ! MA-104
SX Sex undetermined
CA Spontaneously immortalized cell line
//
ID Ma-11
AC CVCL_D064
SY Ma11
RX PubMed=1650680;
CC Doubling time: 41.3 hours (PubMed=1650680).
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C3512; Lung adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID MA-111
AC CVCL_U963
SY MA 111; MA111; Microbiological Associates-111
DR BioSample; SAMN03152039
RX PubMed=20143388;
WW http://iclac.org/wp-content/uploads/Cross-Contaminations-v8_0.pdf
CC Group: Non-human primate cell line.
CC Problematic cell line: Misidentified. Originally thought to be of rabbit origin but found to be from African Green monkey (PubMed=20143388). Originally thought to originate from kidney. Could be a VERO derivative.
OX NCBI_TaxID=9534; ! Chlorocebus aethiops
SX Sex undetermined
CA Undefined cell line type
//
ID Ma-12
AC CVCL_7062
SY MA12; Ma12
DR Cosmic; 801597
DR Cosmic; 876147
DR Cosmic; 917997
DR Cosmic; 1239876
DR Cosmic; 2125273
RX PubMed=1650680;
RX PubMed=9393586;
RX PubMed=11005564;
RX PubMed=19472407;
CC Doubling time: 23.0 hours (PubMed=1650680).
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C3512; Lung adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID MA-12
AC CVCL_U444
RX PubMed=6257492;
RX PubMed=15541572;
OX NCBI_TaxID=10090; ! Mus musculus
OI CVCL_D789 ! MA-10
OI CVCL_3544 ! MLTC-1
SX Male
CA Cancer cell line
//
ID Ma-13
AC CVCL_D065
SY Ma13
RX PubMed=1650680;
CC Doubling time: 71.9 hours (PubMed=1650680).
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4450; Large cell lung carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Ma-14
AC CVCL_D066
SY Ma14
RX PubMed=1650680;
CC Doubling time: 21.0 hours (PubMed=1650680).
DI NCIt; C3512; Lung adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Ma-15
AC CVCL_D067
SY Ma15
RX PubMed=1650680;
CC Doubling time: 29.5 hours (PubMed=1650680).
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C3512; Lung adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Ma-16
AC CVCL_D068
SY Ma16
RX PubMed=1650680;
CC Doubling time: 33.2 hours (PubMed=1650680).
DI NCIt; C3512; Lung adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID MA-160
AC CVCL_8261
SY MA 160; MA160; Microbiological Associates-160
DR BioSample; SAMN03151741
RX CelloPub=CLPUB00262;
RX DOI=10.1007/978-1-4757-1647-4_13;
RX PubMed=66218;
RX PubMed=87387;
RX PubMed=93571;
RX PubMed=535908;
RX PubMed=1246601;
RX PubMed=4319198;
RX PubMed=4469665;
RX PubMed=6451928;
RX PubMed=20143388;
WW http://iclac.org/wp-content/uploads/Cross-Contaminations-v8_0.pdf
CC Problematic cell line: Contaminated. Shown to be a HeLa derivative (PubMed=66218, PubMed=93571, PubMed=1246601, PubMed=4469665, PubMed=6451928, PubMed=20143388). Originally thought to originate from a benign prostatic hyperplasia biopsy from Monroe Vincent one of the authors of the original paper.
CC Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18).
DI NCIt; C4029; Cervical adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0030 ! HeLa
SX Female
CA Cancer cell line
//
ID Ma-17
AC CVCL_7063
SY Ma17
DR Cosmic; 801598
DR Cosmic; 844839
DR Cosmic; 876148
DR Cosmic; 917977
DR Cosmic; 1239877
DR Cosmic; 2125274
RX PubMed=1650680;
RX PubMed=9393586;
RX PubMed=11005564;
RX PubMed=19472407;
CC Doubling time: 63.4 hours (PubMed=1650680).
CC Derived from metastatic site: Ascites.
DI NCIt; C3512; Lung adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Ma-18
AC CVCL_D069
SY Ma18
RX PubMed=1650680;
CC Doubling time: 37.0 hours (PubMed=1650680).
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C3234; Mesothelioma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Ma-19
AC CVCL_D070
SY Ma19
RX PubMed=1650680;
CC Doubling time: 36.0 hours (PubMed=1650680).
DI NCIt; C3493; Squamous cell lung carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Ma-2
AC CVCL_7060
SY Ma2
DR Cosmic; 801594
DR Cosmic; 844837
DR Cosmic; 876177
DR Cosmic; 917990
DR Cosmic; 1239920
DR Cosmic; 2125275
RX PubMed=1650680;
RX PubMed=9393586;
RX PubMed=11005564;
RX PubMed=19472407;
CC Doubling time: 22.8 hours (PubMed=1650680).
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4450; Large cell lung carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Ma-20
AC CVCL_D071
SY Ma20
RX PubMed=1650680;
CC Doubling time: 42.2 hours (PubMed=1650680).
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C3512; Lung adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Ma-24
AC CVCL_7064
SY Ma24
DR Cosmic; 801599
DR Cosmic; 876149
DR Cosmic; 917978
DR Cosmic; 1239878
DR Cosmic; 2125276
RX PubMed=9393586;
RX PubMed=11005564;
RX PubMed=19472407;
DI NCIt; C3512; Lung adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Ma-25
AC CVCL_7065
SY Ma25
DR BTO; BTO:0004155
DR Cosmic; 801600
DR Cosmic; 844840
DR Cosmic; 876178
DR Cosmic; 917981
DR Cosmic; 1047101
DR Cosmic; 1239921
DR Cosmic; 2125277
RX PubMed=9393586;
RX PubMed=11005564;
RX PubMed=17332333;
RX PubMed=19472407;
DI NCIt; C4450; Large cell lung carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Ma-26
AC CVCL_7066
SY Ma26
DR Cosmic; 801601
DR Cosmic; 844841
DR Cosmic; 876150
DR Cosmic; 917998
DR Cosmic; 1239879
DR Cosmic; 2125278
RX PubMed=9393586;
RX PubMed=11005564;
RX PubMed=19472407;
DI NCIt; C3512; Lung adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Ma-29
AC CVCL_7067
SY Ma29
DR Cosmic; 801602
DR Cosmic; 844842
DR Cosmic; 876151
DR Cosmic; 917982
DR Cosmic; 1219059
DR Cosmic; 1239880
DR Cosmic; 1656898
DR Cosmic; 2125189
RX PubMed=9393586;
RX PubMed=11005564;
RX PubMed=19472407;
RX PubMed=22313637;
DI NCIt; C3512; Lung adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Ma-3
AC CVCL_7068
SY Ma3
DR Cosmic; 801595
DR Cosmic; 844814
DR Cosmic; 917986
RX PubMed=1650680;
RX PubMed=9393586;
CC Doubling time: 31.6 hours (PubMed=1650680).
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C3512; Lung adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID Ma-31
AC CVCL_7069
DR BTO; BTO:0004156
DR Cosmic; 1047107
RX PubMed=9393586;
RX PubMed=15802814;
RX PubMed=17332333;
DI NCIt; C3512; Lung adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID MA-31750
AC CVCL_F565
SY 31750; TER283; TER355
DR IMGT/HLA; 11939
CC Part of: International Histocompatibility Workshop cell lines.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Transformed cell line
//
ID Ma-34
AC CVCL_7070
DR BTO; BTO:0004157
DR Cosmic; 1047105
RX PubMed=17332333;
DI NCIt; C3512; Lung adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID Ma-4
AC CVCL_D058
SY Ma4
RX PubMed=1650680;
CC Doubling time: 49.1 hours (PubMed=1650680).
DI NCIt; C3512; Lung adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Ma-43
AC CVCL_IQ46
RX PubMed=9393586;
DI NCIt; C2926; Non-small cell lung carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID Ma-44
AC CVCL_7071
SY Ma44
RX PubMed=10769649;
DI NCIt; C3493; Squamous cell lung carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID Ma-45
AC CVCL_7072
DR BTO; BTO:0004158
DR Cosmic; 1047103
RX PubMed=9393586;
RX PubMed=17332333;
DI NCIt; C3512; Lung adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID Ma-46
AC CVCL_7073
RX PubMed=9393586;
RX PubMed=15802814;
DI NCIt; C3493; Squamous cell lung carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Ma-5
AC CVCL_D059
SY Ma5
RX PubMed=1650680;
CC Doubling time: 61.0 hours (PubMed=1650680).
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C3512; Lung adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Ma-53
AC CVCL_7074
DR BTO; BTO:0004159
DR Cosmic; 1047104
RX PubMed=17332333;
DI NCIt; C3512; Lung adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID Ma-6
AC CVCL_D060
SY Ma6
RX PubMed=1650680;
DI NCIt; C3512; Lung adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Ma-7
AC CVCL_D061
SY Ma7
RX PubMed=1650680;
CC Doubling time: 28.7 hours (PubMed=1650680).
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C3512; Lung adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Ma-8
AC CVCL_D062
SY Ma8
RX PubMed=1650680;
CC Doubling time: 50.0 hours (PubMed=1650680).
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C3512; Lung adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID MA-89
AC CVCL_J293
DR IFO; IFO50293
CC Doubling time: 24-36 hours (IFO).
CC Breed/subspecies: C3H/He.
OX NCBI_TaxID=10090; ! Mus musculus
CA Finite cell line
//
ID Ma-9
AC CVCL_D063
SY Ma9
RX PubMed=1650680;
CC Doubling time: 65.5 hours (PubMed=1650680).
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C3512; Lung adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID MA-Balb
AC CVCL_5795
SY Ma-Balb
DR CLS; 400270/p560_MA-Balb
CC Breed/subspecies: BALB/c.
DI NCIt; C21678; Malignant neoplasms of the mouse mammary gland
OX NCBI_TaxID=10090; ! Mus musculus
SX Female
CA Cancer cell line
//
ID MA-CLS-2
AC CVCL_4571
SY MACLS-2
DR CLS; 300271/p778_MA-CLS-2
CC Derived from metastatic site: Pleural effusion.
ST Source(s): CLS
ST Amelogenin: X
ST CSF1PO: 11
ST D13S317: 11
ST D16S539: 11
ST D18S51: 15
ST D21S11: 29
ST D3S1358: 14,18
ST D5S818: 11
ST D7S820: 8,9
ST D8S1179: 13
ST FGA: 24
ST Penta D: 9,13
ST Penta E: 13
ST TH01: 7
ST TPOX: 8
ST vWA: 17,18
DI NCIt; C4017; Ductal breast carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID Ma-Mel-01
AC CVCL_A115
SY Ma-Mel-1
DR BTO; BTO:0005336
DR ESTDAB; ESTDAB-142
ST Source(s): ESTDAB
ST Amelogenin: X
ST CSF1PO: 10
ST D13S317: 10
ST D3S1358: 15,16
ST D5S818: 12,13
ST D7S820: 10,12
ST FGA: 23,26
ST TH01: 8
ST TPOX: 8,11
ST vWA: 17
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID Ma-Mel-02
AC CVCL_A116
SY Ma-Mel-2; MaMel02
DR Cosmic; 1181742
DR Cosmic; 1467735
DR ESTDAB; ESTDAB-148
DR GEO; GSM436986
RX PubMed=17311103;
CC Derived from metastatic site: Cutaneous/subcutaneous.
ST Source(s): ESTDAB
ST Amelogenin: X
ST CSF1PO: 10,11
ST D13S317: 8,12
ST D3S1358: 16,17
ST D5S818: 11,12
ST D7S820: 10,12
ST FGA: 22,23
ST TH01: 7,9.3
ST TPOX: 8,9
ST vWA: 15,16
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Ma-Mel-04
AC CVCL_A117
SY Ma-Mel-4; MaMel4
DR BTO; BTO:0005337
DR Cosmic; 1846562
DR ECACC; 13012519
DR ESTDAB; ESTDAB-209
RX PubMed=17311103;
CC Derived from metastatic site: Urinary bladder.
ST Source(s): ECACC; ESTDAB
ST Amelogenin: X,Y
ST CSF1PO: 12
ST D13S317: 8,11
ST D16S539: 12
ST D3S1358: 17
ST D5S818: 11,13
ST D7S820: 8,10
ST FGA: 20,24
ST TH01: 6,7
ST TPOX: 8,11
ST vWA: 16,17
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Ma-Mel-05
AC CVCL_A118
SY Ma-Mel-5; MaMel05; MaMel5
DR BTO; BTO:0005338
DR Cosmic; 1181768
DR Cosmic; 1467736
DR Cosmic; 1846563
DR Cosmic; 2163838
DR ECACC; 13012461
DR ESTDAB; ESTDAB-149
DR GEO; GSM436987
RX PubMed=17311103;
CC Derived from metastatic site: Cutaneous/subcutaneous.
ST Source(s): ECACC; ESTDAB
ST Amelogenin: X
ST CSF1PO: 11,12
ST D13S317: 11,13
ST D16S539: 8,13
ST D3S1358: 15,17
ST D5S818: 9,11
ST D7S820: 11
ST FGA: 20,21
ST TH01: 9.3
ST TPOX: 8
ST vWA: 15,17
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID Ma-Mel-06
AC CVCL_A119
SY Ma-Mel-6; MaMel06; MaMel6
DR Cosmic; 1467737
DR Cosmic; 1846564
DR Cosmic; 2163839
DR ECACC; 13012465
DR ESTDAB; ESTDAB-150
DR GEO; GSM436988
RX PubMed=17311103;
CC Derived from metastatic site: Lymph node.
ST Source(s): ECACC; ESTDAB
ST Amelogenin: X,Y
ST CSF1PO: 10,12
ST D13S317: 11,13
ST D16S539: 12,13
ST D3S1358: 14,15
ST D5S818: 12,13
ST D7S820: 10
ST FGA: 22,26
ST TH01: 9.3
ST TPOX: 8,9
ST vWA: 16,18
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Ma-Mel-07
AC CVCL_A120
SY Ma-Mel-7; MaMel7
DR Cosmic; 1846565
DR Cosmic; 2163835
DR ECACC; 13012459
DR ESTDAB; ESTDAB-137
RX PubMed=17311103;
CC Derived from metastatic site: Lymph node.
ST Source(s): ECACC; ESTDAB
ST Amelogenin: X
ST CSF1PO: 11,12
ST D13S317: 10
ST D16S539: 9,12
ST D3S1358: 17,18
ST D5S818: 12,13
ST D7S820: 11,12
ST FGA: 24,25
ST TH01: 6,10
ST TPOX: 8
ST vWA: 16,18
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Ma-Mel-08a
AC CVCL_A121
SY Ma-Mel-8a; MaMel08a
DR Cosmic; 1467738
DR Cosmic; 1846566
DR Cosmic; 2163818
DR ECACC; 13012434
DR ESTDAB; ESTDAB-105
DR GEO; GSM436989
RX PubMed=17311103;
CC Derived from metastatic site: Cutaneous/subcutaneous.
ST Source(s): ECACC; ESTDAB
ST Amelogenin: X,Y
ST CSF1PO: 11,12
ST D13S317: 12
ST D16S539: 9,13
ST D3S1358: 14,15
ST D5S818: 12,13
ST D7S820: 10
ST FGA: 21
ST TH01: 9.3
ST TPOX: 8
ST vWA: 18
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_A122 ! Ma-Mel-08b
SX Male
CA Cancer cell line
//
ID Ma-Mel-08b
AC CVCL_A122
SY Ma-Mel-8b
DR Cosmic; 1846567
DR ESTDAB; ESTDAB-190
ST Source(s): ESTDAB
ST Amelogenin: X
ST CSF1PO: 11,12
ST D13S317: 12
ST D3S1358: 15
ST D5S818: 12,13
ST D7S820: 10
ST FGA: 21
ST TH01: 9.3
ST TPOX: 8
ST vWA: 18
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_A121 ! Ma-Mel-08a
SX Male
CA Cancer cell line
//
ID Ma-Mel-10
AC CVCL_A123
SY MaMel10
DR Cosmic; 1467739
DR ESTDAB; ESTDAB-151
DR GEO; GSM436990
ST Source(s): ESTDAB
ST Amelogenin: X
ST CSF1PO: 11
ST D13S317: 8,11
ST D3S1358: 16,17
ST D5S818: 11
ST D7S820: 8,12
ST FGA: 23,26
ST TH01: 8,9.3
ST TPOX: 8,11
ST vWA: 13,19
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID Ma-Mel-100a
AC CVCL_A124
SY Ma-Mel-100
DR Cosmic; 1846569
RX PubMed=17311103;
CC Derived from metastatic site: Lymph node.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Ma-Mel-101
AC CVCL_A125
SY MaMel101
DR Cosmic; 1467782
DR Cosmic; 1846570
DR GEO; GSM437032
DR IGRhCellID; MaMel101
RX PubMed=17311103;
CC Derived from metastatic site: Cutaneous/subcutaneous.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID Ma-Mel-102a
AC CVCL_A126
SY Ma-Mel-102
DR Cosmic; 1846571
RX PubMed=17311103;
CC Derived from metastatic site: Lymph node.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Ma-Mel-103a
AC CVCL_A127
SY MaMel103a
DR Cosmic; 1467783
DR Cosmic; 1846572
DR GEO; GSM437033
DR IGRhCellID; MaMel103anew
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_A128 ! Ma-Mel-103b
SX Female
CA Cancer cell line
//
ID Ma-Mel-103b
AC CVCL_A128
DR Cosmic; 1846573
RX PubMed=17311103;
CC Derived from metastatic site: Cutaneous/subcutaneous.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_A127 ! Ma-Mel-103a
SX Female
CA Cancer cell line
//
ID Ma-Mel-104
AC CVCL_A129
RX PubMed=17311103;
CC Derived from metastatic site: Lung.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID Ma-Mel-105
AC CVCL_A130
DR Cosmic; 1846575
RX PubMed=17311103;
CC Derived from metastatic site: Liver.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID Ma-Mel-107
AC CVCL_A131
SY MaMel107
DR Cosmic; 1467784
DR GEO; GSM437034
DR IGRhCellID; MaMel107
RX PubMed=17311103;
CC Derived from metastatic site: Lymph node.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Ma-Mel-108
AC CVCL_A132
SY Ma-mel-108
DR Cosmic; 1846577
RX PubMed=17311103;
CC Derived from metastatic site: Cutaneous/subcutaneous.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID Ma-Mel-11
AC CVCL_A133
SY MaMel11
DR BTO; BTO:0005339
DR Cosmic; 1467740
DR Cosmic; 1846578
DR Cosmic; 2163820
DR ESTDAB; ESTDAB-108
DR GEO; GSM436991
RX PubMed=17311103;
CC Derived from metastatic site: Lymph node.
ST Source(s): ESTDAB
ST Amelogenin: X
ST CSF1PO: 10,11
ST D13S317: 12
ST D3S1358: 17
ST D5S818: 10,11
ST D7S820: 10
ST FGA: 25,26
ST TH01: 6
ST TPOX: 8
ST vWA: 14,16
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID Ma-Mel-110
AC CVCL_A134
SY MaMel110
DR Cosmic; 1467785
DR Cosmic; 1846579
DR GEO; GSM437035
DR IGRhCellID; MaMel110
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID Ma-Mel-112
AC CVCL_A135
RX PubMed=17311103;
CC Derived from metastatic site: Lymph node.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Ma-Mel-113
AC CVCL_A136
SY MaMel113
DR Cosmic; 1467786
DR GEO; GSM437036
DR IGRhCellID; MaMel113
RX PubMed=17311103;
CC Derived from metastatic site: Lymph node.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Ma-Mel-114
AC CVCL_A137
SY MaMel114
DR Cosmic; 1467787
DR Cosmic; 1846582
DR GEO; GSM437037
DR IGRhCellID; MaMel114new
RX PubMed=17311103;
CC Derived from metastatic site: Brain.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Ma-Mel-119
AC CVCL_A138
SY MaMel119
DR Cosmic; 1467788
DR Cosmic; 1846583
DR GEO; GSM437038
DR IGRhCellID; MaMel119
RX PubMed=17311103;
CC Derived from metastatic site: Cutaneous/subcutaneous.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Ma-Mel-12
AC CVCL_A139
SY MaMel12
DR BTO; BTO:0005340
DR Cosmic; 1467741
DR Cosmic; 1846584
DR ESTDAB; ESTDAB-103
DR GEO; GSM436992
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID Ma-Mel-120
AC CVCL_A140
DR Cosmic; 1846585
RX PubMed=17311103;
CC Derived from metastatic site: Lymph node.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Ma-Mel-121a
AC CVCL_A141
RX PubMed=17311103;
CC Derived from metastatic site: Lymph node.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Ma-Mel-122
AC CVCL_A142
SY Ma-mel-122
DR Cosmic; 1846587
RX PubMed=17311103;
CC Derived from metastatic site: Lymph node.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Ma-Mel-123
AC CVCL_A143
RX PubMed=17311103;
CC Derived from metastatic site: Cutaneous/subcutaneous.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID Ma-Mel-126
AC CVCL_A144
SY MaMel126
DR Cosmic; 1467789
DR Cosmic; 1846589
DR GEO; GSM437039
DR IGRhCellID; MaMel126
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID Ma-Mel-128a
AC CVCL_A145
SY MaMel128a
DR Cosmic; 1467790
DR Cosmic; 1846590
DR GEO; GSM437040
DR IGRhCellID; MaMel128a
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID Ma-Mel-13
AC CVCL_A146
SY MaMel13
DR Cosmic; 1181754
DR Cosmic; 1467742
DR Cosmic; 1846591
DR GEO; GSM436993
RX PubMed=17311103;
CC Derived from metastatic site: Cutaneous/subcutaneous.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Ma-Mel-130
AC CVCL_A147
SY MaMel130
DR Cosmic; 1467791
DR Cosmic; 1846592
DR GEO; GSM437042
DR IGRhCellID; MaMel130
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID Ma-Mel-134
AC CVCL_A148
SY MaMel134
DR Cosmic; 1467792
DR Cosmic; 1846593
DR GEO; GSM437043
DR IGRhCellID; MaMel134
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID Ma-Mel-136
AC CVCL_A149
SY MaMel136
DR Cosmic; 1467793
DR GEO; GSM437044
DR IGRhCellID; MaMel136
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID Ma-Mel-14
AC CVCL_A150
DR Cosmic; 1181758
DR Cosmic; 1846595
DR ESTDAB; ESTDAB-210
RX PubMed=17311103;
CC Derived from metastatic site: Cutaneous/subcutaneous.
ST Source(s): ESTDAB
ST Amelogenin: X
ST CSF1PO: 10
ST D13S317: 9
ST D3S1358: 15,16
ST D5S818: 12
ST D7S820: 8,10
ST FGA: 20,23
ST TH01: 7
ST TPOX: 9,12
ST vWA: 16,17
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID Ma-Mel-15
AC CVCL_A151
SY Ma-mel-15
DR Cosmic; 1181744
DR ECACC; 13012520
DR ESTDAB; ESTDAB-138
RX PubMed=17311103;
CC Derived from metastatic site: Lymph node.
ST Source(s): ECACC; ESTDAB
ST Amelogenin: X
ST CSF1PO: 10,12
ST D13S317: 12
ST D16S539: 9,11
ST D3S1358: 14,16
ST D5S818: 11,13
ST D7S820: 9,12
ST FGA: 21
ST TH01: 9
ST TPOX: 11
ST vWA: 14,17
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID Ma-Mel-150a
AC CVCL_A152
SY MaMel150a
DR Cosmic; 1467794
DR Cosmic; 1846597
DR GEO; GSM437045
DR IGRhCellID; MaMel150a
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID Ma-Mel-16
AC CVCL_A153
DR Cosmic; 1181756
DR Cosmic; 1846598
DR ESTDAB; ESTDAB-165
RX PubMed=17311103;
CC Derived from metastatic site: Small bowel.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Ma-Mel-16a
AC CVCL_A154
DR Cosmic; 906460
RX PubMed=15760917;
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID Ma-Mel-17
AC CVCL_A155
SY MaMel17
DR BTO; BTO:0005341
DR Cosmic; 1181757
DR Cosmic; 1467743
DR Cosmic; 1846599
DR GEO; GSM436994
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID Ma-Mel-19
AC CVCL_A156
SY MaMel19
DR BTO; BTO:0005342
DR Cosmic; 1181750
DR Cosmic; 1467744
DR Cosmic; 1846600
DR Cosmic; 2163840
DR ECACC; 13012460
DR ESTDAB; ESTDAB-152
DR GEO; GSM436995
RX PubMed=17311103;
CC Derived from metastatic site: Cutaneous/subcutaneous.
ST Source(s): ECACC; ESTDAB
ST Amelogenin: X
ST CSF1PO: 10,12
ST D13S317: 8,12
ST D16S539: 11,13
ST D3S1358: 17
ST D5S818: 9,12
ST D7S820: 8,9
ST FGA: 18,22
ST TH01: 9.3
ST TPOX: 8
ST vWA: 14,18
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID Ma-Mel-20
AC CVCL_A157
DR Cosmic; 1846601
DR Cosmic; 2163841
DR ESTDAB; ESTDAB-153
RX PubMed=17311103;
CC Derived from metastatic site: Cutaneous/subcutaneous.
ST Source(s): ESTDAB
ST Amelogenin: X
ST CSF1PO: 10,12
ST D13S317: 11
ST D3S1358: 15,18
ST D5S818: 12,13
ST D7S820: 10,11
ST FGA: 23
ST TH01: 9.3
ST TPOX: 8
ST vWA: 15,18
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID Ma-Mel-21
AC CVCL_A158
SY MaMel21
DR Cosmic; 1467745
DR Cosmic; 1846602
DR Cosmic; 2163842
DR ESTDAB; ESTDAB-154
DR GEO; GSM436996
ST Source(s): ESTDAB
ST Amelogenin: X
ST CSF1PO: 10,11
ST D13S317: 8,11
ST D3S1358: 16
ST D5S818: 11,12
ST D7S820: 9,11
ST FGA: 23,24
ST TH01: 7
ST TPOX: 11,12
ST vWA: 17,18
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID Ma-Mel-22
AC CVCL_A159
DR Cosmic; 1846603
DR ECACC; 13012452
DR ESTDAB; ESTDAB-143
RX PubMed=17311103;
CC Derived from metastatic site: Kidney.
ST Source(s): ECACC
ST Amelogenin: X
ST CSF1PO: 10,13
ST D13S317: 8,11
ST D16S539: 11,14
ST D5S818: 12
ST D7S820: 10,12
ST TH01: 9.3
ST TPOX: 8,11
ST vWA: 17,18
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID Ma-Mel-23
AC CVCL_A160
SY MaMel23
DR Cosmic; 1467746
DR Cosmic; 2163843
DR ESTDAB; ESTDAB-155
DR GEO; GSM436997
ST Source(s): ESTDAB
ST Amelogenin: X,Y
ST CSF1PO: 12
ST D13S317: 8,11
ST D3S1358: 15,16
ST D5S818: 12
ST D7S820: 9
ST FGA: 21
ST TH01: 6
ST TPOX: 8,11
ST vWA: 18
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Ma-Mel-24
AC CVCL_N784
DR Cosmic; 1846605
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID Ma-Mel-25
AC CVCL_A161
DR Cosmic; 2163851
DR ESTDAB; ESTDAB-167
RX PubMed=17311103;
CC Problematic cell line: Possibly misidentified. Presence of a Y chromosome in cell line that was thought to be of female origin (STR profile).
CC Derived from metastatic site: Cutaneous/subcutaneous.
ST Source(s): ESTDAB
ST Amelogenin: X,Y
ST CSF1PO: 11,12
ST D13S317: 8,12
ST D3S1358: 15,16
ST D5S818: 11,12
ST D7S820: 8,11
ST FGA: 21,25
ST TH01: 8,9
ST TPOX: 8,9
ST vWA: 14,15
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID Ma-Mel-26a
AC CVCL_A162
SY Ma-Mel-26A; MaMel26a
DR Cosmic; 1181764
DR Cosmic; 1467747
DR Cosmic; 1846607
DR ESTDAB; ESTDAB-156
DR GEO; GSM436998
RX PubMed=17311103;
CC Derived from metastatic site: Lymph node.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_N785 ! Ma-Mel-26b
SX Male
CA Cancer cell line
//
ID Ma-Mel-26b
AC CVCL_N785
DR Cosmic; 1846608
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_A162 ! Ma-Mel-26a
SX Male
CA Cancer cell line
//
ID Ma-Mel-27
AC CVCL_A163
SY MaMel27
DR Cosmic; 1181769
DR Cosmic; 1467748
DR Cosmic; 2163852
DR ECACC; 13012485
DR ESTDAB; ESTDAB-168
DR GEO; GSM436999
RX PubMed=17311103;
CC Derived from metastatic site: Cutaneous/subcutaneous.
ST Source(s): ECACC; ESTDAB
ST Amelogenin: X
ST CSF1PO: 10,13 (ECACC)
ST CSF1PO: 10 (ESTDAB)
ST D13S317: 8,11
ST D16S539: 11,14
ST D3S1358: 16,18
ST D5S818: 12
ST D7S820: 10,12
ST FGA: 20,21
ST TH01: 9.3
ST TPOX: 8,11
ST vWA: 17,18
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID Ma-Mel-28
AC CVCL_A164
SY Ma-mel-28; MaMel28
DR Cosmic; 906465
DR Cosmic; 1181763
DR Cosmic; 2163816
DR ECACC; 13012515
DR ESTDAB; ESTDAB-102
RX PubMed=15760917;
RX PubMed=17311103;
CC Derived from metastatic site: Cutaneous/subcutaneous.
ST Source(s): ECACC; ESTDAB
ST Amelogenin: X
ST CSF1PO: 11,12
ST D13S317: 11,12
ST D16S539: 8,12
ST D3S1358: 14
ST D5S818: 11
ST D7S820: 8
ST FGA: 19,21
ST TH01: 7,9.3
ST TPOX: 8
ST vWA: 14,16
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID Ma-Mel-30
AC CVCL_A165
SY MaMel30
DR Cosmic; 1467749
DR Cosmic; 2163817
DR ESTDAB; ESTDAB-104
DR GEO; GSM437000
RX PubMed=17311103;
CC Derived from metastatic site: Cutaneous/subcutaneous.
ST Source(s): ESTDAB
ST Amelogenin: X,Y
ST CSF1PO: 12,13
ST D13S317: 10,11
ST D3S1358: 16
ST D5S818: 12,13
ST D7S820: 11
ST FGA: 21,23.2
ST TH01: 9.3
ST TPOX: 8,11
ST vWA: 16,17
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Ma-Mel-31
AC CVCL_A166
DR Cosmic; 1846612
RX PubMed=17311103;
CC Derived from metastatic site: Lymph node.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID Ma-Mel-32
AC CVCL_A167
SY MaMel32
DR Cosmic; 1467750
DR Cosmic; 1846613
DR Cosmic; 2163853
DR ESTDAB; ESTDAB-170
DR GEO; GSM437001
DR IGRhCellID; MaMel32new
RX PubMed=17311103;
CC Derived from metastatic site: Lymph node.
ST Source(s): ESTDAB
ST Amelogenin: X
ST CSF1PO: 11,13
ST D13S317: 12
ST D3S1358: 15,16
ST D5S818: 9,12
ST D7S820: 9,10
ST FGA: 20
ST TH01: 6,9
ST TPOX: 8
ST vWA: 17
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID Ma-Mel-33
AC CVCL_A168
DR Cosmic; 1846614
DR ESTDAB; ESTDAB-139
RX PubMed=17311103;
CC Derived from metastatic site: Cutaneous/subcutaneous.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Ma-Mel-34
AC CVCL_A169
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID Ma-Mel-35
AC CVCL_A170
SY MaMel35
DR Cosmic; 1467751
DR GEO; GSM437002
DR IGRhCellID; MaMel35
RX PubMed=17311103;
CC Derived from metastatic site: Cutaneous/subcutaneous.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID Ma-Mel-36
AC CVCL_A171
SY MaMel36
DR Cosmic; 1467752
DR Cosmic; 1846616
DR ESTDAB; ESTDAB-144
DR GEO; GSM437003
DR IGRhCellID; MaMel36new
RX PubMed=17311103;
CC Derived from metastatic site: Cutaneous/subcutaneous.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID Ma-Mel-37a
AC CVCL_A172
SY MaMel37a
DR Cosmic; 1467753
DR Cosmic; 1846617
DR GEO; GSM437004
DR IGRhCellID; MaMel37a
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_A173 ! Ma-Mel-37b
SX Female
CA Cancer cell line
//
ID Ma-Mel-37b
AC CVCL_A173
DR BTO; BTO:0005343
DR Cosmic; 1846618
DR ESTDAB; ESTDAB-211
RX PubMed=17311103;
CC Derived from metastatic site: Lymph node.
ST Source(s): ESTDAB
ST Amelogenin: X
ST CSF1PO: 8,10
ST D13S317: 9,11
ST D3S1358: 14,16
ST D5S818: 11,13
ST D7S820: 11,12
ST FGA: 21,25
ST TH01: 6,9
ST TPOX: 8
ST vWA: 14,17
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_A172 ! Ma-Mel-37a
SX Female
CA Cancer cell line
//
ID Ma-Mel-38
AC CVCL_A174
SY MaMel38
DR Cosmic; 1467754
DR Cosmic; 1846619
DR Cosmic; 2163854
DR ESTDAB; ESTDAB-171
DR GEO; GSM437005
DR IGRhCellID; MaMel38
RX PubMed=17311103;
CC Derived from metastatic site: Lymph node.
ST Source(s): ESTDAB
ST Amelogenin: X
ST CSF1PO: 11,13
ST D13S317: 8,10
ST D3S1358: 17,18
ST D5S818: 11,12
ST D7S820: 10
ST FGA: 25
ST TH01: 9
ST TPOX: 8
ST vWA: 17
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID Ma-Mel-39a
AC CVCL_A175
SY Ma-Mel-39A; MaMel39a
DR Cosmic; 1467755
DR Cosmic; 1846620
DR Cosmic; 2163855
DR ECACC; 13012489
DR ESTDAB; ESTDAB-172
DR GEO; GSM437006
DR IGRhCellID; MaMel39a
RX PubMed=17311103;
CC Derived from metastatic site: Cutaneous/subcutaneous.
ST Source(s): ECACC; ESTDAB
ST Amelogenin: X
ST CSF1PO: 10
ST D13S317: 9
ST D16S539: 13
ST D3S1358: 16
ST D5S818: 11
ST D7S820: 10
ST FGA: 21,22
ST TH01: 6,8
ST TPOX: 8,9
ST vWA: 17,18
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID Ma-Mel-40
AC CVCL_A176
SY MaMel40
DR Cosmic; 1467756
DR Cosmic; 1846621
DR ESTDAB; ESTDAB-212
DR GEO; GSM437007
DR IGRhCellID; MaMel40
RX PubMed=17311103;
CC Derived from metastatic site: Cutaneous/subcutaneous.
ST Source(s): ESTDAB
ST Amelogenin: X,Y
ST CSF1PO: 10,11
ST D13S317: 11
ST D3S1358: 16,17
ST D5S818: 10,13
ST D7S820: 8,10
ST FGA: 24
ST TH01: 9,9.3
ST TPOX: 8
ST vWA: 17,18
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Ma-Mel-41
AC CVCL_A177
RX PubMed=17311103;
CC Derived from metastatic site: Cutaneous/subcutaneous.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID Ma-Mel-42
AC CVCL_A178
RX PubMed=17311103;
CC Derived from metastatic site: Ascites.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID Ma-Mel-42a
AC CVCL_C572
SY Ma-Mel-42A
DR ESTDAB; ESTDAB-140
ST Source(s): ESTDAB
ST Amelogenin: X
ST CSF1PO: 10,11
ST D13S317: 9,12
ST D3S1358: 16,18
ST D5S818: 11,12
ST D7S820: 10,14
ST FGA: 19,22
ST TH01: 6,9.3
ST TPOX: 8,9
ST vWA: 16,18
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_C287 ! Ma-Mel-42b
SX Female
CA Cancer cell line
//
ID Ma-Mel-42b
AC CVCL_C287
DR BTO; BTO:0005344
DR ESTDAB; ESTDAB-213
ST Source(s): ESTDAB
ST Amelogenin: X
ST CSF1PO: 10,11
ST D13S317: 9,12
ST D3S1358: 16,18
ST D5S818: 11,12
ST D7S820: 10,14
ST FGA: 19,22
ST TH01: 6,9.3
ST TPOX: 8,9
ST vWA: 16,18
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_C572 ! Ma-Mel-42a
SX Female
CA Cancer cell line
//
ID Ma-Mel-43
AC CVCL_A179
DR Cosmic; 906466
RX PubMed=15760917;
RX PubMed=17311103;
CC Derived from metastatic site: Cutaneous/subcutaneous.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID Ma-Mel-45a
AC CVCL_A180
SY Ma-Mel-45A; MaMel45a
DR Cosmic; 1467757
DR Cosmic; 1846625
DR Cosmic; 2163856
DR ECACC; 13012486
DR ESTDAB; ESTDAB-173
DR GEO; GSM437008
DR IGRhCellID; MaMel45a
RX PubMed=17311103;
CC Derived from metastatic site: Brain.
ST Source(s): ECACC; ESTDAB
ST Amelogenin: X
ST CSF1PO: 10,11
ST D13S317: 8
ST D16S539: 12
ST D3S1358: 14,18
ST D5S818: 12
ST D7S820: 9,13
ST FGA: 21
ST TH01: 7,8
ST TPOX: 11
ST vWA: 16,18
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_C262 ! Ma-Mel-45b
SX Male
CA Cancer cell line
//
ID Ma-Mel-45b
AC CVCL_C262
DR Cosmic; 1846626
DR ESTDAB; ESTDAB-193
ST Source(s): ESTDAB
ST Amelogenin: X
ST CSF1PO: 10,11
ST D13S317: 8
ST D3S1358: 14,18
ST D5S818: 12
ST D7S820: 9,13
ST FGA: 21
ST TH01: 7,8
ST TPOX: 11
ST vWA: 16,18
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_A180 ! Ma-Mel-45a
SX Male
CA Cancer cell line
//
ID Ma-Mel-46
AC CVCL_A181
DR Cosmic; 1846627
DR ESTDAB; ESTDAB-214
RX PubMed=17311103;
CC Derived from metastatic site: Cutaneous/subcutaneous.
ST Source(s): ESTDAB
ST Amelogenin: X
ST CSF1PO: 10
ST D13S317: 11
ST D3S1358: 15
ST D5S818: 12
ST D7S820: 8,10
ST FGA: 19,25
ST TH01: 7
ST TPOX: 8
ST vWA: 18,19
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID Ma-Mel-47
AC CVCL_A182
DR BTO; BTO:0005345
DR Cosmic; 1846628
DR Cosmic; 2163862
DR ESTDAB; ESTDAB-194
RX PubMed=17311103;
CC Derived from metastatic site: Lymph node.
ST Source(s): ESTDAB
ST Amelogenin: X
ST CSF1PO: 11,12
ST D13S317: 9,11
ST D3S1358: 17
ST D5S818: 11,12
ST D7S820: 8,11
ST FGA: 24
ST TH01: 9,9.3
ST TPOX: 8
ST vWA: 16,17
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID Ma-Mel-48a
AC CVCL_A183
SY Ma-Mel-48A
DR Cosmic; 1846629
DR Cosmic; 2163863
DR ESTDAB; ESTDAB-195
RX PubMed=17311103;
CC Derived from metastatic site: Cutaneous/subcutaneous.
ST Source(s): ESTDAB
ST Amelogenin: X,Y
ST CSF1PO: 10
ST D13S317: 14
ST D3S1358: 18
ST D5S818: 11,12
ST D7S820: 9
ST FGA: 21,23
ST TH01: 6,8
ST TPOX: 8,10
ST vWA: 17,19
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_N786 ! Ma-Mel-48b
OI CVCL_N787 ! Ma-Mel-48c
SX Male
CA Cancer cell line
//
ID Ma-Mel-48b
AC CVCL_N786
DR Cosmic; 1846630
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_A183 ! Ma-Mel-48a
OI CVCL_N787 ! Ma-Mel-48c
SX Male
CA Cancer cell line
//
ID Ma-Mel-48c
AC CVCL_N787
DR Cosmic; 1846631
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_A183 ! Ma-Mel-48a
OI CVCL_N786 ! Ma-Mel-48b
SX Male
CA Cancer cell line
//
ID Ma-Mel-49
AC CVCL_A184
RX PubMed=17311103;
CC Derived from metastatic site: Ascites.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Ma-Mel-50
AC CVCL_A185
RX PubMed=17311103;
CC Derived from metastatic site: Ascites.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Ma-Mel-51
AC CVCL_A186
SY MaMel51
DR Cosmic; 906461
DR Cosmic; 1467758
DR Cosmic; 1846635
DR Cosmic; 2163864
DR ESTDAB; ESTDAB-196
DR GEO; GSM437009
DR IGRhCellID; MaMel51
RX PubMed=15760917;
RX PubMed=17311103;
CC Derived from metastatic site: Lymph node.
ST Source(s): ESTDAB
ST Amelogenin: X
ST CSF1PO: 10
ST D13S317: 9,11
ST D3S1358: 15,18
ST D5S818: 12
ST D7S820: 8,9
ST FGA: 24,25
ST TH01: 7,9.3
ST TPOX: 8,11
ST vWA: 15,17
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Ma-Mel-52
AC CVCL_A187
DR BTO; BTO:0005346
DR Cosmic; 1846636
DR ESTDAB; ESTDAB-197
RX PubMed=17311103;
CC Derived from metastatic site: Cutaneous/subcutaneous.
ST Source(s): ESTDAB
ST Amelogenin: X
ST CSF1PO: 11
ST D13S317: 11,13
ST D3S1358: 14,16
ST D5S818: Not_detected
ST D7S820: 8,14
ST FGA: 20,21
ST TH01: 6,9.3
ST TPOX: 8,11
ST vWA: 14
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Ma-Mel-53
AC CVCL_A188
SY MaMel53
DR Cosmic; 1467759
DR Cosmic; 1846637
DR ESTDAB; ESTDAB-198
DR GEO; GSM437010
DR IGRhCellID; MaMel53
RX PubMed=17311103;
CC Derived from metastatic site: Cutaneous/subcutaneous.
ST Source(s): ESTDAB
ST Amelogenin: X
ST CSF1PO: 11,13
ST D13S317: 11,13
ST D3S1358: 17,18
ST D5S818: 12
ST D7S820: 10
ST FGA: 20,23
ST TH01: 6,9.3
ST TPOX: 8
ST vWA: 15,18
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Ma-Mel-54a
AC CVCL_A189
DR Cosmic; 1846639
DR Cosmic; 2163857
DR ECACC; 13012484
DR ESTDAB; ESTDAB-174
RX PubMed=17311103;
CC Derived from metastatic site: Lymph node.
ST Source(s): ECACC; ESTDAB
ST Amelogenin: X
ST CSF1PO: 12
ST D13S317: 12,13
ST D16S539: 9,11
ST D3S1358: 14,16
ST D5S818: 12,13
ST D7S820: 12,13 (ECACC)
ST D7S820: 12 (ESTDAB)
ST FGA: 22,22.2
ST TH01: 6,9.3
ST TPOX: 8,11
ST vWA: 15,18
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_C288 ! Ma-Mel-54b
SX Female
CA Cancer cell line
//
ID Ma-Mel-54b
AC CVCL_C288
DR ESTDAB; ESTDAB-215
ST Source(s): ESTDAB
ST Amelogenin: X
ST CSF1PO: 12
ST D13S317: 12,13
ST D3S1358: 14,16
ST D5S818: 12,13
ST D7S820: 12,13
ST FGA: 22
ST TH01: 6,9.3
ST TPOX: 8,11
ST vWA: 15,18
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_A189 ! Ma-Mel-54a
SX Female
CA Cancer cell line
//
ID Ma-Mel-55
AC CVCL_A190
DR Cosmic; 1846640
DR Cosmic; 2163865
DR ESTDAB; ESTDAB-199
RX PubMed=17311103;
CC Derived from metastatic site: Lymph node.
ST Source(s): ESTDAB
ST Amelogenin: X,Y
ST CSF1PO: 11
ST D13S317: 11,12
ST D3S1358: 15,17
ST D5S818: 10,11
ST D7S820: 8,10
ST FGA: 23,24
ST TH01: 8,9
ST TPOX: 11
ST vWA: 17,19
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Ma-Mel-56
AC CVCL_A191
DR Cosmic; 1846641
DR Cosmic; 2163866
DR ESTDAB; ESTDAB-200
RX PubMed=17311103;
CC Derived from metastatic site: Lymph node.
ST Source(s): ESTDAB
ST Amelogenin: X
ST CSF1PO: 10,12
ST D13S317: 11
ST D3S1358: 17
ST D5S818: 10,12
ST D7S820: 10,11
ST FGA: 25
ST TH01: 8,9.3
ST TPOX: 8
ST vWA: 17
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID Ma-Mel-57
AC CVCL_A192
SY MaMel57
DR Cosmic; 906462
DR Cosmic; 1467760
DR Cosmic; 1846642
DR GEO; GSM437011
DR IGRhCellID; MaMel57
RX PubMed=15760917;
RX PubMed=17311103;
CC Derived from metastatic site: Lymph node.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Ma-Mel-58
AC CVCL_A193
SY MaMel58
DR Cosmic; 1467761
DR GEO; GSM437012
DR IGRhCellID; MaMel58
RX PubMed=17311103;
CC Derived from metastatic site: Ascites.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID Ma-Mel-59a
AC CVCL_A194
SY MaMel59a
DR Cosmic; 1467762
DR Cosmic; 1846644
DR ESTDAB; ESTDAB-202
DR GEO; GSM437013
DR IGRhCellID; MaMel59a
RX PubMed=17311103;
CC Derived from metastatic site: Lymph node.
ST Source(s): ESTDAB
ST Amelogenin: X
ST CSF1PO: 10
ST D13S317: 12,13
ST D3S1358: 17
ST D5S818: 12,13
ST D7S820: 8,12
ST FGA: 20,22
ST TH01: 9
ST TPOX: 9,11
ST vWA: 17
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_C289 ! Ma-Mel-59b
OI CVCL_C290 ! Ma-Mel-59c
SX Male
CA Cancer cell line
//
ID Ma-Mel-59b
AC CVCL_C289
DR Cosmic; 1846645
DR ESTDAB; ESTDAB-216
ST Source(s): ESTDAB
ST Amelogenin: X
ST CSF1PO: 10
ST D13S317: 12,13
ST D3S1358: 17
ST D5S818: 12,13
ST D7S820: 8,12
ST FGA: 20,22
ST TH01: 9
ST TPOX: 9,11
ST vWA: 17
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_A194 ! Ma-Mel-59a
OI CVCL_C290 ! Ma-Mel-59c
SX Male
CA Cancer cell line
//
ID Ma-Mel-59c
AC CVCL_C290
DR Cosmic; 1846646
DR ESTDAB; ESTDAB-217
ST Source(s): ESTDAB
ST Amelogenin: X
ST CSF1PO: 10
ST D13S317: 12,13
ST D3S1358: 17
ST D5S818: 12,13
ST D7S820: 8,12
ST FGA: 20,22
ST TH01: 9
ST TPOX: 8,11
ST vWA: 17
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_A194 ! Ma-Mel-59a
OI CVCL_C289 ! Ma-Mel-59b
SX Male
CA Cancer cell line
//
ID Ma-Mel-60
AC CVCL_A195
SY MaMel60
DR Cosmic; 1467763
DR Cosmic; 1846647
DR ESTDAB; ESTDAB-203
DR GEO; GSM437014
DR IGRhCellID; MaMel60
RX PubMed=17311103;
CC Derived from metastatic site: Cutaneous/subcutaneous.
ST Source(s): ESTDAB
ST Amelogenin: X
ST CSF1PO: 11
ST D13S317: 12
ST D3S1358: 15,16
ST D5S818: 9
ST D7S820: 10
ST FGA: 25
ST TH01: 7
ST TPOX: 8,12
ST vWA: 19
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Ma-Mel-61a
AC CVCL_C291
AS CVCL_A196
SY Ma-Mel-61A; MaMel61a; Ma-Mel-61
DR Cosmic; 1467764
DR Cosmic; 1846648
DR ESTDAB; ESTDAB-218
DR GEO; GSM437015
DR IGRhCellID; MaMel61a
RX PubMed=17311103;
CC Derived from metastatic site: Lymph node.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_C292 ! Ma-Mel-61b
OI CVCL_S666 ! Ma-Mel-61c
OI CVCL_S667 ! Ma-Mel-61e
OI CVCL_S668 ! Ma-Mel-61f
OI CVCL_S669 ! Ma-Mel-61g
OI CVCL_S670 ! Ma-Mel-61h
SX Male
CA Cancer cell line
//
ID Ma-Mel-61b
AC CVCL_C292
DR Cosmic; 1846649
DR ESTDAB; ESTDAB-219
ST Source(s): ESTDAB
ST Amelogenin: X,Y
ST CSF1PO: 11
ST D13S317: 9,12
ST D3S1358: 16
ST D5S818: 11
ST D7S820: 12
ST FGA: 20
ST TH01: 9,9.3
ST TPOX: 8
ST vWA: 16,17
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_C291 ! Ma-Mel-61a
OI CVCL_S666 ! Ma-Mel-61c
OI CVCL_S667 ! Ma-Mel-61e
OI CVCL_S668 ! Ma-Mel-61f
OI CVCL_S669 ! Ma-Mel-61g
OI CVCL_S670 ! Ma-Mel-61h
SX Male
CA Cancer cell line
//
ID Ma-Mel-61c
AC CVCL_S666
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_C291 ! Ma-Mel-61a
OI CVCL_C292 ! Ma-Mel-61b
OI CVCL_S667 ! Ma-Mel-61e
OI CVCL_S668 ! Ma-Mel-61f
OI CVCL_S669 ! Ma-Mel-61g
OI CVCL_S670 ! Ma-Mel-61h
SX Male
CA Cancer cell line
//
ID Ma-Mel-61e
AC CVCL_S667
DR Cosmic; 1846651
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_C291 ! Ma-Mel-61a
OI CVCL_C292 ! Ma-Mel-61b
OI CVCL_S666 ! Ma-Mel-61c
OI CVCL_S668 ! Ma-Mel-61f
OI CVCL_S669 ! Ma-Mel-61g
OI CVCL_S670 ! Ma-Mel-61h
SX Male
CA Cancer cell line
//
ID Ma-Mel-61f
AC CVCL_S668
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_C291 ! Ma-Mel-61a
OI CVCL_C292 ! Ma-Mel-61b
OI CVCL_S666 ! Ma-Mel-61c
OI CVCL_S667 ! Ma-Mel-61e
OI CVCL_S669 ! Ma-Mel-61g
OI CVCL_S670 ! Ma-Mel-61h
SX Male
CA Cancer cell line
//
ID Ma-Mel-61g
AC CVCL_S669
DR Cosmic; 1846653
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_C291 ! Ma-Mel-61a
OI CVCL_C292 ! Ma-Mel-61b
OI CVCL_S666 ! Ma-Mel-61c
OI CVCL_S667 ! Ma-Mel-61e
OI CVCL_S668 ! Ma-Mel-61f
OI CVCL_S670 ! Ma-Mel-61h
SX Male
CA Cancer cell line
//
ID Ma-Mel-61h
AC CVCL_S670
DR Cosmic; 1846654
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_C291 ! Ma-Mel-61a
OI CVCL_C292 ! Ma-Mel-61b
OI CVCL_S666 ! Ma-Mel-61c
OI CVCL_S667 ! Ma-Mel-61e
OI CVCL_S668 ! Ma-Mel-61f
OI CVCL_S669 ! Ma-Mel-61g
SX Male
CA Cancer cell line
//
ID Ma-Mel-62
AC CVCL_A197
SY MaMel62
DR Cosmic; 1467765
DR Cosmic; 1846655
DR GEO; GSM437016
DR IGRhCellID; MaMel62
RX PubMed=17311103;
CC Derived from metastatic site: Lymph node.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Ma-Mel-63a
AC CVCL_A198
SY Ma-Mel-63A; MaMel63a
DR Cosmic; 1181755
DR Cosmic; 1467766
DR Cosmic; 1846656
DR GEO; GSM437017
DR IGRhCellID; MaMel63a
RX PubMed=17311103;
CC Derived from metastatic site: Cutaneous/subcutaneous.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_C293 ! Ma-Mel-63b
SX Female
CA Cancer cell line
//
ID Ma-Mel-63b
AC CVCL_C293
DR Cosmic; 1846657
DR ESTDAB; ESTDAB-220
ST Source(s): ESTDAB
ST Amelogenin: X
ST CSF1PO: 11,12
ST D13S317: 12,13
ST D3S1358: 15,17
ST D5S818: 11,13
ST D7S820: 9,10
ST FGA: 22,23
ST TH01: 9,9.3
ST TPOX: 8
ST vWA: 16,18
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_A198 ! Ma-Mel-63a
SX Female
CA Cancer cell line
//
ID Ma-Mel-64
AC CVCL_A199
RX PubMed=17311103;
CC Derived from metastatic site: Ascites.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Ma-Mel-65
AC CVCL_A200
DR Cosmic; 1846659
DR ESTDAB; ESTDAB-221
RX PubMed=17311103;
CC Derived from metastatic site: Lymph node.
ST Source(s): ESTDAB
ST Amelogenin: X
ST CSF1PO: 10,11
ST D13S317: 11
ST D3S1358: 15,17
ST D5S818: 12,14
ST D7S820: 10,12
ST FGA: 19,23
ST TH01: 7
ST TPOX: 8,11
ST vWA: 14,16
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID Ma-Mel-66a
AC CVCL_A201
SY MaMel66a
DR Cosmic; 1467767
DR Cosmic; 1846660
DR GEO; GSM437018
DR IGRhCellID; MaMel66a
RX PubMed=17311103;
CC Derived from metastatic site: Cutaneous/subcutaneous.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_A202 ! Ma-Mel-66b
SX Female
CA Cancer cell line
//
ID Ma-Mel-66b
AC CVCL_A202
DR Cosmic; 1846661
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_A201 ! Ma-Mel-66a
SX Female
CA Cancer cell line
//
ID Ma-Mel-67
AC CVCL_A203
SY MaMel67
DR Cosmic; 1467768
DR Cosmic; 1846662
DR GEO; GSM437019
DR IGRhCellID; MaMel67
RX PubMed=17311103;
CC Derived from metastatic site: Lymph node.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID Ma-Mel-68
AC CVCL_A204
DR Cosmic; 1846663
RX PubMed=17311103;
CC Derived from metastatic site: Lymph node.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID Ma-Mel-69
AC CVCL_A205
SY MaMel69
DR Cosmic; 1467769
DR Cosmic; 1846664
DR GEO; GSM437020
DR IGRhCellID; MaMel69
RX PubMed=17311103;
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Ma-Mel-70
AC CVCL_A206
DR Cosmic; 1846558
RX PubMed=17311103;
CC Derived from metastatic site: Cutaneous/subcutaneous.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID Ma-Mel-71
AC CVCL_A207
SY MaMel71
DR Cosmic; 1181743
DR Cosmic; 1467770
DR ESTDAB; ESTDAB-205
DR GEO; GSM437021
DR IGRhCellID; MaMel71new
RX PubMed=17311103;
CC Derived from metastatic site: Cutaneous/subcutaneous.
ST Source(s): ESTDAB
ST Amelogenin: X,Y
ST CSF1PO: 10,11
ST D13S317: 12
ST D3S1358: 17
ST D5S818: 9,12
ST D7S820: 10,11
ST FGA: 23
ST TH01: 7
ST TPOX: 8,11
ST vWA: 16
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Ma-Mel-73a
AC CVCL_A208
SY MaMel73a
DR Cosmic; 1467771
DR ESTDAB; ESTDAB-206
DR GEO; GSM437022
DR IGRhCellID; MaMel73a
ST Source(s): ESTDAB
ST Amelogenin: X,Y
ST CSF1PO: 12
ST D13S317: 10,11
ST D3S1358: 14,15
ST D5S818: 11,13
ST D7S820: 11,12
ST FGA: 19
ST TH01: 9
ST TPOX: 11
ST vWA: 17,19
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_A209 ! Ma-Mel-73b
SX Male
CA Cancer cell line
//
ID Ma-Mel-73b
AC CVCL_A209
DR ESTDAB; ESTDAB-207
RX PubMed=17311103;
CC Derived from metastatic site: Lymph node.
ST Source(s): ESTDAB
ST Amelogenin: X,Y
ST CSF1PO: 12
ST D13S317: 10
ST D3S1358: 14,15
ST D5S818: 11,13
ST D7S820: 11,12
ST FGA: 19,26
ST TH01: 9
ST TPOX: 11
ST vWA: 17,19
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_A208 ! Ma-Mel-73a
SX Male
CA Cancer cell line
//
ID Ma-Mel-74
AC CVCL_A210
DR Cosmic; 1846667
DR ESTDAB; ESTDAB-208
RX PubMed=17311103;
CC Derived from metastatic site: Lymph node.
ST Source(s): ESTDAB
ST Amelogenin: X
ST CSF1PO: 12,14
ST D13S317: 9,11
ST D3S1358: 15
ST D5S818: 11,13
ST FGA: 23,24
ST TH01: 6,9.3
ST TPOX: 8
ST vWA: 14,17
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID Ma-Mel-75
AC CVCL_A211
SY MaMel75
DR Cosmic; 1467772
DR GEO; GSM437023
DR IGRhCellID; MaMel75
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID Ma-Mel-76
AC CVCL_A212
SY MaMel76
DR Cosmic; 1467773
DR GEO; GSM437024
DR IGRhCellID; MaMel76
RX PubMed=17311103;
CC Derived from metastatic site: Lymph node.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID Ma-Mel-79
AC CVCL_A213
SY MaMel79
DR Cosmic; 1181761
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID Ma-Mel-79b
AC CVCL_A214
SY Ma-Mel-79B; MaMel79b
DR Cosmic; 1467774
DR GEO; GSM437025
DR IGRhCellID; MaMel79b
RX PubMed=17311103;
CC Derived from metastatic site: Cutaneous/subcutaneous.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Ma-Mel-80a
AC CVCL_A215
SY MaMel80a
DR Cosmic; 1181760
DR Cosmic; 1467775
DR Cosmic; 1846671
DR GEO; GSM437026
DR IGRhCellID; MaMel80anew
RX PubMed=17311103;
CC Derived from metastatic site: Lymph node.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID Ma-Mel-81
AC CVCL_A216
RX PubMed=17311103;
CC Derived from metastatic site: Cutaneous/subcutaneous.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID Ma-Mel-82
AC CVCL_A217
SY MaMel82
DR Cosmic; 1846673
RX PubMed=17311103;
RX PubMed=24581590;
CC Derived from metastatic site: Lymph node.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Ma-Mel-83
AC CVCL_A218
SY MaMel83
DR Cosmic; 1181751
DR Cosmic; 1846674
RX PubMed=17311103;
CC Derived from metastatic site: Lymph node.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID Ma-Mel-84
AC CVCL_A219
DR Cosmic; 1846675
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID Ma-Mel-85
AC CVCL_A220
SY Ma-mel-85; MaMel85
DR Cosmic; 1181753
DR Cosmic; 1467776
DR Cosmic; 1846676
DR GEO; GSM437027
DR IGRhCellID; MaMel85
RX PubMed=17311103;
CC Derived from metastatic site: Cutaneous/subcutaneous.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Ma-Mel-86a
AC CVCL_A221
SY MaMel86a
DR Cosmic; 1181752
DR Cosmic; 1467777
DR Cosmic; 1846677
DR GEO; GSM437028
DR IGRhCellID; MaMel86a
RX PubMed=17311103;
CC Derived from metastatic site: Lymph node.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_A222 ! Ma-Mel-86b
SX Female
CA Cancer cell line
//
ID Ma-Mel-86b
AC CVCL_A222
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_A221 ! Ma-Mel-86a
SX Female
CA Cancer cell line
//
ID Ma-Mel-90
AC CVCL_A223
RX PubMed=17311103;
CC Derived from metastatic site: Cutaneous/subcutaneous.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Ma-Mel-91
AC CVCL_A224
SY MaMel91
DR Cosmic; 1181762
DR Cosmic; 1846679
RX PubMed=17311103;
CC Derived from metastatic site: Cutaneous/subcutaneous.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Ma-Mel-92
AC CVCL_A225
SY MaMel92
DR Cosmic; 1181759
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID Ma-Mel-92d
AC CVCL_A226
DR Cosmic; 1846680
RX PubMed=17311103;
CC Derived from metastatic site: Cutaneous/subcutaneous.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID Ma-Mel-93
AC CVCL_A227
RX PubMed=17311103;
CC Derived from metastatic site: Cutaneous/subcutaneous.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Ma-Mel-94
AC CVCL_A228
SY MaMel94
DR Cosmic; 1467778
DR Cosmic; 1846682
DR GEO; GSM437029
DR IGRhCellID; MaMel94
RX PubMed=17311103;
CC Derived from metastatic site: Lymph node.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Ma-Mel-95
AC CVCL_A229
SY MaMel95
DR Cosmic; 1467779
DR Cosmic; 1846683
DR GEO; GSM437030
DR IGRhCellID; MaMel95
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID Ma-Mel-96
AC CVCL_A230
DR Cosmic; 1846684
RX PubMed=17311103;
CC Derived from metastatic site: Cutaneous/subcutaneous.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Ma-Mel-97
AC CVCL_A231
DR Cosmic; 1846685
RX PubMed=17311103;
CC Derived from metastatic site: Lymph node.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID Ma-Mel-99
AC CVCL_A232
SY MaMel99
DR Cosmic; 1467780
DR Cosmic; 1846686
DR GEO; GSM437031
DR IGRhCellID; MaMel99new
RX PubMed=17311103;
CC Derived from metastatic site: Cutaneous/subcutaneous.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Ma-Mel-KNUD
AC CVCL_C505
SY KNUD; MaMel_KNUD
DR Cosmic; 1467781
DR Cosmic; 2163834
DR ESTDAB; ESTDAB-136
DR GEO; GSM437046
DR IGRhCellID; MaMel_KNUD
ST Source(s): ESTDAB
ST Amelogenin: X
ST CSF1PO: 10
ST D13S317: 8
ST D3S1358: 14,17
ST D5S818: 11,12
ST D7S820: 10,11
ST FGA: 20,24
ST TH01: 9.3
ST TPOX: 8,12
ST vWA: 17,18
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID MA01
AC CVCL_C341
SY MA 01; Ma01; ACTe001-A
DR hPSCreg; ACTe001-A
DR ISCR; 135
RX PubMed=16929302;
WW http://umassmed.edu/uploadedFiles/umscr/Human%20Embryonic%20Stem%20Cell%20lines%20established%20at%20ACT.pdf
CC From: Advanced Cell Technology, Inc.
CC Registration: UK Stem Cell Bank (UKSCB); Steering comm. appl. SCSC06-38(1).
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Embryonic stem cell
//
ID MA03
AC CVCL_C342
SY MA 03
DR ISCR; 136
WW http://umassmed.edu/uploadedFiles/umscr/Human%20Embryonic%20Stem%20Cell%20lines%20established%20at%20ACT.pdf
CC From: Advanced Cell Technology, Inc.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Embryonic stem cell
//
ID MA04
AC CVCL_C343
SY MA 04
DR ISCR; 138
WW http://umassmed.edu/uploadedFiles/umscr/Human%20Embryonic%20Stem%20Cell%20lines%20established%20at%20ACT.pdf
CC From: Advanced Cell Technology, Inc.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Embryonic stem cell
//
ID MA09
AC CVCL_C344
SY MA 09; Ma09; ACTe002-A
DR hPSCreg; ACTe002-A
DR ISCR; 137
RX PubMed=16929302;
WW http://umassmed.edu/uploadedFiles/umscr/Human%20Embryonic%20Stem%20Cell%20lines%20established%20at%20ACT.pdf
WW http://grants.nih.gov/stem_cells/registry/pending.htm
CC From: Advanced Cell Technology, Inc.
CC Registration: NIH Human Embryonic Stem Cell Registry; pending review.
CC Registration: UK Stem Cell Bank (UKSCB); Steering comm. appl. SCSC06-38(2).
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Embryonic stem cell
//
ID MA1-3
AC CVCL_J837
RX PubMed=6809625;
CC Monoclonal antibody target: UniProtKB; Q9I4Z4; Pseudomonas aeruginosa oprL (H2) (also reacts with other species).
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_2155 ! P3/NS1/1-Ag4.1
CA Hybridoma
//
ID MA1-6
AC CVCL_J838
DR CLO; CLO_0007496
DR ATCC; CRL-1783
RX PubMed=6809625;
CC Monoclonal antibody target: UniProtKB; Q9I4Z4; Pseudomonas aeruginosa oprL (H2) (also reacts with other species).
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_2155 ! P3/NS1/1-Ag4.1
CA Hybridoma
//
ID MA1-8
AC CVCL_J839
RX PubMed=6809625;
CC Monoclonal antibody target: UniProtKB; Q9I4Z4; Pseudomonas aeruginosa oprL (H2) (also reacts with other species).
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_2155 ! P3/NS1/1-Ag4.1
CA Hybridoma
//
ID MA126
AC CVCL_B895
SY MA 126; NED1; NED 1
DR ISCR; 144
RX PubMed=18371431;
WW http://umassmed.edu/uploadedFiles/umscr/Human%20Embryonic%20Stem%20Cell%20lines%20established%20at%20ACT.pdf
WW http://grants.nih.gov/stem_cells/registry/pending.htm
CC From: Advanced Cell Technology, Inc.
CC Registration: NIH Human Embryonic Stem Cell Registry; pending review.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Embryonic stem cell
//
ID MA127
AC CVCL_B896
SY MA 127; NED2; NED 2
DR ISCR; 145
RX PubMed=18371431;
WW http://umassmed.edu/uploadedFiles/umscr/Human%20Embryonic%20Stem%20Cell%20lines%20established%20at%20ACT.pdf
WW http://grants.nih.gov/stem_cells/registry/pending.htm
CC From: Advanced Cell Technology, Inc.
CC Registration: NIH Human Embryonic Stem Cell Registry; pending review.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Embryonic stem cell
//
ID MA128
AC CVCL_B897
SY MA 128; NED3; NED 3
DR ISCR; 146
RX PubMed=18371431;
WW http://umassmed.edu/uploadedFiles/umscr/Human%20Embryonic%20Stem%20Cell%20lines%20established%20at%20ACT.pdf
WW http://grants.nih.gov/stem_cells/registry/pending.htm
CC From: Advanced Cell Technology, Inc.
CC Registration: NIH Human Embryonic Stem Cell Registry; pending review.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Embryonic stem cell
//
ID MA129
AC CVCL_B898
SY MA 129; NED4; NED 4
DR ISCR; 147
RX PubMed=18371431;
WW http://umassmed.edu/uploadedFiles/umscr/Human%20Embryonic%20Stem%20Cell%20lines%20established%20at%20ACT.pdf
WW http://grants.nih.gov/stem_cells/registry/pending.htm
CC From: Advanced Cell Technology, Inc.
CC Registration: NIH Human Embryonic Stem Cell Registry; pending review.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Embryonic stem cell
//
ID MA133
AC CVCL_B899
SY MA 133
DR ISCR; 148
WW http://umassmed.edu/uploadedFiles/umscr/Human%20Embryonic%20Stem%20Cell%20lines%20established%20at%20ACT.pdf
CC From: Advanced Cell Technology, Inc.
OX NCBI_TaxID=9606; ! Homo sapiens
CA Embryonic stem cell
//
ID MA135
AC CVCL_B900
SY MA 135
DR ISCR; 149
WW http://umassmed.edu/uploadedFiles/umscr/Human%20Embryonic%20Stem%20Cell%20lines%20established%20at%20ACT.pdf
WW http://grants.nih.gov/stem_cells/registry/current.htm?id=402
CC From: Advanced Cell Technology, Inc.
CC Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0072.
OX NCBI_TaxID=9606; ! Homo sapiens
CA Embryonic stem cell
//
ID MA136
AC CVCL_B901
SY MA 136
DR ISCR; 150
WW http://umassmed.edu/uploadedFiles/umscr/Human%20Embryonic%20Stem%20Cell%20lines%20established%20at%20ACT.pdf
CC From: Advanced Cell Technology, Inc.
OX NCBI_TaxID=9606; ! Homo sapiens
CA Embryonic stem cell
//
ID MA137
AC CVCL_B902
SY MA 137
DR ISCR; 151
WW http://umassmed.edu/uploadedFiles/umscr/Human%20Embryonic%20Stem%20Cell%20lines%20established%20at%20ACT.pdf
CC From: Advanced Cell Technology, Inc.
OX NCBI_TaxID=9606; ! Homo sapiens
CA Embryonic stem cell
//
ID MA138
AC CVCL_B903
SY MA 138
DR ISCR; 152
WW http://umassmed.edu/uploadedFiles/umscr/Human%20Embryonic%20Stem%20Cell%20lines%20established%20at%20ACT.pdf
CC From: Advanced Cell Technology, Inc.
OX NCBI_TaxID=9606; ! Homo sapiens
CA Embryonic stem cell
//
ID MA139
AC CVCL_B904
SY MA 139
DR ISCR; 153
WW http://umassmed.edu/uploadedFiles/umscr/Human%20Embryonic%20Stem%20Cell%20lines%20established%20at%20ACT.pdf
CC From: Advanced Cell Technology, Inc.
OX NCBI_TaxID=9606; ! Homo sapiens
CA Embryonic stem cell
//
ID MA140
AC CVCL_B905
SY MA 140
DR ISCR; 154
WW http://umassmed.edu/uploadedFiles/umscr/Human%20Embryonic%20Stem%20Cell%20lines%20established%20at%20ACT.pdf
CC From: Advanced Cell Technology, Inc.
OX NCBI_TaxID=9606; ! Homo sapiens
CA Embryonic stem cell
//
ID MA141
AC CVCL_C116
SY MA 141
DR ISCR; 155
WW http://umassmed.edu/uploadedFiles/umscr/Human%20Embryonic%20Stem%20Cell%20lines%20established%20at%20ACT.pdf
CC From: Advanced Cell Technology, Inc.
OX NCBI_TaxID=9606; ! Homo sapiens
CA Embryonic stem cell
//
ID MA148
AC CVCL_AK47
SY MA 148; MA-148
RX PubMed=8640821;
RX PubMed=10786683;
RX PubMed=12361951;
DI NCIt; C5228; Ovarian cystadenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID MA1K
AC CVCL_S499
DR ATCC; CRL-6284
CC Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982).
CC Discontinued: ATCC; CRL-6284; true.
OX NCBI_TaxID=10036; ! Mesocricetus auratus
SX Sex undetermined
CA Finite cell line
//
ID MA2.1
AC CVCL_L672
DR CLO; CLO_0007497
DR ATCC; HB-54
RX PubMed=6167544;
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_2155 ! P3/NS1/1-Ag4.1
CA Hybridoma
//
ID MA214L
AC CVCL_5I01
SY RAFT0069
DR ECACC; 07042302
RX PubMed=9138163;
CC Part of: ECACC chromosomal abnormality collection.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
DI NCIt; C3267; Wilms tumor
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Transformed cell line
//
ID MA2T
AC CVCL_S500
DR ATCC; CRL-6285
CC Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982).
CC Discontinued: ATCC; CRL-6285; true.
OX NCBI_TaxID=10036; ! Mesocricetus auratus
SX Sex undetermined
CA Cancer cell line
//
ID MA40
AC CVCL_C337
SY MA 40
DR ISCR; 140
WW http://umassmed.edu/uploadedFiles/umscr/Human%20Embryonic%20Stem%20Cell%20lines%20established%20at%20ACT.pdf
CC From: Advanced Cell Technology, Inc.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Embryonic stem cell
//
ID MA42
AC CVCL_C338
SY MA 42
DR ISCR; 141
WW http://umassmed.edu/uploadedFiles/umscr/Human%20Embryonic%20Stem%20Cell%20lines%20established%20at%20ACT.pdf
WW http://grants.nih.gov/stem_cells/registry/pending.htm
CC From: Advanced Cell Technology, Inc.
CC Registration: NIH Human Embryonic Stem Cell Registry; pending review.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Embryonic stem cell
//
ID Ma44-3
AC CVCL_W133
RX PubMed=15161017;
RX PubMed=16170033;
DI NCIt; C3493; Squamous cell lung carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_7071 ! Ma-44
CA Cancer cell line
//
ID Ma44-3-GFP
AC CVCL_W134
RX PubMed=15161017;
CC Transfected with: UniProtKB; P42212; GFP.
DI NCIt; C3493; Squamous cell lung carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_W133 ! Ma44-3
CA Cancer cell line
//
ID MA50
AC CVCL_C339
SY MA 50
DR ISCR; 142
WW http://umassmed.edu/uploadedFiles/umscr/Human%20Embryonic%20Stem%20Cell%20lines%20established%20at%20ACT.pdf
WW http://grants.nih.gov/stem_cells/registry/pending.htm
CC From: Advanced Cell Technology, Inc.
CC Registration: NIH Human Embryonic Stem Cell Registry; pending review.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Embryonic stem cell
//
ID MA99
AC CVCL_C340
SY MA 99
DR ISCR; 143
WW http://umassmed.edu/uploadedFiles/umscr/Human%20Embryonic%20Stem%20Cell%20lines%20established%20at%20ACT.pdf
CC From: Advanced Cell Technology, Inc.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Embryonic stem cell
//
ID Mab 108
AC CVCL_L581
DR CLO; CLO_0007502
DR ATCC; HB-9764
RX Patent=US6217866;
CC Monoclonal antibody target: UniProtKB; P00533; Human EGFR.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_2155 ! P3/NS1/1-Ag4.1
CA Hybridoma
//
ID Mab 126
AC CVCL_L582
DR CLO; CLO_0007503
DR ATCC; HB-8568
RX Patent=US4675287;
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_3411 ! P3X63Ag8
CA Hybridoma
//
ID mAb 13-1
AC CVCL_L583
DR CLO; CLO_0007504
DR ATCC; HB-10565
RX Patent=US5981714;
CC Monoclonal antibody target: UniProtKB; P13569; Human CFTR.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_3411 ! P3X63Ag8
CA Hybridoma
//
ID mAb 13-2
AC CVCL_L584
DR ATCC; HB-10566
RX Patent=US5981714;
CC Monoclonal antibody target: UniProtKB; P13569; Human CFTR.
CC Discontinued: ATCC; HB-10566; probable.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_3411 ! P3X63Ag8
CA Hybridoma
//
ID MAb 151-45-4
AC CVCL_L585
DR CLO; CLO_0007505
DR ATCC; HB-12682
RX Patent=US6323325;
RX PubMed=10376770;
CC Monoclonal antibody target: UniProtKB; P11509; Human CYP2A6.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_2155 ! P3/NS1/1-Ag4.1
CA Hybridoma
//
ID MAb 175-62
AC CVCL_W643
DR ATCC; PTA-1553
RX Patent=US6998468;
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_2199 ! Sp2/0-Ag14
CA Hybridoma
//
ID MAb 1812-4-8
AC CVCL_L586
DR CLO; CLO_0007506
DR ATCC; HB-12683
RX Patent=US6335428;
CC Monoclonal antibody target: UniProtKB; P05177; Human CYP1A2.
OX NCBI_TaxID=10090; ! Mus musculus
CA Hybridoma
//
ID Mab 1E8
AC CVCL_L587
DR CLO; CLO_0007507
DR ATCC; HB-11490
RX Patent=US6232080;
CC Monoclonal antibody target: UniProtKB; P18428; Human LBP.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID mAb 239
AC CVCL_L687
SY 239
DR ATCC; HB-8288
RX Patent=US5009995;
CC Monoclonal antibody target: UniProtKB; P40189; Human IL6ST/CD130/gp130.
CC Discontinued: ATCC; HB-8288; probable.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_2155 ! P3/NS1/1-Ag4.1
CA Hybridoma
//
ID mAb 24-1
AC CVCL_L588
SY mAB 24-1
DR CLO; CLO_0007508
DR ATCC; HB-11947
RX Patent=US5981714;
CC Monoclonal antibody target: UniProtKB; P13569; Human CFTR.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_3411 ! P3X63Ag8
CA Hybridoma
//
ID mAb 24-2
AC CVCL_L589
SY mAB 24-2
DR CLO; CLO_0007509
DR ATCC; HB-11946
RX Patent=US5981714;
CC Monoclonal antibody target: UniProtKB; P13569; Human CFTR.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_3411 ! P3X63Ag8
CA Hybridoma
//
ID MAb 26-7-5
AC CVCL_L590
DR CLO; CLO_0007510
DR ATCC; HB-12681
RX Patent=US6335428;
CC Monoclonal antibody target: UniProtKB; P05177; Human CYP1A2.
OX NCBI_TaxID=10090; ! Mus musculus
CA Hybridoma
//
ID mAb 270
AC CVCL_9217
DR CLO; CLO_0007511
DR ATCC; HB-189
OX NCBI_TaxID=10090; ! Mus musculus
OX NCBI_TaxID=10116; ! Rattus norvegicus
HI CVCL_4696 ! S194/5.XXO.BU.1
CA Hybridoma
//
ID Mab 2B5
AC CVCL_L591
DR CLO; CLO_0007512
DR ATCC; HB-11491
RX Patent=US6232080;
CC Monoclonal antibody target: UniProtKB; P18428; Human LBP.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID mAb 35
AC CVCL_4539
SY mAB 35; MAB 35; mAb35
DR CLO; CLO_0007513
DR CLO; CLO_0007514
DR CLO; CLO_0007524
DR CLDB; cl5225
DR ATCC; HB-8857
DR ATCC; TIB-175
DR IZSLER; BS Hy 10
RX PubMed=6948300;
CC Monoclonal antibody target: UniProtKB; P09688; Electrophorus electricus chrna1.
OX NCBI_TaxID=10090; ! Mus musculus
OX NCBI_TaxID=10116; ! Rattus norvegicus
HI CVCL_4696 ! S194/5.XXO.BU.1
CA Hybridoma
//
ID MAb 5.2
AC CVCL_L592
SY #5.2
DR CLO; CLO_0007515
DR ATCC; HB-9148
RX Patent=US5376370;
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID Mab 543
AC CVCL_L593
DR CLO; CLO_0007516
DR ATCC; HB-8592
RX Patent=US4672044;
CC Monoclonal antibody target: UniProtKB; P17927; Human CR1/CD35.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID Mab 62B1-PC
AC CVCL_3393
SY 62B1
DR CLO; CLO_0007517
DR CLDB; cl4917
DR ICLC; HYL98001
RX PubMed=3319299;
CC Monoclonal antibody target: Human unidentified plasma cell-associated antigen.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID mAb 64
AC CVCL_8963
SY mAb64
DR CLO; CLO_0007525
DR ATCC; HB-8987
RX PubMed=6948300;
CC Monoclonal antibody target: UniProtKB; P02709; Bovine CHRNA1.
OX NCBI_TaxID=10116; ! Rattus norvegicus
HI CVCL_4342 ! Y3-Ag 1.2.3
CA Hybridoma
//
ID mAb 829
AC CVCL_L688
SY 829
DR ATCC; HB-8289
RX Patent=US5009995;
CC Monoclonal antibody target: UniProtKB; P40189; Human IL6ST/CD130/gp130.
CC Discontinued: ATCC; HB-8289; probable.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_2155 ! P3/NS1/1-Ag4.1
CA Hybridoma
//
ID Mab 8A-PC
AC CVCL_3394
SY 8A
DR CLO; CLO_0007518
DR CLDB; cl4915
DR ICLC; HYL98002
RX PubMed=3319299;
CC Monoclonal antibody target: Human unidentified plasma cell-associated antigen.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID Mab 8F6-PC
AC CVCL_3395
SY 8F6
DR CLO; CLO_0007519
DR CLDB; cl4916
DR ICLC; HYL98003
RX PubMed=3319299;
CC Monoclonal antibody target: Human unidentified plasma cell-associated antigen.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID MAb 951-5-1
AC CVCL_L594
DR CLO; CLO_0007520
DR ATCC; HB-12684
RX Patent=US6335428;
CC Monoclonal antibody target: UniProtKB; P05177; Human CYP1A2.
OX NCBI_TaxID=10090; ! Mus musculus
CA Hybridoma
//
ID Mab 96
AC CVCL_L595
DR CLO; CLO_0007521
DR ATCC; HB-9763
RX Patent=US6217866;
CC Monoclonal antibody target: UniProtKB; P00533; Human EGFR.
CC Discontinued: ATCC; HB-9763; probable.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_2155 ! P3/NS1/1-Ag4.1
CA Hybridoma
//
ID mAb 986.35
AC CVCL_L689
SY 986.35; 986; mAB 986
DR ATCC; HB-9284
RX Patent=US5009995;
CC Monoclonal antibody target: UniProtKB; P40189; Human IL6ST/CD130/gp130.
CC Discontinued: ATCC; HB-9284; probable.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_2155 ! P3/NS1/1-Ag4.1
CA Hybridoma
//
ID mAb BB7
AC CVCL_L596
DR CLO; CLO_0007522
DR ATCC; CRL-2501
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_2199 ! Sp2/0-Ag14
CA Hybridoma
//
ID MAb D10
AC CVCL_Z990
RX Patent=US8975030;
CC Registration: International Depositary Authority, China General Microbiological Culture Collection Center (CGMCC); CGMCC No.2904.
CC Monoclonal antibody target: UniProtKB; P07900; Human HSP90AA1.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_2199 ! Sp2/0-Ag14
CA Hybridoma
//
ID MAb E9
AC CVCL_Z989
RX Patent=US8975030;
CC Registration: International Depositary Authority, China General Microbiological Culture Collection Center (CGMCC); CGMCC No.2903.
CC Monoclonal antibody target: UniProtKB; P07900; Human HSP90AA1.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_2199 ! Sp2/0-Ag14
CA Hybridoma
//
ID MAb104
AC CVCL_G668
DR CLO; CLO_0007523
DR ATCC; CRL-2067
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_2199 ! Sp2/0-Ag14
CA Hybridoma
//
ID Maben
AC CVCL_X194
RX DOI=10.1007/978-1-4757-1647-4_13;
RX PubMed=13258519;
RX PubMed=13472685;
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C3512; Lung adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID MAC 13
AC CVCL_S000
SY MAC13; Murine Adenocarcinoma of the Colon 13
DR ChEMBL-Cells; CHEMBL3307283
DR ChEMBL-Targets; CHEMBL614042
RX PubMed=9683789;
RX PubMed=11440905;
CC Transformant: ChEBI; CHEBI:73755; 1,2-dimethylhydrazine (DMH).
CC Breed/subspecies: NMRI.
DI NCIt; C120044; Mouse colon adenocarcinoma
OX NCBI_TaxID=10090; ! Mus musculus
CA Cancer cell line
//
ID MAC 15A
AC CVCL_H587
SY MAC15A; Murine Adenocarcinoma of the Colon 15A
DR ChEMBL-Cells; CHEMBL3307539
DR ChEMBL-Targets; CHEMBL614121
WW http://www.ukessays.com/essays/sciences/mac-15a-cell-line.php
CC Transformant: ChEBI; CHEBI:73755; 1,2-dimethylhydrazine (DMH).
CC Breed/subspecies: NMRI.
DI NCIt; C120044; Mouse colon adenocarcinoma
OX NCBI_TaxID=10090; ! Mus musculus
CA Cancer cell line
//
ID MAC 16
AC CVCL_S001
SY MAC16; Murine Adenocarcinoma of the Colon 16
DR ChEMBL-Cells; CHEMBL3307490
DR ChEMBL-Targets; CHEMBL614318
RX PubMed=9683789;
RX PubMed=11440905;
CC Transformant: ChEBI; CHEBI:73755; 1,2-dimethylhydrazine (DMH).
CC Breed/subspecies: NMRI.
DI NCIt; C120044; Mouse colon adenocarcinoma
OX NCBI_TaxID=10090; ! Mus musculus
CA Cancer cell line
//
ID MAC 2-48
AC CVCL_L547
DR CLO; CLO_0007526
DR ATCC; HB-10714
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_2155 ! P3/NS1/1-Ag4.1
CA Hybridoma
//
ID MAC 26
AC CVCL_S002
SY MAC26; Murine Adenocarcinoma of the Colon 26
DR ChEMBL-Cells; CHEMBL3307878
DR ChEMBL-Targets; CHEMBL614122
RX PubMed=9683789;
CC Transformant: ChEBI; CHEBI:73755; 1,2-dimethylhydrazine (DMH).
CC Breed/subspecies: NMRI.
DI NCIt; C120044; Mouse colon adenocarcinoma
OX NCBI_TaxID=10090; ! Mus musculus
CA Cancer cell line
//
ID Mac-1
AC CVCL_H631
SY MAC-1; MAC1; McG-1
DR BTO; BTO:0004869
DR Cosmic; 2013355
DR GEO; GSM1217151
RX CelloPub=CLPUB00077;
RX PubMed=1532439;
RX PubMed=2456698;
RX PubMed=2898211;
DI NCIt; C3467; Cutaneous T-cell non-Hodgkin lymphoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_H632 ! Mac-2
SX Male
CA Cancer cell line
//
ID Mac-2
AC CVCL_H632
SY MAC-2; McG-2
RX CelloPub=CLPUB00077;
RX PubMed=2456698;
DI NCIt; C3720; Anaplastic large cell lymphoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_H631 ! Mac-1
SX Male
CA Cancer cell line
//
ID MAC-2
AC CVCL_S921
RX PubMed=8039117;
DI NCIt; C4908; Ovarian carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID Mac-2A
AC CVCL_H637
SY MAC-2A; McG-2A; PB-2A
RX PubMed=1532439;
RX PubMed=2789474;
RX PubMed=15356658;
DI NCIt; C3720; Anaplastic large cell lymphoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_H632 ! Mac-2
SX Male
CA Cancer cell line
//
ID Mac-2B
AC CVCL_H638
SY MAC-2B; McG-2B
RX PubMed=1532439;
RX PubMed=2789474;
RX PubMed=15356658;
DI NCIt; C3720; Anaplastic large cell lymphoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_H632 ! Mac-2
SX Male
CA Cancer cell line
//
ID MAC-21
AC CVCL_M627
SY MAC 21
RX CelloPub=CLPUB00262;
RX PubMed=13806813;
RX PubMed=14098906;
CC Problematic cell line: Contaminated. Shown to be a HeLa derivative. Originally thought to originate from a male patient lung adenocarcinoma. The original MAC-21 cell line was never tested for contamination. See the colorful description of the MAC-21 contamination story in the book from Michael Gold (CLPUB00262).
CC Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18).
DI NCIt; C4029; Cervical adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0030 ! HeLa
SX Female
CA Cancer cell line
//
ID MAC-T
AC CVCL_U226
SY Mac-T; MacT; Mammary Alveolar Cells-large T antigen
DR ATCC; CRL-10274
DR BCRJ; 0315
DR GEO; GSE46476
RX Patent=US5227301;
RX Patent=US5455164;
RX DOI=10.4172/2329-888X.1000103;
RX PubMed=1423654;
RX PubMed=1659986;
RX PubMed=7540186;
RX PubMed=14550508;
RX PubMed=26659725;
CC Doubling time: ~17 hours (PubMed=1659986); 48 hours, in serum-free medium (PubMed=7540186).
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40) [tsA58].
CC Omics: Transcriptome analysis.
CC Anecdotal: Nexia, a former Canadian biotech company was orignally developed to make lactose-free free milk using MAC-T.
CC Discontinued: ATCC; CRL-10274; probable.
OX NCBI_TaxID=9913; ! Bos taurus
SX Female
CA Transformed cell line
//
ID MAC-T CU-1
AC CVCL_U230
SY CU-1; MAC-T Cornell University-1
RX PubMed=7540186;
CC Doubling time: 16 hours, 78 hours, in serum-free medium (PubMed=7540186).
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40) [tsA58].
CC Miscellaneous: Cell line not available (personal communication of Politis I.).
OX NCBI_TaxID=9913; ! Bos taurus
HI CVCL_U226 ! MAC-T
SX Female
CA Transformed cell line
//
ID MAC-T CU-2
AC CVCL_U231
SY CU-2; MAC-T Cornell University-2
RX PubMed=7540186;
CC Doubling time: 15 hours, 46 hours, in serum-free medium (PubMed=7540186).
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40) [tsA58].
CC Miscellaneous: Cell line not available (personal communication of Politis I.).
OX NCBI_TaxID=9913; ! Bos taurus
HI CVCL_U226 ! MAC-T
SX Female
CA Transformed cell line
//
ID MAC-T CU-3
AC CVCL_U232
SY CU-3; MAC-T Cornell University-3
RX PubMed=7540186;
CC Doubling time: 14 hours, 80 hours, in serum-free medium (PubMed=7540186).
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40) [tsA58].
CC Miscellaneous: Cell line not available (personal communication of Politis I.).
OX NCBI_TaxID=9913; ! Bos taurus
HI CVCL_U226 ! MAC-T
SX Female
CA Transformed cell line
//
ID MaCa 1
AC CVCL_M375
SY MaCa1
RX PubMed=7923078;
DI NCIt; C4872; Breast carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID MaCa 2
AC CVCL_M376
SY MaCa2
RX PubMed=7923078;
DI NCIt; C4872; Breast carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID Machi
AC CVCL_R796
DR Wikidata; Q28521737
RX PubMed=92573;
RX PubMed=1690682;
RX PubMed=8891732;
CC Group: Non-human primate cell line.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9595; ! Gorilla gorilla gorilla
SX Male
CA Transformed cell line
//
ID MACKI
AC CVCL_0A71
SY Macki
DR ATCC; CRL-6582
RX PubMed=6500159;
CC Group: Non-human primate cell line.
CC Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982).
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC Discontinued: ATCC; CRL-6582; true.
OX NCBI_TaxID=9595; ! Gorilla gorilla gorilla
SX Female
CA Transformed cell line
//
ID MacKinley
AC CVCL_L362
SY McKinley
DR GEO; GSM1974793
RX PubMed=21908323;
RX PubMed=22916246;
RX PubMed=26842912;
RX PubMed=27197945;
RX PubMed=27257868;
CC Part of: FACC canine tumor cell line panel.
CC Doubling time: 27.6 hours (PubMed=22916246).
CC Omics: Transcriptome analysis.
DI NCIt; C120045; Canine osteosarcoma
OX NCBI_TaxID=9615; ! Canis lupus familiaris
CA Cancer cell line
//
ID MACL-1
AC CVCL_6846
DR BTO; BTO:0005048
RX PubMed=19725227;
RX PubMed=23404580;
DI NCIt; C4872; Breast carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID Mad/C1
AC CVCL_S501
DR ATCC; CRL-6366
CC Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982).
CC Discontinued: ATCC; CRL-6366; true.
DI NCIt; C21762; Adenoma of the mouse pulmonary system
OX NCBI_TaxID=10090; ! Mus musculus
CA Cancer cell line
//
ID Mad/C3
AC CVCL_S502
SY Mad-C3
DR ATCC; CRL-6367
CC Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982).
CC Discontinued: ATCC; CRL-6367; true.
DI NCIt; C21762; Adenoma of the mouse pulmonary system
OX NCBI_TaxID=10090; ! Mus musculus
CA Cancer cell line
//
ID MAD,MF
AC CVCL_E768
SY MAD, MF
DR dbMHC; 48964
DR ECACC; 94082232
DR IHW; IHW9133
DR IMGT/HLA; 11676
RX PubMed=8307784;
WW http://bioinformatics.hsanmartino.it/ecbr/cl133.html
CC Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Transformed cell line
//
ID MADB106
AC CVCL_BT04
DR CCRID; 3142C0001000000125
DR KCB; KCB 2013045YJ
RX PubMed=10220071;
CC Breed/subspecies: Fischer 344.
DI NCIt; C64011; Adenocarcinoma of the rat mammary gland
OX NCBI_TaxID=10116; ! Rattus norvegicus
SX Female
CA Cancer cell line
//
ID Madsen
AC CVCL_M139
DR BTO; BTO:0004329
RX PubMed=19831134;
CC From: Youle R.; National Institutes of Health; Bethesda; USA.
DI NCIt; C3222; Medulloblastoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID MADURA
AC CVCL_E769
SY MADURA-T; GM08598
DR CLO; CLO_0010592
DR Coriell; GM08598
DR dbMHC; 48965
DR ECACC; 88052069
DR IHW; IHW9069
DR IMGT/HLA; 11044
WW http://bioinformatics.hsanmartino.it/ecbr/cl69.html
CC Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Transformed cell line
//
ID MAEC
AC CVCL_U411
DR CLO; CLO_0051046
DR RCB; RCB2712
RX PubMed=17215585;
CC Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53.
OX NCBI_TaxID=10090; ! Mus musculus
SX Female
CA Spontaneously immortalized cell line
//
ID MAF
AC CVCL_R844
SY Megalobrama Amblycephala Fin
RX PubMed=23532304;
CC Group: Fish cell line.
OX NCBI_TaxID=75352; ! Megalobrama amblycephala
SX Sex undetermined
CA Spontaneously immortalized cell line
//
ID Mahlavu
AC CVCL_0405
SY MAHLAVU
DR BTO; BTO:0004471
DR MCCL; MCC:0000299
DR Cosmic; 873398
DR Cosmic; 948064
DR Cosmic; 979727
DR Cosmic; 1019317
DR Cosmic; 2162534
DR Cosmic; 2321039
RX CelloPub=CLPUB00076;
RX PubMed=179808;
RX PubMed=2439335;
RX PubMed=6268737;
RX PubMed=8050184;
RX PubMed=23887712;
RX PubMed=25574106;
CC Misspelling: Occasionally 'Malhavu'.
DI NCIt; C3099; Hepatocellular carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID MAIL8
AC CVCL_0406
DR MCCL; MCC:0000300
RX PubMed=15701651;
CC Transfected with: HGNC; 16608; PYCARD.
CC Transfected with: UniProtKB; P42212; GFP.
CC Transformant: NCBI_TaxID; 28285; Adenovirus 5.
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0045 ! HEK293
SX Female
CA Transformed cell line
//
ID Mais-BL
AC CVCL_7200
SY Mais
RX PubMed=9882297;
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
DI NCIt; C27694; Epstein-Barr virus-related Burkitt lymphoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID Maja
AC CVCL_F516
SY MAJA; GM03099
DR CLO; CLO_0013481
DR Coriell; GM03099
RX PubMed=6806098;
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Transformed cell line
//
ID Maku
AC CVCL_1Q44
AS CVCL_W929
SY MAKU; Mak-BL; MAK-BL; MAK; NK-51; NK51
RX PubMed=170370;
RX PubMed=2824665;
RX PubMed=2943927;
RX PubMed=3027441;
RX PubMed=4122458;
RX PubMed=4320167;
RX PubMed=4364259;
RX PubMed=4907973;
RX PubMed=7316467;
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
DI NCIt; C27694; Epstein-Barr virus-related Burkitt lymphoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Malme-3
AC CVCL_1437
SY MALME-3
DR BTO; BTO:0004161
DR CLO; CLO_0007528
DR ATCC; HTB-102
DR BCRJ; 0286
DR BioSample; SAMN03471086
DR Cosmic; 2233661
CC From: Memorial Sloan-Kettering Cancer Center; New York; USA.
CC Discontinued: BCRJ; 0286; probable.
ST Source(s): ATCC
ST Amelogenin: X,Y
ST CSF1PO: 10,12
ST D13S317: 8,13
ST D16S539: 9,12
ST D5S818: 11,13
ST D7S820: 9,12
ST TH01: 7,8
ST TPOX: 8,9
ST vWA: 15,16
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_1438 ! Malme-3M
OI CVCL_1E90 ! Malme-3S
SX Male
CA Finite cell line
//
ID Malme-3M
AC CVCL_1438
SY MALME-3M; MALME 3M; Malme-3 M; MALME.3M; Malme3M; MALME3M
DR BTO; BTO:0004162
DR CLO; CLO_0007529
DR CLO; CLO_0007530
DR EFO; EFO_0002243
DR CLDB; cl3334
DR ATCC; HTB-64
DR BCRJ; 0287
DR BioSample; SAMN03470851
DR BioSample; SAMN03472750
DR CCLE; MALME3M_SKIN
DR ChEMBL-Cells; CHEMBL3307507
DR ChEMBL-Targets; CHEMBL614021
DR Cosmic; 686474
DR Cosmic; 687438
DR Cosmic; 706116
DR Cosmic; 875884
DR Cosmic; 888864
DR Cosmic; 905953
DR Cosmic; 933002
DR Cosmic; 974071
DR Cosmic; 974256
DR Cosmic; 1006558
DR Cosmic; 1022281
DR Cosmic; 1045408
DR Cosmic; 1067226
DR Cosmic; 1092616
DR Cosmic; 1132592
DR Cosmic; 1155270
DR Cosmic; 1175870
DR Cosmic; 1303042
DR Cosmic; 1305364
DR Cosmic; 1312347
DR Cosmic; 1458963
DR Cosmic; 1459637
DR Cosmic; 1477403
DR Cosmic; 1507615
DR Cosmic; 1669122
DR Cosmic; 1998458
DR Cosmic; 2230113
DR GEO; GSM50202
DR GEO; GSM50264
DR GEO; GSM188223
DR GEO; GSM188253
DR GEO; GSM188312
DR GEO; GSM206522
DR GEO; GSM750822
DR GEO; GSM799353
DR GEO; GSM799416
DR GEO; GSM847035
DR GEO; GSM887288
DR GEO; GSM888363
DR GEO; GSM1138789
DR GEO; GSM1153423
DR GEO; GSM1181293
DR GEO; GSM1181295
DR GEO; GSM1670073
DR IGRhCellID; Malme3M
DR KCLB; 30064
DR SKY/M-FISH/CGH; 2740
RX DOI=10.1007/978-1-4757-1647-4_5;
RX PubMed=327080;
RX PubMed=833871;
RX PubMed=2041050;
RX PubMed=6935474;
RX PubMed=7459858;
RX PubMed=7999427;
RX PubMed=19372543;
RX PubMed=15009714;
RX PubMed=17088437;
RX PubMed=22460905;
RX PubMed=23856246;
RX PubMed=23933261;
RX PubMed=27807467;
RX PubMed=28196595;
WW https://dtp.cancer.gov/discovery_development/nci-60/cell_list.htm
WW https://strap.nci.nih.gov/celline_detail.php?sample_id=44
WW https://www.mskcc.org/research-advantage/support/technology/tangible-material/malme-3m-human-melanoma-cell-line
WW http://tcpaportal.org/mclp/
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Part of: MD Anderson Cell Lines Project.
CC Part of: NCI60 cancer cell line panel.
CC From: Memorial Sloan-Kettering Cancer Center; New York; USA.
CC Registration: Memorial Sloan-Kettering Cancer Center Office of Technology Development; SK2009-092.
CC Doubling time: 46.2 hours (DTP).
CC Omics: Deep exome analysis.
CC Omics: Deep proteome analysis.
CC Omics: DNA methylation analysis.
CC Omics: Protein expression by reverse-phase protein arrays.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
CC Misspelling: 'MELM-3M' in Cosmic 1458963.
CC Derived from metastatic site: Lung.
ST Source(s): ATCC; KCLB; PubMed=19372543
ST Amelogenin: X,Y
ST CSF1PO: 12
ST D13S317: 8,13
ST D16S539: 9,12
ST D18S51: 14
ST D19S433: 13,14
ST D21S11: 30.2,32.2
ST D2S1338: 24
ST D3S1358: 14,18
ST D5S818: 11
ST D7S820: 9,12
ST D8S1179: 13
ST FGA: 21,22
ST TH01: 8
ST TPOX: 8,9
ST vWA: 15,16
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_1437 ! Malme-3
OI CVCL_1E90 ! Malme-3S
SX Male
CA Cancer cell line
//
ID Malme-3S
AC CVCL_1E90
RX DOI=10.1007/978-1-4757-1647-4_5;
CC From: Memorial Sloan-Kettering Cancer Center; New York; USA.
CC Derived from metastatic site: Lung.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_1437 ! Malme-3
OI CVCL_1438 ! Malme-3M
SX Male
CA Cancer cell line
//
ID MAME
AC CVCL_G035
DR IMGT/HLA; 11048
CC Part of: International Histocompatibility Workshop cell lines.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Transformed cell line
//
ID MaMi
AC CVCL_5796
RX PubMed=9740146;
WW http://www.cells-talk.com/index.php/page/copelibrary?key=MaMi
DI NCIt; C8973; Endometrioid stromal sarcoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID Man-1
AC CVCL_B893
SY MAN-1; UMANe001-A
DR hPSCreg; UMANe001-A
DR ISCR; 1647
RX PubMed=20177994;
WW http://www.nibsc.org/science_and_research/advanced_therapies/uk_stem_cell_bank/cell_lines/available_human_cell_lines/laboratory_grade/man-1.aspx
CC From: University of Manchester; Manchester; UK.
CC Registration: UK Stem Cell Bank (UKSCB); R-08-017, Steering comm. appl. SCSC08-02.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Embryonic stem cell
//
ID Man-10
AC CVCL_L198
SY MAN-10
CC From: University of Manchester; Manchester; UK.
CC Registration: UK Stem Cell Bank (UKSCB); Steering comm. appl. SCSC12-17.
OX NCBI_TaxID=9606; ! Homo sapiens
CA Embryonic stem cell
//
ID Man-11
AC CVCL_L199
SY MAN-11; MAN11; Man11
RX PubMed=26607962;
CC Group: Clinical grade hESC cell line.
CC From: University of Manchester; Manchester; UK.
CC Registration: UK Stem Cell Bank (UKSCB); Steering comm. appl. SCSC12-26.
CC Omics: CNV analysis.
CC Omics: SNP array analysis.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Embryonic stem cell
//
ID Man-12
AC CVCL_L200
SY MAN-12; MAN12; Man12
RX PubMed=26607962;
CC Group: Clinical grade hESC cell line.
CC From: University of Manchester; Manchester; UK.
CC Registration: UK Stem Cell Bank (UKSCB); Steering comm. appl. SCSC12-27.
CC Omics: CNV analysis.
CC Omics: SNP array analysis.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Embryonic stem cell
//
ID Man-13
AC CVCL_L201
SY MAN-13; MAN13; Man13; UMANe002-A
DR BioSamples; SAMEA7792168
DR hPSCreg; UMANe002-A
CC Group: Clinical grade hESC cell line.
CC From: University of Manchester; Manchester; UK.
CC Registration: UK Stem Cell Bank (UKSCB); Steering comm. appl. SCSC12-28.
OX NCBI_TaxID=9606; ! Homo sapiens
CA Embryonic stem cell
//
ID Man-14
AC CVCL_BW68
SY MAN-14; MAN14; Man14
CC Group: Clinical grade hESC cell line.
CC From: University of Manchester; Manchester; UK.
CC Registration: UK Stem Cell Bank (UKSCB); Steering comm. appl. SCSC14-23.
OX NCBI_TaxID=9606; ! Homo sapiens
CA Embryonic stem cell
//
ID Man-15
AC CVCL_BW69
SY MAN-15; MAN15; Man15
CC Group: Clinical grade hESC cell line.
CC From: University of Manchester; Manchester; UK.
CC Registration: UK Stem Cell Bank (UKSCB); Steering comm. appl. SCSC14-24.
OX NCBI_TaxID=9606; ! Homo sapiens
CA Embryonic stem cell
//
ID Man-16
AC CVCL_BW70
SY MAN-16; MAN16; Man16
CC Group: Clinical grade hESC cell line.
CC From: University of Manchester; Manchester; UK.
CC Registration: UK Stem Cell Bank (UKSCB); Steering comm. appl. SCSC14-25.
OX NCBI_TaxID=9606; ! Homo sapiens
CA Embryonic stem cell
//
ID Man-2
AC CVCL_B894
SY MAN-2; CMFTe001-A
DR hPSCreg; CMFTe001-A
DR ISCR; 1648
RX PubMed=20177994;
WW http://www.nibsc.org/science_and_research/advanced_therapies/uk_stem_cell_bank/cell_lines/available_human_cell_lines/laboratory_grade/man-2.aspx
CC From: University of Manchester; Manchester; UK.
CC Registration: UK Stem Cell Bank (UKSCB); R-09-011, Steering comm. appl. SCSC09-01.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Embryonic stem cell
//
ID Man-3
AC CVCL_L191
SY MAN-3
CC From: University of Manchester; Manchester; UK.
CC Registration: UK Stem Cell Bank (UKSCB); Steering comm. appl. SCSC12-20.
OX NCBI_TaxID=9606; ! Homo sapiens
CA Embryonic stem cell
//
ID Man-4
AC CVCL_L192
SY MAN-4
CC From: University of Manchester; Manchester; UK.
CC Registration: UK Stem Cell Bank (UKSCB); Steering comm. appl. SCSC12-21.
OX NCBI_TaxID=9606; ! Homo sapiens
CA Embryonic stem cell
//
ID Man-5
AC CVCL_L193
SY MAN-5
CC From: University of Manchester; Manchester; UK.
CC Registration: UK Stem Cell Bank (UKSCB); Steering comm. appl. SCSC12-22.
OX NCBI_TaxID=9606; ! Homo sapiens
CA Embryonic stem cell
//
ID Man-6
AC CVCL_L194
SY MAN-6
CC From: University of Manchester; Manchester; UK.
CC Registration: UK Stem Cell Bank (UKSCB); Steering comm. appl. SCSC12-23.
OX NCBI_TaxID=9606; ! Homo sapiens
CA Embryonic stem cell
//
ID Man-7
AC CVCL_L195
SY MAN-7
CC From: University of Manchester; Manchester; UK.
CC Registration: UK Stem Cell Bank (UKSCB); Steering comm. appl. SCSC12-24.
OX NCBI_TaxID=9606; ! Homo sapiens
CA Embryonic stem cell
//
ID Man-8
AC CVCL_L196
SY MAN-8
CC From: University of Manchester; Manchester; UK.
CC Registration: UK Stem Cell Bank (UKSCB); Steering comm. appl. SCSC12-25.
OX NCBI_TaxID=9606; ! Homo sapiens
CA Embryonic stem cell
//
ID Man-9
AC CVCL_L197
SY MAN-9
CC From: University of Manchester; Manchester; UK.
CC Registration: UK Stem Cell Bank (UKSCB); Steering comm. appl. SCSC12-16.
OX NCBI_TaxID=9606; ! Homo sapiens
CA Embryonic stem cell
//
ID MANIKA
AC CVCL_E770
SY MANIKAM
DR dbMHC; 48966
DR ECACC; 94122027
DR IHW; IHW9106
DR IMGT/HLA; 11640
RX PubMed=11782282;
WW http://bioinformatics.hsanmartino.it/ecbr/cl106.html
CC Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Transformed cell line
//
ID Mano
AC CVCL_W901
SY MANO
RX PubMed=892930;
RX PubMed=6826254;
DI NCIt; C4912; Bladder carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID Mao
AC CVCL_BT01
SY MAO
DR CCRID; 3153C0001000000101
DR KCB; KCB 200711M
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
CA Transformed cell line
//
ID mAQC2
AC CVCL_5A33
SY AQ.C2-9
DR ATCC; PTA-3273
RX Patent=US7358054;
CC Monoclonal antibody target: UniProtKB; P56199; Human ITGA1/CD49a.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_5A32 ! FL653
CA Hybridoma
//
ID MAR
AC CVCL_0B87
SY Mar; MA-R
DR Cosmic; 2239098
RX PubMed=3034934;
RX PubMed=7736387;
RX PubMed=9559344;
DI NCIt; C4917; Small cell lung carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID MAR 18.5
AC CVCL_D294
DR CLO; CLO_0007532
DR ATCC; TIB-216
DR BCRJ; 0158
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_3411 ! P3X63Ag8
CA Hybridoma
//
ID Mar Bel
AC CVCL_G291
SY Mar-Bel; MAR BEL
DR ATCC; CRL-1186
DR ChEMBL-Cells; CHEMBL3308602
DR ChEMBL-Targets; CHEMBL614653
CC Discontinued: ATCC; CRL-1186; true.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Finite cell line
//
ID Mar Nol
AC CVCL_3016
DR CLO; CLO_0007533
DR ATCC; CRL-1257
DI NCIt; C34807; Marfan syndrome
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Finite cell line
//
ID Mar Ton
AC CVCL_3017
DR CLO; CLO_0007534
DR ATCC; CRL-1252
DI NCIt; C34568; Ehlers-Danlos syndrome
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Finite cell line
//
ID Mar Vin
AC CVCL_3018
DR CLO; CLO_0007535
DR ATCC; CRL-1138
DI NCIt; C125696; Ehlers-Danlos syndrome, type I
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Finite cell line
//
ID MAR00333IN
AC CVCL_E164
WW http://www.biologia.uniba.it/primates/cell_lines.html
CC Group: Non-human primate cell line.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9540; ! Macaca arctoides
SX Sex undetermined
CA Transformed cell line
//
ID MAR00334IN
AC CVCL_E165
WW http://www.biologia.uniba.it/primates/cell_lines.html
CC Group: Non-human primate cell line.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9540; ! Macaca arctoides
SX Sex undetermined
CA Transformed cell line
//
ID MARC 29F8
AC CVCL_L546
SY 29F8
DR CLO; CLO_0007537
DR ATCC; CRL-2508
RX PubMed=9041412;
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID MARC 2B7
AC CVCL_L544
SY 2B7
DR CLO; CLO_0007538
DR ATCC; CRL-2509
RX PubMed=8795222;
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID MARC 46E9-9
AC CVCL_L545
SY 46E9-9
RX PubMed=8795222;
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID MARC S5
AC CVCL_L536
SY S5
DR CLO; CLO_0007539
DR ATCC; CRL-2507
RX PubMed=9041412;
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID MARC-145
AC CVCL_4540
SY Marc-145; MARC 145; Marc 145; MARC145; Marc145; Meat Animal Research Center-145
DR CLO; CLO_0007536
DR CLDB; cl5226
DR ATCC; CRL-12219
DR ATCC; CRL-12230
DR GEO; GSM1263300
DR GEO; GSM1263301
DR GEO; GSM1263302
DR GEO; GSM1263303
DR IZSLER; BS CL 127
DR KCB; KCB 200801YJ
RX Patent=US5690940;
RX PubMed=8257302;
RX PubMed=17081295;
RX PubMed=23148668;
CC Group: Non-human primate cell line.
CC Problematic cell line: Misidentified. Parent cell line (MA-104) has been shown to be from African Green monkey instead of Rhesus macaque.
CC Characteristics: Highly permissive to porcine reproductive and respiratory syndrome virus (PRRSV) infection.
CC Omics: Transcriptome analysis.
CC Discontinued: ATCC; CRL-12219; probable.
CC Discontinued: ATCC; CRL-12230; probable.
OX NCBI_TaxID=9534; ! Chlorocebus aethiops
HI CVCL_3845 ! MA-104
SX Sex undetermined
CA Spontaneously immortalized cell line
//
ID MARC-Nsp11
AC CVCL_HA70
DR GEO; GSM1263298
DR GEO; GSM1263299
RX PubMed=24719865;
CC Group: Non-human primate cell line.
CC Problematic cell line: Misidentified. Great-parent cell line (MA-104) has been shown to be from African Green monkey instead of Rhesus macaque.
CC Transfected with: UniProtKB; Q6QDR0; Porcine reproductive and respiratory syndrome virus strain NVSL 97-7895 nsp11 (AA 1088-1310).
CC Omics: Transcriptome analysis.
OX NCBI_TaxID=9534; ! Chlorocebus aethiops
HI CVCL_4540 ! MARC-145
CA Spontaneously immortalized cell line
//
ID MARC.BGCF.1-3
AC CVCL_0F31
SY MARC Bovine Genome Cow Fibroblasts 1-3
DR ATCC; CRL-2875
RX PubMed=20015332;
CC Omics: Genome sequenced.
CC Discontinued: ATCC; CRL-2875; true.
CC Breed/subspecies: Hereford.
OX NCBI_TaxID=9913; ! Bos taurus
OI CVCL_0F30 ! MARC.BGCF.2
SX Female
CA Finite cell line
//
ID MARC.BGCF.2
AC CVCL_0F30
SY MARC Bovine Genome Cow Fibroblasts 2
DR ATCC; CRL-2874
RX PubMed=20015332;
CC Omics: Genome sequenced.
CC Discontinued: ATCC; CRL-2874; true.
CC Breed/subspecies: Hereford.
OX NCBI_TaxID=9913; ! Bos taurus
OI CVCL_0F31 ! MARC.BGCF.1-3
SX Female
CA Finite cell line
//
ID MARC.OKF
AC CVCL_W365
SY USMARC Ovine Kidney Fibroblast; AG19825
DR Coriell; AG19825
RX PubMed=18432399;
CC Discontinued: Coriell; AG19825; probable.
CC Breed/subspecies: Texel.
OX NCBI_TaxID=9940; ! Ovis aries
OI CVCL_W366 ! MARC.OVSM
SX Male
CA Spontaneously immortalized cell line
//
ID MARC.OVSM
AC CVCL_W366
SY USMARC Ovine Vascular Smooth Muscle; AG19826
DR Coriell; AG19826
RX PubMed=18432399;
CC Discontinued: Coriell; AG19826; probable.
CC Breed/subspecies: Texel.
OX NCBI_TaxID=9940; ! Ovis aries
OI CVCL_W365 ! MARC.OKF
SX Male
CA Spontaneously immortalized cell line
//
ID Marcus
AC CVCL_3019
SY AJ
DR BioSample; SAMN03472776
DR CGH-DB; 149-1
DR IFO; IFO50290
RX PubMed=283420;
RX PubMed=16232199;
CC Discontinued: IFO; IFO50290; probable.
ST Source(s): JCRB
ST Amelogenin: X
ST CSF1PO: 12,15
ST D13S317: 11
ST D16S539: 12,13
ST D5S818: 11,12
ST D7S820: 9,11
ST TH01: 9,9.3
ST TPOX: 8,11
ST vWA: 17,18
DI NCIt; C60781; Astrocytoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID Margret
AC CVCL_X929
SY NK11a; NK 11
RX PubMed=4174339;
RX PubMed=4178827;
RX PubMed=5021706;
RX PubMed=5786183;
CC Characteristics: EBV-negative.
DI NCIt; C2912; Burkitt lymphoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID Marimo
AC CVCL_6992
SY MARIMO
DR Cosmic; 787448
DR Cosmic; 975266
DR Cosmic; 1012083
DR Cosmic; 1281324
DR Cosmic; 1465956
DR Cosmic; 1465959
DR Cosmic; 2306195
RX PubMed=9406575;
RX PubMed=16408098;
DI NCIt; C8252; Therapy-related acute myeloid leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID Marisco
AC CVCL_L363
SY Moresco
DR BTO; BTO:0005359
DR GEO; GSM1974794
RX PubMed=21552385;
RX PubMed=21908323;
RX PubMed=22916246;
RX PubMed=27197945;
RX PubMed=27257868;
CC Part of: FACC canine tumor cell line panel.
CC Doubling time: 22.1 hours (PubMed=22916246).
CC Omics: Transcriptome analysis.
DI NCIt; C120045; Canine osteosarcoma
OX NCBI_TaxID=9615; ! Canis lupus familiaris
CA Cancer cell line
//
ID MARMarg
AC CVCL_E771
SY TER236
DR dbMHC; 48967
DR ECACC; 94050340
DR IHW; IHW9307
DR IMGT/HLA; 11052
WW http://bioinformatics.hsanmartino.it/ecbr/cl307.html
CC Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Transformed cell line
//
ID MARMari
AC CVCL_E772
DR dbMHC; 48968
DR IHW; IHW9308
DR IMGT/HLA; 11053
WW http://bioinformatics.hsanmartino.it/ecbr/cl308.html
CC Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
SX Sex undetermined
CA Transformed cell line
//
ID MASE
AC CVCL_HF45
SY Misgurnus Anguillicaudatus Skin Epidermis
RX PubMed=27288257;
CC Group: Fish cell line.
CC Doubling time: 53.3 hours (PubMed=27288257).
OX NCBI_TaxID=75329; ! Misgurnus anguillicaudatus
SX Sex undetermined
CA Spontaneously immortalized cell line
//
ID Mash-1
AC CVCL_8158
DR BioSample; SAMN03151848
DR RCB; RCB1386
RX PubMed=12366446;
RX PubMed=16643607;
RX PubMed=20143388;
WW http://iclac.org/wp-content/uploads/Cross-Contaminations-v8_0.pdf
CC Problematic cell line: Contaminated. Shown to be a MMAc derivative (PubMed=16643607, PubMed=20143388).
CC Discontinued: RCB; RCB1386; true.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_5951 ! MMAc
SX Female
CA Cancer cell line
//
ID Maska-98
AC CVCL_IW67
RX PubMed=11279638;
CC Characteristics: Produces high level of lactate dehydrogenase (LDH).
CC Doubling time: 36-48 hours (PubMed=11279638).
DI NCIt; C3242; Plasma cell myeloma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID MAST
AC CVCL_M374
RX PubMed=8601577;
DI NCIt; C4872; Breast carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID MasterShef1
AC CVCL_BW74
SY MstrShef1; MShef1; UOSe001-A
DR hPSCreg; UOSe001-A
CC Group: Clinical grade hESC cell line.
CC From: University of Sheffield; Sheffield; UK.
CC Registration: UK Stem Cell Bank (UKSCB); Steering comm. appl. SCSC12-02.
OX NCBI_TaxID=9606; ! Homo sapiens
CA Embryonic stem cell
//
ID MasterShef10
AC CVCL_BW82
RX PubMed=26607962;
CC Group: Clinical grade hESC cell line.
CC From: University of Sheffield; Sheffield; UK.
CC Registration: UK Stem Cell Bank (UKSCB); Steering comm. appl. SCSC13-05.
CC Omics: CNV analysis.
CC Omics: SNP array analysis.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Embryonic stem cell
//
ID MasterShef11
AC CVCL_BW83
RX PubMed=26607962;
CC Group: Clinical grade hESC cell line.
CC From: University of Sheffield; Sheffield; UK.
CC Registration: UK Stem Cell Bank (UKSCB); Steering comm. appl. SCSC13-06.
CC Omics: CNV analysis.
CC Omics: SNP array analysis.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Embryonic stem cell
//
ID MasterShef12
AC CVCL_BW84
RX PubMed=26607962;
CC Group: Clinical grade hESC cell line.
CC From: University of Sheffield; Sheffield; UK.
CC Registration: UK Stem Cell Bank (UKSCB); Steering comm. appl. SCSC13-07.
CC Omics: CNV analysis.
CC Omics: SNP array analysis.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Embryonic stem cell
//
ID MasterShef13
AC CVCL_BW85
RX PubMed=26607962;
CC Group: Clinical grade hESC cell line.
CC From: University of Sheffield; Sheffield; UK.
CC Registration: UK Stem Cell Bank (UKSCB); Steering comm. appl. SCSC13-08.
CC Omics: CNV analysis.
CC Omics: SNP array analysis.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Embryonic stem cell
//
ID MasterShef14
AC CVCL_BW86
RX PubMed=26607962;
CC Group: Clinical grade hESC cell line.
CC From: University of Sheffield; Sheffield; UK.
CC Registration: UK Stem Cell Bank (UKSCB); Steering comm. appl. SCSC14-65.
CC Omics: CNV analysis.
CC Omics: SNP array analysis.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Embryonic stem cell
//
ID MasterShef2
AC CVCL_BW75
SY MstrShef2; MShef2; UOSe007-A
DR hPSCreg; UOSe007-A
RX PubMed=26607962;
CC Group: Clinical grade hESC cell line.
CC From: University of Sheffield; Sheffield; UK.
CC Registration: UK Stem Cell Bank (UKSCB); Steering comm. appl. SCSC12-03.
CC Omics: CNV analysis.
CC Omics: SNP array analysis.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Embryonic stem cell
//
ID MasterShef3
AC CVCL_BW76
SY MstrShef3; MShef3; UOSe008-A
DR hPSCreg; UOSe008-A
RX PubMed=26607962;
CC Group: Clinical grade hESC cell line.
CC From: University of Sheffield; Sheffield; UK.
CC Registration: UK Stem Cell Bank (UKSCB); Steering comm. appl. SCSC12-04.
CC Omics: CNV analysis.
CC Omics: SNP array analysis.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Embryonic stem cell
//
ID MasterShef4
AC CVCL_BW77
RX PubMed=26607962;
CC Group: Clinical grade hESC cell line.
CC From: University of Sheffield; Sheffield; UK.
CC Registration: UK Stem Cell Bank (UKSCB); Steering comm. appl. SCSC12-05.
CC Omics: CNV analysis.
CC Omics: SNP array analysis.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Embryonic stem cell
//
ID MasterShef5
AC CVCL_BW78
RX PubMed=26607962;
CC Group: Clinical grade hESC cell line.
CC From: University of Sheffield; Sheffield; UK.
CC Registration: UK Stem Cell Bank (UKSCB); Steering comm. appl. SCSC12-06.
CC Omics: CNV analysis.
CC Omics: SNP array analysis.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Embryonic stem cell
//
ID MasterShef6
AC CVCL_BW79
CC Group: Clinical grade hESC cell line.
CC From: University of Sheffield; Sheffield; UK.
CC Registration: UK Stem Cell Bank (UKSCB); Steering comm. appl. SCSC12-07.
OX NCBI_TaxID=9606; ! Homo sapiens
CA Embryonic stem cell
//
ID MasterShef7
AC CVCL_BW80
RX PubMed=26607962;
CC Group: Clinical grade hESC cell line.
CC From: University of Sheffield; Sheffield; UK.
CC Registration: UK Stem Cell Bank (UKSCB); Steering comm. appl. SCSC12-08.
CC Omics: CNV analysis.
CC Omics: SNP array analysis.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Embryonic stem cell
//
ID MasterShef8
AC CVCL_BW81
RX PubMed=26607962;
CC Group: Clinical grade hESC cell line.
CC From: University of Sheffield; Sheffield; UK.
CC Registration: UK Stem Cell Bank (UKSCB); Steering comm. appl. SCSC12-09.
CC Omics: CNV analysis.
CC Omics: SNP array analysis.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Embryonic stem cell
//
ID MAT-28-24
AC CVCL_J233
DR TKG; TKG 0224
OX NCBI_TaxID=9606; ! Homo sapiens
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_3419 ! SHM-D33
CA Hybridoma
//
ID MAT-28b-12-11-30
AC CVCL_J234
DR TKG; TKG 0225
OX NCBI_TaxID=9606; ! Homo sapiens
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_3419 ! SHM-D33
CA Hybridoma
//
ID MAT-Lu
AC CVCL_3847
DR CLO; CLO_0007540
DR CLDB; cl3337
DR ATCC; JHU-4
DR ECACC; 94102735
RX PubMed=3174494;
RX PubMed=3774632;
CC Discontinued: ATCC; JHU-4; true.
CC Breed/subspecies: Copenhagen.
DI NCIt; C64013; Adenocarcinoma of the rat prostate
OX NCBI_TaxID=10116; ! Rattus norvegicus
HI CVCL_3568 ! R-3327-AT-1
SX Male
CA Cancer cell line
//
ID MAT-LyLu
AC CVCL_3848
AS CVCL_2168
SY Mat-Ly-Lu; MATLyLu; R3327-MATLyLu; R3327-MatLyLu; Dunning R 3327 MAT LyLu; Metastatic AT tumor able to disseminate to lymph nodes and lung
DR BTO; BTO:0003306
DR CLO; CLO_0007541
DR CLDB; cl3338
DR ATCC; JHU-5
DR ATCC; JHU-92
DR ChEMBL-Cells; CHEMBL3307987
DR ChEMBL-Targets; CHEMBL612579
DR DSMZ; ACC-609
DR ECACC; 94101454
RX PubMed=3174494;
RX PubMed=3774632;
RX PubMed=7251319;
RX PubMed=7910810;
RX PubMed=8687134;
RX PubMed=23467722;
CC Doubling time: ~15 hours (DSMZ).
CC Discontinued: ATCC; JHU-5; true.
CC Discontinued: ATCC; JHU-92; true.
CC Breed/subspecies: Copenhagen.
DI NCIt; C64013; Adenocarcinoma of the rat prostate
OX NCBI_TaxID=10116; ! Rattus norvegicus
HI CVCL_3568 ! R-3327-AT-1
SX Male
CA Cancer cell line
//
ID MAT-LyLu-B-1
AC CVCL_Y659
SY MAT-Ly-Lu-B-1; MLLB-1
RX PubMed=9494564;
CC Breed/subspecies: Copenhagen.
DI NCIt; C64013; Adenocarcinoma of the rat prostate
OX NCBI_TaxID=10116; ! Rattus norvegicus
HI CVCL_3848 ! MAT-LyLu
SX Male
CA Cancer cell line
//
ID MAT-LyLu-B-2
AC CVCL_3849
SY MAT-Ly-Lu-B-2; MLLB-2; MLLB2
DR CLO; CLO_0007542
DR ATCC; CRL-2376
RX PubMed=9494564;
CC Breed/subspecies: Copenhagen.
DI NCIt; C64013; Adenocarcinoma of the rat prostate
OX NCBI_TaxID=10116; ! Rattus norvegicus
HI CVCL_3848 ! MAT-LyLu
SX Male
CA Cancer cell line
//
ID MATAG 12
AC CVCL_K144
DR ATCC; CRL-9456
DR ATCC; HB-9456
RX Patent=US5512443;
CC Discontinued: ATCC; CRL-9456; probable.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_2155 ! P3/NS1/1-Ag4.1
CA Hybridoma
//
ID MaTi
AC CVCL_E999
RX PubMed=20444890;
CC Derived from metastatic site: Lymph node.
DI NCIt; C9231; Merkel cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID Matsu
AC CVCL_X925
RX PubMed=7535998;
CC Group: Non-human primate cell line.
CC Transformant: NCBI_TaxID; 33747; Simian T-lymphotropic virus 1 (STLV-1).
OX NCBI_TaxID=9543; ! Macaca fuscata fuscata
CA Transformed cell line
//
ID MaTu
AC CVCL_5328
SY MATU
DR BioSample; SAMN03151742
DR Cosmic; 1523956
RX PubMed=212193;
RX PubMed=9150904;
RX PubMed=10508494;
RX PubMed=15677628;
RX PubMed=20143388;
WW http://iclac.org/wp-content/uploads/Cross-Contaminations-v8_0.pdf
CC Problematic cell line: Contaminated. Shown to be a HeLa derivative (PubMed=10508494, PubMed=20143388). Originally thought to originate from a breast carcinoma.
CC Microsatellite instability: Stable (MSS) (PubMed=15677628).
CC Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18).
DI NCIt; C4029; Cervical adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0030 ! HeLa
SX Female
CA Cancer cell line
//
ID MaTu/Ham
AC CVCL_5329
RX PubMed=11044355;
WW http://www.pawefish.path.cam.ac.uk/BreastCellLineDescriptions/MaTuHam.html
CC Problematic cell line: Contaminated. Parent cell line (Matu) has been shown to be a HeLa derivative.
CC Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18).
DI NCIt; C4029; Cervical adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_5328 ! MaTu
SX Female
CA Cancer cell line
//
ID MAVER-1
AC CVCL_1831
SY Maver-1; MAntle cell VERona-1
DR ATCC; CRL-3008
DR BioSample; SAMN03471709
DR Cosmic; 2078182
DR Cosmic; 2088018
DR DSMZ; ACC-717
RX PubMed=16434369;
RX PubMed=25315077;
CC Part of: Lymphoma Research Foundation Mantle Cell Lymphoma cell bank (LRF MCL cell bank).
CC Doubling time: 24 hours (PubMed=25315077); ~48 hours (DSMZ).
ST Source(s): ATCC; DSMZ
ST Amelogenin: X,Y
ST CSF1PO: 10,11
ST D13S317: 8,13
ST D16S539: 9,12
ST D5S818: 12
ST D7S820: 8
ST TH01: 8,9
ST TPOX: 8,12
ST vWA: 14,18
DI NCIt; C4337; Mantle cell lymphoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID MaWi
AC CVCL_S810
SY Mawi; MAWI; MAwi
DR Cosmic; 687534
RX PubMed=12068308;
DI NCIt; C5105; Colorectal adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID Max-ST
AC CVCL_0D06
WW http://www.cvm.umn.edu/accr/research/modianolab/scientificresources/reagentsandscientificresources/home.html
OX NCBI_TaxID=9615; ! Canis lupus familiaris
CA Cancer cell line
//
ID MAXF 401NL
AC CVCL_D131
SY MAXF401; MAXF 401; MAXF-401; 401NL
DR ChEMBL-Cells; CHEMBL3307805
DR ChEMBL-Targets; CHEMBL612703
RX DOI=10.1016/0165-4608(96)85254-X;
RX PubMed=21556597;
CC Derived from metastatic site: Lung.
DI NCIt; C4872; Breast carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID MAXF 449
AC CVCL_D246
SY MAXF449; MaxF449
DI NCIt; C4872; Breast carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID MAXF 583
AC CVCL_D245
SY MAXF-583; MAXF583
RX DOI=10.1016/0165-4608(96)85254-X;
RX PubMed=21556597;
CC Derived from metastatic site: Lung.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID MAXF 713
AC CVCL_D247
SY MAXF-713
RX DOI=10.1016/0165-4608(96)85254-X;
DI NCIt; C4872; Breast carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID MAY
AC CVCL_E773
DR IHW; IHW1003
WW http://bioinformatics.hsanmartino.it/ecbr/cl377.html
CC Part of: 9th International Histocompatibility Workshop (9IHW) cell line panel.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
CA Transformed cell line
//
ID May Roy
AC CVCL_1864
DR CLO; CLO_0007543
DR ATCC; CRL-1250
DI NCIt; C34807; Marfan syndrome
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Finite cell line
//
ID Mayes
AC CVCL_4Y74
RX PubMed=13502746;
CC Miscellaneous: Cell line has been lost.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Finite cell line
//
ID MB
AC CVCL_5M21
RX PubMed=4735239;
OX NCBI_TaxID=10036; ! Mesocricetus auratus
OI CVCL_5M20 ! KF
OI CVCL_5M22 ! TD
OI CVCL_5M23 ! WE
CA Cancer cell line
//
ID MB III
AC CVCL_3741
SY MB-III; de Bruyn-Gey cells
DR CLO; CLO_0007546
DR CLO; CLO_0007567
DR CLDB; cl3345
DR ATCC; CCL-32
DR ECACC; 90111914
CC Discontinued: ECACC; 90111914; probable.
OX NCBI_TaxID=10090; ! Mus musculus
CA Cancer cell line
//
ID MB-02
AC CVCL_7075
SY MB02; MBO2
DR BTO; BTO:0004767
DR Cosmic; 787449
DR Cosmic; 924045
DR Cosmic; 975267
DR Cosmic; 1012052
DR Cosmic; 1012084
DR Cosmic; 1281325
DR Cosmic; 1465957
DR Cosmic; 2306216
RX PubMed=1954374;
RX PubMed=16408098;
DI NCIt; C7965; Adult acute megakaryoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID MB-020
AC CVCL_Z317
DR CLO; CLO_0007547
DR CLDB; cl3339
DR DSMZ; ACC-79
RX DOI=10.1080/03235408909438893;
CC Group: Insect cell line.
CC Caution: We are not certain that this cell line is derived from MB-H 260. The DSMZ web site points to the original publication of MB-H 260 (DOI 10.1080/03235408909438893) as the reference for the establishment of this cell line.
OX NCBI_TaxID=55057; ! Mamestra brassicae
HI CVCL_Z314 ! MB-H 260
SX Sex undetermined
CA Spontaneously immortalized cell line
//
ID MB-021
AC CVCL_Z318
DR CLO; CLO_0007548
DR CLDB; cl3340
DR DSMZ; ACC-85
RX DOI=10.1080/03235408909438893;
CC Group: Insect cell line.
CC Caution: We are not certain that this cell line is derived from MB-H 260. The DSMZ web site points to the original publication of MB-H 260 (DOI 10.1080/03235408909438893) as the reference for the establishment of this cell line.
OX NCBI_TaxID=55057; ! Mamestra brassicae
HI CVCL_Z314 ! MB-H 260
SX Sex undetermined
CA Spontaneously immortalized cell line
//
ID MB-03
AC CVCL_Z319
DR CLO; CLO_0007549
DR CLDB; cl3341
DR DSMZ; ACC-97
RX DOI=10.1080/03235408909438893;
CC Group: Insect cell line.
CC Caution: We are not certain that this cell line is derived from MB-H 260. The DSMZ web site points to the original publication of MB-H 260 (DOI 10.1080/03235408909438893) as the reference for the establishment of this cell line.
OX NCBI_TaxID=55057; ! Mamestra brassicae
HI CVCL_Z314 ! MB-H 260
SX Sex undetermined
CA Spontaneously immortalized cell line
//
ID MB-03C4
AC CVCL_Z501
SY MB-O3C4
DR CLO; CLO_0007550
DR CLDB; cl3342
WW http://www.rccc.cytspb.rssi.ru/ecellbank/spinless/smb.htm
CC Group: Insect cell line.
OX NCBI_TaxID=47767; ! Agrotis segetum
SX Sex undetermined
CA Spontaneously immortalized cell line
//
ID MB-03C5-688
AC CVCL_Z502
SY MB-O3C5-688
DR CLO; CLO_0007551
DR CLDB; cl3343
CC Group: Insect cell line.
OX NCBI_TaxID=47767; ! Agrotis segetum
SX Sex undetermined
CA Spontaneously immortalized cell line
//
ID MB-04
AC CVCL_Z320
DR CLO; CLO_0007552
DR CLDB; cl3344
DR DSMZ; ACC-122
RX DOI=10.1080/03235408909438893;
CC Group: Insect cell line.
CC Caution: We are not certain that this cell line is derived from MB-H 260. The DSMZ web site points to the original publication of MB-H 260 (DOI 10.1080/03235408909438893) as the reference for the establishment of this cell line.
OX NCBI_TaxID=55057; ! Mamestra brassicae
HI CVCL_Z314 ! MB-H 260
SX Sex undetermined
CA Spontaneously immortalized cell line
//
ID MB-1
AC CVCL_2109
SY MB1
DR BioSample; SAMN03473455
DR DSMZ; ACC-638
RX PubMed=18616678;
CC Doubling time: ~60-100 hours (DSMZ).
ST Source(s): DSMZ
ST Amelogenin: X
ST CSF1PO: 11
ST D13S317: 11
ST D16S539: 11
ST D5S818: 10
ST D7S820: 9
ST TH01: 9
ST TPOX: 11
ST vWA: 14
DI NCIt; C3878; Thyroid gland undifferentiated (anaplastic) carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID MB-9812
AC CVCL_0A72
SY MB 9812; MB9812; MBA 9812; MBA-9812; Line 9812; 9812
DR Cosmic; 2301572
DR GEO; GSM784229
RX PubMed=5431618;
RX PubMed=6500159;
RX PubMed=6935474;
RX PubMed=7459858;
DI NCIt; C4450; Large cell lung carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID MB-H 260
AC CVCL_Z314
RX DOI=10.1080/03235408909438893;
CC Group: Insect cell line.
OX NCBI_TaxID=55057; ! Mamestra brassicae
SX Sex undetermined
CA Spontaneously immortalized cell line
//
ID MB-L11
AC CVCL_Z315
DR CLO; CLO_0007568
DR CLDB; cl3346
DR DSMZ; ACC-113
RX DOI=10.1080/03235408909438893;
CC Group: Insect cell line.
CC Caution: We are not certain that this cell line is derived from MB-H 260. The DSMZ web site points to the original publication of MB-H 260 (DOI 10.1080/03235408909438893) as the reference for the establishment of this cell line.
OX NCBI_TaxID=55057; ! Mamestra brassicae
HI CVCL_Z314 ! MB-H 260
SX Sex undetermined
CA Spontaneously immortalized cell line
//
ID MB-L2
AC CVCL_Z316
DR CLO; CLO_0007569
DR CLDB; cl3347
DR DSMZ; ACC-76
RX DOI=10.1080/03235408909438893;
CC Group: Insect cell line.
CC Caution: We are not certain that this cell line is derived from MB-H 260. The DSMZ web site points to the original publication of MB-H 260 (DOI 10.1080/03235408909438893) as the reference for the establishment of this cell line.
OX NCBI_TaxID=55057; ! Mamestra brassicae
HI CVCL_Z314 ! MB-H 260
SX Sex undetermined
CA Spontaneously immortalized cell line
//
ID MB0002
AC CVCL_8Y12
DR ECACC; 00051801
CC Part of: ECACC chromosomal abnormality collection.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
SX Sex undetermined
CA Transformed cell line
//
ID MB0008
AC CVCL_8Y13
DR ECACC; 00110316
CC Part of: ECACC chromosomal abnormality collection.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
DI NCIt; C26900; Turner syndrome
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_8Y14 ! MB0009
SX Female
CA Transformed cell line
//
ID MB0009
AC CVCL_8Y14
DR ECACC; 00110317
CC Part of: ECACC chromosomal abnormality collection.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
DI NCIt; C26900; Turner syndrome
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_8Y13 ! MB0008
SX Female
CA Transformed cell line
//
ID MB0012
AC CVCL_8Y15
DR ECACC; 00121101
CC Part of: ECACC chromosomal abnormality collection.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
DI NCIt; C84801; Klippel-Trenaunay-Weber syndrome
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Transformed cell line
//
ID MB0014
AC CVCL_8Y16
DR ECACC; 01010504
CC Part of: ECACC chromosomal abnormality collection.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
DI NCIt; C125485; Microcornea
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Transformed cell line
//
ID MB0015
AC CVCL_8Y17
DR ECACC; 01012005
CC Part of: ECACC chromosomal abnormality collection.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
DI NCIt; C26782; Glaucoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Transformed cell line
//
ID MB01
AC CVCL_C382
SY Maria Biotech 01; MIHe001-A
DR hPSCreg; MIHe001-A
DR ISCR; 1110
RX PubMed=14998970;
WW http://stemcells.nih.gov/research/registry/unavailable/pages/maria.aspx
CC From: Maria Infertility Hospital; Seoul; South Korea.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Embryonic stem cell
//
ID MB02
AC CVCL_C383
SY Maria Biotech 02; MIHe002-A
DR hPSCreg; MIHe002-A
DR ISCR; 1111
RX PubMed=14998970;
WW http://stemcells.nih.gov/research/registry/unavailable/pages/maria.aspx
CC From: Maria Infertility Hospital; Seoul; South Korea.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Embryonic stem cell
//
ID MB03
AC CVCL_C384
SY Maria Biotech 03; MIHe003-A
DR hPSCreg; MIHe003-A
DR ISCR; 1112
RX PubMed=14998970;
WW http://stemcells.nih.gov/research/registry/unavailable/pages/maria.aspx
CC From: Maria Infertility Hospital; Seoul; South Korea.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Embryonic stem cell
//
ID MB04
AC CVCL_C385
SY Maria Biotech 04; MIHe004-A
DR hPSCreg; MIHe004-A
DR ISCR; 1113
RX PubMed=14998970;
CC From: Maria Infertility Hospital; Seoul; South Korea.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Embryonic stem cell
//
ID MB05
AC CVCL_C386
SY Maria Biotech 05; MIHe005-A
DR hPSCreg; MIHe005-A
DR ISCR; 1114
RX PubMed=14998970;
CC From: Maria Infertility Hospital; Seoul; South Korea.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Embryonic stem cell
//
ID MB06
AC CVCL_C387
SY Maria Biotech 06; MIHe006-A
DR hPSCreg; MIHe006-A
DR ISCR; 1115
RX PubMed=14998970;
CC From: Maria Infertility Hospital; Seoul; South Korea.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Embryonic stem cell
//
ID MB07
AC CVCL_C388
SY Maria Biotech 07; MIHe007-A
DR hPSCreg; MIHe007-A
DR ISCR; 1116
RX PubMed=14998970;
CC From: Maria Infertility Hospital; Seoul; South Korea.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Embryonic stem cell
//
ID MB08
AC CVCL_C389
SY Maria Biotech 08; MIHe008-A
DR hPSCreg; MIHe008-A
DR ISCR; 1117
RX PubMed=14998970;
CC From: Maria Infertility Hospital; Seoul; South Korea.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Embryonic stem cell
//
ID MB09
AC CVCL_C390
SY Maria Biotech 09; MIHe009-A
DR hPSCreg; MIHe009-A
DR ISCR; 1118
RX PubMed=14998970;
CC From: Maria Infertility Hospital; Seoul; South Korea.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Embryonic stem cell
//
ID MB15C11
AC CVCL_CY50
RX PubMed=2475124;
CC Monoclonal antibody target: UniProtKB; P06800; Mouse Ptprc/Cd45.
OX NCBI_TaxID=10090; ! Mus musculus
OX NCBI_TaxID=10116; ! Rattus norvegicus
HI CVCL_2155 ! P3/NS1/1-Ag4.1
CA Hybridoma
//
ID MB16tsA clone 1B5
AC CVCL_6499
SY Mbeta16tsA clone 1B5
DR CLO; CLO_0007553
DR ATCC; CRL-2307
OX NCBI_TaxID=10090; ! Mus musculus
SX Female
CA Transformed cell line
//
ID MB19tsA clone 2B2
AC CVCL_6500
SY Mbeta19tsA clone 2B2
DR CLO; CLO_0007554
DR ATCC; CRL-2308
OX NCBI_TaxID=10090; ! Mus musculus
CA Transformed cell line
//
ID MB23G2
AC CVCL_9218
DR CLO; CLO_0007555
DR ATCC; HB-220
RX PubMed=2475124;
CC Monoclonal antibody target: UniProtKB; P06800; Mouse Ptprc/Cd45.
OX NCBI_TaxID=10090; ! Mus musculus
OX NCBI_TaxID=10116; ! Rattus norvegicus
HI CVCL_2155 ! P3/NS1/1-Ag4.1
CA Hybridoma
//
ID MB352
AC CVCL_6778
DR CLO; CLO_0007556
DR ATCC; CRL-2821
CC Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53.
OX NCBI_TaxID=10090; ! Mus musculus
CA Spontaneously immortalized cell line
//
ID MB355
AC CVCL_6779
DR CLO; CLO_0007557
DR ATCC; CRL-2818
CC Knockout cell: Method=KO mouse; MGI; MGI:97740; Polb.
CC Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53.
OX NCBI_TaxID=10090; ! Mus musculus
CA Spontaneously immortalized cell line
//
ID MB40.2
AC CVCL_G232
SY MB 40.2
DR CLO; CLO_0007558
DR ATCC; HB-59
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_2155 ! P3/NS1/1-Ag4.1
CA Hybridoma
//
ID MB40.3
AC CVCL_G233
SY MB 40.3
DR CLO; CLO_0007545
DR ATCC; HB-105
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_2155 ! P3/NS1/1-Ag4.1
CA Hybridoma
//
ID MB40.5
AC CVCL_G234
SY MB 40.5
DR CLO; CLO_0007559
DR ATCC; HB-116
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_2155 ! P3/NS1/1-Ag4.1
CA Hybridoma
//
ID MB49
AC CVCL_7076
SY MB-49
DR BTO; BTO:0003562
RX PubMed=107359;
CC Breed/subspecies: C57BL/Icrfa(t).
OX NCBI_TaxID=10090; ! Mus musculus
SX Male
CA Cancer cell line
//
ID MB4B4
AC CVCL_9219
DR CLO; CLO_0007560
DR ATCC; HB-223
RX PubMed=2475124;
CC Monoclonal antibody target: UniProtKB; P06800; Mouse Ptprc/Cd45.
OX NCBI_TaxID=10090; ! Mus musculus
OX NCBI_TaxID=10116; ! Rattus norvegicus
HI CVCL_2155 ! P3/NS1/1-Ag4.1
CA Hybridoma
//
ID MB63
AC CVCL_0F71
RX PubMed=107359;
RX PubMed=6724740;
CC Transformant: ChEBI; CHEBI:59032; 7,12-dimethyltetraphene (DMBA; dimethylbenzanthracene).
CC Breed/subspecies: C57BL/Icrfa(t).
DI NCIt; C25806; Mouse urinary tract neoplasm
OX NCBI_TaxID=10090; ! Mus musculus
SX Male
CA Cancer cell line
//
ID MB86
AC CVCL_J274
DR JCRB; JCRB0090
RX PubMed=2420716;
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_2155 ! P3/NS1/1-Ag4.1
CA Hybridoma
//
ID MBA C57.Li
AC CVCL_P675
DR ATCC; CRL-6369
CC Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982).
CC Discontinued: ATCC; CRL-6369; true.
OX NCBI_TaxID=10090; ! Mus musculus
OI CVCL_S462 ! MBA C57.Ut
OI CVCL_6501 ! MBA C57.We
SX Female
CA Finite cell line
//
ID MBA C57.Ut
AC CVCL_S462
DR ATCC; CRL-6368
CC Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982).
CC Discontinued: ATCC; CRL-6368; true.
OX NCBI_TaxID=10090; ! Mus musculus
OI CVCL_P675 ! MBA C57.Li
OI CVCL_6501 ! MBA C57.We
SX Female
CA Finite cell line
//
ID MBA C57.We
AC CVCL_6501
DR CLO; CLO_0007565
DR ATCC; CRL-6370
CC Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982).
CC Discontinued: ATCC; CRL-6370; true.
OX NCBI_TaxID=10090; ! Mus musculus
OI CVCL_P675 ! MBA C57.Li
OI CVCL_S462 ! MBA C57.Ut
SX Female
CA Finite cell line
//
ID MBA-1
AC CVCL_B418
RX PubMed=2981238;
CC Breed/subspecies: SJL/J.
OX NCBI_TaxID=10090; ! Mus musculus
CA Stromal cell line
//
ID MBA-13
AC CVCL_B419
RX PubMed=2981238;
CC Breed/subspecies: Nude ICR.
OX NCBI_TaxID=10090; ! Mus musculus
CA Stromal cell line
//
ID MBA-14
AC CVCL_B420
RX PubMed=2981238;
RX PubMed=6693503;
CC Breed/subspecies: BALB/c.
OX NCBI_TaxID=10090; ! Mus musculus
CA Stromal cell line
//
ID MBA-15
AC CVCL_B421
DR BTO; BTO:0003051
RX PubMed=2981238;
RX PubMed=6693503;
RX PubMed=7942158;
CC Breed/subspecies: SJL/J.
OX NCBI_TaxID=10090; ! Mus musculus
CA Stromal cell line
//
ID MBA-2
AC CVCL_B422
RX PubMed=2981238;
CC Breed/subspecies: RF/J.
OX NCBI_TaxID=10090; ! Mus musculus
CA Stromal cell line
//
ID MBA-2.1
AC CVCL_B423
RX PubMed=2981238;
CC Breed/subspecies: RF/J.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_B422 ! MBA-2
CA Stromal cell line
//
ID MBA-2.4
AC CVCL_B424
RX PubMed=2981238;
CC Breed/subspecies: RF/J.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_B422 ! MBA-2
CA Stromal cell line
//
ID MBA-HE
AC CVCL_Y447
DR ATCC; CRL-6286
CC Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982).
CC Discontinued: ATCC; CRL-6286; true.
OX NCBI_TaxID=10036; ! Mesocricetus auratus
CA Finite cell line
//
ID MBC(5)
AC CVCL_5330
DR CLO; CLO_0007566
DR ATCC; CRL-6069
CC Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982).
CC Discontinued: ATCC; CRL-6069; true.
OX NCBI_TaxID=9913; ! Bos taurus
SX Sex undetermined
CA Undefined cell line type
//
ID MBC1
AC CVCL_T035
RX PubMed=23106969;
DI NCIt; C4872; Breast carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID MBC2
AC CVCL_T036
RX PubMed=23106969;
DI NCIt; C4872; Breast carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID Mbd3KO
AC CVCL_AR59
DR ECACC; 11041301
RX PubMed=16462733;
CC Knockout cell: Method=KO mouse; MGI; MGI:1333812; Mbd3.
OX NCBI_TaxID=10090; ! Mus musculus
CA Embryonic stem cell
//
ID MBEC4
AC CVCL_0407
SY MBEC-4
DR MCCL; MCC:0000301
RX PubMed=1356979;
RX PubMed=9862771;
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40) [777].
CC Breed/subspecies: BALB/c.
OX NCBI_TaxID=10090; ! Mus musculus
CA Transformed cell line
//
ID MBHL-2
AC CVCL_2I37
DR CLO; CLO_0050501
DR RCB; RCB1444
CC Group: Insect cell line.
OX NCBI_TaxID=55057; ! Mamestra brassicae
SX Sex undetermined
CA Spontaneously immortalized cell line
//
ID MBHL-3
AC CVCL_2I38
DR CLO; CLO_0050502
DR RCB; RCB1445
CC Group: Insect cell line.
OX NCBI_TaxID=55057; ! Mamestra brassicae
SX Sex undetermined
CA Spontaneously immortalized cell line
//
ID MBL-1
AC CVCL_Z537
RX PubMed=2120094;
CC Breed/subspecies: 129/Sv He.
OX NCBI_TaxID=10090; ! Mus musculus
SX Male
CA Embryonic stem cell
//
ID MBL-2 [Mouse ESC]
AC CVCL_Z538
RX PubMed=2120094;
CC Breed/subspecies: 129/Sv He.
OX NCBI_TaxID=10090; ! Mus musculus
SX Male
CA Embryonic stem cell
//
ID MBL-2 [Mouse myeloma]
AC CVCL_J302
SY MBL2
OX NCBI_TaxID=10090; ! Mus musculus
CA Cancer cell line
//
ID MBL-3
AC CVCL_Z539
RX PubMed=2120094;
CC Breed/subspecies: 129/Sv He.
OX NCBI_TaxID=10090; ! Mus musculus
SX Female
CA Embryonic stem cell
//
ID MbL-3
AC CVCL_Z542
RX PubMed=8578995;
CC Group: Insect cell line.
OX NCBI_TaxID=55057; ! Mamestra brassicae
SX Sex undetermined
CA Spontaneously immortalized cell line
//
ID MBL-4
AC CVCL_Z540
RX PubMed=2120094;
CC Breed/subspecies: 129/Sv He.
OX NCBI_TaxID=10090; ! Mus musculus
SX Female
CA Embryonic stem cell
//
ID MBL-5
AC CVCL_Z541
RX PubMed=2120094;
CC Breed/subspecies: 129/Sv He.
OX NCBI_TaxID=10090; ! Mus musculus
SX Male
CA Embryonic stem cell
//
ID MBL-Sm-1A6
AC CVCL_G235
DR CLO; CLO_0007570
DR ATCC; HB-194
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID MBL-Sm-4B1
AC CVCL_G236
DR CLO; CLO_0007571
DR ATCC; HB-193
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID MBM
AC CVCL_F271
RX PubMed=7618261;
OX NCBI_TaxID=9685; ! Felis catus
CA Spontaneously immortalized cell line
//
ID mBMS-B1
AC CVCL_6D84
RX PubMed=9041049;
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40) [tsA58].
CC Breed/subspecies: (C57BL/6 x DBA/2) F2-tsA58 transgenic.
OX NCBI_TaxID=10090; ! Mus musculus
SX Female
CA Conditionally immortalized cell line
//
ID mBMS-B14
AC CVCL_6D86
RX PubMed=9041049;
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40) [tsA58].
CC Breed/subspecies: (C57BL/6 x DBA/2) F2-tsA58 transgenic.
OX NCBI_TaxID=10090; ! Mus musculus
SX Female
CA Conditionally immortalized cell line
//
ID mBMS-B18
AC CVCL_6D87
RX PubMed=9041049;
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40) [tsA58].
CC Breed/subspecies: (C57BL/6 x DBA/2) F2-tsA58 transgenic.
OX NCBI_TaxID=10090; ! Mus musculus
SX Female
CA Conditionally immortalized cell line
//
ID mBMS-B2
AC CVCL_6D85
RX PubMed=9041049;
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40) [tsA58].
CC Breed/subspecies: (C57BL/6 x DBA/2) F2-tsA58 transgenic.
OX NCBI_TaxID=10090; ! Mus musculus
SX Female
CA Conditionally immortalized cell line
//
ID mBMS-B21
AC CVCL_6D88
RX PubMed=9041049;
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40) [tsA58].
CC Breed/subspecies: (C57BL/6 x DBA/2) F2-tsA58 transgenic.
OX NCBI_TaxID=10090; ! Mus musculus
SX Female
CA Conditionally immortalized cell line
//
ID mbn-2
AC CVCL_Z706
SY Mbn-2; mbn2; l(2)mbn; L(2)mbn; Blood II; BII
DR BTO; BTO:0001898
DR EFO; EFO_0005820
DR DGRC; 147
DR ENCODE; ENCBS358WCU
RX CelloPub=CLPUB00202;
RX DOI=10.1002/arch.940020307;
RX DOI=10.1016/B978-012229460-0/50004-X;
RX PubMed=1445351;
RX PubMed=21177962;
RX PubMed=24434506;
RX PubMed=24985917;
RX PubMed=25262759;
CC Group: Insect cell line.
CC Part of: modENCODE project cell lines.
CC Omics: Deep RNAseq analysis.
OX NCBI_TaxID=7227; ! Drosophila melanogaster
SX Sex undetermined
CA Spontaneously immortalized cell line
//
ID mbn-3
AC CVCL_0A30
SY l(3)mbn; Blood III
RX CelloPub=CLPUB00202;
RX DOI=10.1016/B978-012229460-0/50004-X;
CC Group: Insect cell line.
OX NCBI_TaxID=7227; ! Drosophila melanogaster
SX Sex undetermined
CA Spontaneously immortalized cell line
//
ID MBSa1
AC CVCL_L364
RX PubMed=20974873;
CC Breed/subspecies: German Shepherd.
DI NCIt; C128195; Canine sarcoma
OX NCBI_TaxID=9615; ! Canis lupus familiaris
SX Male
CA Cancer cell line
//
ID MBT-2
AC CVCL_4660
SY MBT2; Mouse Bladder Tumor line-2
DR BTO; BTO:0003555
DR CLO; CLO_0050945
DR IFO; IFO50041
DR RCB; RCB0544
RX DOI=10.4051/ibc.2010.2.4.0014;
RX PubMed=406041;
CC Transformant: ChEBI; CHEBI:82328; Nifurthiazole (N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide; FANFT).
CC Breed/subspecies: C3H/He.
DI NCIt; C25823; Mouse bladder transitional cell carcinoma
OX NCBI_TaxID=10090; ! Mus musculus
CA Cancer cell line
//
ID MBU-IM
AC CVCL_EG12
DR DSMZ; ACC-796
RX PubMed=27074337;
CC Doubling time: ~50-60 hours (DSMZ).
CC Transfected with: HGNC; 11730; TERT.
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40).
ST Source(s): DSMZ
ST Amelogenin: X,Y
ST CSF1PO: 10,11
ST D13S317: 8,11
ST D16S539: 11,12
ST D5S818: 10,12
ST D7S820: 8,11
ST TH01: 8,9.3
ST TPOX: 8
ST vWA: 13,15
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Transformed cell line
//
ID MBU-T
AC CVCL_EG13
DR DSMZ; ACC-799
RX PubMed=27074337;
CC Doubling time: ~50-60 hours (DSMZ).
CC Transfected with: HGNC; 5173; HRAS (with V-12).
CC Transfected with: HGNC; 11730; TERT.
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40).
ST Source(s): DSMZ
ST Amelogenin: X,Y
ST CSF1PO: 10,11
ST D13S317: 8,11
ST D16S539: 11,12
ST D5S818: 10,12
ST D7S820: 8,11
ST TH01: 8,9.3
ST TPOX: 8
ST vWA: 13,15
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_EG12 ! MBU-IM
SX Male
CA Transformed cell line
//
ID MBU-Ts1
AC CVCL_EG14
SY MBU-TS1
DR DSMZ; ACC-800
RX PubMed=27074337;
CC Doubling time: ~100-140 hours (DSMZ).
CC Transfected with: HGNC; 5173; HRAS (with V-12).
CC Transfected with: HGNC; 11730; TERT.
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40).
ST Source(s): DSMZ
ST Amelogenin: X,Y
ST CSF1PO: 10,11
ST D13S317: 8,11
ST D16S539: 11,12
ST D5S818: 10,12
ST D7S820: 8,11
ST TH01: 8,9.3
ST TPOX: 8
ST vWA: 13,15
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_EG13 ! MBU-T
SX Male
CA Transformed cell line
//
ID MBU-Ts4
AC CVCL_EG15
SY MBU-TS4
DR DSMZ; ACC-801
RX PubMed=27074337;
CC Doubling time: ~80-100 hours (DSMZ).
CC Transfected with: HGNC; 5173; HRAS (with V-12).
CC Transfected with: HGNC; 11730; TERT.
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40).
ST Source(s): DSMZ
ST Amelogenin: X,Y
ST CSF1PO: 10,11
ST D13S317: 8,11
ST D16S539: 11,12
ST D5S818: 10,12
ST D7S820: 8,11
ST TH01: 8,9.3
ST TPOX: 8
ST vWA: 13,15
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_EG13 ! MBU-T
SX Male
CA Transformed cell line
//
ID MC
AC CVCL_W203
RX DOI=10.1016/B978-0-12-333530-2.50007-1;
RX PubMed=6986835;
CC Doubling time: ~12 hours (PubMed=6986835).
DI NCIt; C6064; Maxillary sinus squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID Mc 39-16
AC CVCL_L537
DR ECACC; 89072609
OX NCBI_TaxID=10090; ! Mus musculus
OX NCBI_TaxID=10116; ! Rattus norvegicus
HI CVCL_2155 ! P3/NS1/1-Ag4.1
CA Hybridoma
//
ID MC-1010
AC CVCL_1396
DR ATCC; CRL-12253
DR Cosmic; 683546
DR Cosmic; 907798
DR Cosmic-CLP; 907798
DR GDSC; 907798
RX Patent=US5804443;
RX PubMed=167748;
RX PubMed=8594420;
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Omics: Deep exome analysis.
ST Source(s): Cosmic-CLP
ST Amelogenin: X,Y
ST CSF1PO: 11
ST D13S317: 11,12
ST D16S539: 9,13
ST D5S818: 11,14
ST D7S820: 8,12
ST TH01: 6,9.3
ST TPOX: 8,11
ST vWA: 18
DI NCIt; C9154; Adult acute myeloid leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID MC-26
AC CVCL_0240
SY MC26; Colon 26; Colon-26; Colon26; C-26; C26
DR BTO; BTO:0004013
DR CLO; CLO_0051596
DR MCCL; MCC:0000130
DR ChEMBL-Cells; CHEMBL3307623
DR ChEMBL-Targets; CHEMBL614466
DR CLS; 400156/p742_Colon-26
DR RCB; RCB2657
DR TKG; TKG 0518
RX PubMed=1149045;
CC Breed/subspecies: BALB/c.
DI NCIt; C120044; Mouse colon adenocarcinoma
OX NCBI_TaxID=10090; ! Mus musculus
SX Female
CA Cancer cell line
//
ID MC-38
AC CVCL_B288
SY MCA-38; MCA 38; MCA38; MC38; Mouse Colon 38; Murine Carcinoma-38; Colon 38; Colon-38; Colon38; C38
DR BTO; BTO:0004163
DR ChEMBL-Cells; CHEMBL3307696
DR ChEMBL-Cells; CHEMBL3307810
DR ChEMBL-Cells; CHEMBL3307933
DR ChEMBL-Targets; CHEMBL612821
DR ChEMBL-Targets; CHEMBL614463
DR ChEMBL-Targets; CHEMBL614739
DR Lonza; 893
RX PubMed=1149045;
RX PubMed=1255804;
RX PubMed=25434994;
WW https://www.kerafast.com/product/2720/mc-38-cell-line
CC Omics: Mitochondrial genome sequenced.
CC Caution: The authors of PubMed=25434994 indicate that they have sequenced the mitochondrial genome of the 'rat' cell line MCA38. Their submitted DNA sequence (KM820832.1) is indeed a rat sequence but is labelled as originating from 'rat isolate 406'.
CC Breed/subspecies: C57BL/6.
DI NCIt; C120044; Mouse colon adenocarcinoma
OX NCBI_TaxID=10090; ! Mus musculus
SX Female
CA Cancer cell line
//
ID MC-38-CEA-1
AC CVCL_5I36
SY MC-38-cea1
RX PubMed=1712245;
WW https://www.kerafast.com/product/2405/mc-38-cea-cell-lines
CC Transfected with: HGNC; 1817; CEACAM5.
CC Breed/subspecies: C57BL/6.
DI NCIt; C120044; Mouse colon adenocarcinoma
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_B288 ! MC-38
SX Female
CA Cancer cell line
//
ID MC-38-CEA-2
AC CVCL_5I37
SY MC-38-cea2
RX PubMed=1712245;
WW https://www.kerafast.com/product/2405/mc-38-cea-cell-lines
CC Transfected with: HGNC; 1817; CEACAM5.
CC Breed/subspecies: C57BL/6.
DI NCIt; C120044; Mouse colon adenocarcinoma
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_B288 ! MC-38
SX Female
CA Cancer cell line
//
ID MC-38-MUC-1
AC CVCL_5I38
SY MC38/MUC1
RX PubMed=9101412;
WW https://www.kerafast.com/product/2406/mc-38-muc-1-cell-line
CC Transfected with: HGNC; 7508; MUC1.
CC Breed/subspecies: C57BL/6.
DI NCIt; C120044; Mouse colon adenocarcinoma
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_B288 ! MC-38
SX Female
CA Cancer cell line
//
ID MC-MA1
AC CVCL_D025
RX PubMed=8120418;
CC Derived from metastatic site: Inguinal lymph node.
DI NCIt; C9231; Merkel cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID MC-NB-1
AC CVCL_E058
DR CLO; CLO_0051541
DR BioSample; SAMN03472326
DR RCB; RCB0482
RX PubMed=6616438;
RX PubMed=6888561;
CC Doubling time: ~35 hours (PubMed=6616438).
CC Misspelling: 'MCN-1' in PubMed=6888561.
CC Derived from metastatic site: Bone marrow.
ST Source(s): RCB
ST Amelogenin: X
ST CSF1PO: 10
ST D13S317: 12,13,14
ST D16S539: 11,12
ST D5S818: 12
ST D7S820: 10,12
ST TH01: 6,7
ST TPOX: 8,11
ST vWA: 15,16
DI NCIt; C3270; Neuroblastoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID MC-SV-HUC T-1
AC CVCL_IP86
SY MC-SV-HUC T1
RX PubMed=2841047;
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40).
CC Transformant: ChEBI; CHEBI:34342; 3-methylcholanthrene (MCA).
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_3798 ! SV-HUC-1
SX Male
CA Transformed cell line
//
ID MC-SV-HUC T-10
AC CVCL_IP89
SY MC-SV-HUC T10
RX PubMed=2841047;
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40).
CC Transformant: ChEBI; CHEBI:34342; 3-methylcholanthrene (MCA).
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_3798 ! SV-HUC-1
SX Male
CA Transformed cell line
//
ID MC-SV-HUC T-11
AC CVCL_IP90
SY MC-SV-HUC T11
RX PubMed=2841047;
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40).
CC Transformant: ChEBI; CHEBI:34342; 3-methylcholanthrene (MCA).
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_3798 ! SV-HUC-1
SX Male
CA Transformed cell line
//
ID MC-SV-HUC T-16
AC CVCL_IP91
SY MC-SV-HUC T16
RX PubMed=2841047;
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40).
CC Transformant: ChEBI; CHEBI:34342; 3-methylcholanthrene (MCA).
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_3798 ! SV-HUC-1
SX Male
CA Transformed cell line
//
ID MC-SV-HUC T-2
AC CVCL_6418
SY MC-SV-HUC T2; MC-T2
DR CLO; CLO_0007620
DR ATCC; CRL-9519
DR BCRC; 60409
DR BioSample; SAMN03471217
RX Patent=US4980290;
RX PubMed=2841047;
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40).
CC Transformant: ChEBI; CHEBI:34342; 3-methylcholanthrene (MCA).
ST Source(s): ATCC
ST Amelogenin: X,Y
ST CSF1PO: 10,11
ST D13S317: 13
ST D16S539: 11
ST D5S818: 12,14
ST D7S820: 10
ST TH01: 9,9.3
ST TPOX: 8,10
ST vWA: 14,16
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_3798 ! SV-HUC-1
SX Male
CA Transformed cell line
//
ID MC-SV-HUC T-7
AC CVCL_IP87
SY MC-SV-HUC T7
RX PubMed=2841047;
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40).
CC Transformant: ChEBI; CHEBI:34342; 3-methylcholanthrene (MCA).
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_3798 ! SV-HUC-1
SX Male
CA Transformed cell line
//
ID MC-SV-HUC T-9
AC CVCL_IP88
SY MC-SV-HUC T9
RX PubMed=2841047;
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40).
CC Transformant: ChEBI; CHEBI:34342; 3-methylcholanthrene (MCA).
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_3798 ! SV-HUC-1
SX Male
CA Transformed cell line
//
ID MC-TGS17-51
AC CVCL_4982
SY MC-TGS17-51 [Mutatect]; MC17-51; Mutatect
DR CLO; CLO_0007579
DR ATCC; CRL-2799
RX PubMed=7577474;
CC Breed/subspecies: C57BL/10.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4983 ! MC1A-C1
SX Male
CA Cancer cell line
//
ID MC/9
AC CVCL_0408
SY MC9; CL MC/9
DR CLO; CLO_0007574
DR MCCL; MCC:0000302
DR ATCC; CRL-8306
DR Lonza; 1232
DR NCBI_Iran; C588
RX Patent=US4559310;
RX PubMed=6972009;
WW http://www.cells-talk.com/index.php/page/copelibrary?key=MC%2f9
CC Characteristics: IL3 dependent.
CC Breed/subspecies: C57BL/6 x A/J.
OX NCBI_TaxID=10090; ! Mus musculus
CA Factor-dependent cell line
//
ID MC/9.IL4
AC CVCL_5428
RX PubMed=8018917;
WW http://www.cells-talk.com/index.php/page/copelibrary?key=MC%2f9%2eIL4
CC Characteristics: IL4 dependent.
CC Breed/subspecies: C57BL/6 x A/J.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_0408 ! MC/9
CA Factor-dependent cell line
//
ID MC/CAR
AC CVCL_1397
SY MC-CAR; MCCAR
DR CLO; CLO_0007575
DR EFO; EFO_0002229
DR CLDB; cl5227
DR ATCC; CRL-8083
DR BioSample; SAMN03471132
DR ChEMBL-Cells; CHEMBL3308240
DR ChEMBL-Targets; CHEMBL2366274
DR Cosmic; 683665
DR Cosmic; 2131565
DR Cosmic-CLP; 683665
DR GDSC; 683665
DR GEO; GSM1670075
DR IGRhCellID; MCCAR
DR IZSLER; BS TCL 134
RX Patent=US4434230;
RX PubMed=2537114;
RX PubMed=10516762;
RX PubMed=10936422;
RX PubMed=27397505;
CC Problematic cell line: Misidentified. Originally thought to be a myeloma cell line but is a B-lymphoblastoid cell line (PubMed=10516762).
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC Omics: Deep exome analysis.
CC Omics: DNA methylation analysis.
ST Source(s): ATCC; Cosmic-CLP
ST Amelogenin: X,Y
ST CSF1PO: 11,12
ST D13S317: 11,13
ST D16S539: 11,12
ST D5S818: 11,14
ST D7S820: 9,13
ST TH01: 6,9
ST TPOX: 8
ST vWA: 17,18
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Transformed cell line
//
ID MC/CAR-Z2
AC CVCL_6671
DR CLO; CLO_0007576
DR ATCC; CRL-8147
DR BioSample; SAMN03471194
CC Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
ST Source(s): ATCC
ST Amelogenin: X,Y
ST CSF1PO: 11,12
ST D13S317: 11,13
ST D16S539: 11,12
ST D5S818: 11,14,15
ST D7S820: 9,13
ST TH01: 6,9
ST TPOX: 8
ST vWA: 17,18
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_1397 ! MC/CAR
SX Male
CA Transformed cell line
//
ID MC1
AC CVCL_H810
CC From: Johns Hopkins University Transgenic Core Facility; Baltimore; USA.
CC Breed/subspecies: 129S6/SvEvTac.
OX NCBI_TaxID=10090; ! Mus musculus
SX Male
CA Embryonic stem cell
//
ID MC116
AC CVCL_1399
SY MC-116; MC 116
DR CLO; CLO_0007577
DR CLO; CLO_0007578
DR EFO; EFO_0002228
DR CLDB; cl3354
DR CLDB; cl3355
DR ATCC; CRL-1649
DR BCRC; 60292
DR BioSample; SAMN03473002
DR CCLE; MC116_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
DR ChEMBL-Cells; CHEMBL3308210
DR ChEMBL-Targets; CHEMBL2366256
DR Cosmic; 687847
DR Cosmic; 907799
DR Cosmic; 931128
DR Cosmic; 1086339
DR Cosmic-CLP; 907799
DR DSMZ; ACC-82
DR ECACC; 90110501
DR GDSC; 907799
DR GEO; GSM887289
DR GEO; GSM888364
DR GEO; GSM1374642
DR GEO; GSM1670074
DR IGRhCellID; MC116
RX PubMed=2052620;
RX PubMed=3080238;
RX PubMed=6243721;
RX PubMed=6243722;
RX PubMed=6265077;
RX PubMed=6286763;
RX PubMed=7757991;
RX PubMed=8316623;
RX PubMed=8344493;
RX PubMed=8515068;
RX PubMed=9473234;
RX PubMed=22460905;
RX PubMed=25355872;
RX PubMed=25485619;
RX PubMed=27397505;
RX PubMed=28196595;
WW http://tcpaportal.org/mclp/
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Part of: MD Anderson Cell Lines Project.
CC Doubling time: ~24-48 hours (DSMZ).
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Omics: Deep exome analysis.
CC Omics: Deep RNAseq analysis.
CC Omics: DNA methylation analysis.
CC Omics: Protein expression by reverse-phase protein arrays.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
CC Omics: Virome analysis using RNAseq.
ST Source(s): ATCC; Cosmic-CLP; DSMZ; ECACC; PubMed=25877200
ST Amelogenin: X,Y
ST CSF1PO: 10,12
ST D13S317: 12
ST D16S539: 12
ST D18S51: 12,13
ST D21S11: 29
ST D3S1358: 14,17
ST D5S818: 12
ST D7S820: 10,13
ST D8S1179: 14,15
ST FGA: 20,26
ST Penta D: 9,13
ST Penta E: 7,12
ST TH01: 9.3,10
ST TPOX: 8,10
ST vWA: 15,17
DI NCIt; C3457; B-cell non-Hodgkin lymphoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID MC1A-C1
AC CVCL_4983
RX PubMed=7577474;
CC Breed/subspecies: C57BL/10.
OX NCBI_TaxID=10090; ! Mus musculus
SX Male
CA Cancer cell line
//
ID MC2/3
AC CVCL_4588
DR CLO; CLO_0007580
DR ATCC; CRL-2143
RX PubMed=8000142;
OX NCBI_TaxID=10029; ! Cricetulus griseus
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_HE53 ! CAK-TK-
CA Hybrid cell line
//
ID MC3
AC CVCL_0087
SY MC-3
DR CLO; CLO_0007581
DR Cosmic; 787502
DR Cosmic; 1012085
RX PubMed=7787756;
RX PubMed=8632663;
RX PubMed=16408098;
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID MC38/0
AC CVCL_0A68
RX PubMed=15055737;
CC Breed/subspecies: C57BL/6.
DI NCIt; C120044; Mouse colon adenocarcinoma
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_B288 ! MC-38
SX Female
CA Cancer cell line
//
ID MC38/IL-12
AC CVCL_0A69
RX PubMed=15055737;
CC Transfected with: MGI; MGI:96539; Il12a.
CC Transfected with: MGI; MGI:96540; Il12b.
CC Breed/subspecies: C57BL/6.
DI NCIt; C120044; Mouse colon adenocarcinoma
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_0A68 ! MC38/0
SX Female
CA Cancer cell line
//
ID MC38Luc1
AC CVCL_0A67
RX PubMed=19128467;
CC Transfected with: UniProtKB; P08659; Firefly luciferase.
CC Breed/subspecies: C57BL/6.
DI NCIt; C120044; Mouse colon adenocarcinoma
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_B288 ! MC-38
SX Female
CA Cancer cell line
//
ID MC3T3
AC CVCL_0D74
SY MC-3T3; MC3T3-E
DR BTO; BTO:0005485
DR Wikidata; Q6714803
RX DOI=10.2330/joralbiosci1965.23.899;
WW https://en.wikipedia.org/wiki/MC3T3
CC Breed/subspecies: C57BL/6.
OX NCBI_TaxID=10090; ! Mus musculus
CA Spontaneously immortalized cell line
//
ID MC3T3-E1
AC CVCL_0409
SY MC3T3E1; MC-3T3-E1; MC 3T3-E1
DR BTO; BTO:0001957
DR CLO; CLO_0007582
DR CLO; CLO_0050208
DR MCCL; MCC:0000303
DR CLDB; cl40
DR ATCC; CRL-2953
DR CCRID; 3111C0001CCC000012
DR DSMZ; ACC-210
DR ECACC; 99072810
DR KCB; KCB 200786YJ
DR Lonza; 521
DR RCB; RCB1126
RX DOI=10.2330/joralbiosci1965.23.899;
RX DOI=10.4051/ibc.2010.2.4.0014;
RX PubMed=6826647;
WW https://en.wikipedia.org/wiki/MC3T3
WW http://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/m/cell-lines-detail-393.html
CC Doubling time: ~1-2 days (DSMZ).
CC Discontinued: ATCC; CRL-2953; probable.
CC Breed/subspecies: C57BL/6.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_0D74 ! MC3T3
CA Spontaneously immortalized cell line
//
ID MC3T3-E1 Subclone 14
AC CVCL_5437
SY MC3T3-E1 SUBCLONE 14
DR CLO; CLO_0007583
DR ATCC; CRL-2594
DR BCRJ; 0285
CC Breed/subspecies: C57BL/6.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_0409 ! MC3T3-E1
CA Spontaneously immortalized cell line
//
ID MC3T3-E1 Subclone 24
AC CVCL_5438
DR CLO; CLO_0007584
DR ATCC; CRL-2595
DR CCRID; 3131C0001000300015
DR IZSLER; BS CL 201
CC Breed/subspecies: C57BL/6.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_0409 ! MC3T3-E1
CA Spontaneously immortalized cell line
//
ID MC3T3-E1 Subclone 30
AC CVCL_5439
DR CLO; CLO_0007585
DR ATCC; CRL-2596
CC Breed/subspecies: C57BL/6.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_0409 ! MC3T3-E1
CA Spontaneously immortalized cell line
//
ID MC3T3-E1 Subclone 4
AC CVCL_5440
SY MC3T3, E1 subgroup-4 clone; MC3T3-E1(C4)
DR BTO; BTO:0004473
DR CLO; CLO_0007586
DR ATCC; CRL-2593
DR IZSLER; BS CL 181
DR TOKU-E; 2372
CC Breed/subspecies: C57BL/6.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_0409 ! MC3T3-E1
CA Spontaneously immortalized cell line
//
ID MC3T3-G2/PA6
AC CVCL_5441
SY MC3T3-G2-PA6; PA6
DR RCB; RCB1127
RX PubMed=2787384;
RX PubMed=3264531;
RX PubMed=7107717;
RX PubMed=7107718;
WW http://www.cells-talk.com/index.php/page/copelibrary?key=PA6
CC Breed/subspecies: C57BL/6.
OX NCBI_TaxID=10090; ! Mus musculus
CA Stromal cell line
//
ID MC4-L1
AC CVCL_0R48
RX PubMed=11196177;
CC Breed/subspecies: BALB/c.
DI NCIt; C21678; Malignant neoplasms of the mouse mammary gland
OX NCBI_TaxID=10090; ! Mus musculus
OI CVCL_0R49 ! MC4-L2
OI CVCL_0R50 ! MC4-L3
OI CVCL_0R51 ! MC4-L5
SX Female
CA Cancer cell line
//
ID MC4-L2
AC CVCL_0R49
RX PubMed=11196177;
CC Breed/subspecies: BALB/c.
DI NCIt; C21678; Malignant neoplasms of the mouse mammary gland
OX NCBI_TaxID=10090; ! Mus musculus
OI CVCL_0R48 ! MC4-L1
OI CVCL_0R50 ! MC4-L3
OI CVCL_0R51 ! MC4-L5
SX Female
CA Cancer cell line
//
ID MC4-L3
AC CVCL_0R50
RX PubMed=11196177;
CC Breed/subspecies: BALB/c.
DI NCIt; C21678; Malignant neoplasms of the mouse mammary gland
OX NCBI_TaxID=10090; ! Mus musculus
OI CVCL_0R48 ! MC4-L1
OI CVCL_0R49 ! MC4-L2
OI CVCL_0R51 ! MC4-L5
SX Female
CA Cancer cell line
//
ID MC4-L5
AC CVCL_0R51
RX PubMed=11196177;
CC Breed/subspecies: BALB/c.
DI NCIt; C21678; Malignant neoplasms of the mouse mammary gland
OX NCBI_TaxID=10090; ! Mus musculus
OI CVCL_0R48 ! MC4-L1
OI CVCL_0R49 ! MC4-L2
OI CVCL_0R50 ! MC4-L3
SX Female
CA Cancer cell line
//
ID MC4000
AC CVCL_5331
SY MC-4000
DR BioSample; SAMN03151743
RX PubMed=9150904;
RX PubMed=10508494;
RX PubMed=20143388;
WW http://iclac.org/wp-content/uploads/Cross-Contaminations-v8_0.pdf
CC Problematic cell line: Contaminated. Shown to be a HeLa derivative (PubMed=10508494, PubMed=20143388). Originally thought to originate from a breast carcinoma.
CC Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18).
DI NCIt; C4029; Cervical adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0030 ! HeLa
SX Female
CA Cancer cell line
//
ID MC5
AC CVCL_1N49
SY MC-5
RX PubMed=2687628;
RX PubMed=7404270;
OX NCBI_TaxID=10029; ! Cricetulus griseus
HI CVCL_4386 ! CHO-AA8
SX Female
CA Spontaneously immortalized cell line
//
ID MC57G
AC CVCL_4985
SY MC57
DR BTO; BTO:0005218
DR CLO; CLO_0007587
DR ATCC; CRL-2295
DR Lonza; 130
CC Transformant: ChEBI; CHEBI:34342; 3-methylcholanthrene (MCA).
CC Breed/subspecies: C57BL/6J.
DI NCIt; C24017; Mouse fibrosarcoma
OX NCBI_TaxID=10090; ! Mus musculus
CA Cancer cell line
//
ID MC615
AC CVCL_0410
DR MCCL; MCC:0000304
RX PubMed=7682698;
CC Transfected with: UniProtKB; P00552; Transposon Tn5 neo.
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40).
CC Breed/subspecies: CD-1.
OX NCBI_TaxID=10090; ! Mus musculus
CA Transformed cell line
//
ID MC615 4B5
AC CVCL_H341
SY 4B5
RX PubMed=19670270;
CC Transfected with: UniProtKB; P00552; Transposon Tn5 neo.
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40).
CC Breed/subspecies: CD-1.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_0410 ! MC615
CA Transformed cell line
//
ID MC615 4C1
AC CVCL_H342
SY 4C1
RX PubMed=19670270;
CC Transfected with: UniProtKB; P00552; Transposon Tn5 neo.
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40).
CC Breed/subspecies: CD-1.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_0410 ! MC615
CA Transformed cell line
//
ID MC615 4C3
AC CVCL_H343
SY 4C3
RX PubMed=19670270;
CC Transfected with: UniProtKB; P00552; Transposon Tn5 neo.
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40).
CC Breed/subspecies: CD-1.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_0410 ! MC615
CA Transformed cell line
//
ID MC615 4C6
AC CVCL_H344
SY 4C6
RX PubMed=19670270;
CC Transfected with: UniProtKB; P00552; Transposon Tn5 neo.
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40).
CC Breed/subspecies: CD-1.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_0410 ! MC615
CA Transformed cell line
//
ID MC615 4C9
AC CVCL_H345
SY 4C9
RX PubMed=19670270;
CC Transfected with: UniProtKB; P00552; Transposon Tn5 neo.
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40).
CC Breed/subspecies: CD-1.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_0410 ! MC615
CA Transformed cell line
//
ID MC615 4D5
AC CVCL_H346
SY 4D5
RX PubMed=19670270;
CC Transfected with: UniProtKB; P00552; Transposon Tn5 neo.
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40).
CC Breed/subspecies: CD-1.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_0410 ! MC615
CA Transformed cell line
//
ID MC615 4D7
AC CVCL_H347
SY 4D7
RX PubMed=19670270;
CC Transfected with: UniProtKB; P00552; Transposon Tn5 neo.
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40).
CC Breed/subspecies: CD-1.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_0410 ! MC615
CA Transformed cell line
//
ID MC615 4E3
AC CVCL_H348
SY 4E3
RX PubMed=19670270;
CC Transfected with: UniProtKB; P00552; Transposon Tn5 neo.
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40).
CC Breed/subspecies: CD-1.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_0410 ! MC615
CA Transformed cell line
//
ID MC615 4F6
AC CVCL_H349
SY 4F6
RX PubMed=19670270;
CC Transfected with: UniProtKB; P00552; Transposon Tn5 neo.
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40).
CC Breed/subspecies: CD-1.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_0410 ! MC615
CA Transformed cell line
//
ID MC615 4G11
AC CVCL_H350
SY 4G11
RX PubMed=19670270;
CC Transfected with: UniProtKB; P00552; Transposon Tn5 neo.
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40).
CC Breed/subspecies: CD-1.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_0410 ! MC615
CA Transformed cell line
//
ID MC615 4H4
AC CVCL_H351
SY 4H4
RX PubMed=19670270;
CC Transfected with: UniProtKB; P00552; Transposon Tn5 neo.
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40).
CC Breed/subspecies: CD-1.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_0410 ! MC615
CA Transformed cell line
//
ID MC615 5A2
AC CVCL_H352
SY 5A2
RX PubMed=19670270;
CC Transfected with: UniProtKB; P00552; Transposon Tn5 neo.
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40).
CC Breed/subspecies: CD-1.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_0410 ! MC615
CA Transformed cell line
//
ID MC615 5F12
AC CVCL_H353
SY 5F12
RX PubMed=19670270;
CC Transfected with: UniProtKB; P00552; Transposon Tn5 neo.
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40).
CC Breed/subspecies: CD-1.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_0410 ! MC615
CA Transformed cell line
//
ID MC615 5F9
AC CVCL_H354
SY 5F9
RX PubMed=19670270;
CC Transfected with: UniProtKB; P00552; Transposon Tn5 neo.
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40).
CC Breed/subspecies: CD-1.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_0410 ! MC615
CA Transformed cell line
//
ID MC7-2A
AC CVCL_0R52
RX PubMed=14758093;
CC Breed/subspecies: BALB/c.
DI NCIt; C21678; Malignant neoplasms of the mouse mammary gland
OX NCBI_TaxID=10090; ! Mus musculus
OI CVCL_0R53 ! MC7-2B
OI CVCL_0R54 ! MC7-L1
SX Female
CA Cancer cell line
//
ID MC7-2B
AC CVCL_0R53
RX PubMed=14758093;
CC Breed/subspecies: BALB/c.
DI NCIt; C21678; Malignant neoplasms of the mouse mammary gland
OX NCBI_TaxID=10090; ! Mus musculus
OI CVCL_0R52 ! MC7-2A
OI CVCL_0R54 ! MC7-L1
SX Female
CA Cancer cell line
//
ID MC7-L1
AC CVCL_0R54
RX PubMed=11196177;
CC Breed/subspecies: BALB/c.
DI NCIt; C21678; Malignant neoplasms of the mouse mammary gland
OX NCBI_TaxID=10090; ! Mus musculus
OI CVCL_0R52 ! MC7-2A
OI CVCL_0R53 ! MC7-2B
SX Female
CA Cancer cell line
//
ID MCA-B1
AC CVCL_W820
RX PubMed=7709052;
CC Breed/subspecies: Aika.
OX NCBI_TaxID=9615; ! Canis lupus familiaris
SX Male
CA Cancer cell line
//
ID McA-RH7777
AC CVCL_0444
SY McA-RH 7777; MCA-RH 7777; McArdle RH-7777; McARH7777; RH7777; Mc Ardle 7777
DR BTO; BTO:0000358
DR CLO; CLO_0007594
DR CLO; CLO_0007595
DR MCCL; MCC:0000340
DR CLDB; cl3362
DR CLDB; cl3363
DR CLDB; cl3364
DR CLDB; cl4991
DR ATCC; CRL-1601
DR BCRJ; 0159
DR ChEMBL-Cells; CHEMBL3307729
DR ChEMBL-Targets; CHEMBL614876
DR ECACC; 90021504
DR ICLC; ATL00002
DR IZSLER; BS TCL 217
DR Lonza; 1280
WW http://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/m/cell-lines-detail-142.html
WW http://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/m/cell-lines-detail-595.html
CC Breed/subspecies: Buffalo.
DI NCIt; C60416; Rat hepatocellular carcinoma
OX NCBI_TaxID=10116; ! Rattus norvegicus
OI CVCL_2113 ! MH-7777A
OI CVCL_0F78 ! 7777-14b-aza
SX Female
CA Cancer cell line
//
ID McA-RH8994
AC CVCL_3396
SY McA-RH 8994; RH8994
DR CLO; CLO_0007596
DR ATCC; CRL-1602
DR BCRC; 60232
DI NCIt; C60416; Rat hepatocellular carcinoma
OX NCBI_TaxID=10116; ! Rattus norvegicus
SX Male
CA Cancer cell line
//
ID MCA-TCL15
AC CVCL_U204
SY MCA-TCL15/P3; MCA-TCL-15; TCL-15
RX PubMed=4796800;
CC Breed/subspecies: C3H.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_0190 ! C3H/10T1/2 clone 8
CA Transformed cell line
//
ID MCA-TCL16
AC CVCL_U205
SY MCA-TCL16/P3
DR JCRB; JCRB0712
RX PubMed=4796800;
CC Breed/subspecies: C3H.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_0190 ! C3H/10T1/2 clone 8
CA Transformed cell line
//
ID MCa3D
AC CVCL_5797
SY MCA3D; MCA-3D; MCA/3D; MCA 3D
DR CLS; 400437/p519_MCA-3D
DR NCBI_Iran; C619
RX PubMed=1934268;
RX PubMed=6196137;
CC Transformant: ChEBI; CHEBI:59032; 7,12-dimethyltetraphene (DMBA; dimethylbenzanthracene).
CC Breed/subspecies: BALB/c.
OX NCBI_TaxID=10090; ! Mus musculus
CA Transformed cell line
//
ID MCa3F
AC CVCL_5U31
SY MCA-3F; MCA 3F
RX PubMed=1934268;
RX PubMed=6196137;
CC Transformant: ChEBI; CHEBI:21759; N-methyl-N'-nitro-N-nitrosoguanidine (MNNG).
CC Breed/subspecies: BALB/c.
OX NCBI_TaxID=10090; ! Mus musculus
CA Transformed cell line
//
ID MCAS
AC CVCL_3020
DR EFO; EFO_0006453
DR BioSample; SAMN03472857
DR CCLE; MCAS_OVARY
DR CGH-DB; 343-2
DR CGH-DB; 9356-4
DR Cosmic; 849612
DR Cosmic; 931362
DR Cosmic; 948290
DR Cosmic; 1707559
DR Cosmic; 2429301
DR Cosmic; 2582802
DR Cosmic-CLP; 1240171
DR GDSC; 1240171
DR GEO; GSM659382
DR GEO; GSM827228
DR GEO; GSM851924
DR GEO; GSM887290
DR GEO; GSM888365
DR JCRB; JCRB0240
DR TKG; TKG 0662
RX PubMed=4056530;
RX PubMed=9290701;
RX PubMed=11330945;
RX PubMed=12417041;
RX PubMed=17671176;
RX PubMed=22246397;
RX PubMed=22460905;
RX PubMed=22710073;
RX PubMed=23839242;
RX PubMed=24023729;
RX PubMed=25485619;
RX PubMed=28196595;
WW http://tcpaportal.org/mclp/
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Part of: MD Anderson Cell Lines Project.
CC Doubling time: 27 hours (PubMed=4056530).
CC Omics: Deep exome analysis.
CC Omics: Deep RNAseq analysis.
CC Omics: Protein expression by reverse-phase protein arrays.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
ST Source(s): JCRB; PubMed=25877200; TKG
ST Amelogenin: X
ST CSF1PO: 10,11
ST D13S317: 8,12
ST D16S539: 12
ST D18S51: 15
ST D21S11: 29,31
ST D3S1358: 16,17
ST D5S818: 11,13
ST D7S820: 8,11
ST D8S1179: 11,12
ST FGA: 18,21
ST Penta D: 10,12
ST Penta E: 16
ST TH01: 6,8
ST TPOX: 8,11
ST vWA: 14,17
DI NCIt; C4026; Ovarian mucinous cystadenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID MCAS-3
AC CVCL_U210
RX PubMed=7882618;
DI NCIt; C4026; Ovarian mucinous cystadenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_3020 ! MCAS
SX Female
CA Cancer cell line
//
ID MCB3901
AC CVCL_6419
SY AV12-664; AV12
DR CLO; CLO_0007597
DR ATCC; CRL-9595
DR CCRID; 3142C0001000000434
RX Patent=US4975369;
OX NCBI_TaxID=10036; ! Mesocricetus auratus
CA Transformed cell line
//
ID MCC-1
AC CVCL_D730
DR Cosmic; 1623851
RX PubMed=11319762;
DI NCIt; C9231; Merkel cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID MCC-2
AC CVCL_6B10
RX PubMed=11329612;
RX PubMed=11520047;
RX PubMed=17233813;
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40) [tsA58].
CC Breed/subspecies: C57BL/6 SV40-tsA58 transgenic.
OX NCBI_TaxID=10090; ! Mus musculus
CA Conditionally immortalized cell line
//
ID MCC-35
AC CVCL_6B12
RX PubMed=11329612;
RX PubMed=11520047;
RX PubMed=17233813;
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40) [tsA58].
CC Breed/subspecies: C57BL/6 SV40-tsA58 transgenic.
OX NCBI_TaxID=10090; ! Mus musculus
CA Conditionally immortalized cell line
//
ID MCC-5
AC CVCL_6B11
RX PubMed=11329612;
RX PubMed=11520047;
RX PubMed=17233813;
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40) [tsA58].
CC Breed/subspecies: C57BL/6 SV40-tsA58 transgenic.
OX NCBI_TaxID=10090; ! Mus musculus
CA Conditionally immortalized cell line
//
ID MCC1 [Human Merkel cell carcinoma]
AC CVCL_4558
SY MCC1TC; MCC1 TC
DR Cosmic; 912927
RX PubMed=8244578;
CC Caution: Was briefly displayed in Cell Bank Australia under catalog number CBA-1335 but was never distributed.
DI NCIt; C9231; Merkel cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID MCC1 [Human mucinous cystic carcinoma]
AC CVCL_D729
RX PubMed=15688169;
DI NCIt; C41247; Pancreatic mucinous-cystic neoplasm
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID MCC12
AC CVCL_4446
SY MCC12TC; MCC12 TC
RX PubMed=8244578;
CC Caution: Was briefly displayed in Cell Bank Australia under catalog number CBA-1337 but was never distributed.
DI NCIt; C9231; Merkel cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID MCC13
AC CVCL_2583
SY MCC13TC; MCC13 TC
DR CBA; CBA-1338
DR Cosmic; 912929
DR Cosmic; 1693075
DR Cosmic; 1699815
DR Cosmic; 2273913
DR Cosmic-CLP; 1333003
DR ECACC; 10092302
DR GDSC; 1333003
RX PubMed=7814141;
RX PubMed=12209990;
RX PubMed=20444890;
CC Omics: Deep exome analysis.
CC Derived from metastatic site: Cervical lymph node.
DI NCIt; C9231; Merkel cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID MCC14/1
AC CVCL_4447
SY MCC14/1TC; MCC14/1 TC
DR Cosmic; 912930
RX PubMed=7814141;
CC Caution: Was briefly displayed in Cell Bank Australia under catalog number CBA-1339 but is not yet ready for distribution.
CC Derived from metastatic site: Iliac lymph node.
DI NCIt; C9231; Merkel cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_2584 ! MCC14/2
SX Male
CA Cancer cell line
//
ID MCC14/2
AC CVCL_2584
SY MCC14/2TC; MCC14/2 TC
DR CBA; CBA-1340
DR Cosmic; 912931
DR Cosmic; 2273914
DR ECACC; 10092303
RX PubMed=7814141;
CC Derived from metastatic site: Iliac lymph node.
DI NCIt; C9231; Merkel cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_4447 ! MCC14/1
SX Male
CA Cancer cell line
//
ID MCC15
AC CVCL_D021
SY MCC15TC; MCC15 TC
RX PubMed=7814141;
CC Derived from metastatic site: Axillary lymph node.
DI NCIt; C9231; Merkel cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID MCC19
AC CVCL_4448
SY MCC19TC; MCC19 TC
DR Cosmic; 912932
RX PubMed=12209986;
CC Caution: Was briefly displayed in Cell Bank Australia under catalog number CBA-1343 but was never distributed.
DI NCIt; C9231; Merkel cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID MCC26
AC CVCL_2585
SY MCC26TC; MCC26 TC
DR CBA; CBA-1341
DR Cosmic; 912933
DR Cosmic; 1693076
DR Cosmic; 1699816
DR Cosmic; 2273915
DR Cosmic-CLP; 1298234
DR ECACC; 10092304
DR GDSC; 1298234
RX PubMed=12209986;
RX PubMed=12209990;
CC Omics: Deep exome analysis.
DI NCIt; C9231; Merkel cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID MCC5
AC CVCL_4444
SY MCC5TC; MCC5 TC
RX PubMed=8244578;
CC Caution: Was briefly displayed in Cell Bank Australia under catalog number CBA-1336 but was never distributed.
DI NCIt; C9231; Merkel cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID MCC6
AC CVCL_4445
SY MCC6TC; MCC6 TC
DR Cosmic; 912928
RX PubMed=8244578;
CC Caution: Was briefly displayed in Cell Bank Australia under catalog number CBA-1334 but was never distributed.
DI NCIt; C9231; Merkel cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID MCCL-1
AC CVCL_D026
SY MC-MA2
DR Cosmic; 740970
RX PubMed=8120418;
RX PubMed=11992403;
CC Derived from metastatic site: Cutaneous.
DI NCIt; C9231; Merkel cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID MCCL-2
AC CVCL_IR17
DR Cosmic; 740972
RX PubMed=11992403;
CC Derived from metastatic site: Cutaneous.
DI NCIt; C9231; Merkel cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID MCCL-3
AC CVCL_IR18
DR Cosmic; 740975
RX PubMed=11992403;
DI NCIt; C9231; Merkel cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID MCCL-4
AC CVCL_IR19
DR Cosmic; 740977
RX PubMed=11992403;
DI NCIt; C9231; Merkel cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID MCCL-5
AC CVCL_IR20
DR Cosmic; 740979
RX PubMed=11992403;
DI NCIt; C9231; Merkel cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID MCCL-6
AC CVCL_IR21
DR Cosmic; 740981
RX PubMed=11992403;
DI NCIt; C9231; Merkel cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID McCoy
AC CVCL_3742
SY MCCOY; Mc Coy; McCoy B
DR CLO; CLO_0007573
DR CLO; CLO_0007598
DR CLDB; cl3349
DR CLDB; cl3350
DR CLDB; cl3352
DR ATCC; CRL-1696
DR BCRC; 60064
DR BCRJ; 0160
DR BioSample; SAMN03151926
DR ECACC; 90010305
DR IZSLER; BS CL 62
DR NCBI_Iran; C123
RX PubMed=4110420;
RX PubMed=6451928;
RX PubMed=20143388;
WW http://iclac.org/wp-content/uploads/Cross-Contaminations-v8_0.pdf
WW http://en.vircell.com/products/mccoy-cell-line/
CC Problematic cell line: Misidentified. Originally thought to be of human origin but found to be a mouse NCTC clone 929 derivative (PubMed=6451928, PubMed=20143388). Were thought to originate from the synovial fluid in the knee joint of a patient suffering from degenerative arthritis.
CC Breed/subspecies: C3H/An.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_0462 ! NCTC clone 929
SX Male
CA Spontaneously immortalized cell line
//
ID MCD-1
AC CVCL_M701
RX PubMed=8971690;
DI NCIt; C3222; Medulloblastoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID MCE301
AC CVCL_6B09
SY MCE 301
RX PubMed=11235898;
RX PubMed=11520047;
RX PubMed=16678170;
RX PubMed=17233813;
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40) [tsA58].
CC Omics: Transcriptome analysis.
CC Breed/subspecies: C57BL/6 SV40-tsA58 transgenic.
OX NCBI_TaxID=10090; ! Mus musculus
CA Conditionally immortalized cell line
//
ID MCEC
AC CVCL_D355
SY Mouse Cardiac Endothelial Cells
RX PubMed=17317723;
WW https://www.cedarlanelabs.com/Products/Detail/CLU510?lob=Cellutions
CC Transfected with: HGNC; 11730; TERT.
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40).
CC Breed/subspecies: FVB.
OX NCBI_TaxID=10090; ! Mus musculus
CA Transformed cell line
//
ID MCF 10A-H2B-mCherry
AC CVCL_IV14
DR LINCS; 51124
RX PubMed=27135972;
CC Characteristics: Retroviral transformation with an H2B-mCherry expression cassette.
CC Transfected with: UniProtKB; X5DSL3; mCherry fluorescent protein.
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0598 ! MCF-10A
SX Female
CA Spontaneously immortalized cell line
//
ID MCF-10-2A
AC CVCL_3743
DR CLO; CLO_0007602
DR ATCC; CRL-10781
DR BioSample; SAMN03471306
RX Patent=US5238840;
ST Source(s): ATCC
ST Amelogenin: X
ST CSF1PO: 10,12
ST D13S317: 9
ST D16S539: 11,12
ST D5S818: 10,13
ST D7S820: 10,11
ST TH01: 8
ST TPOX: 9,11
ST vWA: 15,17
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_0598 ! MCF-10A
OI CVCL_3633 ! MCF-10F
OI CVCL_5553 ! MCF-10-2F
SX Female
CA Spontaneously immortalized cell line
//
ID MCF-10-2F
AC CVCL_5553
DR ATCC; CRL-10780
DR BioSample; SAMN03471305
RX Patent=US5238840;
ST Source(s): ATCC
ST Amelogenin: X
ST CSF1PO: 10,12
ST D13S317: 8
ST D16S539: 11,12
ST D5S818: 10,13
ST D7S820: 10,11
ST TH01: 8
ST TPOX: 9,11
ST vWA: 15,17
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_0598 ! MCF-10A
OI CVCL_3633 ! MCF-10F
OI CVCL_3743 ! MCF-10-2A
SX Female
CA Spontaneously immortalized cell line
//
ID MCF-10A
AC CVCL_0598
SY MCF 10A; MCF.10A; MCF10A; MCF10a; Michigan Cancer Foundation-10A
DR BTO; BTO:0001939
DR CLO; CLO_0007599
DR EFO; EFO_0001200
DR MCCL; MCC:0000305
DR ATCC; CRL-10317
DR BCRJ; 0161
DR BioSample; SAMN03471375
DR CCRID; 3131C0001000200025
DR ChEMBL-Cells; CHEMBL3307364
DR ChEMBL-Targets; CHEMBL614321
DR Cosmic; 1136376
DR Cosmic; 1176649
DR Cosmic; 2318371
DR ENCODE; ENCBS066ENC
DR ENCODE; ENCBS067ENC
DR ENCODE; ENCBS617ENC
DR ENCODE; ENCBS618ENC
DR ENCODE; ENCBS619ENC
DR ENCODE; ENCBS620ENC
DR ENCODE; ENCBS621ENC
DR ENCODE; ENCBS622ENC
DR ENCODE; ENCBS623ENC
DR GEO; GSM155217
DR GEO; GSM320171
DR GEO; GSM350543
DR GEO; GSM498022
DR GEO; GSM498026
DR GEO; GSM756371
DR GEO; GSM845395
DR GEO; GSM844584
DR GEO; GSM1328939
DR GEO; GSM1328940
DR GEO; GSM1328941
DR IGRhCellID; MCF10A
DR IZSLER; BS CL 174
DR KCB; KCB 2014066YJ
DR LINCS; 50583
DR Lonza; 131
DR NCBI_Iran; C609
DR PRIDE; PXD000309
DR PRIDE; PXD000593
DR PRIDE; PXD000691
DR TOKU-E; 2378
RX Patent=US5436152;
RX PubMed=12661003;
RX PubMed=15375546;
RX PubMed=17157791;
RX PubMed=19582160;
RX PubMed=20169162;
RX PubMed=22414580;
RX PubMed=24162158;
RX PubMed=24262153;
RX PubMed=25485619;
RX PubMed=26055192;
RX PubMed=26218769;
RX PubMed=28196595;
WW https://strap.nci.nih.gov/celline_detail.php?sample_id=81
WW http://lincs.hms.harvard.edu/resources/reagents/icbp43/
WW http://tcpaportal.org/mclp/
CC Part of: ICBP43 breast cancer cell line panel.
CC Part of: MD Anderson Cell Lines Project.
CC Microsatellite instability: Stable (MSS) (PubMed=12661003).
CC Omics: CNV analysis.
CC Omics: Deep proteome analysis.
CC Omics: Deep RNAseq analysis.
CC Omics: Glycoproteome analysis by proteomics.
CC Omics: Metabolome analysis.
CC Omics: Protein expression by reverse-phase protein arrays.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
ST Source(s): ATCC; PubMed=25877200
ST Amelogenin: X
ST CSF1PO: 10,12
ST D13S317: 8,9
ST D16S539: 11,12
ST D18S51: 18,19
ST D21S11: 28,30
ST D3S1358: 14,18
ST D5S818: 10,13
ST D7S820: 10,11
ST D8S1179: 14,16
ST FGA: 22,24
ST Penta D: 10,12
ST Penta E: 13,14
ST TH01: 8,9.3
ST TPOX: 9,11
ST vWA: 15,17
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_3633 ! MCF-10F
OI CVCL_3743 ! MCF-10-2A
OI CVCL_5553 ! MCF-10-2F
SX Female
CA Spontaneously immortalized cell line
//
ID MCF-10A-erbB-2
AC CVCL_IP85
SY MCF-10AerbB-2
RX PubMed=10433219;
CC Transfected with: HGNC; 3430; ERBB2.
CC Transfected with: UniProtKB; P00552; Transposon Tn5 neo.
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0598 ! MCF-10A
SX Female
CA Spontaneously immortalized cell line
//
ID MCF-10A-neo
AC CVCL_6C54
SY MCF-10A neo; MCF-10ANeo; MCF10A-neo; MCF10Aneo
RX PubMed=1885681;
RX PubMed=2009132;
CC Transfected with: UniProtKB; P00552; Transposon Tn5 neo.
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0598 ! MCF-10A
SX Female
CA Spontaneously immortalized cell line
//
ID MCF-10A-neoN
AC CVCL_6C55
SY MCF-10A neoN; MCF-10AneoN; MCF10AneoN
RX PubMed=1885681;
RX PubMed=2009132;
CC Transfected with: HGNC; 5173; HRAS.
CC Transfected with: UniProtKB; P00552; Transposon Tn5 neo.
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0598 ! MCF-10A
SX Female
CA Spontaneously immortalized cell line
//
ID MCF-10A-neoT
AC CVCL_5554
SY MCF-10A neoT; MCF-10AneoT; MCF10AneoT; MCF10-AneoT
DR BTO; BTO:0005127
RX PubMed=1885681;
RX PubMed=2009132;
CC Transfected with: HGNC; 5173; HRAS (with V-12).
CC Transfected with: UniProtKB; P00552; Transposon Tn5 neo.
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0598 ! MCF-10A
SX Female
CA Transformed cell line
//
ID MCF-10A/Twist
AC CVCL_DS00
RX PubMed=20019840;
CC Transfected with: HGNC; 12428; TWIST1.
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0598 ! MCF-10A
SX Female
CA Spontaneously immortalized cell line
//
ID MCF-10AT
AC CVCL_5555
SY MCF10AT
DR GEO; GSM498023
DR GEO; GSM498027
DR IGRhCellID; MCF10AT
RX PubMed=8546221;
RX PubMed=15375546;
RX PubMed=20169162;
RX PubMed=24262153;
CC Transfected with: HGNC; 5173; HRAS (with V-12).
CC Transfected with: UniProtKB; P00552; Transposon Tn5 neo.
CC Omics: CNV analysis.
CC Omics: Glycoproteome analysis by proteomics.
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_5554 ! MCF-10A-neoT
SX Female
CA Transformed cell line
//
ID MCF-10F
AC CVCL_3633
SY MCF 10F; MCF10F; Michigan Cancer Foundation-10F
DR BTO; BTO:0003900
DR CLO; CLO_0007600
DR ATCC; CRL-10318
DR Cosmic; 1136377
DR LINCS; 50584
RX Patent=US5436152;
RX PubMed=12353263;
RX PubMed=12800145;
WW http://lincs.hms.harvard.edu/resources/reagents/icbp43/
CC Part of: ICBP43 breast cancer cell line panel.
ST Source(s): ATCC
ST Amelogenin: X
ST CSF1PO: 10,12
ST D13S317: 8,9
ST D16S539: 11,12
ST D5S818: 10,13
ST D7S820: 10,11
ST TH01: 8,9.3
ST TPOX: 9,11
ST vWA: 15,17
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_0598 ! MCF-10A
OI CVCL_3743 ! MCF-10-2A
OI CVCL_5553 ! MCF-10-2F
SX Female
CA Spontaneously immortalized cell line
//
ID MCF-12A
AC CVCL_3744
SY MCF12A; Michigan Cancer Foundation-12A
DR BTO; BTO:0002544
DR CLO; CLO_0007603
DR EFO; EFO_0001202
DR ATCC; CRL-10782
DR BioSample; SAMN03472816
DR ChEMBL-Cells; CHEMBL3307365
DR ChEMBL-Targets; CHEMBL614322
DR Cosmic; 1017163
DR Cosmic; 1136378
DR Cosmic; 1176637
DR GEO; GSM756372
DR GEO; GSM845396
DR GEO; GSM844585
DR LINCS; 51089
DR TOKU-E; 2381
RX Patent=US5206165;
RX PubMed=17157791;
RX PubMed=24162158;
WW http://lincs.hms.harvard.edu/resources/reagents/icbp43/
CC Part of: ICBP43 breast cancer cell line panel.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
ST Source(s): ATCC
ST Amelogenin: X
ST CSF1PO: 10,11
ST D13S317: 9,11
ST D16S539: 9,12
ST D5S818: 11,13
ST D7S820: 8,11
ST TH01: 7
ST TPOX: 8
ST vWA: 18
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_3745 ! MCF-12F
SX Female
CA Spontaneously immortalized cell line
//
ID MCF-12F
AC CVCL_3745
SY MCF12F; Michigan Cancer Foundation-12F
DR BTO; BTO:0002545
DR CLO; CLO_0007604
DR ATCC; CRL-10783
DR GEO; GSM756373
RX Patent=US5206165;
RX PubMed=24162158;
ST Source(s): ATCC
ST Amelogenin: X
ST CSF1PO: 10,11
ST D13S317: 9,11
ST D16S539: 9,12
ST D5S818: 11,13
ST D7S820: 8,11
ST TH01: 7
ST TPOX: 8
ST vWA: 18
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_3744 ! MCF-12A
SX Female
CA Spontaneously immortalized cell line
//
ID MCF-7
AC CVCL_0031
SY MCF 7; MCF.7; MCF7; Michigan Cancer Foundation-7; ssMCF-7; ssMCF7; MCF7/WT; IBMF-7; MCF7-CTRL
DR BTO; BTO:0000093
DR CLO; CLO_0007601
DR CLO; CLO_0007605
DR CLO; CLO_0007606
DR CLO; CLO_0050868
DR EFO; EFO_0001203
DR MCCL; MCC:0000307
DR CLDB; cl3366
DR CLDB; cl3367
DR CLDB; cl3368
DR CLDB; cl3369
DR CLDB; cl3370
DR CLDB; cl3371
DR CLDB; cl3372
DR CLDB; cl3373
DR CLDB; cl3375
DR ATCC; CRL-12584
DR ATCC; HTB-22
DR BCRC; 60436
DR BCRJ; 0162
DR BioSample; SAMN01821575
DR BioSample; SAMN01821646
DR BioSample; SAMN01821698
DR BioSample; SAMN03473276
DR CCLE; MCF7_BREAST
DR CCRID; 3111C0001CCC000013
DR CCRID; 3111C0001CCC000328
DR CCRID; 3131C0001000700074
DR CCRID; 3142C0001000000054
DR ChEMBL-Cells; CHEMBL3307491
DR ChEMBL-Cells; CHEMBL3308403
DR ChEMBL-Targets; CHEMBL387
DR ChEMBL-Targets; CHEMBL614345
DR CLS; 300273/p2720_MCF-7
DR Cosmic; 687490
DR Cosmic; 755293
DR Cosmic; 809239
DR Cosmic; 871143
DR Cosmic; 875876
DR Cosmic; 877449
DR Cosmic; 894096
DR Cosmic; 897419
DR Cosmic; 904373
DR Cosmic; 905946
DR Cosmic; 912001
DR Cosmic; 921976
DR Cosmic; 923059
DR Cosmic; 934534
DR Cosmic; 944293
DR Cosmic; 947352
DR Cosmic; 949189
DR Cosmic; 970089
DR Cosmic; 979723
DR Cosmic; 991328
DR Cosmic; 997916
DR Cosmic; 1000123
DR Cosmic; 1010932
DR Cosmic; 1017161
DR Cosmic; 1018463
DR Cosmic; 1019310
DR Cosmic; 1046936
DR Cosmic; 1047712
DR Cosmic; 1066224
DR Cosmic; 1071901
DR Cosmic; 1092612
DR Cosmic; 1102382
DR Cosmic; 1136341
DR Cosmic; 1152527
DR Cosmic; 1175832
DR Cosmic; 1176603
DR Cosmic; 1176648
DR Cosmic; 1183770
DR Cosmic; 1287893
DR Cosmic; 1289391
DR Cosmic; 1305382
DR Cosmic; 1308991
DR Cosmic; 1312369
DR Cosmic; 1326278
DR Cosmic; 1434950
DR Cosmic; 1436031
DR Cosmic; 1477426
DR Cosmic; 1481420
DR Cosmic; 1523770
DR Cosmic; 1524349
DR Cosmic; 1571788
DR Cosmic; 1603215
DR Cosmic; 1609459
DR Cosmic; 1945860
DR Cosmic; 1995500
DR Cosmic; 1998454
DR Cosmic; 2162161
DR Cosmic; 2165024
DR Cosmic; 2301233
DR Cosmic; 2301526
DR Cosmic; 2307194
DR Cosmic; 2318370
DR Cosmic; 2361358
DR Cosmic; 2525755
DR Cosmic; 2553502
DR Cosmic-CLP; 905946
DR DSMZ; ACC-115
DR ECACC; 86012803
DR ENCODE; ENCBS000AAA
DR ENCODE; ENCBS001AAA
DR ENCODE; ENCBS017ENC
DR ENCODE; ENCBS034XKZ
DR ENCODE; ENCBS036ENC
DR ENCODE; ENCBS037ENC
DR ENCODE; ENCBS050QMU
DR ENCODE; ENCBS053YJT
DR ENCODE; ENCBS056AAA
DR ENCODE; ENCBS094ENC
DR ENCODE; ENCBS095ENC
DR ENCODE; ENCBS096ENC
DR ENCODE; ENCBS097ENC
DR ENCODE; ENCBS098ENC
DR ENCODE; ENCBS102ENC
DR ENCODE; ENCBS103ENC
DR ENCODE; ENCBS104ENC
DR ENCODE; ENCBS105ENC
DR ENCODE; ENCBS108ENC
DR ENCODE; ENCBS123ZGI
DR ENCODE; ENCBS134PJO
DR ENCODE; ENCBS135SOE
DR ENCODE; ENCBS143XXF
DR ENCODE; ENCBS155VQC
DR ENCODE; ENCBS158RRU
DR ENCODE; ENCBS168ISE
DR ENCODE; ENCBS174OTK
DR ENCODE; ENCBS200IWR
DR ENCODE; ENCBS216AOQ
DR ENCODE; ENCBS236AAA
DR ENCODE; ENCBS237AAA
DR ENCODE; ENCBS240AAA
DR ENCODE; ENCBS241AAA
DR ENCODE; ENCBS242AAA
DR ENCODE; ENCBS243AAA
DR ENCODE; ENCBS244AAA
DR ENCODE; ENCBS245AAA
DR ENCODE; ENCBS246AAA
DR ENCODE; ENCBS247AAA
DR ENCODE; ENCBS248AAA
DR ENCODE; ENCBS249AAA
DR ENCODE; ENCBS250AAA
DR ENCODE; ENCBS251AAA
DR ENCODE; ENCBS252AAA
DR ENCODE; ENCBS254AYH
DR ENCODE; ENCBS267CRP
DR ENCODE; ENCBS308QKF
DR ENCODE; ENCBS325VCY
DR ENCODE; ENCBS328UKJ
DR ENCODE; ENCBS331EJR
DR ENCODE; ENCBS488MMM
DR ENCODE; ENCBS496HCC
DR ENCODE; ENCBS530DHL
DR ENCODE; ENCBS536NWC
DR ENCODE; ENCBS546VBU
DR ENCODE; ENCBS547AXB
DR ENCODE; ENCBS564FRY
DR ENCODE; ENCBS567IJO
DR ENCODE; ENCBS581MUA
DR ENCODE; ENCBS584TFV
DR ENCODE; ENCBS609QTY
DR ENCODE; ENCBS614ENC
DR ENCODE; ENCBS615ENC
DR ENCODE; ENCBS616ENC
DR ENCODE; ENCBS616MBU
DR ENCODE; ENCBS661RDG
DR ENCODE; ENCBS670IYV
DR ENCODE; ENCBS705BBA
DR ENCODE; ENCBS747ZRJ
DR ENCODE; ENCBS748WRO
DR ENCODE; ENCBS789UPK
DR ENCODE; ENCBS866ZXX
DR ENCODE; ENCBS867ORK
DR ENCODE; ENCBS873NNF
DR ENCODE; ENCBS912WOF
DR ENCODE; ENCBS957OEW
DR ENCODE; ENCBS959SHH
DR ENCODE; ENCBS967MVZ
DR ENCODE; ENCBS974BZV
DR GDSC; 905946
DR GEO; GSM1723
DR GEO; GSM50183
DR GEO; GSM50247
DR GEO; GSM69199
DR GEO; GSM73693
DR GEO; GSM115111
DR GEO; GSM155207
DR GEO; GSM156025
DR GEO; GSM185091
DR GEO; GSM185092
DR GEO; GSM211175
DR GEO; GSM276773
DR GEO; GSM276774
DR GEO; GSM276775
DR GEO; GSM276776
DR GEO; GSM276777
DR GEO; GSM276778
DR GEO; GSM276779
DR GEO; GSM320172
DR GEO; GSM344347
DR GEO; GSM344397
DR GEO; GSM350552
DR GEO; GSM378140
DR GEO; GSM388212
DR GEO; GSM459726
DR GEO; GSM472936
DR GEO; GSM481303
DR GEO; GSM510510
DR GEO; GSM533396
DR GEO; GSM533413
DR GEO; GSM590108
DR GEO; GSM679692
DR GEO; GSM679693
DR GEO; GSM679694
DR GEO; GSM739996
DR GEO; GSM739997
DR GEO; GSM739998
DR GEO; GSM750771
DR GEO; GSM750777
DR GEO; GSM750778
DR GEO; GSM750801
DR GEO; GSM783949
DR GEO; GSM799320
DR GEO; GSM799383
DR GEO; GSM816627
DR GEO; GSM816670
DR GEO; GSM827593
DR GEO; GSM847394
DR GEO; GSM847490
DR GEO; GSM844586
DR GEO; GSM844587
DR GEO; GSM887291
DR GEO; GSM888366
DR GEO; GSM945269
DR GEO; GSM945274
DR GEO; GSM967819
DR GEO; GSM967823
DR GEO; GSM1008565
DR GEO; GSM1008581
DR GEO; GSM1008603
DR GEO; GSM1008904
DR GEO; GSM1029440
DR GEO; GSM1029441
DR GEO; GSM1029442
DR GEO; GSM1029443
DR GEO; GSM1029444
DR GEO; GSM1029445
DR GEO; GSM1029446
DR GEO; GSM1029447
DR GEO; GSM1029448
DR GEO; GSM1029449
DR GEO; GSM1040306
DR GEO; GSM1040376
DR GEO; GSM1068138
DR GEO; GSM1068139
DR GEO; GSM1153389
DR GEO; GSM1181258
DR GEO; GSM1181263
DR GEO; GSM1214589
DR GEO; GSM1374643
DR GEO; GSM1374644
DR GEO; GSM1374645
DR GEO; GSM1401653
DR GEO; GSM1670076
DR GEO; GSM1833626
DR GEO; GSM2046560
DR GEO; GSM2046561
DR GEO; GSM2046562
DR GEO; GSM2046563
DR GEO; GSM2046564
DR GEO; GSM2046565
DR GEO; GSM2046566
DR GEO; GSM2046567
DR GEO; GSM2046568
DR GEO; GSM2046569
DR GEO; GSM2046570
DR GEO; GSM2046571
DR GEO; GSM2046572
DR GEO; GSM2046573
DR GEO; GSM2046574
DR GEO; GSM2046575
DR GEO; GSM2046576
DR GEO; GSM2046577
DR GEO; GSM2046578
DR GEO; GSM2046579
DR GEO; GSM2046580
DR GEO; GSM2046581
DR GEO; GSM2046582
DR GEO; GSM2046583
DR GEO; GSM2046584
DR GEO; GSM2046585
DR GEO; GSM2046586
DR GEO; GSM2046587
DR GEO; GSM2046588
DR GEO; GSM2046589
DR GEO; GSM2046590
DR GEO; GSM2046591
DR GEO; GSM2046592
DR GEO; GSM2046593
DR GEO; GSM2046594
DR GEO; GSM2046595
DR GEO; GSM2046596
DR GEO; GSM2046597
DR GEO; GSM2046598
DR GEO; GSM2046599
DR GEO; GSM2046600
DR GEO; GSM2046601
DR GEO; GSM2046602
DR GEO; GSM2046603
DR GEO; GSM2046604
DR GEO; GSM2046605
DR GEO; GSM2046606
DR GEO; GSM2046607
DR GEO; GSM2136630
DR GEO; GSM2136631
DR GEO; GSM2136632
DR GEO; GSM2136633
DR GEO; GSM2136634
DR GEO; GSM2136635
DR GEO; GSM2176269
DR GEO; GSM2176270
DR ICLC; HTL95021
DR IGRhCellID; MCF7
DR IZSLER; BS TCL 38
DR JCRB; JCRB0134
DR JCRB; NIHS0200
DR KCB; KCB 200831YJ
DR KCLB; 30022
DR LINCS; 50029
DR Lonza; 113
DR MeSH; D061986
DR NCBI_Iran; C135
DR PRIDE; PXD000275
DR PRIDE; PXD000281
DR PRIDE; PXD000309
DR PRIDE; PXD000623
DR PRIDE; PXD000691
DR PRIDE; PXD001274
DR PRIDE; PXD001352
DR PRIDE; PXD001812
DR PRIDE; PXD002104
DR PRIDE; PXD002192
DR PRIDE; PXD002395
DR PRIDE; PXD002421
DR PRIDE; PXD002998
DR PRIDE; PXD004051
DR PRIDE; PXD004085
DR PRIDE; PXD004357
DR PRIDE; PXD005032
DR RCB; RCB1904
DR SKY/M-FISH/CGH; 2814
DR TKG; TKG 0479
DR TOKU-E; 2383
DR TOKU-E; 3748
DR Wikidata; Q1881253
RX CelloPub=CLPUB00336;
RX DOI=10.4172/2157-7145.S2-005;
RX PubMed=1000504;
RX PubMed=1000505;
RX PubMed=1000506;
RX PubMed=1911442;
RX PubMed=2041050;
RX PubMed=3702420;
RX PubMed=4357757;
RX PubMed=6582512;
RX PubMed=6935474;
RX PubMed=7498097;
RX PubMed=8626706;
RX PubMed=8824553;
RX PubMed=9242427;
RX PubMed=9671407;
RX PubMed=10862037;
RX PubMed=11044355;
RX PubMed=11078910;
RX PubMed=12353263;
RX PubMed=12661003;
RX PubMed=12800145;
RX PubMed=15677628;
RX PubMed=15767549;
RX PubMed=17088437;
RX PubMed=17157791;
RX PubMed=17254797;
RX PubMed=19372543;
RX PubMed=19582160;
RX PubMed=19727395;
RX PubMed=20070913;
RX PubMed=21247443;
RX PubMed=21378333;
RX PubMed=22278370;
RX PubMed=22336246;
RX PubMed=22414580;
RX PubMed=22460905;
RX PubMed=23325432;
RX PubMed=23601657;
RX PubMed=23671654;
RX PubMed=23770244;
RX PubMed=23856246;
RX PubMed=23868472;
RX PubMed=23933261;
RX PubMed=24162158;
RX PubMed=24618588;
RX PubMed=25321415;
RX PubMed=25485619;
RX PubMed=25984343;
RX PubMed=26055192;
RX PubMed=26330541;
RX PubMed=27362937;
RX PubMed=27397505;
RX PubMed=27456714;
RX PubMed=27761513;
RX PubMed=27807467;
RX PubMed=28196595;
WW https://en.wikipedia.org/wiki/MCF-7
WW http://mcf7.com/
WW http://www.cells-talk.com/index.php/page/copelibrary?key=MCF-7
WW https://dtp.cancer.gov/discovery_development/nci-60/cell_list.htm
WW https://strap.nci.nih.gov/celline_detail.php?sample_id=1
WW http://www.proteinatlas.org/learn/cellines
WW http://141.61.102.20/mxdb/project/show/9191407937500
WW http://www.genboree.org/java-bin/MCF7/index.jsp?isPublic=Yes
WW http://www.pawefish.path.cam.ac.uk/BreastCellLineDescriptions/mcf7.htm
WW http://colt.ccbr.utoronto.ca/cancer/get_cellline.pl?cellline=MCF7
WW http://genome.ucsc.edu/ENCODE/protocols/cell/human/MCF-7_Crawford_protocol.pdf
WW http://lincs.hms.harvard.edu/resources/reagents/icbp43/
WW http://www.addexbio.com/productdetail?pid=402
WW http://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/m/cell-lines-detail-36.html
WW http://archive.bcaction.org/index.php?page=newsletter-66i
WW http://tcpaportal.org/mclp/
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Part of: ENCODE project common cell types; tier 2.
CC Part of: JFCR39 cancer cell line panel.
CC Part of: JFCR45 cancer cell line panel.
CC Part of: ICBP43 breast cancer cell line panel.
CC Part of: KuDOS 95 cell line panel.
CC Part of: MD Anderson Cell Lines Project.
CC Part of: NCI60 cancer cell line panel.
CC Registration: Chiron Master Culture Collection; CMCC 10377 (CMCC #10377).
CC Doubling time: 1.8 days (PubMed=9671407); 80 hours (PubMed=25984343); 25.4 hours (DTP); ~50 hours, with a range of 30-72 hours (DSMZ).
CC Microsatellite instability: Stable (MSS) (PubMed=12661003; PubMed=23671654; Sanger).
CC Omics: Array-based CGH.
CC Omics: CNV analysis.
CC Omics: Deep antibody staining analysis.
CC Omics: Deep exome analysis.
CC Omics: Deep phosphoproteome analysis.
CC Omics: Deep proteome analysis.
CC Omics: Deep RNAseq analysis.
CC Omics: DNA methylation analysis.
CC Omics: H3K4me3 ChIP-seq epigenome analysis.
CC Omics: miRNA expression profiling.
CC Omics: Protein expression by reverse-phase protein arrays.
CC Omics: shRNA library screening.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
CC Omics: Virome analysis using proteomics.
CC Anecdotal: This is the first hormone-responsive breast cancer cell line to have been established.
CC Anecdotal: Frances Mallon, the patient from which this cell line is derived was a nun (Sister Catherine Frances) at the Immaculate Heart of Mary Convent in Monroe, Michigan.
CC Misspelling: 'MFC-7'in ChEMBL CHEMBL614345 and CHEMBL3307491.
CC Discontinued: ATCC; CRL-12584; probable.
CC Discontinued: JCRB; NIHS0200; true.
CC Derived from metastatic site: Pleural effusion.
ST Source(s): ATCC; CLS; Cosmic-CLP; DSMZ; ECACC; JCRB; KCLB; DOI=10.4172/2157-7145.S2-005; PubMed=11416159; PubMed=17254797; PubMed=19372543; PubMed=25321415; PubMed=25877200; PubMed=27456714; RCB; TKG
ST Amelogenin: X
ST CSF1PO: 10
ST D13S317: 11
ST D16S539: 11,12
ST D18S51: 14
ST D19S433: 13,14
ST D21S11: 30
ST D2S1338: 21,23
ST D3S1358: 16
ST D5S818: 11,12 (ATCC; Cosmic-CLP; DSMZ; ECACC; JCRB; KCLB; DOI=10.4172/2157-7145.S2-005; PubMed=11416159; PubMed=17254797; PubMed=19372543; PubMed=25321415; PubMed=25877200; PubMed=27456714; RCB; TKG)
ST D5S818: 12 (CLS)
ST D7S820: 8,9
ST D8S1179: 10,14
ST FGA: 23,25
ST Penta D: 12
ST Penta E: 7,12
ST TH01: 6
ST TPOX: 9,12
ST vWA: 14,15
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_N481 ! Hs 631.T
SX Female
CA Cancer cell line
//
ID MCF-7 clone 33
AC CVCL_4Y65
RX PubMed=2055945;
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF-7 eGFP-CEBPG
AC CVCL_HA11
DR ENCODE; ENCBS467NVT
DR ENCODE; ENCBS787WNX
DR ENCODE; ENCBS948XBF
CC Transfected with: HGNC; 1837; CEBPG.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF-7 eGFP-E2F4
AC CVCL_HA12
DR ENCODE; ENCBS452IKC
DR ENCODE; ENCBS660MSK
DR ENCODE; ENCBS742UIG
CC Transfected with: HGNC; 3118; E2F4.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF-7 eGFP-ELF1
AC CVCL_HA13
DR ENCODE; ENCBS370XRA
DR ENCODE; ENCBS377JBD
DR ENCODE; ENCBS580NZH
CC Transfected with: HGNC; 3316; ELF1.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF-7 eGFP-GABPA
AC CVCL_HA14
DR ENCODE; ENCBS274OZJ
DR ENCODE; ENCBS368ZAX
DR ENCODE; ENCBS980KNO
CC Transfected with: HGNC; 4071; GABPA.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF-7 eGFP-GTF2E2
AC CVCL_HA15
DR ENCODE; ENCBS071FIF
DR ENCODE; ENCBS829WBT
DR ENCODE; ENCBS948MKG
CC Transfected with: HGNC; 4651; GTF2E2.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF-7 eGFP-HBP1
AC CVCL_HA16
DR ENCODE; ENCBS812LYE
CC Transfected with: HGNC; 23200; HBP1.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF-7 eGFP-KLF4
AC CVCL_HA17
DR ENCODE; ENCBS033ECJ
DR ENCODE; ENCBS949BEW
DR ENCODE; ENCBS984RGW
CC Transfected with: HGNC; 6348; KLF4.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF-7 eGFP-KLF9
AC CVCL_HA18
DR ENCODE; ENCBS180ROE
DR ENCODE; ENCBS183KOB
DR ENCODE; ENCBS418UGY
CC Transfected with: HGNC; 1123; KLF9.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF-7 eGFP-ZNF148
AC CVCL_HA19
DR ENCODE; ENCBS004ION
CC Transfected with: HGNC; 12933; ZNF148.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF-7 RR1
AC CVCL_IU96
SY MCF-7_RR1
DR Cosmic; 2553503
RX PubMed=27279227;
CC Characteristics: Has a MTOR p.Ala2034Val mutation.
CC Selected for resistance to: ChEBI; CHEBI:9168; Sirolimus (Rapamycin).
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF-7 RR2
AC CVCL_IU97
SY MCF-7_RR2
DR Cosmic; 2553505
RX PubMed=27279227;
CC Characteristics: Has a MTOR p.Phe2108Leu mutation.
CC Selected for resistance to: ChEBI; CHEBI:9168; Sirolimus (Rapamycin).
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF-7 SimpleCell O-GalNAc
AC CVCL_S030
SY MCF-7 SimpleCell; MCF-7 SC
RX PubMed=23584533;
CC Characteristics: Cell engineered to produce only truncated GalNAc or NeuAc-alpha-2-6-GalNAc O-glycans.
CC Knockout cell: Method=ZFN; HGNC; 24338; C1GALT1C1.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF-7 TKi-R
AC CVCL_IU98
SY MCF-7_TKi-R
DR Cosmic; 2553506
RX PubMed=27279227;
CC Characteristics: Has a MTOR p.Met2327Ile mutation.
CC Selected for resistance to: ChEBI; CHEBI:91329; AZD8055.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF-7-2a
AC CVCL_4Y54
SY MCF-7/2a; MCF7-2A; MCF7-2a; MCF-7.2A
DR ChEMBL-Cells; CHEMBL3307366
DR ChEMBL-Targets; CHEMBL614323
RX PubMed=8138561;
RX PubMed=8903422;
CC Transfected with: UniProtKB; P08659; Firefly luciferase.
CC Caution: There is confusion in the literature between estrogen-independent MCF-7:2A (CVCL_4Y53), L-mimosine-resistant MCF-7/2a (CVCL_0412) and EREwtcluc transfected MCF-7-2a (CVCL_4Y54).
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF-7.5C
AC CVCL_DC70
SY MCF-7 clone 5C; 5C
RX PubMed=9242427;
RX PubMed=1301400;
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF-7-BAG
AC CVCL_R954
SY MCF-7 BAG
RX PubMed=1384607;
CC Transfected with: UniProtKB; P00722; E.coli lacZ.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF-7-EpiR
AC CVCL_4V96
RX PubMed=23514751;
CC Selected for resistance to: ChEBI; CHEBI:47898; 4'-epidoxorubicin (Epirubicin).
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF-7-FLV1000
AC CVCL_5I64
SY MCF-7 FLV1000; MCF-7/Flv1000; MCF7-FLV1000; MCF-7FL-1000; MCF-7-FL1000; MCF-7 FL1000; MCF7FL1000
RX PubMed=11205902;
CC Selected for resistance to: ChEBI; CHEBI:47344; Alvocidib (Flavopiridol; HMR-1275).
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF-7-Luc
AC CVCL_J259
DR JCRB; JCRB1372
DR JCRB; NIHS0638
CC Transfected with: UniProtKB; P08659; Firefly luciferase.
CC Discontinued: JCRB; NIHS0638; true.
CC Derived from metastatic site: Pleural effusion.
ST Source(s): JCRB
ST Amelogenin: X
ST CSF1PO: 10
ST D13S317: 11
ST D16S539: 11,12
ST D5S818: 11,12
ST D7S820: 8,9
ST TH01: 6
ST TPOX: 9,12
ST vWA: 14,15
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF-7-luc-F5
AC CVCL_5J35
CC Transfected with: UniProtKB; P08659; Firefly luciferase.
CC Discontinued: PerkinElmer; Catalog number 119262.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF-7-Red-Fluc
AC CVCL_5J04
SY MCF7-Red-Fluc; MCF7 Red-Fluc
WW http://www.perkinelmer.com/Catalog/Product/ID/BW119262
CC Transfected with: UniProtKB; Q1AG35; Italian firefly luciferase.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF-7-TaxR
AC CVCL_4V97
RX PubMed=23514751;
CC Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol).
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF-7/164R-1
AC CVCL_1D48
SY MCF7/164R-1; 164R-1
DR Ximbio; 152091
RX PubMed=7759159;
CC Selected for resistance to: ChEBI; CHEBI:31638; Fulvestrant (ICI 182780).
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_1D47 ! MCF-7/S0.5
SX Female
CA Cancer cell line
//
ID MCF-7/164R-4
AC CVCL_1D49
SY MCF7/164R-4; 164R-4
DR Ximbio; 152101
RX PubMed=7759159;
CC Selected for resistance to: ChEBI; CHEBI:31638; Fulvestrant (ICI 182780).
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_1D47 ! MCF-7/S0.5
SX Female
CA Cancer cell line
//
ID MCF-7/164R-5
AC CVCL_1D38
SY MCF7/164R-5; MCF-7/164(R)-5; 164R-5
DR Ximbio; 152102
RX PubMed=7759159;
RX PubMed=16172194;
RX PubMed=25362855;
CC Selected for resistance to: ChEBI; CHEBI:31638; Fulvestrant (ICI 182780).
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_1D47 ! MCF-7/S0.5
SX Female
CA Cancer cell line
//
ID MCF-7/164R-7
AC CVCL_1D39
SY MCF7/164R-7; 164R-7
DR Ximbio; 152103
RX PubMed=7759159;
RX PubMed=25362855;
CC Selected for resistance to: ChEBI; CHEBI:31638; Fulvestrant (ICI 182780).
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_1D47 ! MCF-7/S0.5
SX Female
CA Cancer cell line
//
ID MCF-7/182R-1
AC CVCL_1D40
SY MCF7/182R-1; 182R-1
DR Ximbio; 152104
RX PubMed=7759159;
RX PubMed=16172194;
RX PubMed=25362855;
CC Selected for resistance to: ChEBI; CHEBI:31638; Fulvestrant (ICI 182780).
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_1D47 ! MCF-7/S0.5
SX Female
CA Cancer cell line
//
ID MCF-7/182R-6
AC CVCL_W536
SY MCF-7/182(R)-6; MCF7/182R-6; 182R-6
DR ECACC; 16022506
DR Ximbio; 152105
RX PubMed=7759159;
RX PubMed=10027303;
RX PubMed=16172194;
RX PubMed=25362855;
CC Doubling time: 24 hours, in estradiol-deprived medium (PubMed=10027303).
CC Selected for resistance to: ChEBI; CHEBI:31638; Fulvestrant (ICI 182780).
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_1D47 ! MCF-7/S0.5
SX Female
CA Cancer cell line
//
ID MCF-7/182R-7
AC CVCL_1D41
SY MCF7/182R-7; 182R-7
DR Ximbio; 152106
RX PubMed=7759159;
RX PubMed=16172194;
CC Selected for resistance to: ChEBI; CHEBI:31638; Fulvestrant (ICI 182780).
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_1D47 ! MCF-7/S0.5
SX Female
CA Cancer cell line
//
ID MCF-7/2a
AC CVCL_0412
SY MCF-7/2A; MCF7/2a; MCF-7 clone 2A
DR BTO; BTO:0002270
DR MCCL; MCC:0000308
RX PubMed=10766749;
RX PubMed=15531579;
CC Selected for resistance to: ChEBI; CHEBI:29063; L-mimosine.
CC Caution: There is confusion in the literature between estrogen-independent MCF-7:2A (CVCL_4Y53), L-mimosine-resistant MCF-7/2a (CVCL_0412) and EREwtcluc transfected MCF-7-2a (CVCL_4Y54).
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF-7/4-HC
AC CVCL_4V53
SY MCF-7/4-hc; MCF7/4HC; MCF-7/OAP
RX PubMed=3180059;
RX PubMed=8328987;
CC Selected for resistance to: ChEBI; CHEBI:196991; 4-hydroperoxycyclophosphamide.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF-7/5-23
AC CVCL_4V44
SY MCF 7/5-23; MCF 5-23; 5-23
RX PubMed=8244585;
RX PubMed=10070856;
CC Selected for resistance to: ChEBI; CHEBI:41774; Tamoxifen.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF-7/6
AC CVCL_W972
SY MCF-7-6
DR Cosmic; 2036670
RX PubMed=1648947;
RX PubMed=8528519;
RX PubMed=22161839;
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF-7/AdrVp
AC CVCL_4Y46
SY MCF7/AdrVp; MCF-7-ADRVP
RX PubMed=1972154;
RX PubMed=9865745;
RX PubMed=14576842;
CC Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Adriamycin).
CC Selected for resistance to: ChEBI; CHEBI:9948; Verapamil (VPL).
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF-7/AnaR-1
AC CVCL_5A09
SY MCF7/AnaR-1; AnaR-1
DR Ximbio; 152551
RX PubMed=25625755;
CC Selected for resistance to: ChEBI; CHEBI:2704; Anastrozole.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_1D47 ! MCF-7/S0.5
SX Female
CA Cancer cell line
//
ID MCF-7/AnaR-2
AC CVCL_5A10
SY MCF7/AnaR-2; AnaR-2
DR Ximbio; 152552
RX PubMed=25625755;
CC Selected for resistance to: ChEBI; CHEBI:2704; Anastrozole.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_1D47 ! MCF-7/S0.5
SX Female
CA Cancer cell line
//
ID MCF-7/AnaR-3
AC CVCL_5A11
SY MCF7/AnaR-3; AnaR-3
DR Ximbio; 152553
RX PubMed=25625755;
CC Selected for resistance to: ChEBI; CHEBI:2704; Anastrozole.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_1D47 ! MCF-7/S0.5
SX Female
CA Cancer cell line
//
ID MCF-7/AnaR-4
AC CVCL_5A12
SY MCF7/AnaR-4; AnaR-4
DR ECACC; 16022519
DR Ximbio; 152554
RX PubMed=25625755;
CC Selected for resistance to: ChEBI; CHEBI:2704; Anastrozole.
CC Derived from metastatic site: Pleural effusion.
ST Source(s): ECACC
ST Amelogenin: X
ST CSF1PO: 10
ST D13S317: 11
ST D16S539: 11,12
ST D18S51: 14
ST D21S11: 30
ST D3S1358: 16
ST D5S818: 11,12
ST D7S820: 9
ST D8S1179: 10,14
ST FGA: 23,25
ST Penta D: 12
ST Penta E: 7,12
ST TH01: 6
ST TPOX: 9,12
ST vWA: 14,15
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_1D47 ! MCF-7/S0.5
SX Female
CA Cancer cell line
//
ID MCF-7/AZ
AC CVCL_W971
SY MCF-7AZ
DR Cosmic; 2036668
RX PubMed=1648947;
RX PubMed=8528519;
RX PubMed=22161839;
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF-7/C4-12
AC CVCL_GX99
SY MCF-7 C4-12; MCF7 C4-12; MCF-7:C4-12; MCF-7C4-12; C4-12
DR TOKU-E; 4086
RX PubMed=11479214;
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF-7/CG-4
AC CVCL_4D03
SY CG-4
RX PubMed=6575841;
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF-7/CG-5
AC CVCL_4D04
SY CG-5; CG5
DR CLO; CLO_0002398
RX PubMed=6575841;
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF-7/E2F1
AC CVCL_HA20
DR ENCODE; ENCBS106ENC
DR ENCODE; ENCBS107ENC
CC Characteristics: Transfected with E2F1 fused at the N-terminus to an HA tag and the estrogen receptor ligand binding domain.
CC Transfected with: HGNC; 3113; E2F1.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF-7/E6
AC CVCL_M439
SY MCF7-E6; MCF 7 E6
RX PubMed=7712469;
CC Transfected with: UniProtKB; P03126; HPV16 E6.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF-7/ExeR-1
AC CVCL_5A13
SY MCF7/ExeR-1; MCF-7/S0.5/ExeR-1; ExeR-1
DR Ximbio; 152555
RX PubMed=25625755;
RX PubMed=25667100;
CC Selected for resistance to: ChEBI; CHEBI:4953; Exemestane.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_1D47 ! MCF-7/S0.5
SX Female
CA Cancer cell line
//
ID MCF-7/ExeR-2
AC CVCL_5A14
SY MCF7/ExeR-2; ExeR-2
DR Ximbio; 152556
RX PubMed=25625755;
CC Selected for resistance to: ChEBI; CHEBI:4953; Exemestane.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_1D47 ! MCF-7/S0.5
SX Female
CA Cancer cell line
//
ID MCF-7/ExeR-3
AC CVCL_5A15
SY MCF7/ExeR-3; MCF-7/S0.5/ExeR-3; ExeR-3
DR Ximbio; 152557
RX PubMed=25625755;
RX PubMed=25667100;
CC Selected for resistance to: ChEBI; CHEBI:4953; Exemestane.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_1D47 ! MCF-7/S0.5
SX Female
CA Cancer cell line
//
ID MCF-7/ExeR-4
AC CVCL_5A16
SY MCF7/ExeR-4; ExeR-4
DR ECACC; 16022523
DR Ximbio; 152558
RX PubMed=25625755;
CC Selected for resistance to: ChEBI; CHEBI:4953; Exemestane.
CC Derived from metastatic site: Pleural effusion.
ST Source(s): ECACC
ST Amelogenin: X
ST CSF1PO: 10
ST D13S317: 11
ST D16S539: 11,12
ST D18S51: 14
ST D21S11: 30
ST D3S1358: 16
ST D5S818: 11,12
ST D7S820: 9
ST D8S1179: 10,14
ST FGA: 23,25
ST Penta D: 12
ST Penta E: 7,12
ST TH01: 6
ST TPOX: 9,12
ST vWA: 14,15
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_1D47 ! MCF-7/S0.5
SX Female
CA Cancer cell line
//
ID MCF-7/GFP
AC CVCL_5J37
WW http://www.cellbiolabs.com/mcf-7-reporter-cells
CC Transfected with: UniProtKB; P42212; GFP.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF-7/HER2-18
AC CVCL_0U80
SY MCF-7 HER2-18; MCF-7/Her2-18; MCF7/HER2-clone 18; MCF7/HER2-18; MCF/HER2-18
DR BioSample; SAMN03471643
RX PubMed=8095168;
CC Transfected with: HGNC; 3430; ERBB2.
CC Derived from metastatic site: Pleural effusion.
ST Source(s): PubMed=25877200
ST Amelogenin: X
ST CSF1PO: 10
ST D13S317: 11
ST D16S539: 11,12
ST D18S51: 14
ST D21S11: 30
ST D3S1358: 16
ST D5S818: 12
ST D7S820: 8,9
ST D8S1179: 10,14
ST FGA: 23,25
ST Penta D: 12
ST Penta E: 7,12
ST TH01: 6
ST TPOX: 9,12
ST vWA: 14,15
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF-7/LetR-1
AC CVCL_5A17
SY MCF7/LetR-1; MCF-7/S0.5/LetR-1; LetR-1
DR ECACC; 16022524
DR Ximbio; 152547
RX PubMed=25625755;
RX PubMed=25667100;
CC Selected for resistance to: ChEBI; CHEBI:6413; Letrozole.
CC Derived from metastatic site: Pleural effusion.
ST Source(s): ECACC
ST Amelogenin: X
ST CSF1PO: 10
ST D13S317: 11
ST D16S539: 11,12
ST D18S51: 14
ST D21S11: 30
ST D3S1358: 16
ST D5S818: 11,12
ST D7S820: 9
ST D8S1179: 10,14
ST FGA: 23,25
ST Penta D: 12
ST Penta E: 7,12
ST TH01: 6
ST TPOX: 9,12
ST vWA: 14,15
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_1D47 ! MCF-7/S0.5
SX Female
CA Cancer cell line
//
ID MCF-7/LetR-2
AC CVCL_5A18
SY MCF7/LetR-2; LetR-2
DR Ximbio; 152548
RX PubMed=25625755;
CC Selected for resistance to: ChEBI; CHEBI:6413; Letrozole.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_1D47 ! MCF-7/S0.5
SX Female
CA Cancer cell line
//
ID MCF-7/LetR-3
AC CVCL_5A19
SY MCF7/LetR-3; MCF-7/S0.5/LetR-3; LetR-3
DR Ximbio; 152549
RX PubMed=25625755;
RX PubMed=25667100;
CC Selected for resistance to: ChEBI; CHEBI:6413; Letrozole.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_1D47 ! MCF-7/S0.5
SX Female
CA Cancer cell line
//
ID MCF-7/LetR-4
AC CVCL_5A20
SY MCF7/LetR-4; LetR-4
DR Ximbio; 152550
RX PubMed=25625755;
CC Selected for resistance to: ChEBI; CHEBI:6413; Letrozole.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_1D47 ! MCF-7/S0.5
SX Female
CA Cancer cell line
//
ID MCF-7/Luc
AC CVCL_5J36
WW http://www.cellbiolabs.com/mcf-7-reporter-cells
CC Transfected with: UniProtKB; P08659; Firefly luciferase.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF-7/LY2
AC CVCL_9579
SY LY2; LY-2
DR EFO; EFO_0001199
DR Cosmic; 1136350
DR LINCS; 51095
DR Lonza; 982
RX PubMed=4029083;
RX PubMed=17157791;
CC Selected for resistance to: ChEBI; CHEBI:90187; Lilly 117018 (LY 117018).
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF-7/MDD2
AC CVCL_Z704
SY MDD2
RX PubMed=8700512;
RX PubMed=11802204;
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF-7/MN1
AC CVCL_Z705
SY MN1; MN-1
RX PubMed=8700512;
RX PubMed=11802204;
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF-7/RTx6
AC CVCL_4V43
SY MCF-7 Rtx6; RTx6; RTX6; RTx-6; Rtx-6
RX PubMed=6574477;
CC Selected for resistance to: ChEBI; CHEBI:41774; Tamoxifen.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF-7/RU58R-1
AC CVCL_K235
SY MCF-7/RU58(R)-1; RU58(R)-1; RU58R-1
RX PubMed=15868441;
RX PubMed=16172194;
CC Selected for resistance to: ChEBI; CHEBI:90223; RU 58668.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF-7/S0.5
AC CVCL_1D47
SY MCF7/S0.5; MCF7 S0.5
DR ECACC; 16022501
DR Millipore; SCC100
DR Ximbio; 152090
RX PubMed=6362856;
CC Derived from metastatic site: Pleural effusion.
ST Source(s): ECACC
ST Amelogenin: X
ST CSF1PO: 10
ST D13S317: 11
ST D16S539: 11,12
ST D18S51: 14
ST D21S11: 30
ST D3S1358: 16
ST D5S818: 11,12
ST D7S820: 9
ST D8S1179: 10,14
ST FGA: 23,25
ST Penta D: 12
ST Penta E: 7,12
ST TH01: 6
ST TPOX: 9,12
ST vWA: 14,15
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF-7/S9
AC CVCL_AS09
SY MCF7/S9
DR Ximbio; 152602
RX PubMed=3513694;
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF-7/TAMR-1
AC CVCL_M436
SY MCF7/TAMR-1; MCF7 TAMR-1; MCF-7/TAM(R)-1; TAMR-1; TamR-1; TamR1; AL-1
DR Millipore; SCC101
DR Ximbio; 152089
RX PubMed=1622627;
RX PubMed=7664983;
RX PubMed=16172194;
RX PubMed=25362855;
CC Selected for resistance to: ChEBI; CHEBI:41774; Tamoxifen.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_1D47 ! MCF-7/S0.5
SX Female
CA Cancer cell line
//
ID MCF-7/TAMR-4
AC CVCL_1D42
SY MCF7/TAMR-4; TAMR-4; TamR-4; TamR4
DR Ximbio; 152088
RX PubMed=16172194;
RX PubMed=25362855;
CC Selected for resistance to: ChEBI; CHEBI:41774; Tamoxifen.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_1D47 ! MCF-7/S0.5
SX Female
CA Cancer cell line
//
ID MCF-7/TAMR-7
AC CVCL_1D43
SY MCF7/TAMR-7; TAMR-7; TamR7
DR ECACC; 16022509
DR Ximbio; 152087
RX PubMed=16172194;
RX PubMed=25362855;
CC Selected for resistance to: ChEBI; CHEBI:41774; Tamoxifen.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_1D47 ! MCF-7/S0.5
SX Female
CA Cancer cell line
//
ID MCF-7/TAMR-8
AC CVCL_1D44
SY MCF7/TAMR-8; TAMR-8; TamR8
DR Ximbio; 152086
RX PubMed=16172194;
RX PubMed=25362855;
CC Selected for resistance to: ChEBI; CHEBI:41774; Tamoxifen.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_1D47 ! MCF-7/S0.5
SX Female
CA Cancer cell line
//
ID MCF-7/TAX
AC CVCL_IJ26
RX PubMed=24289639;
CC Doubling time: 44.60 +- 1 hours (PubMed=24289639).
CC Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol).
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF-7/Taxol
AC CVCL_M355
RX PubMed=20926015;
CC Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol).
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF-7/TMX2
AC CVCL_4Y63
SY TMX2
RX PubMed=12943988;
CC Selected for resistance to: ChEBI; CHEBI:41774; Tamoxifen.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_4Y65 ! MCF-7 clone 33
SX Female
CA Cancer cell line
//
ID MCF-7/TMX2-11
AC CVCL_4Y64
SY TMX2-11
RX PubMed=12943988;
RX PubMed=24225485;
CC Selected for resistance to: ChEBI; CHEBI:41774; Tamoxifen.
CC Omics: DNA methylation analysis.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_4Y63 ! MCF-7/TMX2
SX Female
CA Cancer cell line
//
ID MCF-7/TMX2-28
AC CVCL_6957
SY TMX2-28
RX PubMed=12943988;
RX PubMed=17189381;
RX PubMed=24225485;
CC Selected for resistance to: ChEBI; CHEBI:41774; Tamoxifen.
CC Omics: DNA methylation analysis.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_4Y63 ! MCF-7/TMX2
SX Female
CA Cancer cell line
//
ID MCF-7/TPT300
AC CVCL_4V42
SY MCF7/TPT300
RX PubMed=10930538;
CC Selected for resistance to: ChEBI; CHEBI:63632; Topotecan.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF-7/Twist
AC CVCL_DR99
RX PubMed=16322226;
RX PubMed=20019840;
CC Transfected with: HGNC; 12428; TWIST1.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF-7/VD(R)
AC CVCL_2Z97
RX PubMed=11500919;
CC Selected for resistance to: ChEBI; CHEBI:27300; Vitamin D.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF-7/VP
AC CVCL_5I65
SY MCF7-VP; MCF7/VP; MCF-7/VP16; MCF7-VP16
DR ChEMBL-Cells; CHEMBL3307299
DR ChEMBL-Cells; CHEMBL3307368
DR ChEMBL-Targets; CHEMBL614128
DR ChEMBL-Targets; CHEMBL614329
RX PubMed=7903202;
CC Selected for resistance to: ChEBI; CHEBI:4911; Etoposide (VP-16).
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF-7:2A
AC CVCL_4Y53
RX PubMed=7780972;
CC Caution: There is confusion in the literature between estrogen-independent MCF-7:2A (CVCL_4Y53), L-mimosine-resistant MCF-7/2a (CVCL_0412) and EREwtcluc transfected MCF-7-2a (CVCL_4Y54).
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF-7aro
AC CVCL_9580
SY MCF-7-Aro; MCF7aro
DR EFO; EFO_0002072
RX PubMed=2208160;
RX PubMed=9449203;
CC Transfected with: HGNC; 2594; CYP19A1.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF-7aro Let-R
AC CVCL_W348
SY MCF-7aro/LetR; MCF-7-AroR-Let-R; MCF7aroLetR; Let-R
DR Ximbio; 151781
RX DOI=10.1186/1753-6561-6-S4-P3;
WW http://www.rcsismj.com/wp-content/uploads/RCSIsmj-Vol5-Aromatase-Inhibitor-Resistant-Breast-Ca.pdf
CC Selected for resistance to: ChEBI; CHEBI:6413; Letrozole.
CC Transfected with: HGNC; 2594; CYP19A1.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_9580 ! MCF-7aro
SX Female
CA Cancer cell line
//
ID MCF-7aro/ERE
AC CVCL_9581
RX PubMed=18550029;
CC Transfected with: HGNC; 2594; CYP19A1.
CC Transfected with: UniProtKB; P08659; Firefly luciferase.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_9580 ! MCF-7aro
SX Female
CA Cancer cell line
//
ID MCF-7B
AC CVCL_6860
SY MCF 7B
DR CCRID; 3111C0001CCC000041
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF-7D3Res
AC CVCL_2Z98
RX PubMed=8593782;
CC Selected for resistance to: ChEBI; CHEBI:27300; Vitamin D.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF-7L
AC CVCL_0088
SY MCF-7 L
RX PubMed=10811993;
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF-7M
AC CVCL_6672
SY MCF-7 M
RX PubMed=9671407;
RX PubMed=10811993;
CC Doubling time: 1.4 days (PubMed=9671407).
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF-7N
AC CVCL_6673
SY MCF-7 N; MCF-7n
RX PubMed=10811993;
RX PubMed=15138590;
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF-7R
AC CVCL_Y493
SY MCF7R
DR ChEMBL-Cells; CHEMBL3307593
DR ChEMBL-Targets; CHEMBL614327
RX PubMed=17671737;
CC Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Adriamycin).
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF-7TN-R
AC CVCL_6674
RX PubMed=15138590;
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_6673 ! MCF-7N
SX Female
CA Cancer cell line
//
ID MCF-hGH
AC CVCL_9V74
SY MCF-HGH
DR NCBI_Iran; C628
RX PubMed=10388519;
CC Transfected with: HGNC; 4261; GH1.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF/MX
AC CVCL_4Y47
SY MCF-7/MX; MCF-7/mtxR
RX PubMed=1358431;
RX PubMed=9865745;
CC Selected for resistance to: ChEBI; CHEBI:50729; Mitoxantrone.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF10A-Er-Src
AC CVCL_N805
WW http://genome.ucsc.edu/ENCODE/protocols/cell/human/MCF-10A_Struhl_protocol.pdf
CC Part of: ENCODE project common cell types; tier 3.
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0598 ! MCF-10A
SX Female
CA Spontaneously immortalized cell line
//
ID MCF10A-Myc
AC CVCL_0411
SY MCF10AMyc
DR MCCL; MCC:0000306
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0598 ! MCF-10A
SX Female
CA Spontaneously immortalized cell line
//
ID MCF10CA1a
AC CVCL_6675
DR GEO; GSM498025
DR GEO; GSM498029
DR IGRhCellID; MCF10CA1a
RX PubMed=11261825;
RX PubMed=15375546;
RX PubMed=20169162;
RX PubMed=24262153;
CC Transfected with: HGNC; 5173; HRAS (with V-12).
CC Transfected with: UniProtKB; P00552; Transposon Tn5 neo.
CC Omics: CNV analysis.
CC Omics: Glycoproteome analysis by proteomics.
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_5554 ! MCF-10A-neoT
SX Female
CA Transformed cell line
//
ID MCF10CA1a.cl1
AC CVCL_6676
RX PubMed=11261825;
CC Transfected with: HGNC; 5173; HRAS (with V-12).
CC Transfected with: UniProtKB; P00552; Transposon Tn5 neo.
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_6675 ! MCF10CA1a
SX Female
CA Transformed cell line
//
ID MCF10CA1b
AC CVCL_6677
RX PubMed=11261825;
CC Transfected with: HGNC; 5173; HRAS (with V-12).
CC Transfected with: UniProtKB; P00552; Transposon Tn5 neo.
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_5554 ! MCF-10A-neoT
SX Female
CA Transformed cell line
//
ID MCF10CA1c
AC CVCL_6678
RX PubMed=11261825;
CC Transfected with: HGNC; 5173; HRAS (with V-12).
CC Transfected with: UniProtKB; P00552; Transposon Tn5 neo.
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_5554 ! MCF-10A-neoT
SX Female
CA Transformed cell line
//
ID MCF10CA1d
AC CVCL_6679
RX PubMed=11261825;
CC Transfected with: HGNC; 5173; HRAS (with V-12).
CC Transfected with: UniProtKB; P00552; Transposon Tn5 neo.
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_5554 ! MCF-10A-neoT
SX Female
CA Transformed cell line
//
ID MCF10CA1d.cl1
AC CVCL_6680
RX PubMed=11261825;
CC Transfected with: HGNC; 5173; HRAS (with V-12).
CC Transfected with: UniProtKB; P00552; Transposon Tn5 neo.
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_6679 ! MCF10CA1d
SX Female
CA Transformed cell line
//
ID MCF10CA1d.cl2
AC CVCL_6681
RX PubMed=11261825;
CC Transfected with: HGNC; 5173; HRAS (with V-12).
CC Transfected with: UniProtKB; P00552; Transposon Tn5 neo.
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_6679 ! MCF10CA1d
SX Female
CA Transformed cell line
//
ID MCF10CA1d.cl3
AC CVCL_6682
RX PubMed=11261825;
CC Transfected with: HGNC; 5173; HRAS (with V-12).
CC Transfected with: UniProtKB; P00552; Transposon Tn5 neo.
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_6679 ! MCF10CA1d
SX Female
CA Transformed cell line
//
ID MCF10CA1h
AC CVCL_6683
DR GEO; GSM271344
DR GEO; GSM498024
DR GEO; GSM498028
DR IGRhCellID; MCF10CA1h
RX PubMed=11261825;
RX PubMed=20169162;
CC Transfected with: HGNC; 5173; HRAS (with V-12).
CC Transfected with: UniProtKB; P00552; Transposon Tn5 neo.
CC Omics: CNV analysis.
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_5554 ! MCF-10A-neoT
SX Female
CA Transformed cell line
//
ID MCF10DCIS.com
AC CVCL_5552
SY MCF10DCIS.COM; MCF10ADCIS.com; MCF10DCIS; MCFDCIS; DCIS.COM
DR EFO; EFO_0006643
DR Cosmic; 1219447
DR GEO; GSM271345
DR GEO; GSM271398
RX PubMed=10904098;
RX PubMed=18455123;
RX PubMed=25485619;
CC Transfected with: HGNC; 5173; HRAS (with V-12).
CC Transfected with: UniProtKB; P00552; Transposon Tn5 neo.
CC Omics: Deep RNAseq analysis.
CC Omics: SNP array analysis.
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_5555 ! MCF-10AT
SX Female
CA Transformed cell line
//
ID MCF3B
AC CVCL_M373
RX PubMed=11079502;
CC Transfected with: RGD; 69267; Slc5a5.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF7 NucLight Green
AC CVCL_DF45
WW http://www.essenbioscience.com/essen-products/reagents-and-consumables/mcf7-nuclight-green-cells/
CC Characteristics: Stably expresses a non-perturbing nuclear restricted green fluorescent label.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF7 NucLight Red
AC CVCL_DF46
WW http://www.essenbioscience.com/essen-products/reagents-and-consumables/mcf7-nuclight-red-cells/
CC Characteristics: Stably expresses a non-perturbing nuclear restricted red fluorescent label.
CC Transfected with: mKate2; a bright red fluorescent protein derived from eqFP578.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF7 Tet-Off
AC CVCL_V357
SY MCF-7 Tet-Off
DR PRIDE; PXD001202
WW http://www.clontech.com/US/Products/Inducible_Systems/Tetracycline-Inducible_Expression/Tet-Off_Cell_Lines
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF7 Tet-On
AC CVCL_V332
SY MCF-7 Tet-On
WW http://www.clontech.com/US/Products/Inducible_Systems/Tetracycline-Inducible_Expression/Tet-On_Cell_Lines
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF7 tTS
AC CVCL_V358
WW http://www.clontech.com/US/Products/Inducible_Systems/Tetracycline-Inducible_Expression/Tet-tTS_Cell_Lines
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF7-382
AC CVCL_3397
DR CLO; CLO_0007607
DR CLDB; cl3376
DR CLDB; cl3377
DR ICLC; HTL95018
CC Characteristics: Control line for MCF7-422 (CVCL_3398) and MCF7-432 (CVCL_3399); transfected with emtpy vector pBact.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF7-422
AC CVCL_3398
DR CLO; CLO_0007608
DR CLDB; cl3378
DR CLDB; cl3379
DR ICLC; HTL95017
CC Transfected with: HGNC; 3467; ESR1.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF7-432
AC CVCL_3399
DR CLO; CLO_0007609
DR CLDB; cl3380
DR CLDB; cl3381
DR ICLC; HTL95019
CC Transfected with: HGNC; 3467; ESR1 (exon 4 defective).
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF7-488X1
AC CVCL_3400
DR CLO; CLO_0007610
DR CLDB; cl3382
DR CLDB; cl3383
DR ICLC; HTL96004
CC Transfected with: HGNC; 3467; ESR1 (exon 5 defective).
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF7-490X1
AC CVCL_3401
DR CLO; CLO_0007611
DR CLDB; cl3384
DR CLDB; cl3385
DR ICLC; HTL96002
CC Transfected with: HGNC; 3467; ESR1 (exon 4 defective).
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF7-492X1
AC CVCL_3402
DR CLO; CLO_0007612
DR CLDB; cl3386
DR ICLC; HTL96028
CC Transfected with: UniProtKB; P00722; E.coli lacZ.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF7-AFA[r]
AC CVCL_4V66
WW http://www.chemoscreen.com/product/mcf7-afar-dna
CC Selected for resistance to: ChEBI; CHEBI:61390; Afatinib (BIBW-2992).
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF7-TamR
AC CVCL_EG55
DR PRIDE; PXD001812
RX PubMed=26330541;
CC Selected for resistance to: ChEBI; CHEBI:41774; Tamoxifen.
CC Omics: Deep phosphoproteome analysis.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF7/BUS
AC CVCL_0413
SY MCF-7/BUS; MCF-7 BUS; MCF7 BUS
DR MCCL; MCC:0000309
RX PubMed=7498097;
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF7/c
AC CVCL_EQ28
DR GEO; GSM212605
DR GEO; GSM212606
DR GEO; GSM212607
RX PubMed=17660348;
CC Omics: Transcriptome analysis.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF7/D40
AC CVCL_M437
SY MCF-7/D40
RX PubMed=1676902;
CC Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Adriamycin).
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF7/LCC1
AC CVCL_DP50
SY MCF-7/LCC-1; MCF-7/LCC1; LCC1
RX PubMed=8324732;
RX PubMed=8380254;
RX PubMed=8380760;
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_DP49 ! MCF7/MIII
SX Female
CA Cancer cell line
//
ID MCF7/LCC2
AC CVCL_DP51
SY MCF-7/LCC-2; MCF-7/LCC2; MCF-7-LCC2; LCC2
DR PRIDE; PXD000281
RX PubMed=8324732;
RX PubMed=11078910;
RX PubMed=23868472;
CC Selected for resistance to: ChEBI; CHEBI:44616; Afimoxifene (4-hydroxytamoxifen; 4-OH TAM).
CC Omics: Proteome analysis.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_DP50 ! MCF7/LCC1
SX Female
CA Cancer cell line
//
ID MCF7/LCC9
AC CVCL_DP52
SY MCF-7/LCC9; LCC9
DR BTO; BTO:0005970
RX PubMed=9270017;
CC Selected for resistance to: ChEBI; CHEBI:31638; Fulvestrant (ICI 182780).
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_DP50 ! MCF7/LCC1
SX Female
CA Cancer cell line
//
ID MCF7/MIII
AC CVCL_DP49
SY MCF-7/MIII; MIII
RX PubMed=8380254;
RX PubMed=8380760;
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF7/Mitox
AC CVCL_M438
SY MCF-7/Mitox; MCF-7/MITOX
RX PubMed=1676902;
CC Selected for resistance to: ChEBI; CHEBI:50729; Mitoxantrone.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF7/XBP1
AC CVCL_EQ29
DR GEO; GSM212608
DR GEO; GSM212609
DR GEO; GSM212610
RX PubMed=17660348;
CC Transfected with: HGNC; 12801; XBP1.
CC Omics: Transcriptome analysis.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCF7mp53
AC CVCL_0415
SY MCF7 mp53; MCF-7-mp53; MCF-7mp53
DR MCCL; MCC:0000311
RX PubMed=11278253;
CC Transfected with: HGNC; 11998; TP53.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCH-MN-1
AC CVCL_C855
DR Cosmic; 1181080
RX PubMed=11441343;
DI NCIt; C6569; Congenital mesoblastic nephroma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID MCH015
AC CVCL_0D90
SY MCH15
RX PubMed=3478720;
CC From: Montreal Children's Hospital cell repository; Montreal; Canada.
OX NCBI_TaxID=9606; ! Homo sapiens
CA Finite cell line
//
ID MCH024
AC CVCL_0F57
SY MCH24; MCH 24
RX PubMed=3478720;
RX PubMed=7909321;
CC From: Montreal Children's Hospital cell repository; Montreal; Canada.
OX NCBI_TaxID=9606; ! Homo sapiens
CA Finite cell line
//
ID MCH029
AC CVCL_0D91
SY MCH29
RX PubMed=3478720;
CC From: Montreal Children's Hospital cell repository; Montreal; Canada.
OX NCBI_TaxID=9606; ! Homo sapiens
CA Finite cell line
//
ID MCH039
AC CVCL_0D92
SY MCH 39; MCH39
RX PubMed=1437403;
RX PubMed=3478720;
CC From: Montreal Children's Hospital cell repository; Montreal; Canada.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Finite cell line
//
ID MCH045
AC CVCL_U483
SY MCH45
RX PubMed=3478720;
WW http://www.cellbank.mcgill.ca/cgi-bin/cellbank/allnormals.cgi
CC From: Montreal Children's Hospital cell repository; Montreal; Canada.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Finite cell line
//
ID MCH046
AC CVCL_0D93
SY MCH 46; MCH46
RX PubMed=3478720;
CC From: Montreal Children's Hospital cell repository; Montreal; Canada.
OX NCBI_TaxID=9606; ! Homo sapiens
CA Finite cell line
//
ID MCH047
AC CVCL_U484
WW http://www.cellbank.mcgill.ca/cgi-bin/cellbank/allnormals.cgi
CC From: Montreal Children's Hospital cell repository; Montreal; Canada.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Finite cell line
//
ID MCH055
AC CVCL_U485
WW http://www.cellbank.mcgill.ca/cgi-bin/cellbank/allnormals.cgi
CC From: Montreal Children's Hospital cell repository; Montreal; Canada.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Finite cell line
//
ID MCH058
AC CVCL_U486
SY MCH58
RX PubMed=3478720;
WW http://www.cellbank.mcgill.ca/cgi-bin/cellbank/allnormals.cgi
CC From: Montreal Children's Hospital cell repository; Montreal; Canada.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Finite cell line
//
ID MCH059
AC CVCL_U487
WW http://www.cellbank.mcgill.ca/cgi-bin/cellbank/allnormals.cgi
CC From: Montreal Children's Hospital cell repository; Montreal; Canada.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Finite cell line
//
ID MCH060
AC CVCL_U488
WW http://www.cellbank.mcgill.ca/cgi-bin/cellbank/allnormals.cgi
CC From: Montreal Children's Hospital cell repository; Montreal; Canada.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Finite cell line
//
ID MCH064
AC CVCL_U489
SY MCH 064; MCH 64; M64
WW http://www.cellbank.mcgill.ca/cgi-bin/cellbank/allnormals.cgi
CC From: Montreal Children's Hospital cell repository; Montreal; Canada.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Finite cell line
//
ID MCH065
AC CVCL_U490
SY MCH 065; M65
RX PubMed=20876107;
WW http://www.cellbank.mcgill.ca/cgi-bin/cellbank/allnormals.cgi
CC From: Montreal Children's Hospital cell repository; Montreal; Canada.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Finite cell line
//
ID MCH068
AC CVCL_U491
WW http://www.cellbank.mcgill.ca/cgi-bin/cellbank/allnormals.cgi
CC From: Montreal Children's Hospital cell repository; Montreal; Canada.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Finite cell line
//
ID MCH069
AC CVCL_U492
WW http://www.cellbank.mcgill.ca/cgi-bin/cellbank/allnormals.cgi
CC From: Montreal Children's Hospital cell repository; Montreal; Canada.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Finite cell line
//
ID MCH070
AC CVCL_U493
SY MCH 70
RX PubMed=1437403;
WW http://www.cellbank.mcgill.ca/cgi-bin/cellbank/allnormals.cgi
CC From: Montreal Children's Hospital cell repository; Montreal; Canada.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Finite cell line
//
ID MCH071
AC CVCL_U494
WW http://www.cellbank.mcgill.ca/cgi-bin/cellbank/allnormals.cgi
CC From: Montreal Children's Hospital cell repository; Montreal; Canada.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Finite cell line
//
ID MCH072
AC CVCL_U495
WW http://www.cellbank.mcgill.ca/cgi-bin/cellbank/allnormals.cgi
CC From: Montreal Children's Hospital cell repository; Montreal; Canada.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Finite cell line
//
ID MCH073
AC CVCL_U496
WW http://www.cellbank.mcgill.ca/cgi-bin/cellbank/allnormals.cgi
CC From: Montreal Children's Hospital cell repository; Montreal; Canada.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Finite cell line
//
ID MCH074
AC CVCL_U497
SY MCH 74
WW http://www.cellbank.mcgill.ca/cgi-bin/cellbank/allnormals.cgi
CC From: Montreal Children's Hospital cell repository; Montreal; Canada.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Finite cell line
//
ID MCH262A1.D6
AC CVCL_6C50
SY MCH-262A1D6; MCH262-A1D6
RX PubMed=1559705;
RX PubMed=2300817;
RX PubMed=8302587;
OX NCBI_TaxID=9606; ! Homo sapiens
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_3984 ! A-9
CA Hybrid cell line
//
ID MCHR2-SHG-44
AC CVCL_L602
RX DOI=10.3724/SP.J.1008.2008.00896;
CC Transfected with: HGNC; 20867; MCHR2.
DI NCIt; C60781; Astrocytoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_6728 ! SHG-44
CA Cancer cell line
//
ID MCJB2
AC CVCL_AV59
RX DOI=10.1158/1538-7445.AM2014-LB-95;
WW http://technologies.ventures.mayoclinic.org/technologies/2010-305_new-cell-lines
DI NCIt; C71732; Triple-negative breast carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID MCL-5
AC CVCL_5332
DR CLO; CLO_0007616
DR ATCC; CRL-10575
RX PubMed=1793807;
CC Discontinued: ATCC; CRL-10575; probable.
ST Source(s): ATCC
ST Amelogenin: X,Y
ST CSF1PO: 10
ST D13S317: 11,13
ST D16S539: 10
ST D5S818: 12,13
ST D7S820: 10,11
ST TH01: 6,9.3
ST TPOX: 8,9
ST vWA: 18,19
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_3640 ! AHH-1
SX Male
CA Transformed cell line
//
ID MCM-B2
AC CVCL_L365
RX PubMed=7659855;
CC Breed/subspecies: Pointer.
DI NCIt; C124249; Canine mammary carcinoma
OX NCBI_TaxID=9615; ! Canis lupus familiaris
SX Female
CA Cancer cell line
//
ID MCM1
AC CVCL_DH35
DR GEO; GSM878881
RX PubMed=22570180;
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID MCM1G
AC CVCL_DH36
RX PubMed=22570180;
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_DH35 ! MCM1
SX Male
CA Cancer cell line
//
ID MCO-Y4
AC CVCL_L366
RX PubMed=17085882;
CC Breed/subspecies: Mixed breed.
DI NCIt; C120045; Canine osteosarcoma
OX NCBI_TaxID=9615; ! Canis lupus familiaris
SX Female
CA Cancer cell line
//
ID MCP-5
AC CVCL_R863
SY MCP5
RX PubMed=7683224;
CC Breed/subspecies: BALB/c.
OX NCBI_TaxID=10090; ! Mus musculus
CA Transformed cell line
//
ID MCP21
AC CVCL_L538
DR ECACC; 96030418
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_2199 ! Sp2/0-Ag14
CA Hybridoma
//
ID MCP6
AC CVCL_1Q51
SY MCP-6; GM09191
DR CLO; CLO_0010632
DR Coriell; GM09191
RX PubMed=6641706;
RX PubMed=6686281;
RX PubMed=6951167;
CC Group: Human/rodent somatic cell hybrid.
OX NCBI_TaxID=9606; ! Homo sapiens
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_1Q46 ! G3.32.2
HI CVCL_1Q47 ! PCC4AO
CA Hybrid cell line
//
ID MCPV-8
AC CVCL_D803
RX PubMed=9745959;
RX PubMed=12382283;
CC Transformant: NCBI_TaxID; 333760; Human papillomavirus type 16 (HPV16) [E6/E7].
OX NCBI_TaxID=10047; ! Meriones unguiculatus
SX Male
CA Transformed cell line
//
ID MCS-2
AC CVCL_R955
DR BTO; BTO:0002271
RX PubMed=14623544;
CC Transfected with: HGNC; 11425; STS.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID MCT
AC CVCL_0416
SY Mouse Cortical Tubule cells
DR MCCL; MCC:0000312
RX PubMed=3170633;
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40).
CC Breed/subspecies: SJL.
OX NCBI_TaxID=10090; ! Mus musculus
CA Transformed cell line
//
ID mCT1
AC CVCL_IN71
RX PubMed=11121394;
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40) [tsA58].
CC Breed/subspecies: [(CBA/Ca x C57BL/10)Tg(H2Kb-tsA58) Immortomouse.
OX NCBI_TaxID=10090; ! Mus musculus
CA Conditionally immortalized cell line
//
ID mCT1-CF
AC CVCL_IN72
RX PubMed=11121394;
CC Characteristics: Homozygous for the Cftr p.Ser489Ter mutation.
CC Knockout cell: Method=KO mouse; MGI; MGI:88388; Cftr.
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40) [tsA58].
CC Breed/subspecies: [(CBA/Ca x C57BL/10)Tg(H2Kb-tsA58) Immortomouse x (C57BL/6J x 129)Cftr-/-].
OX NCBI_TaxID=10090; ! Mus musculus
CA Conditionally immortalized cell line
//
ID MCW12
AC CVCL_Z799
DR DGRC; 160
RX PubMed=16537908;
WW http://flybase.org/reports/FBrf0205933.html
CC Group: Insect cell line.
OX NCBI_TaxID=7227; ! Drosophila melanogaster
SX Sex undetermined
CA Spontaneously immortalized cell line
//
ID MCW23
AC CVCL_Z800
DR DGRC; 161
WW http://flybase.org/reports/FBrf0205933.html
CC Group: Insect cell line.
OX NCBI_TaxID=7227; ! Drosophila melanogaster
SX Sex undetermined
CA Spontaneously immortalized cell line
//
ID MD
AC CVCL_6420
DR CLO; CLO_0007622
DR ATCC; CRL-9850
DR BioSample; SAMN03471074
RX Patent=US5447861;
ST Source(s): ATCC; PubMed=11416159
ST Amelogenin: X,Y
ST CSF1PO: 10,12
ST D13S317: 12
ST D16S539: 11,15
ST D18S51: 14
ST D21S11: 27,30
ST D5S818: 11,13
ST D7S820: 10,11
ST D8S1179: 13,14
ST FGA: 23,24
ST TH01: 8
ST TPOX: 8,11
ST vWA: 16,17
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Finite cell line
//
ID MD 144
AC CVCL_J841
DR ATCC; HB-8409
RX Patent=US4666845;
CC Discontinued: ATCC; HB-8409; probable.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_2155 ! P3/NS1/1-Ag4.1
CA Hybridoma
//
ID MD-IGF-I
AC CVCL_HG41
RX Patent=US5455164;
RX PubMed=1480169;
CC Transfected with: UniProtKB; P10763; Sheep IGF1.
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40) [tsA58].
OX NCBI_TaxID=9913; ! Bos taurus
HI CVCL_U226 ! MAC-T
SX Female
CA Transformed cell line
//
ID MD0003
AC CVCL_8Y18
DR ECACC; 00102801
CC Part of: ECACC chromosomal abnormality collection.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
SX Sex ambiguous
CA Transformed cell line
//
ID MD2
AC CVCL_9220
DR CLO; CLO_0007623
DR ATCC; HB-229
OX NCBI_TaxID=10090; ! Mus musculus
OX NCBI_TaxID=10116; ! Rattus norvegicus
HI CVCL_2199 ! Sp2/0-Ag14
CA Hybridoma
//
ID MD901
AC CVCL_D709
SY MD-901
DR Cosmic; 2297016
DR GEO; GSM119487
RX PubMed=8274736;
RX PubMed=16960149;
DI NCIt; C8851; Diffuse large B-cell lymphoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID MD903
AC CVCL_D710
SY MD-903
DR Cosmic; 1670151
DR Cosmic; 2297017
DR GEO; GSM119488
RX PubMed=16960149;
RX PubMed=23699601;
CC Omics: Genome sequenced.
DI NCIt; C8851; Diffuse large B-cell lymphoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID MDA 435TR
AC CVCL_J435
SY MDA 435(TR)
CC Problematic cell line: Contaminated. Parent cell line (MDA-MB-435) has been shown to be a M14 derivative.
CC Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol).
CC Derived from metastatic site: Subcutaneous; right buttock.
DI NCIt; C3802; Amelanotic melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0417 ! MDA-MB-435
SX Male
CA Cancer cell line
//
ID MDA-1186
AC CVCL_6977
SY MDA 1186; MDA1186
DR BTO; BTO:0002716
DR Cosmic; 2513917
RX PubMed=11389082;
RX PubMed=21868764;
RX PubMed=28196595;
WW http://tcpaportal.org/mclp/
CC Part of: MD Anderson Cell Lines Project.
CC Omics: Protein expression by reverse-phase protein arrays.
ST Source(s): PubMed=21868764
ST Amelogenin: X,Y
ST CSF1PO: 12
ST D13S317: 9,10
ST D16S539: 12,13
ST D5S818: 12
ST D7S820: 11,12
ST TH01: 6,9.3
ST TPOX: 8,10
ST vWA: 17,18
DI NCIt; C4044; Laryngeal squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID MDA-1386
AC CVCL_6979
SY MDA 1386; MDA1386
RX PubMed=11389082;
DI NCIt; C4043; Hypopharyngeal squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID MDA-1386Ln
AC CVCL_H541
SY MDA-1386LN; MDA1386LN; MDA1386Ln; 1386LN; 1386Ln
DR Cosmic; 2131849
DR Cosmic; 2439757
RX PubMed=14724901;
RX PubMed=15641986;
RX PubMed=21868764;
RX PubMed=28196595;
WW http://tcpaportal.org/mclp/
CC Part of: MD Anderson Cell Lines Project.
CC Omics: Protein expression by reverse-phase protein arrays.
CC Omics: Transcriptome analysis.
CC Derived from metastatic site: Lymph node.
ST Source(s): PubMed=21868764
ST Amelogenin: X
ST CSF1PO: 11
ST D13S317: 11
ST D16S539: 9,13
ST D5S818: 12
ST D7S820: 8,12
ST TH01: 9
ST TPOX: 8
ST vWA: 20
DI NCIt; C4043; Hypopharyngeal squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_6979 ! MDA-1386
SX Male
CA Cancer cell line
//
ID MDA-1386tu
AC CVCL_H542
SY MDA1386TU; MDA1386Tu; 1386TU; 1386Tu
DR Cosmic; 2131850
RX PubMed=14724901;
RX PubMed=15641986;
RX PubMed=21868764;
RX PubMed=28196595;
WW http://tcpaportal.org/mclp/
CC Part of: MD Anderson Cell Lines Project.
CC Omics: Protein expression by reverse-phase protein arrays.
CC Omics: Transcriptome analysis.
ST Source(s): PubMed=21868764
ST Amelogenin: X
ST CSF1PO: 11
ST D13S317: 11
ST D16S539: 9,13
ST D5S818: 12
ST D7S820: 8,12
ST TH01: 9
ST TPOX: 8
ST vWA: 20
DI NCIt; C4043; Hypopharyngeal squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_6979 ! MDA-1386
SX Male
CA Cancer cell line
//
ID MDA-1483
AC CVCL_6980
SY MDA 1483; MDA1483; Line 1483; 1483; SCC 1483
DR BTO; BTO:0003304
DR Cosmic; 948038
DR Cosmic; 2131841
RX DOI=10.1016/B978-0-12-333530-2.50007-1;
RX PubMed=2452013;
RX PubMed=11389082;
RX PubMed=21868764;
ST Source(s): PubMed=21868764
ST Amelogenin: X
ST CSF1PO: 10
ST D13S317: 10,12
ST D16S539: 9,11
ST D5S818: 13
ST D7S820: 7,10
ST TH01: 9,9.3
ST TPOX: 11
ST vWA: 14,18
DI NCIt; C4833; Oral cavity squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID MDA-1586
AC CVCL_6981
SY MDA 1586; MDA1586
DR Cosmic; 2043892
DR Cosmic; 2550365
RX PubMed=11389082;
RX PubMed=21868764;
RX PubMed=28196595;
WW http://tcpaportal.org/mclp/
CC Part of: MD Anderson Cell Lines Project.
CC Omics: Protein expression by reverse-phase protein arrays.
ST Source(s): PubMed=21868764
ST Amelogenin: X,Y
ST CSF1PO: 8,9
ST D13S317: 12
ST D16S539: 10
ST D5S818: 11,12
ST D7S820: 8,10
ST TH01: 7,9
ST TPOX: 10,11
ST vWA: 16,17
DI NCIt; C4044; Laryngeal squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID MDA-1686
AC CVCL_AT79
SY MDA 1686; MDA1686
DR Cosmic; 2131851
RX PubMed=21868764;
RX PubMed=28196595;
WW http://tcpaportal.org/mclp/
CC Part of: MD Anderson Cell Lines Project.
CC Omics: Protein expression by reverse-phase protein arrays.
ST Source(s): PubMed=21868764
ST Amelogenin: X,Y
ST CSF1PO: 12
ST D13S317: 8,12
ST D16S539: 12,13
ST D5S818: 13
ST D7S820: 8,11
ST TH01: 7,10
ST TPOX: 8
ST vWA: 14,16
DI NCIt; C4833; Oral cavity squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID MDA-183
AC CVCL_6978
SY MDA 183; MDA183; Line 183; 183; 183A
DR Cosmic; 948036
RX DOI=10.1016/B978-0-12-333530-2.50007-1;
RX PubMed=2452013;
RX PubMed=21868764;
ST Source(s): PubMed=21868764
ST Amelogenin: X,Y
ST CSF1PO: 10,11
ST D13S317: 11,12
ST D16S539: 13
ST D5S818: 10,13
ST D7S820: 9
ST TH01: 6
ST TPOX: 8
ST vWA: 18
DI NCIt; C4833; Oral cavity squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID MDA-1986
AC CVCL_6982
SY MDA 1986; MDA1986
DR Cosmic; 1530749
RX PubMed=11389082;
DI NCIt; C4833; Oral cavity squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_AT80 ! MDA-1986LN
CA Cancer cell line
//
ID MDA-1986LN
AC CVCL_AT80
SY MDA 1986LN; MDA1986LN
RX PubMed=21868764;
WW http://iclac.org/wp-content/uploads/Cross-Contaminations-v8_0.pdf
CC Problematic cell line: Partially contaminated. Some stocks are contaminated by UM-SCC-1 (PubMed=21868764).
CC Derived from metastatic site: Lymph node.
ST Source(s): PubMed=21868764
ST Amelogenin: X
ST CSF1PO: 11,14
ST D13S317: 13
ST D16S539: 9,12
ST D5S818: 9,11
ST D7S820: 8,9
ST TH01: 7
ST TPOX: 8
ST vWA: 17,19,20
DI NCIt; C4833; Oral cavity squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_6982 ! MDA-1986
CA Cancer cell line
//
ID MDA-584
AC CVCL_V278
SY 584A2; 584-A2; 584
DR Cosmic; 2043889
RX PubMed=3148118;
RX PubMed=11389082;
RX PubMed=21868764;
RX PubMed=28196595;
WW http://tcpaportal.org/mclp/
CC Part of: MD Anderson Cell Lines Project.
CC Omics: Protein expression by reverse-phase protein arrays.
ST Source(s): PubMed=21868764
ST Amelogenin: X,Y
ST CSF1PO: 10,12
ST D13S317: 6,12
ST D16S539: 11,13
ST D5S818: 12
ST D7S820: 11
ST TH01: 6,9
ST TPOX: 11
ST vWA: 16,18
DI NCIt; C4044; Laryngeal squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID MDA-686
AC CVCL_6983
SY MDA 686; MDA686
RX PubMed=11389082;
DI NCIt; C8181; Oropharyngeal squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID MDA-686Ln
AC CVCL_6984
SY MDA 686Ln; MDA686Ln; MDA686LN; MDA 686LN; MDA 686-LN; MDA 686 Ln; 686LN; 686Ln
DR BTO; BTO:0003052
RX PubMed=14724901;
RX PubMed=15641986;
RX PubMed=21868764;
WW http://iclac.org/wp-content/uploads/Cross-Contaminations-v8_0.pdf
CC Problematic cell line: Partially contaminated. Some stocks are contaminated by UM-SCC-1 (PubMed=21868764).
CC Omics: Transcriptome analysis.
CC Derived from metastatic site: Lymph node.
ST Source(s): PubMed=21868764
ST Amelogenin: X
ST CSF1PO: 12
ST D13S317: 12
ST D16S539: 8,9
ST D5S818: 12
ST D7S820: 10
ST TH01: 7,8
ST TPOX: 10,11
ST vWA: 15,16
DI NCIt; C8181; Oropharyngeal squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_6983 ! MDA-686
SX Male
CA Cancer cell line
//
ID MDA-686Tu
AC CVCL_6985
SY MDA 686Tu; MDA686Tu; MDA686TU; 686TU; 686Tu
RX PubMed=14724901;
RX PubMed=15641986;
RX PubMed=21868764;
CC Omics: Transcriptome analysis.
ST Source(s): PubMed=21868764
ST Amelogenin: X
ST CSF1PO: 12
ST D13S317: 11,12
ST D16S539: 8,9
ST D5S818: 12
ST D7S820: 10
ST TH01: 7,8
ST TPOX: 10,11
ST vWA: 15,16
DI NCIt; C8181; Oropharyngeal squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_6983 ! MDA-686
SX Male
CA Cancer cell line
//
ID MDA-8788-6
AC CVCL_H539
SY MDA8788-6
RX PubMed=23032744;
ST Source(s): PubMed=23032744;
ST Amelogenin: X
ST CSF1PO: 12,13
ST D13S317: 9,11
ST D16S539: 12,13
ST D5S818: 11
ST D7S820: 10
ST TH01: 7,9.3
ST TPOX: 8,11
ST vWA: 14,17
DI NCIt; C54294; Sinonasal undifferentiated carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_H540 ! MDA-8788-7
SX Female
CA Cancer cell line
//
ID MDA-8788-7
AC CVCL_H540
SY MDA8788-7
RX PubMed=23032744;
ST Source(s): PubMed=23032744;
ST Amelogenin: X
ST CSF1PO: 12,13
ST D13S317: 9,11
ST D16S539: 12,13
ST D5S818: 11
ST D7S820: 10
ST TH01: 7,9.3
ST TPOX: 8,11
ST vWA: 14,17
DI NCIt; C54294; Sinonasal undifferentiated carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_H539 ! MDA-8788-6
SX Female
CA Cancer cell line
//
ID MDA-886
AC CVCL_6986
SY MDA 886; MDA886; HN 886
DR BTO; BTO:0002717
RX PubMed=11389082;
DI NCIt; C4044; Laryngeal squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID MDA-886Ln
AC CVCL_6987
SY MDA 886Ln; MDA-886LN; MDA 886-Ln; MDA886Ln; MDA886LN
DR Cosmic; 948037
RX DOI=10.1016/B978-0-12-333530-2.50007-1;
RX PubMed=21868764;
RX PubMed=28196595;
WW http://tcpaportal.org/mclp/
CC Part of: MD Anderson Cell Lines Project.
CC Omics: Protein expression by reverse-phase protein arrays.
ST Source(s): PubMed=21868764
ST Amelogenin: X,Y
ST CSF1PO: 10
ST D13S317: 9
ST D16S539: 11
ST D5S818: 12
ST D7S820: 10
ST TH01: 9
ST TPOX: 8
ST vWA: 17,19
DI NCIt; C4044; Laryngeal squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_6986 ! MDA-886
SX Male
CA Cancer cell line
//
ID MDA-ACC-01(hTERT)
AC CVCL_GZ62
RX PubMed=25086988;
CC Transfected with: HGNC; 11730; TERT.
DI NCIt; C8026; Salivary gland adenoid cystic carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Telomerase immortalized cell line
//
ID MDA-AMP7
AC CVCL_EI94
SY MDAAmp-7
DR PRIDE; PXD002657
RX PubMed=1582987;
RX PubMed=26951071;
CC Omics: Deep proteome analysis.
CC Derived from metastatic site: Peritoneum.
DI NCIt; C6650; Ampulla of Vater adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID MDA-BoM-1833
AC CVCL_DP48
SY BoM-1833; 1833 BoM; MDA-MB-231 1833 BoM; MDA-MB-231-1833; MDA-MB-231 subline 1833; MDA-MB-231 Bone Tropic 1833 subclone; 1833
DR PRIDE; PXD000397
RX PubMed=12842083;
RX PubMed=18425382;
RX PubMed=26649326;
CC Omics: Proteome analysis by 2D-DE.
CC Omics: Secretome proteome analysis.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C5214; Breast adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0062 ! MDA-MB-231
SX Female
CA Cancer cell line
//
ID MDA-IBC-3
AC CVCL_HC47
SY MDA-IBC3; MDAIBC3
DR GEO; GSM1008922
DR GEO; GSM1215265
RX PubMed=20808935;
RX PubMed=24162158;
CC Omics: Transcriptome analysis.
ST Source(s): PubMed=20808935
ST Amelogenin: X
ST CSF1PO: 12,13
ST D13S317: 11,12
ST D16S539: 9,12
ST D5S818: 10,11
ST D7S820: 8,12
ST TH01: 8
ST TPOX: 10,11
ST vWA: 18,19
DI NCIt; C4001; Inflammatory breast carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID MDA-kb2
AC CVCL_6421
SY MDA-Kb2
DR CLO; CLO_0007630
DR ATCC; CRL-2713
RX PubMed=11861974;
CC Transfected with: UniProtKB; P08659; Firefly luciferase.
CC Derived from metastatic site: Pericardial effusion.
ST Source(s): ATCC
ST Amelogenin: X
ST CSF1PO: 10,12
ST D13S317: 12
ST D16S539: 9
ST D5S818: 11
ST D7S820: 10
ST TH01: 6
ST TPOX: 10
ST vWA: 17,18
DI NCIt; C5214; Breast adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0418 ! MDA-MB-453
SX Female
CA Cancer cell line
//
ID MDA-MB-134-VI
AC CVCL_0617
SY MDA-MB-134 VI; MDA MB 134VI; MDA-MB-134VI; MDAMB134VI; MDA-MB-134; MDAMB134; MDA-134; MDA134; MM134
DR CLO; CLO_0007631
DR EFO; EFO_0001205
DR CLDB; cl3398
DR ATCC; HTB-23
DR BioSample; SAMN03471473
DR CCLE; MDAMB134VI_BREAST
DR CCRID; 3111C0001CCC000380
DR ChEMBL-Cells; CHEMBL3308340
DR ChEMBL-Targets; CHEMBL2366242
DR Cosmic; 687491
DR Cosmic; 735125
DR Cosmic; 809233
DR Cosmic; 904374
DR Cosmic; 908119
DR Cosmic; 934525
DR Cosmic; 997933
DR Cosmic; 1000129
DR Cosmic; 1046947
DR Cosmic; 1047696
DR Cosmic; 1090333
DR Cosmic; 1136347
DR Cosmic; 1152519
DR Cosmic; 1287908
DR Cosmic; 1289392
DR Cosmic; 1603216
DR GDSC; 908119
DR GEO; GSM115107
DR GEO; GSM186432
DR GEO; GSM186433
DR GEO; GSM186434
DR GEO; GSM217584
DR GEO; GSM320180
DR GEO; GSM350523
DR GEO; GSM783960
DR GEO; GSM847398
DR GEO; GSM847491
DR GEO; GSM887292
DR GEO; GSM888367
DR GEO; GSM1215268
DR GEO; GSM1226522
DR GEO; GSM1226523
DR GEO; GSM1226524
DR GEO; GSM1226525
DR GEO; GSM1226526
DR GEO; GSM1226527
DR GEO; GSM1226528
DR GEO; GSM1226529
DR GEO; GSM1226530
DR GEO; GSM1226531
DR GEO; GSM1226532
DR GEO; GSM1226533
DR GEO; GSM1226534
DR GEO; GSM1226535
DR GEO; GSM1226536
DR GEO; GSM1226537
DR GEO; GSM1226538
DR GEO; GSM1226539
DR GEO; GSM1226540
DR GEO; GSM1226541
DR GEO; GSM1374647
DR GEO; GSM1401662
DR GEO; GSM1661981
DR GEO; GSM1670078
DR IZSLER; BS TCL 236
DR LINCS; 50327
RX PubMed=730202;
RX PubMed=833871;
RX PubMed=4412247;
RX PubMed=9671407;
RX PubMed=10862037;
RX PubMed=11044355;
RX PubMed=12353263;
RX PubMed=12800145;
RX PubMed=15677628;
RX PubMed=17157791;
RX PubMed=19582160;
RX PubMed=22460905;
RX PubMed=23601657;
RX PubMed=24162158;
RX PubMed=24425047;
RX PubMed=25485619;
RX PubMed=28196595;
WW http://www.pawefish.path.cam.ac.uk/BreastCellLineDescriptions/mda-mb-134.htm
WW http://lincs.hms.harvard.edu/resources/reagents/icbp43/
WW http://tcpaportal.org/mclp/
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Part of: FGFR genetic alteration cell panel (ATCC TCP-1034).
CC Part of: ICBP43 breast cancer cell line panel.
CC Part of: MD Anderson Cell Lines Project.
CC Doubling time: 6.4 days (PubMed=9671407).
CC Omics: CNV analysis.
CC Omics: Deep RNAseq analysis.
CC Omics: DNA methylation analysis.
CC Omics: miRNA expression profiling.
CC Omics: Protein expression by reverse-phase protein arrays.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
CC Misspelling: 'MDA-MB-134IV' in Cosmic 1000129.
CC Misspelling: 'MDA-MB-134-IV' in Cosmic 1090333.
CC Derived from metastatic site: Pleural effusion.
ST Source(s): ATCC; PubMed=25877200
ST Amelogenin: X
ST CSF1PO: 10,12
ST D13S317: 8
ST D16S539: 13
ST D18S51: 10,16
ST D21S11: 26,28
ST D3S1358: 15,17
ST D5S818: 11,12
ST D7S820: 10,11
ST D8S1179: 14
ST FGA: 21,22
ST Penta D: 12,13
ST Penta E: 7,9
ST TH01: 6,9
ST TPOX: 8,11
ST vWA: 14,15
DI NCIt; C7950; Invasive lobular breast carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID MDA-MB-157
AC CVCL_0618
AS CVCL_3740
SY MDA-MB157; MDAMB157; MDA-157; MDA157; MB 157; MB157
DR CLO; CLO_0007544
DR CLO; CLO_0007632
DR EFO; EFO_0001206
DR CLDB; cl3400
DR CLDB; cl3401
DR ATCC; HTB-24
DR ATCC; CRL-7721
DR BCRJ; 0319
DR BioSample; SAMN03472739
DR BioSample; SAMN03473083
DR CCLE; MDAMB157_BREAST
DR CCLE; MB157_BREAST
DR CCRID; 3111C0001CCC000077
DR ChEMBL-Cells; CHEMBL3308759
DR ChEMBL-Targets; CHEMBL1075496
DR Cosmic; 687492
DR Cosmic; 809234
DR Cosmic; 871144
DR Cosmic; 897421
DR Cosmic; 904375
DR Cosmic; 925338
DR Cosmic; 934535
DR Cosmic; 979714
DR Cosmic; 1010921
DR Cosmic; 1017166
DR Cosmic; 1018462
DR Cosmic; 1027052
DR Cosmic; 1044207
DR Cosmic; 1044228
DR Cosmic; 1046954
DR Cosmic; 1047692
DR Cosmic; 1136372
DR Cosmic; 1176640
DR Cosmic; 1287919
DR Cosmic; 1289393
DR Cosmic; 1477429
DR Cosmic; 1523776
DR Cosmic; 1603217
DR Cosmic; 1609468
DR Cosmic; 1995501
DR Cosmic; 2009506
DR Cosmic; 2301527
DR Cosmic-CLP; 925338
DR ECACC; 92020422
DR GDSC; 925338
DR GDSC; 1298233
DR GEO; GSM73731
DR GEO; GSM115112
DR GEO; GSM186435
DR GEO; GSM186436
DR GEO; GSM217585
DR GEO; GSM350548
DR GEO; GSM783948
DR GEO; GSM783970
DR GEO; GSM827192
DR GEO; GSM847399
DR GEO; GSM847492
DR GEO; GSM844591
DR GEO; GSM887293
DR GEO; GSM888368
DR GEO; GSM1374648
DR GEO; GSM1374649
DR GEO; GSM1401671
DR GEO; GSM1670079
DR LINCS; 50324
DR LINCS; 50328
RX PubMed=730202;
RX PubMed=833871;
RX PubMed=4412247;
RX PubMed=4471183;
RX PubMed=9671407;
RX PubMed=10862037;
RX PubMed=11044355;
RX PubMed=12353263;
RX PubMed=12800145;
RX PubMed=15677628;
RX PubMed=17157791;
RX PubMed=19582160;
RX PubMed=20679594;
RX PubMed=22460905;
RX PubMed=23601657;
RX PubMed=25485619;
RX PubMed=27397505;
RX PubMed=28196595;
WW http://www.pawefish.path.cam.ac.uk/BreastCellLineDescriptions/mda-mb-157.htm
WW http://colt.ccbr.utoronto.ca/cancer/get_cellline.pl?cellline=MDA-MB-157
WW http://lincs.hms.harvard.edu/resources/reagents/icbp43/
WW http://tcpaportal.org/mclp/
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Part of: ICBP43 breast cancer cell line panel.
CC Part of: MD Anderson Cell Lines Project.
CC Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982).
CC Doubling time: 2.8 days (PubMed=9671407).
CC Microsatellite instability: Stable (MSS) (PubMed=15677628; Sanger).
CC Omics: CNV analysis.
CC Omics: Deep exome analysis.
CC Omics: Deep RNAseq analysis.
CC Omics: DNA methylation analysis.
CC Omics: miRNA expression profiling.
CC Omics: Protein expression by reverse-phase protein arrays.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
CC Misspelling: 'MDA-MB-15' in Cosmic 897421.
CC Discontinued: BCRJ; 0319; probable.
CC Derived from metastatic site: Pleural effusion.
ST Source(s): ATCC; Cosmic-CLP; ECACC; PubMed=20679594; PubMed=25877200
ST Amelogenin: X
ST CSF1PO: 10
ST D13S317: 11,12 (ATCC)
ST D13S317: 11 (Cosmic-CLP; ECACC; PubMed=20679594; PubMed=25877200)
ST D16S539: 11
ST D18S51: 16
ST D21S11: 31,31.2
ST D3S1358: 16
ST D5S818: 12
ST D7S820: 10,11
ST D8S1179: 12,14
ST FGA: 23
ST Penta D: 3.2,9
ST Penta E: 11
ST TH01: 7,8
ST TPOX: 9,11 (ATCC; ECACC; PubMed=20679594; PubMed=25877200)
ST TPOX: 11 (Cosmic-CLP)
ST vWA: 15
DI NCIt; C4872; Breast carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID MDA-MB-175-VII
AC CVCL_1400
SY MDA MB 175 VII; MDA-MB-175VII; MDAMB175VII; MDA-MB-175; MDAMB175; MDA-175; MDA175
DR BTO; BTO:0003471
DR CLO; CLO_0007633
DR EFO; EFO_0001208
DR ATCC; HTB-25
DR BioSample; SAMN03472690
DR CCLE; MDAMB175VII_BREAST
DR CCRID; 3111C0001CCC000349
DR ChEMBL-Cells; CHEMBL3308404
DR ChEMBL-Targets; CHEMBL1075497
DR Cosmic; 687493
DR Cosmic; 809236
DR Cosmic; 871145
DR Cosmic; 894086
DR Cosmic; 897422
DR Cosmic; 904376
DR Cosmic; 908120
DR Cosmic; 934526
DR Cosmic; 997917
DR Cosmic; 1010931
DR Cosmic; 1044227
DR Cosmic; 1046955
DR Cosmic; 1047690
DR Cosmic; 1176646
DR Cosmic; 1287894
DR Cosmic; 1289394
DR Cosmic; 1309001
DR Cosmic; 1434951
DR Cosmic; 1603218
DR Cosmic; 1609470
DR Cosmic; 2165025
DR Cosmic-CLP; 908120
DR GDSC; 908120
DR GEO; GSM115106
DR GEO; GSM217586
DR GEO; GSM320175
DR GEO; GSM344348
DR GEO; GSM344398
DR GEO; GSM350511
DR GEO; GSM466359
DR GEO; GSM783950
DR GEO; GSM847400
DR GEO; GSM847493
DR GEO; GSM844592
DR GEO; GSM844593
DR GEO; GSM887294
DR GEO; GSM888369
DR GEO; GSM1374650
DR IGRhCellID; MDAMB175VII
DR LINCS; 50329
DR NCBI_Iran; C432
RX PubMed=730202;
RX PubMed=4412247;
RX PubMed=11044355;
RX PubMed=12353263;
RX PubMed=12800145;
RX PubMed=15677628;
RX PubMed=17157791;
RX PubMed=19582160;
RX PubMed=20070913;
RX PubMed=22460905;
RX PubMed=23601657;
RX PubMed=25485619;
RX PubMed=28196595;
WW http://www.pawefish.path.cam.ac.uk/BreastCellLineDescriptions/MDA-MB-175.html
WW http://lincs.hms.harvard.edu/resources/reagents/icbp43/
WW http://www.addexbio.com/productdetail?pid=4885
WW http://tcpaportal.org/mclp/
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Part of: ICBP43 breast cancer cell line panel.
CC Part of: MD Anderson Cell Lines Project.
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Omics: Array-based CGH.
CC Omics: CNV analysis.
CC Omics: Deep exome analysis.
CC Omics: Deep RNAseq analysis.
CC Omics: miRNA expression profiling.
CC Omics: Protein expression by reverse-phase protein arrays.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
CC Derived from metastatic site: Pleural effusion.
ST Source(s): ATCC; Cosmic-CLP; PubMed=25877200
ST Amelogenin: X
ST CSF1PO: 7,8
ST D13S317: 11,12
ST D16S539: 11,13
ST D18S51: 15
ST D21S11: 29,30
ST D3S1358: 16,18
ST D5S818: 11
ST D7S820: 11,12
ST D8S1179: 14,17
ST FGA: 23,26
ST Penta D: 3.2
ST Penta E: 8,15
ST TH01: 7
ST TPOX: 6,8
ST vWA: 15,16
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID MDA-MB-231
AC CVCL_0062
SY MDA-MB 231; MDA.MB.231; MDA MB 231; MDA MB231; MDA Mb231; MDA-MB231; MDAMB231; MDA-231; MDA231; MB231
DR BTO; BTO:0000815
DR CLO; CLO_0007634
DR EFO; EFO_0001209
DR MCCL; MCC:0000313
DR CLDB; cl3402
DR CLDB; cl3404
DR CLDB; cl3405
DR CLDB; cl4945
DR ATCC; CRL-12532
DR ATCC; HTB-26
DR ATCC; CRM-HTB-26
DR BCRC; 60425
DR BCRJ; 0164
DR BioSample; SAMN03472205
DR CCLE; MDAMB231_BREAST
DR CCRID; 3111C0001CCC000014
DR CCRID; 3131C0001000700104
DR ChEMBL-Cells; CHEMBL3307960
DR ChEMBL-Targets; CHEMBL400
DR CLS; 300275/p536_MDA-MB-231
DR Cosmic; 687494
DR Cosmic; 871146
DR Cosmic; 875878
DR Cosmic; 877450
DR Cosmic; 894087
DR Cosmic; 897423
DR Cosmic; 904377
DR Cosmic; 905960
DR Cosmic; 934536
DR Cosmic; 944294
DR Cosmic; 974235
DR Cosmic; 991324
DR Cosmic; 997929
DR Cosmic; 1010924
DR Cosmic; 1018477
DR Cosmic; 1027053
DR Cosmic; 1044226
DR Cosmic; 1046950
DR Cosmic; 1047693
DR Cosmic; 1071900
DR Cosmic; 1092613
DR Cosmic; 1136369
DR Cosmic; 1152528
DR Cosmic; 1175833
DR Cosmic; 1176602
DR Cosmic; 1176636
DR Cosmic; 1183773
DR Cosmic; 1219444
DR Cosmic; 1287926
DR Cosmic; 1289395
DR Cosmic; 1305383
DR Cosmic; 1309003
DR Cosmic; 1312370
DR Cosmic; 1434952
DR Cosmic; 1436032
DR Cosmic; 1466805
DR Cosmic; 1477428
DR Cosmic; 1481426
DR Cosmic; 1524347
DR Cosmic; 1571793
DR Cosmic; 1609458
DR Cosmic; 1927242
DR Cosmic; 1945862
DR Cosmic; 1998455
DR Cosmic; 2009512
DR Cosmic; 2036667
DR Cosmic; 2164997
DR Cosmic; 2301528
DR Cosmic; 2318377
DR Cosmic; 2361355
DR Cosmic-CLP; 905960
DR DSMZ; ACC-732
DR ECACC; 92020424
DR GDSC; 905960
DR GEO; GSM812
DR GEO; GSM50184
DR GEO; GSM50248
DR GEO; GSM69194
DR GEO; GSM155213
DR GEO; GSM185093
DR GEO; GSM185094
DR GEO; GSM344349
DR GEO; GSM344399
DR GEO; GSM350547
DR GEO; GSM378148
DR GEO; GSM388213
DR GEO; GSM459713
DR GEO; GSM481304
DR GEO; GSM587393
DR GEO; GSM587394
DR GEO; GSM750781
DR GEO; GSM799321
DR GEO; GSM799384
DR GEO; GSM847036
DR GEO; GSM847401
DR GEO; GSM844594
DR GEO; GSM844595
DR GEO; GSM887295
DR GEO; GSM888370
DR GEO; GSM967818
DR GEO; GSM1008905
DR GEO; GSM1153390
DR GEO; GSM1181242
DR GEO; GSM1181365
DR GEO; GSM1214569
DR GEO; GSM1374651
DR GEO; GSM1374652
DR GEO; GSM1401658
DR GEO; GSM1613823
DR GEO; GSM1670080
DR GEO; GSM1833624
DR ICLC; HTL99004
DR IZSLER; BS TCL 223
DR KCB; KCB 200776YJ
DR KCLB; 30026
DR LINCS; 50058
DR Lonza; 815
DR NCBI_Iran; C578
DR PRIDE; PXD000239
DR PRIDE; PXD000397
DR PRIDE; PXD000691
DR PRIDE; PXD000914
DR PRIDE; PXD001553
DR PRIDE; PXD002192
DR PRIDE; PXD002649
DR SKY/M-FISH/CGH; 2815
DR TOKU-E; 2394
DR Wikidata; Q17577870
RX DOI=10.4172/2157-7145.S2-005;
RX PubMed=730202;
RX PubMed=833871;
RX PubMed=1000504;
RX PubMed=1000505;
RX PubMed=1000506;
RX PubMed=2041050;
RX PubMed=4412247;
RX PubMed=6582512;
RX PubMed=6935474;
RX PubMed=7000337;
RX PubMed=7272986;
RX PubMed=7459858;
RX PubMed=8824553;
RX PubMed=9671407;
RX PubMed=11697798;
RX PubMed=12353263;
RX PubMed=12661003;
RX PubMed=12800145;
RX PubMed=15677628;
RX PubMed=15767549;
RX PubMed=17088437;
RX PubMed=17157791;
RX PubMed=18714363;
RX PubMed=19372543;
RX PubMed=19582160;
RX PubMed=20070913;
RX PubMed=21378333;
RX PubMed=22336246;
RX PubMed=22460905;
RX PubMed=23601657;
RX PubMed=23856246;
RX PubMed=23933261;
RX PubMed=24162158;
RX PubMed=25485619;
RX PubMed=26055192;
RX PubMed=26218769;
RX PubMed=26649326;
RX PubMed=27397505;
RX PubMed=27807467;
RX PubMed=28196595;
WW https://de.wikipedia.org/wiki/MDA-MB-231_(Zelllinie)
WW https://dtp.cancer.gov/discovery_development/nci-60/cell_list.htm
WW https://strap.nci.nih.gov/celline_detail.php?sample_id=2
WW http://colt.ccbr.utoronto.ca/cancer/get_cellline.pl?cellline=MDA-MB-231
WW http://genome.ucsc.edu/ENCODE/protocols/cell/human/MDA-MB-231_Struhl_protocol.pdf
WW http://lincs.hms.harvard.edu/resources/reagents/icbp43/
WW http://www.addexbio.com/productdetail?pid=58
WW http://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/m/cell-lines-detail-394.html
WW http://tcpaportal.org/mclp/
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Part of: ENCODE project common cell types; tier 3.
CC Part of: ICBP43 breast cancer cell line panel.
CC Part of: JFCR39 cancer cell line panel.
CC Part of: JFCR45 cancer cell line panel.
CC Part of: KuDOS 95 cell line panel.
CC Part of: MD Anderson Cell Lines Project.
CC Part of: NCI60 cancer cell line panel.
CC Registration: Chiron Master Culture Collection; CMCC 10583 (CMCC #10583).
CC Doubling time: 1.3 days (PubMed=9671407); 41.9 hours (DTP); 38 hours (ATCC); ~25-30 hours (DSMZ).
CC Microsatellite instability: Stable (MSS) (PubMed=12661003; Sanger).
CC Omics: Array-based CGH.
CC Omics: Cell surface proteome.
CC Omics: CNV analysis.
CC Omics: Deep exome analysis.
CC Omics: Deep proteome analysis.
CC Omics: Deep RNAseq analysis.
CC Omics: DNA methylation analysis.
CC Omics: Metabolome analysis.
CC Omics: miRNA expression profiling.
CC Omics: Protein expression by reverse-phase protein arrays.
CC Omics: Secretome proteome analysis.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
CC Misspelling: 'MDA-MD-231' in Cosmic 1071900 and Cosmic 1176602.
CC Misspelling: 'MDA-321' in GEO GSM459713.
CC Misspelling: 'MDA-MG-231' in PubMed=6582512.
CC Discontinued: ATCC; CRL-12532; probable.
CC Derived from metastatic site: Pleural effusion.
ST Source(s): ATCC; CLS; Cosmic-CLP; DSMZ; ECACC; KCLB; DOI=10.4172/2157-7145.S2-005; PubMed=19372543; PubMed=25877200
ST Amelogenin: X
ST CSF1PO: 12,13
ST D13S317: 13
ST D16S539: 12
ST D18S51: 11,16
ST D19S433: 11,14
ST D21S11: 30,33.2 (CLS)
ST D21S11: 33.2 (DOI=10.4172/2157-7145.S2-005; PubMed=19372543; PubMed=25877200)
ST D2S1338: 20,21
ST D3S1358: 16
ST D5S818: 12
ST D7S820: 8,9
ST D8S1179: 13
ST FGA: 22,23
ST Penta D: 11,14
ST Penta E: 11
ST TH01: 7,9.3
ST TPOX: 8,9
ST vWA: 15,18 (ATCC; Cosmic-CLP; DSMZ; ECACC; KCLB; DOI=10.4172/2157-7145.S2-005; PubMed=19372543; PubMed=25877200)
ST vWA: 15,19 (CLS)
DI NCIt; C5214; Breast adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID MDA-MB-231 25PACR
AC CVCL_4Y38
RX PubMed=25312014;
CC Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol).
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C5214; Breast adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0062 ! MDA-MB-231
SX Female
CA Cancer cell line
//
ID MDA-MB-231 50PACR
AC CVCL_4Y39
RX PubMed=25312014;
CC Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol).
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C5214; Breast adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0062 ! MDA-MB-231
SX Female
CA Cancer cell line
//
ID MDA-MB-231 CMV
AC CVCL_IN16
SY MDA Mb231 (CMV)
DR GEO; GSM246285
DR GEO; GSM246286
DR GEO; GSM246287
DR GEO; GSM246288
DR GEO; GSM246289
DR GEO; GSM246290
DR GEO; GSM246267
DR GEO; GSM246268
DR GEO; GSM246269
DR GEO; GSM246270
DR GEO; GSM246271
DR GEO; GSM246272
RX PubMed=19321454;
CC Characteristics: Control cell line for the MDA-MB-231 ERalpha (CVCL_IN17), MDA-MB-231 ERalpha203/4/11 (CVCL_IN15), MDA-MB-231 ERbeta (CVCL_IN18) and MDA-MB-231 ERbetaDBD (CVCL_IN19) cell lines.
CC Omics: Transcriptome analysis.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C5214; Breast adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0062 ! MDA-MB-231
SX Female
CA Cancer cell line
//
ID MDA-MB-231 ERalpha
AC CVCL_IN17
SY MDA Mb231 (ERa)
DR GEO; GSM246273
DR GEO; GSM246274
DR GEO; GSM246275
DR GEO; GSM246276
DR GEO; GSM246277
DR GEO; GSM246278
RX PubMed=19321454;
CC Transfected with: HGNC; 3467; ESR1.
CC Omics: Transcriptome analysis.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C5214; Breast adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0062 ! MDA-MB-231
SX Female
CA Cancer cell line
//
ID MDA-MB-231 ERalpha203/4/11
AC CVCL_IN15
SY MDA Mb231 (ERa3411)
DR GEO; GSM246279
DR GEO; GSM246280
DR GEO; GSM246281
DR GEO; GSM246282
DR GEO; GSM246283
DR GEO; GSM246284
RX PubMed=19321454;
CC Transfected with: HGNC; 3467; ESR1 (with A-203; A-204 and E-211).
CC Omics: Transcriptome analysis.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C5214; Breast adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0062 ! MDA-MB-231
SX Female
CA Cancer cell line
//
ID MDA-MB-231 ERbeta
AC CVCL_IN18
SY MDA Mb231 (ERb)
DR GEO; GSM246297
DR GEO; GSM246298
DR GEO; GSM246299
DR GEO; GSM246300
DR GEO; GSM246301
DR GEO; GSM246302
RX PubMed=19321454;
CC Transfected with: HGNC; 3468; ESR2.
CC Omics: Transcriptome analysis.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C5214; Breast adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0062 ! MDA-MB-231
SX Female
CA Cancer cell line
//
ID MDA-MB-231 ERbetaDBD
AC CVCL_IN19
SY MDA Mb231 (ERbDBD)
DR GEO; GSM246303
DR GEO; GSM246304
DR GEO; GSM246305
DR GEO; GSM246306
DR GEO; GSM246307
DR GEO; GSM246308
RX PubMed=19321454;
CC Transfected with: HGNC; 3468; ESR2 (ERE-binding defective).
CC Omics: Transcriptome analysis.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C5214; Breast adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0062 ! MDA-MB-231
SX Female
CA Cancer cell line
//
ID MDA-MB-231 NucLight Green
AC CVCL_DF47
CC Characteristics: Stably expresses a non-perturbing nuclear restricted green fluorescent label.
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C5214; Breast adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0062 ! MDA-MB-231
SX Female
CA Cancer cell line
//
ID MDA-MB-231 NucLight Red
AC CVCL_DF48
CC Characteristics: Stably expresses a non-perturbing nuclear restricted red fluorescent label.
CC Transfected with: mKate2; a bright red fluorescent protein derived from eqFP578.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C5214; Breast adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0062 ! MDA-MB-231
SX Female
CA Cancer cell line
//
ID MDA-MB-231 SimpleCell O-GalNAc
AC CVCL_S031
SY MDA-MB-231 SimpleCell; MDA-MB-231 SC
RX PubMed=23584533;
CC Characteristics: Cell engineered to produce only truncated GalNAc or NeuAc-alpha-2-6-GalNAc O-glycans.
CC Knockout cell: Method=ZFN; HGNC; 24338; C1GALT1C1.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C5214; Breast adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0062 ! MDA-MB-231
SX Female
CA Cancer cell line
//
ID MDA-MB-231 SimpleCell O-GalNAC/O-Man
AC CVCL_S032
RX PubMed=24101494;
CC Characteristics: Cell engineered to produce only truncated GalNAc, NeuAc-alpha-2-6-GalNAc and Man O-glycans.
CC Knockout cell: Method=ZFN; HGNC; 24338; C1GALT1C1.
CC Knockout cell: Method=ZFN; HGNC; 19139; POMGNT1.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C5214; Breast adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_S031 ! MDA-MB-231 SimpleCell O-GalNAc
SX Female
CA Cancer cell line
//
ID MDA-MB-231-5a
AC CVCL_9U30
SY MDA-5a
RX PubMed=16309168;
RX PubMed=17129361;
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C5214; Breast adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0062 ! MDA-MB-231
SX Female
CA Cancer cell line
//
ID MDA-MB-231-5a-D
AC CVCL_9U31
SY MDA-231-D
RX PubMed=17129361;
RX PubMed=18663362;
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C5214; Breast adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_9U30 ! MDA-MB-231-5a
SX Female
CA Cancer cell line
//
ID MDA-MB-231-5a-D-TbetaFluc/Rluc
AC CVCL_9U32
SY MDA-231-D-TbetaFluc/Rluc; MDA-D-TbetaFluc/Rluc; 5a-D-Luc
RX PubMed=17129361;
RX PubMed=18663362;
RX PubMed=26691676;
CC Transfected with: UniProtKB; P08659; Firefly luciferase.
CC Transfected with: UniProtKB; P27652; Renilla-type luciferase.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C5214; Breast adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_9U31 ! MDA-MB-231-5a-D
SX Female
CA Cancer cell line
//
ID MDA-MB-231-5a-D-TbetaFluc/Rluc-ZsGreen
AC CVCL_9U33
SY 5a-D-Luc-ZsGreen
RX PubMed=26691676;
CC Transfected with: UniProtKB; P08659; Firefly luciferase.
CC Transfected with: UniProtKB; P27652; Renilla-type luciferase.
CC Transfected with: UniProtKB; Q9U6Y4; Zoanthus sp. chromoprotein FP538 (modified and distributed as ZsGreen1).
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C5214; Breast adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_9U32 ! MDA-MB-231-5a-D-TbetaFluc/Rluc
SX Female
CA Cancer cell line
//
ID MDA-MB-231-BAG
AC CVCL_R956
SY MDA-MB-231 BAG
DR BTO; BTO:0004474
RX PubMed=1384607;
CC Transfected with: UniProtKB; P00722; E.coli lacZ.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C5214; Breast adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0062 ! MDA-MB-231
SX Female
CA Cancer cell line
//
ID MDA-MB-231-luc-D3H1
AC CVCL_1D88
SY D3H1
RX PubMed=15987449;
CC Transfected with: UniProtKB; P08659; Firefly luciferase.
CC Discontinued: PerkinElmer; Catalog number 119261.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C5214; Breast adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0062 ! MDA-MB-231
SX Female
CA Cancer cell line
//
ID MDA-MB-231-luc-D3H2LN
AC CVCL_D257
SY D3H2LN
RX PubMed=15987449;
WW http://web.archive.org/web/20150202002416/http://www.perkinelmer.com/catalog/product/id/119369
CC Transfected with: UniProtKB; P08659; Firefly luciferase.
CC Discontinued: PerkinElmer; Catalog number 119369.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C5214; Breast adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_1D88 ! MDA-MB-231-luc-D3H1
SX Female
CA Cancer cell line
//
ID MDA-MB-231-luc2
AC CVCL_D582
SY MDA-MB-231-Luc2
DR BTO; BTO:0005172
RX DOI=10.1158/1538-7445.AM2013-3908;
CC Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression).
CC Discontinued: PerkinElmer; Catalog number 124319.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C5214; Breast adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0062 ! MDA-MB-231
SX Female
CA Cancer cell line
//
ID MDA-MB-231-luc2-GFP
AC CVCL_1D89
CC Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression).
CC Transfected with: UniProtKB; P42212; GFP.
CC Discontinued: PerkinElmer; Catalog number 128442.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C5214; Breast adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_D582 ! MDA-MB-231-luc2
SX Female
CA Cancer cell line
//
ID MDA-MB-231-luc2-LN
AC CVCL_1D92
RX DOI=10.1158/1538-7445.AM2013-3908;
CC Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression).
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C5214; Breast adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_D582 ! MDA-MB-231-luc2
SX Female
CA Cancer cell line
//
ID MDA-MB-231-luc2-tdTomato
AC CVCL_1D90
SY MDA-MB231-luc2-tdTomato
RX DOI=10.1158/1538-7445.AM2013-3908;
CC Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression).
CC Transfected with: tdTomato; a bright red fluorescent protein derived from drFP583 (DsRed).
CC Discontinued: PerkinElmer; Catalog number 125738.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C5214; Breast adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_D582 ! MDA-MB-231-luc2
SX Female
CA Cancer cell line
//
ID MDA-MB-231-luc2-tdTomato-LN
AC CVCL_1E88
RX DOI=10.1158/1538-7445.AM2013-3908;
CC Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression).
CC Transfected with: tdTomato; a bright red fluorescent protein derived from drFP583 (DsRed).
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C5214; Breast adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_1D90 ! MDA-MB-231-luc2-tdTomato
SX Female
CA Cancer cell line
//
ID MDA-MB-231-MEK-R
AC CVCL_V403
DR Cosmic; 1927243
RX PubMed=22402123;
CC Selected for resistance to: ChEBI; CHEBI:88249; 391210-10-9 (PD0325901).
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C5214; Breast adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0062 ! MDA-MB-231
SX Female
CA Cancer cell line
//
ID MDA-MB-231-Red-FLuc
AC CVCL_5J05
SY MDA-MB231-Red-FLuc
WW http://www.perkinelmer.com/Catalog/Product/ID/BW124319
CC Transfected with: UniProtKB; Q1AG35; Italian firefly luciferase.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C5214; Breast adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0062 ! MDA-MB-231
SX Female
CA Cancer cell line
//
ID MDA-MB-231-Red-FLuc-GFP
AC CVCL_5J06
SY MDA-MB231-Red-FLuc-GFP
WW http://www.perkinelmer.com/Catalog/Product/ID/BW128442
CC Transfected with: UniProtKB; Q1AG35; Italian firefly luciferase.
CC Transfected with: UniProtKB; P42212; GFP.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C5214; Breast adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0062 ! MDA-MB-231
SX Female
CA Cancer cell line
//
ID MDA-MB-231-tdTomato
AC CVCL_1D91
CC Transfected with: tdTomato; a bright red fluorescent protein derived from drFP583 (DsRed).
CC Discontinued: PerkinElmer; Catalog number 125737.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C5214; Breast adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0062 ! MDA-MB-231
SX Female
CA Cancer cell line
//
ID MDA-MB-231/B02
AC CVCL_5T76
SY MDA-MB-231-B02; MDA-B02; B02
DR BTO; BTO:0004955
RX PubMed=11697798;
RX PubMed=18714363;
CC Omics: Cell surface proteome.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C5214; Breast adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0062 ! MDA-MB-231
SX Female
CA Cancer cell line
//
ID MDA-MB-231/PacR
AC CVCL_4Z64
RX CelloPub=CLPUB00286;
RX PubMed=25275030;
CC Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol).
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C5214; Breast adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0062 ! MDA-MB-231
SX Female
CA Cancer cell line
//
ID MDA-MB-231DR
AC CVCL_4Z65
RX PubMed=16928833;
CC Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Adriamycin).
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C5214; Breast adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0062 ! MDA-MB-231
SX Female
CA Cancer cell line
//
ID MDA-MB-231LLM
AC CVCL_M354
RX PubMed=22977471;
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C5214; Breast adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0062 ! MDA-MB-231
SX Female
CA Cancer cell line
//
ID MDA-MB-231/5-FU
AC CVCL_S511
RX PubMed=24126575;
CC Selected for resistance to: ChEBI; CHEBI:46345; 5-fluorouracil (5-FU).
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C5214; Breast adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0062 ! MDA-MB-231
SX Female
CA Cancer cell line
//
ID MDA-MB-253
AC CVCL_M384
RX PubMed=730202;
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4872; Breast carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID MDA-MB-309
AC CVCL_M385
RX PubMed=730202;
RX PubMed=833871;
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4872; Breast carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID MDA-MB-330
AC CVCL_0619
SY MDAMB330; MDA-330; MDA330
DR CLO; CLO_0007635
DR EFO; EFO_0006454
DR ATCC; HTB-127
DR BioSample; SAMN03473067
DR Cosmic; 871154
DR Cosmic; 904378
DR Cosmic; 934537
DR Cosmic; 979725
DR Cosmic; 997918
DR Cosmic; 1046956
DR Cosmic; 1152521
DR Cosmic; 1287917
DR Cosmic; 1289396
DR Cosmic; 1603219
DR Cosmic-CLP; 1330941
DR GDSC; 1330941
DR GEO; GSM783951
DR GEO; GSM1661982
DR GEO; GSM1670081
RX PubMed=327080;
RX PubMed=730202;
RX PubMed=833871;
RX PubMed=9671407;
RX PubMed=23601657;
RX PubMed=25485619;
RX PubMed=27397505;
CC Doubling time: 1.7 days (PubMed=9671407).
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Omics: Deep exome analysis.
CC Omics: Deep RNAseq analysis.
CC Omics: DNA methylation analysis.
CC Omics: miRNA expression profiling.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
CC Derived from metastatic site: Pleural effusion.
ST Source(s): ATCC; Cosmic-CLP; PubMed=25877200
ST Amelogenin: X
ST CSF1PO: 10
ST D13S317: 9
ST D16S539: 9,12
ST D18S51: 21
ST D21S11: 29
ST D3S1358: 17
ST D5S818: 13
ST D7S820: 10,11
ST D8S1179: 13,15
ST FGA: 21,22
ST Penta D: 9,14
ST Penta E: 12,13,17
ST TH01: 8,9.3
ST TPOX: 8,11
ST vWA: 14,16
DI NCIt; C4872; Breast carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID MDA-MB-331
AC CVCL_M386
RX PubMed=730202;
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4872; Breast carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID MDA-MB-361
AC CVCL_0620
SY MDA-MB 361; MDA MB 361; MDA-MB361; MDAMB361; MDA-361; MDA361
DR BTO; BTO:0001569
DR CLO; CLO_0007636
DR EFO; EFO_0001211
DR CLDB; cl3406
DR ATCC; HTB-27
DR BCRC; 60549
DR BioSample; SAMN03472909
DR CCLE; MDAMB361_BREAST
DR CCRID; 3111C0001CCC000381
DR ChEMBL-Cells; CHEMBL3308405
DR ChEMBL-Targets; CHEMBL614129
DR Cosmic; 687495
DR Cosmic; 809235
DR Cosmic; 871147
DR Cosmic; 904379
DR Cosmic; 908121
DR Cosmic; 934527
DR Cosmic; 979709
DR Cosmic; 997919
DR Cosmic; 1000124
DR Cosmic; 1010928
DR Cosmic; 1017160
DR Cosmic; 1018464
DR Cosmic; 1046933
DR Cosmic; 1047695
DR Cosmic; 1136355
DR Cosmic; 1176627
DR Cosmic; 1287895
DR Cosmic; 1289397
DR Cosmic; 1308994
DR Cosmic; 1348961
DR Cosmic; 1434953
DR Cosmic; 1523777
DR Cosmic; 1603220
DR Cosmic; 1609461
DR Cosmic; 2165011
DR Cosmic; 2301529
DR Cosmic-CLP; 908121
DR ECACC; 92020423
DR GDSC; 908121
DR GEO; GSM73751
DR GEO; GSM115119
DR GEO; GSM155208
DR GEO; GSM186437
DR GEO; GSM186438
DR GEO; GSM186439
DR GEO; GSM217587
DR GEO; GSM344350
DR GEO; GSM344400
DR GEO; GSM350546
DR GEO; GSM481306
DR GEO; GSM783952
DR GEO; GSM827280
DR GEO; GSM847402
DR GEO; GSM847494
DR GEO; GSM887296
DR GEO; GSM888371
DR GEO; GSM1008906
DR GEO; GSM1264070
DR GEO; GSM1264072
DR GEO; GSM1264112
DR GEO; GSM1264114
DR GEO; GSM1374653
DR GEO; GSM1374654
DR GEO; GSM1374655
DR GEO; GSM1401664
DR GEO; GSM1670082
DR LINCS; 50331
DR Lonza; 143
DR NCBI_Iran; C433
RX PubMed=730202;
RX PubMed=833871;
RX PubMed=6935474;
RX PubMed=7272986;
RX PubMed=9671407;
RX PubMed=10862037;
RX PubMed=11044355;
RX PubMed=12800145;
RX PubMed=15677628;
RX PubMed=17157791;
RX PubMed=19582160;
RX PubMed=20070913;
RX PubMed=22460905;
RX PubMed=23601657;
RX PubMed=25485619;
RX PubMed=27397505;
RX PubMed=28196595;
WW http://www.pawefish.path.cam.ac.uk/BreastCellLineDescriptions/mda-mb-361.html
WW http://colt.ccbr.utoronto.ca/cancer/get_cellline.pl?cellline=MDA-MB-361
WW http://lincs.hms.harvard.edu/resources/reagents/icbp43/
WW http://tcpaportal.org/mclp/
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Part of: EGFR genetic alteration cell panel (ATCC TCP-1027).
CC Part of: ICBP43 breast cancer cell line panel.
CC Part of: KuDOS 95 cell line panel.
CC Part of: MD Anderson Cell Lines Project.
CC Part of: PI3K genetic alteration cell panel (ATCC TCP-1028).
CC Doubling time: 4.3 days (PubMed=9671407).
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Omics: Array-based CGH.
CC Omics: CNV analysis.
CC Omics: Deep exome analysis.
CC Omics: Deep RNAseq analysis.
CC Omics: DNA methylation analysis.
CC Omics: miRNA expression profiling.
CC Omics: Protein expression by reverse-phase protein arrays.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
CC Derived from metastatic site: Brain.
ST Source(s): ATCC; Cosmic-CLP; PubMed=25877200
ST Amelogenin: X
ST CSF1PO: 12
ST D13S317: 11
ST D16S539: 11,12
ST D18S51: 12,15
ST D21S11: 30,32.2
ST D3S1358: 16
ST D5S818: 10,11
ST D7S820: 9,12
ST D8S1179: 15
ST FGA: 20,24
ST Penta D: 12,13
ST Penta E: 8,14
ST TH01: 9.3
ST TPOX: 8,11
ST vWA: 17
DI NCIt; C5214; Breast adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID MDA-MB-361-Luc#1
AC CVCL_4Y09
DR JCRB; NIHS0718
CC Transfected with: UniProtKB; P08659; Firefly luciferase.
CC Derived from metastatic site: Brain.
DI NCIt; C5214; Breast adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0620 ! MDA-MB-361
SX Female
CA Cancer cell line
//
ID MDA-MB-390
AC CVCL_M387
RX PubMed=730202;
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4872; Breast carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID MDA-MB-411
AC CVCL_M388
RX PubMed=730202;
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4872; Breast carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID MDA-MB-415
AC CVCL_0621
SY MDA-MB415; MDAMB415; MDA-415; MDA415
DR CLO; CLO_0007637
DR EFO; EFO_0001212
DR CLDB; cl3407
DR CLDB; cl7127
DR ATCC; HTB-128
DR BioSample; SAMN03471279
DR CCLE; MDAMB415_BREAST
DR CCRID; 3111C0001CCC000350
DR ChEMBL-Cells; CHEMBL3308760
DR ChEMBL-Targets; CHEMBL1075498
DR Cosmic; 871148
DR Cosmic; 894088
DR Cosmic; 897424
DR Cosmic; 904380
DR Cosmic; 924240
DR Cosmic; 949190
DR Cosmic; 1010917
DR Cosmic; 1027054
DR Cosmic; 1044225
DR Cosmic; 1046928
DR Cosmic; 1047697
DR Cosmic; 1090334
DR Cosmic; 1136348
DR Cosmic; 1176650
DR Cosmic; 1287896
DR Cosmic; 1289398
DR Cosmic; 1434954
DR Cosmic; 1502207
DR Cosmic; 1603221
DR Cosmic; 1609460
DR Cosmic; 2165026
DR Cosmic; 2301530
DR Cosmic-CLP; 924240
DR GDSC; 924240
DR GEO; GSM115101
DR GEO; GSM149982
DR GEO; GSM149990
DR GEO; GSM149998
DR GEO; GSM186440
DR GEO; GSM186441
DR GEO; GSM217588
DR GEO; GSM344351
DR GEO; GSM344401
DR GEO; GSM783953
DR GEO; GSM847415
DR GEO; GSM847495
DR GEO; GSM844596
DR GEO; GSM844597
DR GEO; GSM844598
DR GEO; GSM844599
DR GEO; GSM887297
DR GEO; GSM888372
DR GEO; GSM1008907
DR GEO; GSM1215266
DR GEO; GSM1374656
DR GEO; GSM1670083
DR ICLC; HTL02005
DR LINCS; 50332
DR Lonza; 1252
DR PRIDE; PXD002486
RX PubMed=730202;
RX PubMed=6935474;
RX PubMed=7272986;
RX PubMed=12800145;
RX PubMed=17157791;
RX PubMed=20070913;
RX PubMed=22460905;
RX PubMed=23601657;
RX PubMed=24162158;
RX PubMed=25485619;
RX PubMed=27397505;
RX PubMed=28196595;
WW http://www.pawefish.path.cam.ac.uk/BreastCellLineDescriptions/MDA-MB-415.html
WW http://lincs.hms.harvard.edu/resources/reagents/icbp43/
WW http://tcpaportal.org/mclp/
CC Part of: AKT genetic alteration cell panel (ATCC TCP-1029).
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Part of: ICBP43 breast cancer cell line panel.
CC Part of: MD Anderson Cell Lines Project.
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Omics: Array-based CGH.
CC Omics: Deep exome analysis.
CC Omics: Deep RNAseq analysis.
CC Omics: DNA methylation analysis.
CC Omics: miRNA expression profiling.
CC Omics: Protein expression by reverse-phase protein arrays.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
CC Derived from metastatic site: Pleural effusion.
ST Source(s): ATCC; Cosmic-CLP; PubMed=25877200
ST Amelogenin: X
ST CSF1PO: 10,12
ST D13S317: 11,13
ST D16S539: 13
ST D18S51: 13
ST D21S11: 27,28
ST D3S1358: 17
ST D5S818: 11,13
ST D7S820: 9,10
ST D8S1179: 8,12
ST FGA: 22
ST Penta D: 9,10
ST Penta E: 7,16
ST TH01: 7,9.3
ST TPOX: 8
ST vWA: 17
DI NCIt; C5214; Breast adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID MDA-MB-416
AC CVCL_M389
RX PubMed=730202;
RX PubMed=7272986;
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4872; Breast carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID MDA-MB-431
AC CVCL_M390
RX PubMed=730202;
RX PubMed=7272986;
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4872; Breast carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID MDA-MB-435
AC CVCL_0417
SY MDA-MB435; MDAMB435; MDA.MB.435; MDA-435; MDA 435; MDA435
DR BTO; BTO:0001567
DR EFO; EFO_0001213
DR MCCL; MCC:0000314
DR ATCC; CRL-12583
DR BioSample; SAMN03151832
DR BioSample; SAMN03470861
DR CCRID; 3111C0001CCC000351
DR ChEMBL-Cells; CHEMBL3307686
DR ChEMBL-Cells; CHEMBL3308414
DR ChEMBL-Targets; CHEMBL614333
DR ChEMBL-Targets; CHEMBL614697
DR Cosmic; 687496
DR Cosmic; 875879
DR Cosmic; 905988
DR Cosmic; 974069
DR Cosmic; 974236
DR Cosmic; 991325
DR Cosmic; 1000131
DR Cosmic; 1010930
DR Cosmic; 1044219
DR Cosmic; 1092614
DR Cosmic; 1175834
DR Cosmic; 1176643
DR Cosmic; 1219445
DR Cosmic; 1305366
DR Cosmic; 1312349
DR Cosmic; 1477425
DR Cosmic; 1524346
DR Cosmic; 1571794
DR Cosmic; 1945861
DR Cosmic; 1998456
DR GEO; GSM50203
DR GEO; GSM50265
DR GEO; GSM206523
DR GEO; GSM344352
DR GEO; GSM344402
DR GEO; GSM750814
DR GEO; GSM783965
DR GEO; GSM799354
DR GEO; GSM799417
DR GEO; GSM844589
DR GEO; GSM844590
DR GEO; GSM847037
DR GEO; GSM1008908
DR GEO; GSM1153424
DR GEO; GSM1181294
DR GEO; GSM1181337
DR GEO; GSM1215267
DR GEO; GSM1670084
DR SKY/M-FISH/CGH; 2816
DR TOKU-E; 3544
RX DOI=10.1038/npjbcancer.2015.2;
RX DOI=10.4172/2157-7145.S2-005;
RX PubMed=730202;
RX PubMed=2041050;
RX PubMed=7272986;
RX PubMed=11044355;
RX PubMed=17004106;
RX PubMed=17088437;
RX PubMed=17157791;
RX PubMed=19372543;
RX PubMed=19549886;
RX PubMed=20143388;
RX PubMed=23856246;
RX PubMed=23933261;
RX PubMed=24162158;
RX PubMed=25485619;
RX PubMed=27397505;
RX PubMed=27807467;
WW https://dtp.cancer.gov/discovery_development/nci-60/cell_list.htm
WW https://dtp.cancer.gov/discovery_development/nci-60/mda-mb-435.htm
WW https://strap.nci.nih.gov/celline_detail.php?sample_id=51
WW http://www.pawefish.path.cam.ac.uk/BreastCellLineDescriptions/mda-mb-435.htm
WW http://iclac.org/wp-content/uploads/Cross-Contaminations-v8_0.pdf
WW https://www.ncbi.nlm.nih.gov/pubmed/25902968#cm25902968_13561
CC Problematic cell line: Contaminated. Shown to be a M14 derivative (PubMed=17004106, PubMed=20143388). Originally thought to originate from a breast carcinoma. See also PubMed=19549886 for a dissenting view that states that M14 is a breast cancer cell line.
CC Part of: NCI60 cancer cell line panel.
CC Doubling time: 25.8 hours (DTP).
CC Omics: Deep exome analysis.
CC Omics: Deep proteome analysis.
CC Omics: Deep RNAseq analysis.
CC Omics: DNA methylation analysis.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
CC Misspelling: 'MDA-MB-43' in ChEMBL CHEMBL614333 and CHEMBL3308414.
CC Discontinued: ATCC; CRL-12583; probable.
CC Derived from metastatic site: Subcutaneous; right buttock.
ST Source(s): DOI=10.4172/2157-7145.S2-005; PubMed=19372543; PubMed=25877200
ST Amelogenin: X
ST CSF1PO: 11
ST D13S317: 12
ST D16S539: 13
ST D18S51: 13,17 (DOI=10.4172/2157-7145.S2-005; PubMed=19372543)
ST D18S51: 13 (PubMed=25877200)
ST D19S433: 14
ST D21S11: 30
ST D2S1338: 19,24
ST D3S1358: 14
ST D5S818: 11,12 (DOI=10.4172/2157-7145.S2-005; PubMed=19372543)
ST D5S818: 12 (PubMed=25877200)
ST D7S820: 8,10
ST D8S1179: 13
ST FGA: 21
ST Penta D: 9,11
ST Penta E: 10,12
ST TH01: 6,7
ST TPOX: 8,11
ST vWA: 16,18
DI NCIt; C3802; Amelanotic melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_1395 ! M14
SX Male
CA Cancer cell line
//
ID MDA-MB-435-BAG
AC CVCL_R957
SY MDA-MB-435 BAG
RX PubMed=1384607;
CC Problematic cell line: Contaminated. Parent cell line (MDA-MB-435) has been shown to be a M14 derivative.
CC Transfected with: UniProtKB; P00722; E.coli lacZ.
CC Derived from metastatic site: Subcutaneous; right buttock.
DI NCIt; C3802; Amelanotic melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0417 ! MDA-MB-435
SX Male
CA Cancer cell line
//
ID MDA-MB-435-LCC15
AC CVCL_1U14
SY LCC15-MB
RX PubMed=9637769;
RX PubMed=10432004;
RX PubMed=15679051;
CC Problematic cell line: Contaminated. Parent cell line (MDA-MB-435) has been shown to be a M14 derivative. Was first thought to originate from the femoral metastasis of a breast carcinoma but was later shown to be contaminated by MDA-MB-435 (PubMed=15679051).
CC Derived from metastatic site: Subcutaneous; right buttock.
DI NCIt; C3802; Amelanotic melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0417 ! MDA-MB-435
SX Male
CA Cancer cell line
//
ID MDA-MB-435-Luc#1
AC CVCL_4Y10
DR JCRB; NIHS0719
CC Problematic cell line: Contaminated. Parent cell line (MDA-MB-435) has been shown to be a M14 derivative.
CC Transfected with: UniProtKB; P08659; Firefly luciferase.
CC Derived from metastatic site: Subcutaneous; right buttock.
DI NCIt; C3802; Amelanotic melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0417 ! MDA-MB-435
SX Male
CA Cancer cell line
//
ID MDA-MB-435HGF
AC CVCL_6684
SY MDA-MB-435 HGF; MDA-MB-HGF
DR BTO; BTO:0004164
CC Problematic cell line: Contaminated. Parent cell line (MDA-MB-435) has been shown to be a M14 derivative.
CC Derived from metastatic site: Subcutaneous; right buttock.
DI NCIt; C3802; Amelanotic melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0417 ! MDA-MB-435
SX Male
CA Cancer cell line
//
ID MDA-MB-435S
AC CVCL_0622
SY MDA-MB-435s; MDA-MB-435 S; MDA-MB-435-S; MDAMB435S
DR BTO; BTO:0003941
DR CLO; CLO_0007638
DR CLDB; cl7142
DR ATCC; HTB-129
DR BCRJ; 0165
DR CCLE; MDAMB435S_SKIN
DR CCRID; 3111C0001CCC000015
DR CCRID; 3131C0001000700036
DR CCRID; 3142C0001000000052
DR CLS; 300277/p513_MDA-MB-435S
DR Cosmic; 809237
DR Cosmic; 871155
DR Cosmic; 894089
DR Cosmic; 904381
DR Cosmic; 1044202
DR Cosmic; 1046951
DR Cosmic; 1287922
DR Cosmic; 1289399
DR Cosmic; 1523969
DR Cosmic; 1609477
DR Cosmic; 2301531
DR GEO; GSM149983
DR GEO; GSM149991
DR GEO; GSM149999
DR GEO; GSM887298
DR GEO; GSM888373
DR GEO; GSM1374657
DR ICLC; HTL03006
DR LINCS; 50030
RX PubMed=12661003;
RX PubMed=15677628;
RX PubMed=20070913;
RX PubMed=22460905;
RX PubMed=23601657;
WW http://www.atcc.org/support/faqs/91699/ATCC%20HTB-129%20Derivative-1051.aspx
WW http://www.atcc.org/support/faqs/79d25/Morphology%20of%20ATCC%20HTB-129-495.aspx
CC Problematic cell line: Contaminated. Parent cell line (MDA-MB-435) has been shown to be a M14 derivative.
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Part of: KuDOS 95 cell line panel.
CC Microsatellite instability: Stable (MSS) (PubMed=12661003).
CC Omics: Array-based CGH.
CC Omics: miRNA expression profiling.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
CC Derived from metastatic site: Subcutaneous; right buttock.
ST Source(s): ATCC; CLS
ST Amelogenin: X
ST CSF1PO: 11
ST D13S317: 12
ST D16S539: 13
ST D18S51: 13,17
ST D21S11: 30
ST D3S1358: 14
ST D5S818: 12
ST D7S820: 8,10
ST D8S1179: 13
ST FGA: 21
ST Penta D: 9,11
ST Penta E: 10,12
ST TH01: 6,7
ST TPOX: 8,11
ST vWA: 16,18
DI NCIt; C3802; Amelanotic melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0417 ! MDA-MB-435
SX Male
CA Cancer cell line
//
ID MDA-MB-435s-mKate2
AC CVCL_5T70
RX PubMed=25902968;
CC Problematic cell line: Contaminated. Grand-parent cell line (MDA-MB-435) has been shown to be a M14 derivative.
CC Transfected with: mKate2; a bright red fluorescent protein derived from eqFP578.
CC Derived from metastatic site: Subcutaneous; right buttock.
DI NCIt; C3802; Amelanotic melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0622 ! MDA-MB-435S
SX Male
CA Cancer cell line
//
ID MDA-MB-436
AC CVCL_0623
SY MDA MB 436; MDA-Mb-436; MDA-MB436; MDAMB436; MDA-436; MDA436
DR BTO; BTO:0001568
DR CLO; CLO_0007639
DR EFO; EFO_0001214
DR CLDB; cl7218
DR ATCC; HTB-130
DR BioSample; SAMN03471588
DR BioSample; SAMN03472712
DR CCLE; MDAMB436_BREAST
DR CCRID; 3111C0001CCC000352
DR CLS; 300278/p514_MDA-MB-436
DR Cosmic; 809240
DR Cosmic; 871156
DR Cosmic; 897425
DR Cosmic; 904382
DR Cosmic; 934528
DR Cosmic; 949191
DR Cosmic; 979718
DR Cosmic; 1010926
DR Cosmic; 1017165
DR Cosmic; 1027055
DR Cosmic; 1044206
DR Cosmic; 1044222
DR Cosmic; 1046957
DR Cosmic; 1071902
DR Cosmic; 1176604
DR Cosmic; 1287923
DR Cosmic; 1289400
DR Cosmic; 1309008
DR Cosmic; 1434955
DR Cosmic; 1609474
DR Cosmic; 2009513
DR Cosmic; 2164998
DR Cosmic; 2361353
DR Cosmic-CLP; 1240172
DR GDSC; 1240172
DR GEO; GSM115100
DR GEO; GSM149985
DR GEO; GSM149993
DR GEO; GSM150001
DR GEO; GSM217589
DR GEO; GSM344354
DR GEO; GSM344404
DR GEO; GSM350541
DR GEO; GSM783954
DR GEO; GSM845397
DR GEO; GSM847416
DR GEO; GSM847496
DR GEO; GSM844600
DR GEO; GSM844601
DR GEO; GSM887299
DR GEO; GSM888374
DR GEO; GSM1008909
DR GEO; GSM1214583
DR GEO; GSM1374658
DR GEO; GSM1374659
DR GEO; GSM1401656
DR GEO; GSM1670085
DR ICLC; HTL11005
DR IZSLER; BS TCL 246
DR LINCS; 50333
DR TOKU-E; 2399
RX PubMed=730202;
RX PubMed=7272986;
RX PubMed=10862037;
RX PubMed=15677628;
RX PubMed=17157791;
RX PubMed=19582160;
RX PubMed=22460905;
RX PubMed=23601657;
RX PubMed=24162158;
RX PubMed=25485619;
RX PubMed=27397505;
RX PubMed=28196595;
WW http://lincs.hms.harvard.edu/resources/reagents/icbp43/
WW http://tcpaportal.org/mclp/
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Part of: ICBP43 breast cancer cell line panel.
CC Part of: KuDOS 95 cell line panel.
CC Part of: MD Anderson Cell Lines Project.
CC Microsatellite instability: Instable (MSI-low) (Sanger).
CC Omics: CNV analysis.
CC Omics: Deep exome analysis.
CC Omics: Deep RNAseq analysis.
CC Omics: DNA methylation analysis.
CC Omics: miRNA expression profiling.
CC Omics: Protein expression by reverse-phase protein arrays.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
CC Derived from metastatic site: Pleural effusion.
ST Source(s): ATCC; CLS; Cosmic-CLP; PubMed=25877200
ST Amelogenin: X
ST CSF1PO: 12
ST D13S317: 10
ST D16S539: 9,11 (ATCC)
ST D16S539: 9 (CLS; Cosmic-CLP; PubMed=25877200)
ST D18S51: 12
ST D21S11: 30,31.2
ST D3S1358: 18
ST D5S818: 13
ST D7S820: 10
ST D8S1179: 10,14
ST FGA: 24
ST Penta D: 9
ST Penta E: 10,12
ST TH01: 9.3
ST TPOX: 8
ST vWA: 14,20
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID MDA-MB-453
AC CVCL_0418
SY MDA-MB 453; MDA MB 453; MDA-MB453; MDAMB453; MDA-453; MDA453
DR BTO; BTO:0001908
DR CLO; CLO_0007640
DR CLO; CLO_0050867
DR EFO; EFO_0001215
DR MCCL; MCC:0000315
DR CLDB; cl3411
DR CLDB; cl7187
DR ATCC; HTB-131
DR BCRC; 60429
DR BioSample; SAMN01821576
DR BioSample; SAMN01821647
DR BioSample; SAMN03472899
DR CCLE; MDAMB453_BREAST
DR CCRID; 3111C0001CCC000016
DR CCRID; 3131C0001000700035
DR ChEMBL-Cells; CHEMBL3307596
DR ChEMBL-Targets; CHEMBL614334
DR Cosmic; 687497
DR Cosmic; 871157
DR Cosmic; 897426
DR Cosmic; 904383
DR Cosmic; 908122
DR Cosmic; 923060
DR Cosmic; 934529
DR Cosmic; 979712
DR Cosmic; 991326
DR Cosmic; 997920
DR Cosmic; 1010927
DR Cosmic; 1018468
DR Cosmic; 1027056
DR Cosmic; 1044223
DR Cosmic; 1046931
DR Cosmic; 1047694
DR Cosmic; 1129656
DR Cosmic; 1136356
DR Cosmic; 1152522
DR Cosmic; 1176651
DR Cosmic; 1287911
DR Cosmic; 1289401
DR Cosmic; 1308995
DR Cosmic; 1434956
DR Cosmic; 1524345
DR Cosmic; 1601924
DR Cosmic; 1603222
DR Cosmic; 1609457
DR Cosmic; 2165012
DR Cosmic; 2301532
DR Cosmic; 2318375
DR Cosmic; 2564832
DR Cosmic-CLP; 908122
DR DSMZ; ACC-65
DR GDSC; 908122
DR GEO; GSM813
DR GEO; GSM115117
DR GEO; GSM217590
DR GEO; GSM344355
DR GEO; GSM344405
DR GEO; GSM350530
DR GEO; GSM481307
DR GEO; GSM783928
DR GEO; GSM847417
DR GEO; GSM844602
DR GEO; GSM887300
DR GEO; GSM888375
DR GEO; GSM1008910
DR GEO; GSM1264071
DR GEO; GSM1264075
DR GEO; GSM1264113
DR GEO; GSM1264117
DR GEO; GSM1374660
DR GEO; GSM1374661
DR GEO; GSM1374662
DR GEO; GSM1401667
DR GEO; GSM1421431
DR GEO; GSM1664568
DR GEO; GSM1661983
DR GEO; GSM1670086
DR ICLC; HTL01013
DR IGRhCellID; MDAMB453
DR IZSLER; BS TCL 247
DR KCLB; 30131
DR LINCS; 50334
DR Lonza; 837
DR NCBI_Iran; C214
DR PRIDE; PXD000309
DR RCB; RCB1192
RX PubMed=730202;
RX PubMed=9671407;
RX PubMed=12353263;
RX PubMed=12800145;
RX PubMed=17157791;
RX PubMed=19582160;
RX PubMed=21378333;
RX PubMed=22414580;
RX PubMed=22460905;
RX PubMed=23601657;
RX PubMed=25485619;
RX PubMed=25984343;
RX PubMed=26218769;
RX PubMed=27397505;
RX PubMed=28196595;
WW http://www.pawefish.path.cam.ac.uk/BreastCellLineDescriptions/MDA-MB-453.html
WW http://colt.ccbr.utoronto.ca/cancer/get_cellline.pl?cellline=MDA-MB-453
WW http://lincs.hms.harvard.edu/resources/reagents/icbp43/
WW http://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/m/cell-lines-detail-56.html
WW http://tcpaportal.org/mclp/
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Part of: ICBP43 breast cancer cell line panel.
CC Part of: KuDOS 95 cell line panel.
CC Part of: MD Anderson Cell Lines Project.
CC Part of: PI3K genetic alteration cell panel (ATCC TCP-1028).
CC Doubling time: 38 hours (PubMed=25984343); ~50-60 hours (DSMZ).
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Omics: CNV analysis.
CC Omics: Deep exome analysis.
CC Omics: Deep proteome analysis.
CC Omics: Deep RNAseq analysis.
CC Omics: DNA methylation analysis.
CC Omics: Metabolome analysis.
CC Omics: miRNA expression profiling.
CC Omics: Protein expression by reverse-phase protein arrays.
CC Omics: shRNA library screening.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
CC Misspelling: 'MDA-MB-345' in Cosmic 1129656.
CC Discontinued: IZSLER; BS TCL 247; probable.
CC Derived from metastatic site: Pericardial effusion.
ST Source(s): ATCC; Cosmic-CLP; DSMZ; KCLB; PubMed=25877200; RCB
ST Amelogenin: X
ST CSF1PO: 10,12
ST D13S317: 12
ST D16S539: 9
ST D18S51: 15,20
ST D21S11: 29,31
ST D3S1358: 15
ST D5S818: 11
ST D7S820: 10
ST D8S1179: 10,12
ST FGA: 18,23
ST Penta D: 9,10
ST Penta E: 11
ST TH01: 6
ST TPOX: 10
ST vWA: 17,18
DI NCIt; C5214; Breast adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID MDA-MB-461
AC CVCL_M391
DR Cosmic; 1129657
RX PubMed=730202;
CC Derived from metastatic site: Brain.
DI NCIt; C4872; Breast carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID MDA-MB-468
AC CVCL_0419
SY MDA-MB 468; MDA-MB468; MDAMB468; MDA-468; MDA468; MB468
DR BTO; BTO:0001570
DR CLO; CLO_0007641
DR EFO; EFO_0001216
DR MCCL; MCC:0000316
DR CLDB; cl4973
DR ATCC; HTB-132
DR BCRJ; 0166
DR BioSample; SAMN03473056
DR CCLE; MDAMB468_BREAST
DR CCRID; 3111C0001CCC000249
DR CCRID; 3131C0001000700120
DR ChEMBL-Cells; CHEMBL3308424
DR ChEMBL-Targets; CHEMBL614335
DR CLS; 300279/NA
DR Cosmic; 809241
DR Cosmic; 850823
DR Cosmic; 871149
DR Cosmic; 877448
DR Cosmic; 897427
DR Cosmic; 904384
DR Cosmic; 908123
DR Cosmic; 923061
DR Cosmic; 934530
DR Cosmic; 949192
DR Cosmic; 991327
DR Cosmic; 997921
DR Cosmic; 1000125
DR Cosmic; 1010920
DR Cosmic; 1017167
DR Cosmic; 1018467
DR Cosmic; 1046929
DR Cosmic; 1044224
DR Cosmic; 1047691
DR Cosmic; 1136363
DR Cosmic; 1152526
DR Cosmic; 1176635
DR Cosmic; 1287918
DR Cosmic; 1289402
DR Cosmic; 1305384
DR Cosmic; 1309004
DR Cosmic; 1477427
DR Cosmic; 1523775
DR Cosmic; 1524344
DR Cosmic; 1571795
DR Cosmic; 1603223
DR Cosmic; 1609465
DR Cosmic; 1998490
DR Cosmic; 2009514
DR Cosmic; 2036673
DR Cosmic; 2164999
DR Cosmic; 2301533
DR Cosmic; 2318380
DR Cosmic; 2361357
DR Cosmic-CLP; 908123
DR DSMZ; ACC-738
DR GDSC; 908123
DR GEO; GSM75169
DR GEO; GSM185095
DR GEO; GSM185096
DR GEO; GSM217591
DR GEO; GSM344356
DR GEO; GSM344406
DR GEO; GSM350502
DR GEO; GSM388214
DR GEO; GSM459714
DR GEO; GSM459722
DR GEO; GSM466357
DR GEO; GSM783955
DR GEO; GSM847418
DR GEO; GSM847497
DR GEO; GSM887301
DR GEO; GSM888376
DR GEO; GSM1008911
DR GEO; GSM1214565
DR GEO; GSM1374663
DR GEO; GSM1374664
DR GEO; GSM1374665
DR GEO; GSM1401650
DR GEO; GSM1556177
DR GEO; GSM1556178
DR GEO; GSM1556179
DR GEO; GSM1556180
DR GEO; GSM1556181
DR GEO; GSM1661984
DR GEO; GSM1670087
DR GEO; GSM1833629
DR ICLC; HTL99024
DR KCB; KCB 2011114YJ
DR LINCS; 50335
DR Lonza; 809
DR NCBI_Iran; C208
DR PRIDE; PXD001680
DR TOKU-E; 2401
DR TOKU-E; 3604
DR Wikidata; Q16880225
RX PubMed=730202;
RX PubMed=2041050;
RX PubMed=9671407;
RX PubMed=11414198;
RX PubMed=12353263;
RX PubMed=12800145;
RX PubMed=15677628;
RX PubMed=17157791;
RX PubMed=18262045;
RX PubMed=19582160;
RX PubMed=20070913;
RX PubMed=22460905;
RX PubMed=23601657;
RX PubMed=23856246;
RX PubMed=23933261;
RX PubMed=24162158;
RX PubMed=25485619;
RX PubMed=27397505;
RX PubMed=27807467;
RX PubMed=28196595;
WW https://en.wikipedia.org/wiki/MDA-MB-468
WW https://dtp.cancer.gov/discovery_development/nci-60/cell_list.htm
WW http://www.pawefish.path.cam.ac.uk/BreastCellLineDescriptions/mda-mb-468.html
WW http://colt.ccbr.utoronto.ca/cancer/get_cellline.pl?cellline=MDA-MB-468
WW http://lincs.hms.harvard.edu/resources/reagents/icbp43/
WW http://www.addexbio.com/productdetail?pid=4673
WW http://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/m/cell-lines-detail-53.html
WW http://tcpaportal.org/mclp/
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Part of: EGFR genetic alteration cell panel (ATCC TCP-1027).
CC Part of: ICBP43 breast cancer cell line panel.
CC Part of: KuDOS 95 cell line panel.
CC Part of: MD Anderson Cell Lines Project.
CC Part of: NCI60 cancer cell line panel.
CC Doubling time: 62 hours (DTP); ~30-40 hours (DSMZ).
CC Microsatellite instability: Stable (MSS) (PubMed=15677628; Sanger).
CC Omics: Array-based CGH.
CC Omics: CNV analysis.
CC Omics: Deep exome analysis.
CC Omics: Deep proteome analysis.
CC Omics: Deep RNAseq analysis.
CC Omics: DNA methylation analysis.
CC Omics: miRNA expression profiling.
CC Omics: Protein expression by reverse-phase protein arrays.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
CC Discontinued: CLS; 300279; true.
CC Derived from metastatic site: Pleural effusion.
ST Source(s): ATCC; Cosmic-CLP; DSMZ; PubMed=25877200
ST Amelogenin: X
ST CSF1PO: 12
ST D13S317: 12
ST D16S539: 9
ST D18S51: 17
ST D21S11: 27,28
ST D3S1358: 15
ST D5S818: 12
ST D7S820: 8
ST D8S1179: 13
ST FGA: 23
ST Penta D: 8,10
ST Penta E: 5
ST TH01: 7
ST TPOX: 8,9
ST vWA: 18
DI NCIt; C5214; Breast adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID MDA-MB-468GFP
AC CVCL_DH83
SY 468GFP
DR GEO; GSM390975
DR GEO; GSM390978
RX PubMed=16170671;
RX PubMed=20084286;
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
CC Omics: CNV analysis.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C5214; Breast adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0419 ! MDA-MB-468
SX Female
CA Cancer cell line
//
ID MDA-MB-468LN
AC CVCL_M372
SY MDA-MB-468GFP-LN; 468GFP-LN; 468LN
DR GEO; GSM390976
DR GEO; GSM390977
RX PubMed=16170671;
RX PubMed=18262045;
RX PubMed=20084286;
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
CC Omics: CNV analysis.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C5214; Breast adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_DH83 ! MDA-MB-468GFP
SX Female
CA Cancer cell line
//
ID MDA-MB-469
AC CVCL_M392
RX PubMed=730202;
RX PubMed=7272986;
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C4872; Breast carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID MDA-N
AC CVCL_1910
SY MDAN
DR BioSample; SAMN03151833
DR ChEMBL-Cells; CHEMBL3307532
DR ChEMBL-Targets; CHEMBL614078
DR Cosmic; 875880
DR Cosmic; 1998491
DR GEO; GSM750823
DR GEO; GSM799355
DR GEO; GSM799418
DR GEO; GSM1153425
DR GEO; GSM1181357
DR GEO; GSM1181358
RX PubMed=2041050;
RX PubMed=12661003;
RX PubMed=19372543;
RX PubMed=20143388;
WW https://dtp.cancer.gov/discovery_development/nci-60/cell_list.htm
WW https://dtp.cancer.gov/discovery_development/nci-60/mda-mb-435.htm
WW https://strap.nci.nih.gov/celline_detail.php?sample_id=52
WW http://iclac.org/wp-content/uploads/Cross-Contaminations-v8_0.pdf
CC Problematic cell line: Contaminated. Parent cell line (MDA-MB-435) has been shown to be a M14 derivative (PubMed=20143388).
CC Part of: NCI60 cancer cell line panel.
CC Doubling time: 22.5 hours (DTP).
CC Microsatellite instability: Stable (MSS) (PubMed=12661003).
CC Derived from metastatic site: Subcutaneous; right buttock.
ST Source(s): PubMed=19372543
ST Amelogenin: X
ST CSF1PO: 11
ST D13S317: 12
ST D16S539: 13
ST D18S51: 13,17
ST D19S433: 14
ST D21S11: 30
ST D2S1338: 19,24
ST D3S1358: 14
ST D5S818: 11,12
ST D7S820: 8,10
ST D8S1179: 13
ST FGA: 21
ST TH01: 6,7
ST TPOX: 8,11
ST vWA: 16,18
DI NCIt; C3802; Amelanotic melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0417 ! MDA-MB-435
SX Male
CA Cancer cell line
//
ID MDA-Panc-28
AC CVCL_3917
SY MDA Panc-28; MDAPanc-28; MDAPanc28
DR BTO; BTO:0003303
RX PubMed=8656025;
DI NCIt; C8294; Pancreatic adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID MDA-Panc-3
AC CVCL_3918
SY MDA Panc-3; MDAPanc-3; MDAPanc3
DR BTO; BTO:0003302
DR Cosmic; 710860
RX PubMed=1688394;
RX PubMed=11169959;
RX PubMed=11787853;
WW http://www.pawefish.path.cam.ac.uk/PancCellLineDescriptions/MDA%20Panc-3.html
DI NCIt; C8294; Pancreatic adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID MDA-PCa-2a
AC CVCL_4747
SY MDA PCa 2a; MDAPC2A; MDA2A
DR ATCC; CRL-2421
DR BioSample; SAMN03471839
DR GEO; GSM91925
RX PubMed=9815652;
RX PubMed=12725112;
RX PubMed=14518029;
RX PubMed=15486987;
WW http://capcelllines.ca/details.asp?id=158
CC Omics: Array-based CGH.
CC Omics: Transcriptome analysis.
CC Discontinued: ATCC; CRL-2421; true.
CC Derived from metastatic site: Bone.
ST Source(s): ATCC
ST Amelogenin: X,Y
ST CSF1PO: 10,12
ST D13S317: 11,12
ST D16S539: 10,11
ST D5S818: 12,13
ST D7S820: 8,10
ST TH01: 8,9
ST TPOX: 8,11
ST vWA: 15,16
DI NCIt; C4863; Prostate carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_4748 ! MDA-PCa-2b
SX Male
CA Cancer cell line
//
ID MDA-PCa-2b
AC CVCL_4748
SY MDA PCa 2b; MDAPCa-2b; MDAPC2B; MDA2B
DR BTO; BTO:0005050
DR CLO; CLO_0007629
DR ATCC; CRL-2422
DR BioSample; SAMN03471841
DR CCLE; MDAPCA2B_PROSTATE
DR Cosmic; 1689712
DR GEO; GSM91928
DR GEO; GSM648821
DR GEO; GSM887302
DR GEO; GSM888377
RX PubMed=9815652;
RX PubMed=12725112;
RX PubMed=14518029;
RX PubMed=15486987;
RX PubMed=22460905;
RX PubMed=23671654;
WW http://capcelllines.ca/details.asp?id=160
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Microsatellite instability: Instable (MSI) (PubMed=23671654).
CC Omics: Array-based CGH.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
CC Derived from metastatic site: Bone.
ST Source(s): ATCC
ST Amelogenin: X,Y
ST CSF1PO: 10,12
ST D13S317: 11,12
ST D16S539: 10,11
ST D5S818: 12,13
ST D7S820: 8,10
ST TH01: 8,9
ST TPOX: 8,11
ST vWA: 16
DI NCIt; C4863; Prostate carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_4747 ! MDA-PCa-2a
SX Male
CA Cancer cell line
//
ID MDA-PCa-2b-hr
AC CVCL_4867
SY MDA PCa 2b-hr
RX PubMed=14500404;
WW http://capcelllines.ca/details.asp?id=162
CC Derived from metastatic site: Bone.
DI NCIt; C4863; Prostate carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_4748 ! MDA-PCa-2b
SX Male
CA Cancer cell line
//
ID MDA-T32
AC CVCL_W913
DR Cosmic; 2054087
RX PubMed=23833040;
DI NCIt; C4035; Thyroid gland papillary carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID MDA-T41
AC CVCL_W914
DR Cosmic; 2054114
RX PubMed=23833040;
DI NCIt; C4035; Thyroid gland papillary carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID MDA231-DOX[r]
AC CVCL_4V67
WW http://www.chemoscreen.com/product/mda231-doxr-cells
CC Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Adriamycin).
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C5214; Breast adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0062 ! MDA-MB-231
SX Female
CA Cancer cell line
//
ID MDA231-LM2-4142
AC CVCL_DG21
SY LM2-4142
DR GEO; GSM587389
RX PubMed=16049480;
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C5214; Breast adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0062 ! MDA-MB-231
SX Female
CA Cancer cell line
//
ID MDA231-LM2-4175
AC CVCL_5998
SY MDA231-LM2; LM2-4175; 4175
DR GEO; GSM587391
RX PubMed=16049480;
RX PubMed=18425382;
CC Omics: Proteome analysis by 2D-DE.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C5214; Breast adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0062 ! MDA-MB-231
SX Female
CA Cancer cell line
//
ID MDA435/LCC6
AC CVCL_IN99
DR BTO; BTO:0005866
RX PubMed=8546900;
CC Problematic cell line: Contaminated. Parent cell line (MDA-MB-435) has been shown to be a M14 derivative.
CC Derived from metastatic site: Subcutaneous; right buttock.
DI NCIt; C3802; Amelanotic melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0417 ! MDA-MB-435
SX Male
CA Cancer cell line
//
ID MDA435/LCC6MDR1
AC CVCL_IP00
SY MDA435/LCC6MDR
DR BTO; BTO:0005867
RX PubMed=8546900;
CC Problematic cell line: Contaminated. Grand-parent cell line (MDA-MB-435) has been shown to be a M14 derivative.
CC Transfected with: HGNC; 40; ABCB1.
CC Derived from metastatic site: Subcutaneous; right buttock.
DI NCIt; C3802; Amelanotic melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_IN99 ! MDA435/LCC6
SX Male
CA Cancer cell line
//
- 公告/新闻
